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Abstract 
The plant kingdom contains a large number of unique phytochemicals, some of 
which are known to be beneficial to the function of human cells.  Where the macro- 
and micronutrients in plant foods were once thought to be the reason for their 
essentiality in human health, phytochemicals have emerged as being significant non-
nutritive contributors.  The rapidly-evolving science of nutrigenomics directs greater 
focus on the intricate signalling pathways that relate dietary phytochemicals and 
human biomolecules. The effects of phytochemicals in modifying gene expression 
are becoming increasingly documented.  
This thesis investigates the nutrigenomic effects of two unrelated plant-derived 
materials (SOD/gliadin and sulforaphane) in terms of their clinical potential. The 
original plan was to conduct two clinical trials using SOD/gliadin only; however, the 
first study resulted in null findings leading to the decision to investigate a second 
supplement for the remainder of the thesis.  
The thesis is divided into two sections, with each covering one of the compounds. 
Section 1 contains Chapters 1-3 with Chapter 3 describing a randomised placebo-
controlled trial conducted to examine the potential health benefits of SOD/gliadin 
supplementation. This chapter has been published in the Journal, Phytomedicine. 
The trial examined the effects of 3 months of SOD/gliadin supplementation on 
perceived fatigue in 40 post-menopausal women. It was hypothesised that the 
SOD/gliadin would increase the activity of the primary antioxidant enzymes, 
superoxide dismutase (SOD) glutathione peroxidase (GPx) and Catalase (Cat) and 
that this would lead to a decrease in aconitase, the rate-limiting enzyme in the 
synthesis of adenosine triphosphate (ATP), with a view to reducing perceived fatigue 
in this population. The results showed that the SOD/gliadin supplement had no 
significant effect on self-perceived fatigue, antioxidants, oxidative stress or hormones 
in women aged 50-65 years. 
Section 2 (Chapters 4-9) sees the focus of the thesis shift to investigating a broccoli 
sprout-containing product which yields sulforaphane (SFN). Chapters 5 and 6 
contain two published review articles (Nutrition Reviews and Oxidative Medicine and 
Cell Longevity respectively). Chapter 7 highlights methodological issues associated 
with using phytochemicals like SFN in clinical trials.  
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Chapter 8 details the second clinical trial (The EASYGENEX Study).  The primary 
objective was to examine gene expression across two dose levels of encapsulated 
whole broccoli sprout raw material, optimised for its sulforaphane yield.  An open-
label dose-escalation study was conducted with 21 young, healthy, physically-active 
men.  Plasma was collected before and after consuming encapsulated whole 
broccoli sprout supplements over two 7-day continuous periods (53 g SFN/day 
during Week 1 then 106 g SFN/day in Week 2). Genotypes were identified from 
buccal swab samples. Liquid chromatography with tandem mass spectrometry was 
used to measure plasma SFN and its metabolites. Gene expression analysis was 
conducted using Ingenuity Pathway Analysis with peripheral blood mononuclear cells 
(PBMCs) on a microarray platform. 
Both upregulated and downregulated significantly differentially-expressed genes 
were identified over the 14-day period of the study, with downregulated genes 
predominating.  The major network identified by Ingenuity Pathway Analysis (IPA) 
centred on NF-kB, a transcription factor associated with pro-inflammatory effects; the 
study confirmed the known inhibitory effect of SFN on NF-kB. Also identified were 8 
differentially-expressed genes not documented elsewhere in association with SFN.   
Two were upregulated, DDC and ACSM2A, with the remainder downregulated: 
HERC6, PDIA4, ZBTB2, IGF2B2, DDX3X and GK5. All the significantly differentially-
expressed genes could be grouped by function into the six overlapping categories: 
immune modulation (anti-inflammatory), metabolism (adipogenesis, glucose 
metabolism, insulin sensitivity), neurotransmitter synthesis, cytoprotection, 
cardioprotection and redox modulation.  Some are known to exhibit multiple effects.   
Development of the EASYGENEX Study highlighted a number of significant 
methodological issues inherent in using phytochemicals like SFN as intervention 
materials.  Chapter 7 identifies these issues, describes their potential for flawed 
outcomes and suggests ways to mitigate against such design flaws.  In so doing, it 
highlights the background to the key genes discussed in Chapter 8, exploring 
relevant aspects of their mechanisms in the function of human cells. 
The summation and concluding remarks for this thesis form the final chapter, 
Chapter 9. 
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CHAPTER ONE 
Introduction 
1.0 General Principles 
We live in an era where modern medicine is strongly focused on relief of symptoms, 
the pharmaceutical industry providing many solutions to address this demand.  It is 
becoming increasingly apparent however, that the diseases which cause most 
distress at the individual level and are the most expensive at the public health level 
are typically managed by pharmaceuticals which may provide only short-lived 
symptomatic relief.  Few if any modern pharmaceuticals modulate fundamental 
etiological disease processes.  As a consequence, there is a groundswell of interest 
in therapies which address the fundamental upstream causes of disease as opposed 
to symptom-relief alone.  Strategies to address these fundamental causes of disease 
may help elucidate the pathophysiology of both chronic diseases and acute self-
limiting conditions.  Such findings may inform development of new therapeutic 
solutions. 
1.0.1 Searching for Upstream Factors 
A search for upstream factors in the etiological processes of disease is the focus of 
considerable global research, with such research closely investigating signalling 
pathways within cells and organelles.  Typical of the current trajectory for chronic 
disease as a whole is the increasing global prevalence of cardiovascular disease 
and type 2 diabetes.  It is emerging3 that the primary upstream factor which links 
endothelial dysfunction with cardiovascular disease and type 2 diabetes is closely 
related to oxidative stress.4  Attempts to intervene with the classical antioxidant 
vitamins to enhance endothelial function and related glucose regulation have largely 
resulted in no response in some studies and adverse effects in others.5-9 
1.0.2 Phytochemicals as Inducers of Endogenous Defences 
A possible alternative approach to the modulation of the oxidative stress 
underpinning such cellular dysfunction involves the application of phytochemicals 
with nutrigenomic potential.10   By definition, a phytochemical is a plant-derived 
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chemical substance that is biologically active but typically non-nutritive11; 
nutrigenomics describes the way in which phytochemicals may affect gene 
expression.  As such, the application of nutrigenomic principles may allow effective 
dietary intervention strategies to recover normal homeostasis and to prevent or even 
treat disease.12 
This thesis focuses on the modulation of gene expression that may occur using 
plant-derived compounds with desirable and demonstrable nutrigenomic properties.  
One of the intended effects of this strategy is to increase the production of 
endogenous antioxidant compounds, including the antioxidant enzymes.  Whilst 
some phytochemicals may upregulate cellular endogenous defences, others may 
downregulate pathways associated with undesirable effects, including prolonged 
inflammation.   
Although such plant-derived compounds may exhibit direct antioxidant activity, it is 
their indirect antioxidant effect which is attracting growing interest.  At the upstream 
cellular level, the effect of the antioxidant enzymes in quenching Reactive Oxygen 
Species (ROS) and Reactive Nitrogen Species (RNS) is catalytic, compared with 
non-enzyme antioxidants which exhibit only a one-for-one stoichiometric effect.  
There is considerable evidence to show that induction of such cytoprotective 
compounds has multiple beneficial effects.13,14,15,16  
The two compounds selected for investigation in this thesis are derived respectively 
from the fruit flesh of a particular strain of melon (Cucumis melo) and the young 
germinated seeds of broccoli (Brassica oleracea var. italica).  An extract from the 
melon, combined with wheat-derived gliadin polymers has been shown to contain a 
nutrigenomically-active SOD17; the germinated broccoli yields a similarly 
nutrigenomically-active isothiocyanate, sulforaphane (SFN). 
1.1 SOD/Gliadin as an Intervention Compound  
The melon-derived nutrigenomic compound (SOD/gliadin)17 has been shown to be 
capable of inducing the endogenous synthesis of the three antioxidant enzymes, 
SOD, glutathione peroxidase (GPx) and catalase (Cat).18 Each capsule claims to 
provide 250 U of SOD activity in an orally-bioavailable form, protected from digestive 
degradation by biopolymers of gliadin.  In one study19 of this compound, it was 
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shown that treatment with SOD/gliadin (but not vitamins C and E)20,21 was able to 
prevent the severe DNA damage associated with hyperbaric oxygen exposure.  
It could be hypothesised that treatment with SOD/gliadin may have benefit in any 
condition where oxidative stress is a contributor to redox dysregulation.  Two 
contrasting cellular events are relevant to this hypothesis: 1) endogenous synthesis 
of antioxidant and other protective enzymes is known to decline with age and illness.  
2) production of the superoxide radical increases with age, illness and various 
environmental conditions.22  
Fatigue is one of the most common complaints of patients seen by all health 
practitioners. In many cases, no obvious or specific cause is found.  Anecdotal 
evidence supplied by the patent-holder suggests that treatment with SOD/gliadin can 
decrease fatigue in those who use it.  The first study described in this thesis and 
forming Section 1 is the Fatigue Study2 which was designed as a randomised 
placebo-controlled trial to investigate the effect of SOD/gliadin capsules on 
unexplained fatigue in otherwise healthy post-menopausal women.  However, 
compared with placebo, this investigation did not find a significant change in fatigue 
in the subjects taking the intervention capsules.  It was subsequently decided to 
discontinue further investigation of this compound, having become aware of the 
more extensive and growing database of publications on bioactive compounds 
derived from cruciferous plants. 
1.2 Sulforaphane as an Intervention Compound  
1.2.1 Properties and Relevance 
Sulforaphane is a plant-derived biomolecule shown to demonstrate nutrigenomic 
potential.  Sulforaphane is naturally derived from certain species of the Brassica 
vegetable family23 and most notably from broccoli. These vegetables are also known 
as cruciferous vegetables,a well-known for their disease-preventive effects.24,25   
Broccoli has been shown to be the most significant dietary source26 of the precursor 
compound, glucoraphanin (GRN) which on ingestion in the presence of the 
myrosinase (MYR) enzyme, is metabolised to SFN.  Very young sprouted broccoli 
                                            
a Cruciferous Vegetables include broccoli, cabbage, cauliflower, Brussels sprouts, rocket, arugula, bok choy and others 
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seeds in the order of 3-7 days have been shown to contain the highest levels of 
GRN.27 
There is evidence to suggest that SFN’s nutrigenomic effects contribute to the 
enhancement of the cell’s antioxidant capacity.28 Of the endogenous antioxidants 
induced by SFN, the better-known include glutathione (GSH), Thioredoxin (Trx), 
Thioredoxin reductase (TrxR) and Haemoxygenase-1 (HO-1).  In addition, a 
significant role in endogenous cellular defence processes is emerging for the Phase 
2 detoxification enzyme, NAD(P)H: quinone oxidase reductase1 (NQO1) which is 
also substantially upregulated by SFN.27 
It has now been firmly established that NQO1 provides major antioxidant functions 
by virtue of its obligatory two-electron reduction mechanism which diverts quinones 
from participating in oxidative cycling and generation of reactive oxygen 
intermediates.  The finding that the gene coding for NQO1 is highly-inducible and 
that increased induction protected animals and their cells against oxidative stress, 
provided a major new perspective on the functional importance of this enzyme.29-31  
SFN is considered to be one of most potent phytochemical inducers of NQO1.32,33 
Given that classical antioxidant supplements have failed to demonstrate significant 
chemoprotection or preventive benefits against cancer, cardiovascular disease and 
type 2 diabetes,5,34-36 it could be hypothesised that intervention with SFN may 
provide an alternative but effective strategy.  A growing number of studies use 
broccoli sprouts to enhance cellular defences and have been described as showing 
promising results.37,38,39,40,41,42  However, these studies fail to provide consistent 
clinical responses that correlate with the concentration of SFN yielded from its plant 
source.  The issue of dose-response is discussed in greater detail in Chapter 7.  
The second more comprehensive study in this thesis and forming Chapter 8 was 
designed to investigate the potential for SFN to modulate gene expression in young 
healthy men, using a broccoli sprout ingredient which specifies its level of the key 
bioactive, glucoraphanin as well as the sulforaphane it yielded via a MYR-dependent 
enzymatic reaction.  The SFN-yielding ingredient was provided to participants at 
practical doses obtainable from taking broccoli sprout capsules.  Chapter 5 provides 
tabulated data of the available clinical trials for which a dose-response for a 
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quantifiable amount of SFN can be correlated with clinical outcomes in a variety of 
human illnesses and abnormalities.
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SECTION ONE 
CHAPTER 2 
Review of Literature – SOD/Gliadin 
2.0 Introduction 
This review of the literature provides the scientific foundation associated with the 
mechanisms and clinical application of a patented nutrigenomically-active 
melon/gliadin used in a clinical trial conducted by our group and published in 
Phytomedicine.2 
2.1 Background - the History of Superoxide Dismutase Research 
The antioxidant enzyme, superoxide dismutase (SOD) was discovered by McCord 
and Fridovich in 1968.  Following recognition of its role in cellular defence 
mechanisms,43,44 its potential in clinical medicine was considered appropriate for 
translation into therapeutic applications.  Injectable forms of bovine SOD appeared 
as pharmaceuticals and were used in a range of conditions45,46,47,48,49,50,51 for some 
years until the onset of Creutzfeldt-Jakob disease (‘mad cow’ disease) which 
necessitated their removal from the market. 
In the late 1990’s, plant alternatives to bovine SOD were sought.  Because SOD as 
an enzyme is degraded by proteolytic gastric, duodenal and pancreatic enzymes in 
humans, it was necessary that the SOD be protected against such proteolysis. A 
French company identified a source of SOD in a particular strain of cantaloupe, or 
melon (Cucumis melo LC) and in 2000, a U.S. patent for the SOD/gliadin 
combination was granted.52   The material is known commercially as GliSODin 
(www.glisodin.org). 
The resulting melon-based product was a unique compound bound with gliadin 
(8.3mg per 250 U enzyme dose), the resulting gliadin biopolymer protecting the SOD 
from proteolysis.17  In addition to protection against degradation by gastrointestinal 
secretions, ingestion of the SOD/gliadin combination was shown in rats to result in 
significant increases in the three primary antioxidant enzymes, SOD, Glutathione 
peroxidase (GPx) and Catalase (Cat).17,18 
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These two SOD/gliadin proof-of-concept studies by Vouldoukis et al.17,18 showed that 
neither the melon nor the gliadin extract alone was capable of inducing endogenous 
synthesis of the antioxidant enzymes; it was the combination which demonstrated 
increases in all three antioxidant enzymes together with an increase in the anti-
inflammatory cytokine, interleukin-10 (IL-10). 
2.1.1 The SOD/Gliadin Research Timeline 
Figure 2.1 shows the evolution of SOD/gliadin research since patent issue in 2000, 
together with the nature of the clinical trials using SOD/gliadin as the intervention 
material. The studies undertaken include in vitro mechanistic and pharmacokinetic 
studies, animal studies and human clinical trials.  The latter studies focus on 
conditions known to be associated with cellular redox imbalance, investigating 
reduction of atheromatous plaque in adults with metabolic syndrome19 as well as 
investigations into SOD/gliadin’s protective effect against UV radiation-induced 
fibrosis,53 hyperbaric oxygen19 and surgical stress (as ischaemia-reperfusion).54  
The first intervention study undertaken as part of this thesis was to clinically test the 
hypothesis that the SOD/gliadin phytochemical combination could increase 
endogenous synthesis of SOD, Glutathione peroxidase (GPx) and Catalase (Cat) 
and in so doing might be capable of reducing fatigue in otherwise healthy older 
women. 
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Figure 2.1 Evolution of SOD/gliadin research 2000-2016.     
Source www.glisodin.org 
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2.2 More Recent SOD/Gliadin Research Investigation 
Since our study was published, there have been four publications focused on the 
SOD/gliadin compound.  In the first of these55 and using chloroplasts from the same 
cantaloupe strain, the patent-holders developed a stable recombinant Cu-Zn SOD 
fused to a gliadin peptide.  Unlike the SOD/gliadin used in our study which has 1 U 
SOD activity per mg, the recombinant form demonstrated ~ 5,000 U SOD activity per 
mg.  The authors concluded that although the fundamental action of the recombinant 
form was similar to the lower potency SOD/gliadin, it was also able to switch the 
gliadin-induced pro-inflammatory cytokine production to the anti-inflammatory 
pathway. 
The second of these studies investigated the effect of 500 mg daily of the same 
SOD/gliadin used in our trial on 19 male rowers exercising to exhaustion.56  SOD 
was shown to be higher in the supplemented group and C-reactive protein lower, 
although there was no effect on oxidative damage in muscle tissue.  A third 
publication57 is a review paper summarising the suggested mechanisms of action of 
the SOD/gliadin combination in addition to tabulating recent studies considered to be 
significant. The last of these studies53 examined the effect of SOD/gliadin in mice 
exposed to ionising radiation on Day 0 and then to the supplement over an 8-day 
period at age 6 months.  Excised tissue in those administered the supplement 
showed significantly reduced dermal thickness.  The value of this animal study may 
be of limited comparative value in that the doses were much greater than those 
administered in the reported human clinical trials.  However, the development by 
Intes et al. of the more potent recombinant SOD/gliadin form in their group’s study55 
may enable such findings to be replicated in humans. 
2.3 The Role of Endogenous Antioxidant Enzymes  
SOD is the primary human endogenously-synthesised antioxidant enzyme 
quenching the ROS, superoxide anion.  It is well understood that free radical injury 
plays a role in all types of cellular damage and is implicated in many diseases58,59-62 
including cardiovascular disease, diabetes and cancer.  SOD exists in three main 
forms, a cytosolic form which uses copper and zinc at its active site, a mitochondrial 
form which uses manganese at its active site and an extracellular form which also 
uses copper and zinc as its cofactors.  
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Dietary antioxidant supplements have been used as intervention tools in a variety of 
clinical expressions of oxidative stress63; the results are conflicting, with some 
studies showing benefit and others showing no benefit.5,64  Yet other studies65 have 
shown that in some circumstances, there may be reason to avoid the use of isolated 
antioxidant supplements in supraphysiological doses. 
It is known that endogenous synthesis of the three primary antioxidant enzymes, 
SOD, GPx and Cat declines with increasing age and with illness.22  It is also known 
that production of the superoxide radical increases with age, illness and various 
environmental situations.66,67 
2.3.1 Biochemical Considerations Associating Elevated ROS with Cellular 
Dysfunction 
In testing the hypothesis that elevated ROS may contribute to unexplained fatigue in 
humans, the following biochemical factors may be relevant: 
• The cell produces energy in the form of Adenosine Triphosphate (ATP), mostly 
via the mitochondrial electron transport system   
• Ageing typically results in a reduction of the endogenous synthesis of 
antioxidant enzymes, including mitochondrial manganese-dependent SOD 
(MnSOD).  The potential for a greater oxidative burden exists as individuals 
age.68 
• Superoxide radical in the presence of nitric oxide generates a toxic ROS, 
peroxynitrite.69   
• SOD is deactivated by peroxynitrite.70 
• A range of stressors can initiate stimulation of inducible nitric oxide synthase 
(iNOS) activity and its oxidant product, peroxynitrite (in the presence of 
superoxide).71 
• The ageing process is associated with pro-inflammatory NF-kappa B (NF-kB) 
activation.  Certain redox-modulating phytochemicals are capable of 
ameliorating such age-related alterations in signal transduction, in vitro.72 
• The transcription factor NF-kB stimulates iNOS activity, so that increased levels 
of nitric oxide are produced.  This initiates a feed-forward loop where an 
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initiation of inflammatory activity continues to produce more nitric oxide which in 
turn produces more peroxynitrite.73 
• Peroxynitrite has several effects which deplete ATP, including its effect on the 
mitochondrial electron transport system.  Nitric oxide inhibits one of the 
component enzymes of this system, cytochrome oxidase.74   Both of these 
factors produce increased superoxide, potentially providing further positive 
feedback 
• Peroxynitrite is formed during sepsis, inflammation, excito-toxicity and 
ischaemia-reperfusion of tissues, conditions under which cellular production of 
both superoxide and nitric oxide increase; such elevated sustained peroxynitrite 
can cause chronic fatigue syndrome.70 
• Multiple mechanisms have been found to produce increases in both superoxide 
and nitric oxide, leading to increased levels of the peroxynitrite free radical.75  
Because peroxynitrite inhibits mitochondrial energy production, it is plausible to 
consider that interventions directed at favourably regulating the production of 
superoxide and/or nitric oxide could be expected to impact on energy 
production.  It is on this hypothesis that this study is based 
• The cell’s redox status can have a modulating effect on aconitase in intact 
mitochondria.  As such, superoxide can inhibit the rate-limiting enzyme in the 
ATP-generating Kreb’s Cycle.76  
In considering these interactions which provide a plausible mechanism linking 
oxidative stress to reduced ATP synthesis and the possibility of subjective fatigue, 
the first study in this thesis investigates whether the SOD/gliadin combination has 
an effect on these processes. 
The challenge in such nutrigenomic investigations is to identify oral therapeutics 
with the ability to enhance activity of the cell’s endogenous antioxidant enzymes, 
since the findings for the therapeutic application of exogenous antioxidant 
vitamins are equivocal. 
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2.4 The Intervention Compound 
The SOD/gliadin compound has been designed to deliver SOD in an oral delivery 
system, typically a 2-piece hard vegetable capsule.  Its mode of action18 in inducing 
the primary antioxidant enzymes makes it different from other exogenous 
compounds such as the SOD-mimetics which are drugs seeking to mimic the effect 
of endogenous superoxide dismutase enzyme in human cells.  SOD/gliadin is not an 
SOD-mimetic.  The SOD/melon extract is specified for its SOD enzyme activity and 
has been shown to induce other enzymes apart from SOD.18  In this capacity, it 
could be classified as a nutrigenomically-active compound. 
As a complex of melon-derived SOD bound to a gliadin biopolymer, SOD/gliadin is 
structurally different from the SOD-mimetics which in turn are structurally different 
from native SOD.  Native SOD is a homo-tetramer, a polymer consisting of four 
identical monomers,77 with an individual subunit molecular weight of about 23,000 
Daltons and containing around 205 amino acids per monomer.  Although all three 
compounds have been shown to exhibit superoxide-quenching activity, each is 
structurally different. 
2.4.1 Studies Utilising SOD/Gliadin as the Intervention 
The timeline in Figure 2.1 lists the studies performed using SOD/gliadin. The 
manufacturer of the SOD/gliadin used in this study, (IsoCell NUTRA, Paris, France) 
has conducted research into the therapeutic properties of the compound. One of 
these studies demonstrated that in humans, treatment with SOD/gliadin was able to 
prevent the severe DNA damage associated with hyperbaric oxygen exposure in 
deep sea divers.19  By contrast, two similar studies21,20 using vitamins C and E as 
intervention tools failed to show any protection by these vitamins against hyperbaric 
oxygen.  Thus, it is hypothesised that treatment with SOD/gliadin is likely to have 
benefit in conditions wherein marked oxidative stress occurs and that this benefit 
may occur in conditions where no benefit results from supraphysiological dosages 
traditional antioxidant vitamin supplements. 
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2.5 The Rationale for Investigating Fatigue 
Fatigue is a common presenting complaint to primary care clinicians.78 It can be 
defined as a pervasive sense of tiredness or lack of energy that is not related 
exclusively to exertion.79 In many cases, no obvious or specific cause is found.  It 
has been estimated that there is an overall prevalence of fatigue of 27% in 
ambulatory Australians 60 years of age and over.80 Studies81,82,83 in other 
populations report prevalence from 10-25%, with marked cross-cultural variability.84  
Fatigue syndromes lie along a continuum of severity, from ubiquitous transient and 
mild states to the more severe and prolonged fatigue disorders, including chronic 
fatigue syndrome (CFS).  If fatigue is prolonged beyond six months, is disabling, and 
is accompanied by other characteristic constitutional and neuropsychiatric 
symptoms, then a diagnosis of CFS should be considered.79  Because the 
measurement of fatigue is usually based on subjective assessment, there can be 
considerable confusion in the minds of both patients and practitioners about how to 
define a particular patient’s condition even when it has been longstanding.  Is it 
simple fatigue caused by a medical condition, is it chronic fatigue which has been 
present over an extended period or is it the more complex CFS? 
Chronic Fatigue and CFS can be difficult to distinguish from neuropsychiatric 
syndromes and as such may confound studies on fatigue.85 Somatoform disorders 
wherein no physical cause can be found for a symptom, anxiety disorders and major 
depression can all contribute to fatigue.  Fatigue is often found in association with 
sleep apnea86 and with a muscle-related condition, fibromyalgia.87  A 2007 Canadian 
Consensus document88 reveals the complexity of the diagnostic process required to 
classify an individual with CFS, now more frequently described as ME/CFS to 
incorporate its Myalgic Encephalomyelitis aspects.   
The Canadian document classifies ME/CFS as “an acquired organic, 
pathophysiological, multi-systemic illness that occurs in both sporadic and epidemic 
forms (ICD10 G93.3)89 and stresses that ME/CFS must not be confused with 
‘chronic fatigue’ because ME/CFS represents pathophysiological exhaustion and is 
only one of many symptoms.  Other symptoms include post-exertional malaise, sleep 
dysfunction, autonomic, neuroendocrine and immune manifestations.  This situation 
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is made worse because there are no precise or validated diagnostic tests for this 
condition.  CFS is usually made on the basis of a diagnosis of exclusion.90   
The cause of chronic fatigue in apparently healthy individuals may not always be 
determined, even after established etiological factors such as lifestyle behaviours, 
anaemia, thyroid abnormalities and other medical conditions are excluded.  A high 
rate of co-morbidity with psychological disorders (most often anxiety and depression) 
has been noted91 but there still remains a significant percentage of fatigued 
individuals for whom there is no known somatic or psychological cause.92  About 
one-third of this group could be classified as experiencing chronic unexplained 
fatigue and thereby meeting the formal criteria for classification under WHO’s ICD-10 
as F48.0 neurasthenia.93   
2.5.1 The Potential for Oxidative Stress to be Associated with Chronic Fatigue    
Oxidative stress has been demonstrated to underpin a range of human illnesses and 
is the result of an imbalance between exogenously and endogenously-generated 
free radicals and the body’s defences.94,95,96,97,98  When the body is unable to 
adequately contain the adverse effects of free radical activity leading to redox 
imbalance, the result is oxidative stress.99  Not all free radical activity is responsible 
for adverse effects and indeed much of the body’s free radical activity is an essential 
component of a healthy immune response100 and with healthy cellular function in 
general.101,102  Free radicals are also an integral part of the signal transduction 
pathways which allow intra and inter-cell communication.103  
CFS has been associated with oxidative stress but there is little reference to the 
possible association of oxidative stress with uncomplicated but unexplained chronic 
fatigue.104,105,106  
2.5.2   Putative Mechanism - Effect of SOD/Gliadin on Superoxide Dismutase 
Activity  
SOD/gliadin has been developed to deliver SOD as an oral treatment to human cells.   
The data below is taken from a patent-holder sponsored proof-of-concept study18 
designed to show the effect of SOD/gliadin in mice.  The study compared the effects 
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of free SOD, free gliadin and the combined SOD/gliadin compound, GliSODin®, on 
blood levels of SOD.    
Figure 2.2   Effect of a supplementation with SOD/gliadin (GliSODin™) on circulating 
SOD activity. 
Only the SOD/gliadin compound was shown to increase SOD activity; maximal activity occurred within 
14 days with a slower increase thereafter for a total of 28 days. 
The same study measured the 
effects of supplementing the 
animals with only SOD/gliadin 
for a 28-day period and 
measured erythrocyte levels of 
the endogenous antioxidant 
enzymes SOD, GPx and Cat.  
As shown in Figure 10 of the 
Vouldoukis study below (and 
as Table 2.1 here), there were 
increases in Total Antioxidants, 
SOD, GPx and Cat. 
 
 
 
 
 
 
 
 
Table 2.1    Effect of SOD/gliadin on erythrocyte changes to antioxidant levels 
in mice. 
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2.6 The Role of SOD-mimetic Drugs in Human Pathophysiology 
Another avenue in therapeutics has been the exploration of SOD-mimetic drugs.  
Studies using SOD-mimetics as investigational drugs107,108,109 are helpful in gaining a 
better understanding of the role of SOD enzyme in human systems.  The use of 
SOD-mimetics illustrates the diverse application of SOD in a broad range of 
pathophysiological states.  SOD/gliadin differs from the SOD-mimetics in that it is 
manufactured from a plant extract,17 whereas the SOD-mimetics are synthetic and 
are structurally unrelated to those found in nature.  Research107,110 into the SOD-
mimetics provides some evidence of the clinical effects of increased levels of SOD in 
cells.  These findings may lend some support to the design of trials in which 
SOD/gliadin is the intervention compound. 
Acting nutrigenomically, SOD/gliadin provides a new class of antioxidant intervention 
tool for application in conditions related to oxidative stress.  By inducing the cell’s 
own antioxidant enzyme synthesis, it has the potential to quench free radicals such 
as superoxide much earlier in the process and before the cascade of free radical 
activity is well-established.  Where membrane-bound diet-derived lipophilic 
antioxidants such as vitamin E and β-carotene can act only when free radicals are in 
proximity to the membrane, antioxidant enzymes exist in several forms located 
throughout the cell and its organelles.  MnSOD is located in the mitochondria and is 
considered to offer significant protection against the continuously-generated 
superoxide anion radical.  A number of studies111,112,113,114 related to the secondary 
complications of diabetes refer to the role of MnSOD overexpression as a positive 
intervention in controlling the progression of such complications. 
In summary, SOD/gliadin is a nutraceutical material derived from Cucumis melo LC 
and bound to gliadin. Each nutrigenomically-active capsule provides 250 U SOD 
activity in an orally-bioavailable form, protected from digestive degradation by 
biopolymers of gliadin. 
2.7 Hypothetical Construct for the Study   
As described in 1.1, it is known that endogenous synthesis of the antioxidant 
enzymes, SOD, GPx and Cat declines with increasing age and with illness.22  It is 
also known that production of the free radical superoxide increases with age, illness 
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and various environmental conditions.115  As an individual ages, these opposing 
effects contribute to greater likelihood for the development of redox-related 
conditions. 
SOD is the primary human endogenously-synthesised antioxidant enzyme 
quenching the free radical superoxide anion.  It is well understood that free radical 
injury plays a role in all types of cellular damage and is implicated in many diseases, 
including cardiovascular disease, type 2 diabetes (T2DM) and cancer.  SOD exists in 
three main forms, a cytosolic form which uses copper and zinc at its active site, a 
mitochondrial form which uses manganese at its active site (MnSOD) and an 
extracellular form which also uses copper and zinc for its activity.  
It appeared that there existed sufficient biochemical evidence to suggest that the 
SOD/gliadin intervention may ameliorate subjective feelings of fatigue and change 
biomarkers indicated by earlier research. 
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CHAPTER 3 
The ‘Fatigue’ Study 
Effects of a Gliadin-combined Plant Superoxide Dismutase Extract on Self-
Perceived Fatigue in Women aged 50-65 years. 
 
This chapter was published in Phytomedicine (Elsevier) as an original investigation. 
The abbreviations and referencing style of this document have been altered slightly 
to more closely reflect the formatting of other chapters and published work in this 
thesis.   
A pdf version of the published manuscript is attached as Appendix A. 
 
 
Effects of a gliadin-combined plant superoxide dismutase extract on self-perceived 
fatigue in women aged 50-65 years. Phytomedicine. 2011 Apr 15;18(6):521-6  
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3.0 Abstract  
Fatigue syndromes exist on a continuum of severity from mild and transient to the 
disabling Chronic Fatigue Syndrome, with oxidative stress linked to its pathogenesis. 
A thermolabile gliadin-combined plant SOD extract has shown potential in clinical 
trials as a therapeutic antioxidant. This study investigated the effects of 12 weeks of 
500 mg/day of a SOD/gliadin supplement on fatigue. Thirty-eight women aged 50-65 
years with self-perceived fatigue entered this randomised, double-blind, placebo-
controlled trial. The primary outcome measure was general fatigue determined by the 
Multidimensional Fatigue Inventory (MFI). Secondary outcome measures included 
other measures of fatigue from the MFI and blood measures of oxidative stress, 
antioxidant status and hormones. There were no significant (P>0.05) differences 
between, or within groups, for decreases in general fatigue (active = 1.6%, placebo = 
4.1%). There were no within or between group differences (P>0.05) in other 
measures of fatigue (physical fatigue, reduced activity, reduced motivation, mental 
fatigue and total fatigue score). In regard to the biochemical measures, there were 
non-significant (P>0.05) differences in increases in plasma SOD activity 
(active=7.1%, placebo=12.2%), plasma GPx activity (active=2.4%, placebo=0.7%), 
red blood cell GPx activity (active=9.8%, placebo=4.4%).  Markers of oxidative stress 
were decreased but there were no differences (P>0.05) within or between groups; 
malondialdehyde (active=4.1%, placebo=1.6%), F-2 isoprostanes (active=14.7%, 
placebo=22.4%).  There was a trend (P=0.08) for a decrease in cortisol in the active 
group (24.6%), however this was not significantly different from the decrease in the 
placebo participants (4.1%). DHEA differences were not significant (P<0.05) and 
declined 1.3% in the active group and 14.4% in the placebo group.  In summary, the 
thermolabile SOD/gliadin supplement had no significant effect on self-perceived 
fatigue, antioxidants, oxidative stress or hormones in women aged 50-65 years. 
3.1 Introduction  
Fatigue is a complaint commonly presenting to primary care practitioners. It can be 
defined as a pervasive sense of tiredness or lack of energy that is not related 
exclusively to exertion. It has been estimated that there is an overall prevalence of 
fatigue of 27% in ambulatory Australians 60 years of age and over.80 The cause of 
fatigue in apparently healthy individuals may not always be determined, even after 
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established etiological factors are excluded.  A high rate of co-morbidity with 
psychological disorders (most often anxiety and depression) has been noted 91 but 
there still remains a significant percentage of fatigued individuals for whom there is 
no known somatic or psychological cause.92  Fatigue syndromes lie along a 
continuum of severity, from ubiquitous transient and mild states to the more severe 
and prolonged fatigue disorders, including CFS characterised in part by disabling 
fatigue prolonged beyond six months. 
Oxidative stress is defined as a disturbance in the balance between the production of 
reactive species (e.g. free radicals) and  antioxidant  defences,  which  may  lead  to  
tissue injury.116  CFS has been associated with oxidative stress104 but little work has 
been done on the possible association of oxidative stress with milder forms of 
uncomplicated but unexplained fatigue.  Although classical dietary antioxidants have 
been trialled extensively as therapeutic agents for fatigue, the results are 
conflicting.117,118,119 
Catalytic endogenous enzyme antioxidants such as SOD have a greater capacity to 
quench free radicals than the classical dietary or supplemental antioxidants.120, 6,121  
An orally-active SOD, derived from a combination of melon (Cucumis melo LC) and 
polymers of gliadin from wheat (Triticum vulgare) (SOD/gliadin) has shown promise 
as a novel means of inducing antioxidant enzyme activity (SOD, Glutathione 
peroxidase and Catalase) in human cells.122 
The gliadin-combined SOD preparation is a water-dispersible form of a SOD 
lyophilised extract from melon, spray-dried using maltodextrin as a support 
(Vouldoukis et al.2004b).  The gliadin biopolymer is used to firstly protect the enzyme 
against gastric proteolysis and secondly it exhibits bio-adhesive properties when in 
contact with the intestinal mucosa to improve and/or promote the delivery of the 
active ingredient.123 
The antioxidant and anti-inflammatory activities of SOD combined with a gliadin 
polymer have been demonstrated in animal and human trials, producing positive 
biochemical and clinical outcomes.17  In healthy volunteers, SOD/gliadin showed 
protection against DNA strand break induced by hyperbaric oxygen.19  The same 
research group later showed that 14 days pre-treatment with SOD/gliadin before 
aortic cross-clamping to simulate surgery, prevented the oxidative stress 
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characteristics of ischaemia/reperfusion.54   A recent study using restraint-stressed 
mice showed that SOD/gliadin prevented stress-induced impairment of cognitive 
function, decreased lipid peroxidation and maintained neurogenesis in the 
hippocampus.124  Furthermore, a double-blind placebo-controlled study using 
SOD/gliadin in metabolic syndrome patients following the Lyon Heart Diet showed 
that intima medial thickening regressed over a 2-year period.19 
Given that SOD/gliadin has shown positive responses and that oxidative stress may 
be associated with fatigue as it is with CFS, the aim of this study was to evaluate the 
effects of the supplement in reducing levels of fatigue in otherwise healthy women 
aged between 50 and 65 years who self-reported fatigue.  It was hypothesised that 
the encapsulated SOD/gliadin would decrease the perceived fatigue in these 
individuals.  
3.2 Materials and Methods 
3.2.1 Study Design 
A single-centre, randomised, double-blind, placebo-controlled trial was conducted 
with approval from the Ethics Committees of The University of Queensland and the 
Endeavour College of Natural Health. 
 3.2.2 Participants 
The participants were recruited in Brisbane, Queensland, Australia through 
newspaper advertisements.  Respondents underwent an initial telephone screening 
via non-structured questions to determine eligibility and severity of fatigue. Inclusion 
criteria were: women aged 50-65 years of age (inclusive) with longstanding (6 
months or more) unexplained fatigue. This was defined as fatigue to which a medical 
cause (e.g. CFS) had not been assigned. Participants needed a history of generally 
good health and be able to attend fortnightly assessments over a 12-week period.  
They were ineligible if any of the following exclusion criteria applied: Coeliac Disease 
or known gluten sensitivity, presence of any serious disease or condition or limited 
life expectancy of < 1 year due to pre-existing malignancy or other disease, 
depression according to the PHQ-9 nine item depression scale Questionnaire PHQ-9 
Depression Rating Scale during screening,125 history of alcohol or drug abuse, 
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primary sleep or movement disorders, recent history of anaemia, history of thyroid 
dysfunction, currently enrolled in another investigational study, unlikely to comply 
with study requirements, following a particular dietary pattern considered to be 
extreme or unbalanced, have had investigational drugs used for diagnosis or 
evaluation of health status during preceding 30 days, currently supplementing with 
antioxidants or has supplemented with antioxidants for at least 4 weeks in the 
previous 3 months or not in a position to obtain adequate sleep (7-8 hours), such as 
shift workers.  Where the women were also taking prescribed medication, they were 
included as long as the condition for which the medication had been prescribed had 
stabilised over time.     
The trial was conducted at the Clinic of the Endeavour College of Natural Health 
Clinic in Brisbane, Australia.  Two female clinicians experienced in the practice of 
Nutritional Medicine made all contact with the participants at these premises over 
seven fortnightly sessions. 
At the first meeting, the subjects were given information relating to the nature of the 
trial and its goals as well as the nature of the supplement they may be randomised to 
take.  Informed consent was obtained from each participant, anthropometric baseline 
measurements (height and weight) were taken and instructions for baseline collection 
of blood samples provided. In addition, further information regarding medical history, 
medications, menstrual status and whether the fatigue appeared to be related to 
onset of menopause was collected by individual interview. The survey asked 
participants to rate aspects of their fatigue and its effect on daily life on a Yes/No 
basis as a means of ensuring that subjects were not experiencing fatigue so 
debilitating that they were unable to perform normal daily activities.  Women were 
considered to be menopausal if they had finished their last menstruation at least 12 
months prior to enrolment in the study. 
3.2.3 Intervention 
Subjects were randomised to receive either 500mg/day of the SOD/gliadin 
supplement, or placebo, as 2 x 250 mg capsules per day.  The SOD/gliadin was 
encapsulated in a hard shell 2-piece vegetable cellulose capsule with maltodextrin as 
the excipient.   The placebo capsule appeared identical to the intervention capsule 
and contained only maltodextrin.  At the first group session, the participants were 
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issued with sufficient capsules for the 12-week trial period plus a small overage 
allowance (180 capsules supplied, 168 required). Compliance was monitored by 
counting unused tablets after completion of the trial. 
3.2.4 Randomisation and Concealment 
Randomisation was achieved using a computer-generated random number 
sequence at the Launceston General Hospital Pharmacy, Tasmania, Australia.  The 
randomisation sequence and trial codes were stored by the Hospital. Neither the 
participants nor the personnel implementing the trial had access to any un-blinded 
data until the code was revealed at the completion of all data collection.   
3.3 SOD/Gliadin 
Each capsule was specified as containing 3.11mg lyophilised orally-bioavailable and 
water-dispersible SOD derived from the fruit of Cucumis melo LC (melon) 
standardised to 90 IU/mg combined with a 40% hydro-alcoholic soft gel of gliadin (7.9 
mg per capsule).  The melon-gliadin combination is spray-dried using maltodextrin as 
a support and ratio adjusted to obtain a theoretical activity of 1 IU/mg of final dry 
powder (7.9 mg gliadin).18  Individuals with gluten intolerance were excluded from the 
study even though this amount of gliadin is unlikely to trigger a coeliac-like 
response.126 The product has been shown to exhibit no acute or chronic toxicity at 
doses up to 2000 mg/kg in rat studies performed by Laboratoires Lavipharm in Les 
Oncins, France in January 1999.127,128  Gliadin, a vegetable prolamine (biopolymer), 
protects SOD from gastric juices, delays release of the compound in the small 
intestine, and eases its passage into the bloodstream through the mucosa.  The SOD 
activity of the SOD/gliadin combination had been certified prior to randomisation 
using a specific enzymatic assay.129 The capsules (both active and placebo) were 
manufactured by BTT Synerlab, a division of the Synerlab Group, Erstein 67150, 
France. 
3.4 Outcome Measures 
The primary outcome measure was general fatigue determined by the MFI that was 
repeated at 2-week intervals throughout the 12-week period.  The developer of the 
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MFI recommends that for a single measure of non-specific fatigue, the score for 
General Fatigue only should be the main consideration.130 
Secondary outcome measures included other measures from the MFI; Physical 
Fatigue, Reduced Activity, Reduced Motivation, Mental Fatigue and Total Fatigue 
(assessed every two weeks). In addition, blood was collected at approximately 8am 
at baseline, six and twelve weeks and plasma was analysed for measures of 
oxidative stress (malondialdehyde; MDA and F2-isoprostanes), antioxidant status 
(SOD and glutathione peroxidase (GPx) activity, total antioxidant status) and 
hormones (dehydroepiandrosterone DHEA and cortisol).   
3.4.1 Multidimensional Fatigue Inventory (MFI)   
The MFI instrument consists of 20 questions that ask respondents to rate aspects of 
fatigue on a scale of 1 to 5.  The responses are then tallied according to a scale, 
which classifies the fatigue into 5 categories. It was developed using populations of 
both healthy and unhealthy people across a range of age groups.  The MFI has been 
validated in more than 1000 individuals, including cancer patients receiving 
radiotherapy, CFS patients, psychology students, medical students, army recruits 
and junior physicians.131  
3.4.2 Oxidative Stress 
High performance liquid chromatography (HPLC) was used to determine plasma 
MDA using a modification of the method of Sim.132 The principle is that MDA in 
plasma is derivatised with 2,4-di-nitrophenylhydrazine (DNPH), which forms stable 
hydrazones that can be easily separated by HPLC and detected with diode array 
detection (Shimadzu, Kyoto, Japan). F2-isoprostanes were quantified using stable 
isotope dilution capillary gas chromatography/electron capture negative ionisation 
mass spectrometry with slight modifications to the method of Mori et al.133 
3.4.3 Antioxidants 
Plasma SOD activity was quantified by a modified method of Madesh and 
Balasubramanian134 that measures the ability of the enzyme to inhibit reduction of a 
tetrazolium dye. Inhibition is calculated based on the absorbances of two blanks (0 
and 100% superoxide production – corresponding to 100 and 0% inhibition 
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respectively). Glutathione peroxidase (GPx) activity was measured via the oxidation 
of NADPH to NADP2+, according to the method of Wheeler et al.135 One unit of GPx 
activity was defined as 1 Kmol NADPH oxidised per minute. The total antioxidant 
status (TAS) of the plasma was measured using the method of Miller et al.136 The 
method uses the radical cation ABTS·+ that absorbs at 600 nm. The higher the 
antioxidant status of the plasma, the greater the quenching of the compound. The 
concentration of TAS in the plasma was calculated as the mean gradient of the 
absorbance (relative to trolox standards). All assays were adapted for use on an 
automated spectrophotometer (Cobas, Mira, Roche Diagnostics, Switzerland) and 
measured in duplicate. In our laboratory, the coefficients of variation for the SOD, 
GPx and TAS assays are 7%, 4% and 3% respectively. 
3.4.4 Hormones   
Serum cortisol was assayed with the ADVIA Centaur test, which is based on a 
competitive immunoassay using direct chemiluminescent technology.  Similarly, 
serum DHEA-S was measured using the Immulite 2000 solid-phase 
chemiluminescent enzyme immunoassay. Both tests were supplied by Siemens 
Healthcare Diagnostics. 
3.5 Adverse Events 
Adverse events were recorded at each fortnightly meeting with the investigators.  
3.6 Determination of Sample Size 
To observe a 95% chance of detecting a 2-point difference between the two groups 
in the mean MFI perceived General Fatigue Score (at the 2-sided 5% level) with an 
assumed standard deviation of 8 and a loss to follow-up of 20%, 20 women in each 
group (40 in total) were required.    
3.7 Statistical Analysis 
Data were first tested for normality using the Shapiro-Wilk normality test. The 
student’s t-test for dependent samples was used to compare baseline data. General 
linear model two-way (group x time) repeated measures ANOVAs with student t-test 
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post-hoc tests were used to assess the outcome measures. Two-sided significance 
tests were used throughout. A p-value of ≤ 0.05 was considered significant. 
3.8 Results 
Participant flow is shown in Figure 3.1. Forty-nine telephone respondents were 
interviewed. Seven were not eligible (based on inclusion and exclusion criteria), one 
was withdrawn due to an inability of the phlebotomist to obtain blood on two 
occasions, one withdrew after the first session and one was subsequently excluded 
after selection, due to admitting concealing information relating to current treatment 
for a serious illness. Table 3.1 shows there were no significant (P>0.05) differences 
between groups in age, body mass, body mass index, menopausal status and 
number of patients taking anti-hypertensive, anti-depressant or hormone replacement 
therapy.  
Compliance was 89% for the active group and 92% for the placebo group.  There 
were no adverse events reported by any of the women throughout the trial.   
There were no significant (P>0.05) changes within or between groups for the primary 
outcome measure; general fatigue (Figure 3.1). There was a trend for a decrease in 
the fatigue score in the placebo group from baseline to week 12 (P= 0.06).   
Table 3.2 presents secondary outcomes’ data. There were no within or between 
group differences (P>0.05) in other measures of fatigue (physical fatigue, reduced 
activity, reduced motivation, mental fatigue and total fatigue score). For the 
biochemical measures, there were no significant (P>0.05) differences in increases in 
plasma SOD activity, plasma GPx activity, red blood cell GPx activity, or total 
antioxidant status.  Markers of oxidative stress (malondialdehyde, F2 -isoprostanes) 
were decreased in both groups but there were no significant (P>0.05) differences 
within or between groups.   
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Figure 3.1:   Fatigue Study; Participant flow through the study 
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Table 3.1.    Fatigue Study; Participant characteristics. Mean ± SD 
 
Active Placebo 
n=19 n=19 
Age (years) 56 ± 4.6 56 ± 4.3 
Body Mass (kg) 70.9 ± 14.5 71.0 ± 12.5 
Body Mass Index 27.0 ± 5.9 27.0 ± 5.4 
Pre-Menopausal n (%)  2 (11%) 1 (5%) 
Menopausal n (%) 7 (36.8%) 7 (36.8%) 
Post-Menopausal n (%) 10 (53%) 11 (58%) 
Medication  - Anti-hypertensive  n (%) 2 (11%) 2 (11%) 
Medication - Anti-depressant   n (%) 1 (5%) 4 (21%) 
Medication - HRT   n (%) 4 (21%) 3 (16%) 
 
 
 
 
 
 
 
 
 
Figure 3.2: Changes in general fatigue in active and placebo groups over the twelve 
weeks. Mean +/- SD 
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Table 3.2    Effects of SOD/gliadin supplementation on secondary outcome measures at baseline, and after 6 and 12 weeks of 
supplementation. Mean ± SD. 
 
AU = Arbitrary Units; SOD = Superoxide dismutase; MDA = Malondialdehyde; GPx = Glutathione peroxidase; TAS = Total 
Antioxidant Status; DHEA = Dehydroepiandrosterone.  
 Active Group (n=19) Placebo Group (n=19) 
Baseline 6 weeks 12 weeks Baseline 6 weeks 12 weeks 
General Fatigue (AU) 15.5 ± 2.5 14.8 ± 4.3 13.9 ± 4.2 15.3 ± 2.4 12.2 ± 3.8 11.2 ± 3.6 
Physical Fatigue (AU) 13.7 ± 13.7 13.3 ± 3.8 12.1 ± 4.0 14.3 ± 3.9 12.2 ± 3.8 11.2 ± 3.5 
Reduced Activity (AU) 12.1 ± 4.0 10.1± 3.8 10.3 ± 4.0 11.7 ± 4.6 9.5 ±3.6 8.6 ± 3.3 
Reduced Motivation (AU) 10.8 ± 2.7 9.7 ± 3.6 8.7 ± 3.6 9.7 ± 3.0 8.7 ± 3.5 8.1 ± 2.9 
Mental Fatigue (AU) 14.2 ± 6.2 10.6 ± 4.2 11.2 ± 3.8 12.8 ± 4.3 10.7 ± 4.2 9.8 ± 3.9 
Total Fatigue Score (AU) 66.0 ± 10.7 56.3± 4.4 54.4 ± 16.9 64.1± 13.5 55.2 ± 18.3 50.3 ± 15.2 
Plasma SOD activity (U/L) 2.0 ± 0.6 1.7 ± 0.3 2.2 ± 0.4 1.8 ± 0.3 1.9 ± 0.2 2.0 ± 0.3 
Plasma GPx activity (U/L) 453.2 ± 53.0 465.3±57.7 464.2±59.9 438.5 ± 47.0 450.5 ± 50.4 441.6 ± 50.0 
Red blood cell GPx activity 
(U/g Hb) 
37.7 ± 14.0 40.9 ± 11.8 41.8 ± 13.1 38.9 ± 11.0 40.9 ± 8.9 40.7 ± 8.2 
Plasma TAS (mmol/L) 1.8 ± 0.1 1.8 ± 0.1 1.8 ± 0.1 1.8 ± 0.05 1.8 ± 0.1 1.8 ± 0.1 
Plasma MDA µmol/L 11.7 ± 1.2 12.9 ± 3.3 11.3 ± 3.5 11.6 ± 1.4 13.5 ± 3.2 11.5 ± 2.8 
Plasma F-2 Isoprostanes 
pg/ml 
444.2 ± 107.3 427.7± 92.8 520.4± 122.2 658.5 ± 77.6 436.4 ± 65.1 538.1 ± 111.5 
Plasma Cortisol (ng/ml) 454.2 ± 143.3 421.6± 151.1 364.4± 151.1 499.5 ± 148.1 340.5± 128.0 478.3 ± 160.6 
Plasma DHEA (ng/ml) 1082.1± 612.1 998.9± 443.4 1068.4± 611.3 782.0 ± 372.3 719.5± 346.2 683.3 ± 268.4 
Cortisol/DHEA Ratio 0.42 0.42 0.34 0.64 0.47 0.70 
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3.9 Discussion 
Twelve weeks’ supplementation with a gliadin-combined plant SOD extract had 
no effect on general fatigue in women aged 50-65 years with longstanding 
unexplained fatigue. There was a trend (P=0.08) for the supplement to lower 
cortisol (24.4% decrease). There were no effects on plasma SOD activity or other 
antioxidants. In addition, the supplement did not significantly lower oxidative 
stress or change DHEA. 
The lack of an effect of the SOD/gliadin supplement is in contrast to previous 
studies that have shown positive benefits of an oral SOD supplement.18,19,137 This 
includes protection against DNA damage following exposure to hyperbaric 
oxygen,19 regression of carotid intima medial thickening in metabolic syndrome 
subjects,137 prevention of oxidative stress following ischaemia/reperfusion138 and 
prevention of stress-induced impairment of cognitive function.124  The dosage 
used in these studies was equivalent to that used in our study.  
In two of these studies the SOD/gliadin increased tissue activity of SOD, 
Glutathione peroxidase and Catalase.19,138  However, we failed to find any 
changes in either endogenous antioxidant enzymes or oxidative stress. 
Therefore, a lack of antioxidant effect in our study is a potential explanation for 
the lack of an impact on general fatigue. 
It is possible that the supplement did not have the necessary bioactivity. We did 
not assay the SOD/gliadin capsules for SOD enzyme activity prior to 
randomisation.  SOD/gliadin contains the temperature-sensitive SOD enzyme 
which, when exposed to temperatures greater than 40OC can be irreversibly 
damaged.139 SOD/gliadin has a shelf life of 2 years when stored between 5 and 
25OC.41  Even though assay of an intervention tool is not customary prior to 
commencement of a trial, we do not know whether the capsules were exposed to 
higher temperatures during transit and therefore we cannot be certain that the 
capsules were bioactive at point of distribution to the participants in the study.  
Our findings are in agreement with Zidenberg-Cherr140 who also failed to find an 
effect of an oral SOD supplement. However, they used a form of SOD which was 
degraded by gastric proteolytic enzymes and as such is not likely to increase 
SOD activity. 
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Another possible explanation is that fatigue is not responsive to this intervention.  
Although there were no significant differences in the effects of the SOD/gliadin 
supplement on general fatigue, there was a substantial non-significant (P=0.06) 
4.1% decrease in the placebo group.  This is likely explained by a placebo effect 
although it is surprising that the same was not seen in the active group. It is 
possible that other biases may have been present and not assessed. For 
example, some of the participants were being treated for depression (albeit 
controlled with medication) whilst others reported living in family circumstances 
that caused them considerable anxiety. These incidental findings were not 
systematically recorded during the trial.  It is known that anxiety/depression and 
fatigue can be closely correlated and up to three-quarters of patients with fatigue 
syndromes have co-morbid mood or anxiety disorders.141  If the underlying and 
undiagnosed anxiety is contributing to the observed fatigue, rather than oxidative 
stress, then the supplement would not likely affect this process.  
There was a trend for a decrease in cortisol over the twelve weeks in the active 
group with a non-significant (P<0.08) 24.4% decrease compared to a 4.2% 
decrease in the placebo group. Elevated cortisol levels are associated with 
extreme fatigue.142 An association between CFS and abnormalities of the 
hypothalamo-pituitary-adrenal axis has also been described.143  The non-
significant lowering of cortisol is interesting but more research, perhaps over a 
longer period, would need to further investigate this. 
In summary, supplementation with the thermolabile SOD/gliadin had no effect on 
general fatigue in women aged 50-65 years experiencing fatigue. No adverse 
effects towards the intervention were recorded. The failure of the supplement to 
affect plasma SOD activity or lower oxidative stress implies that there was either 
a lack of antioxidant ability or that fatigue in this population was not related to 
oxidative stress.  
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SECTION TWO 
CHAPTER 4 
Sulforaphane Literature Review 
INTRODUCTION 
The introductory material for this section is supported by two published review 
papers on clinical aspects of SFN.  These publications are separately entitled, 
Sulforaphane: translational research from laboratory bench to clinic144 and 
Sulforaphane and Other Nutrigenomic Nrf2 Activators: Can the Clinician’s 
Expectation be Matched by the Reality?145 
These reviews follow this chapter’s background discussion as Chapters 5 and 6. 
 
4.0 OVERVIEW  
It is 25 years since the identification and isolation of the transcription factor, Nrf2 
(coded by the gene NF-E2-related factor 2) was first described in the scientific 
literature.146  In the ensuing years, Nrf2 has become a focus of active research 
on mechanisms of defence in mammalian cells.147,148,149  The role of Nrf2 in 
human cells is very relevant to the subject matter of this thesis because SFN 
significantly activates Nrf2 and as such has the potential to modulate the 
expression of genes associated with cellular defence.  Figure 4.1 illustrates the 
upward trend in SFN research over the period.   
Nrf2 has been variously described by several researchers as an ‘activator of 
cellular defence mechanisms,’150 ‘the master redox switch’151 and ‘a guardian of 
health span and gatekeeper of species longevity’.152  As a mediator for 
amplification of the mammalian defence system against various stressors, Nrf2 
sits at the interface between our prior understanding of oxidative stress and the 
endogenous mechanisms cells use to deal with it.153   
What is emerging is that diseases known to be underpinned by oxidative stress 
are proving to be more responsive to such amplification of cellular defences via 
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Nrf2 activation than by administration of direct-acting antioxidant 
supplements.154,35   
Figure 4.1   Sulforaphane Research Timeline.   
Sulforaphane research appears to be accelerating, showing that by mid-2017, the number of 
published studies is already ~75% of that for the same period in the previous year. 
4.1 Phytochemicals on the Drug Discovery Path? 
For a phytochemical to be considered as a therapeutic agent, it must be 
evaluated using many of the same tools used in pharmaceutical product 
development.  Whereas a pharmaceutical is typically a single molecule, plants 
are complex multicomponent mixtures, the phytochemical composition of which is 
not constant due to factors which include inherent agricultural and environmental 
variability.155  Of the published SFN research to date, the intervention materials 
are non-standard, with some studies using the pure chemical SFN as the 
intervention material where others use broccoli vegetable or fresh, dried  or 
homogenised broccoli sprouts; therefore comparison of clinical trial outcomes 
becomes more difficult.   
Nevertheless, when working with isolated bioactive phytochemicals and whole 
foods as a source of the same bioactive, the biopharmaceutical processes 
typically used in pharmaceutical development should equally apply.  The LADME 
principles (liberation, absorption, distribution, metabolism, and excretion) 
described in connection with the pharmacokinetics of pharmaceuticals are 
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equally relevant to phytochemicals.156  However, such data is seldom available 
for the more popular phytochemicals used preventively or medicinally.155  A 
comprehensive review on this subject by Pferschy-Wenzig and Bauer155 
highlights the many issues that can be under-appreciated by consumers who 
self-medicate on the basis of limited safety and efficacy data. 
The literature for SFN indicates that many researchers have addressed the 
various LADME principles, thereby producing a more extensive database that is 
useful for interpreting the dose-response. 
4.2 Pleiotropic Effects of SFN 
Although SFN is most often considered for its Nrf2-dependent effects, largely 
associated with the induction of antioxidant and Phase 2 detoxification enzymes, 
other less well-characterised mechanisms are associated with this lipophilic, low 
molecular weight pleiotropic phytochemical molecule.  The Nrf2-independent 
mechanisms include but are not limited to the induction of apoptotic pathways, 
suppression of cell cycle progression, inhibition of angiogenesis and anti-
inflammatory activity and inhibition of metastasis, primarily relevant to cancer.157   
One such effect is its action as a Histone Deacetylase Inhibitor (HDAC)158,159 and 
there is a growing focus on the role of SFN and other phytochemicals on such 
epigenetic effects160,161 and more recently on the role of SFN as an inhibitor of 
microRNAs.162 Epigenetic effects are of particular clinical interest in that such 
changes are potentially reversible and thereby may provide an opportunity for 
intervention in earlier stages of the cancer process.163  Tumour suppressor genes 
may be epigenetically inhibited so that therapies aimed at removing such 
suppression are attractive options, especially if they can be available through 
dietary means. 
No discussion of SFN and Nrf2 would be complete without reference to the fact 
that both Nrf2 activators and Nrf2 inhibitors can be utilised in cancer therapy.  A 
very recent paper164 highlights this dual role and its implications for Nrf2 
activation. It suggests that because Nrf2 can modulate the detoxification 
pathways, its effect on anti-cancer drugs may lead to chemoresistance and that 
the switch between a beneficial and a detrimental role for Nrf2 in cancer cells 
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depends on a number of factors which include the tight control of its activity. This 
poses an obvious dilemma which is already under active discussion and 
investigation165-167; SFN and other phytochemicals capable of modulating Nrf2 
form part of such investigation.164 
4.3 History and Evolution of Sulforaphane Research  
Interest in SFN as a food-derived compound with significant clinical potential 
began in 1992 when a group at Johns Hopkins University published its findings.27  
It appeared that SFN was capable of activating a cytoplasmic transcription factor, 
Nrf2 which in turn translocated to the nucleus to activate the Antioxidant 
Response Element (ARE) in the promoter region of several hundred identified 
genes,13,168,169,170 many of which are related to cellular defence processes.  
Interestingly, SFN was identified here as a potent activator of cellular defence 
mechanisms approximately two years before the isolation of Nrf2.27,146   
Of the earlier studies, the potential for SFN to intervene in the prevention and/or 
treatment of cancer through several relevant mechanism gained most 
attention.151,171  As SFN research has continued and laboratory techniques have 
become more sophisticated and widely-available, it has become apparent that 
this molecule exerts its actions at the level of several of the most fundamental 
disease-causing biochemical processes.151  Its mechanism would appear to have 
clinical implications for chronic disease in general and in this context, SFN has 
been shown to inhibit endothelial dysfunction172,173,174 and other aspects of 
cardiovascular and endocrine174 function.  As endothelial dysfunction 
compromises normal function of the circulatory system, it has the potential to 
contribute to chronic disease in general. 
4.3.1 Development of Sulforaphane Analogues 
Initially, the research focused on SFN itself but as this evolved, SFN 
analogues175,176,177 were being developed and investigated for their biochemical 
and clinical effects.   Interestingly however, attempts to develop synthetic 
analogues have failed to produce compounds with any greater potency and 
pleiotropy than SFN itself.178  Some analogues have demonstrated greater 
  
                                                                                                          
 
Page 36 of 308 
 
effects in particular aspects under investigation but none has been shown to 
replicate all the properties of plant-derived SFN.   
Nevertheless, pharmaceutical research has resulted in molecules capable of 
more potently mimicking some of the actions of SFN.  A pharmaceutical, 
Bardoxolone methyl,179 discussed in context in Chapters 6 and 7 is capable of 
activating the same transcription factor, Nrf2 as SFN but is many times more 
potent in this action. 
4.3.2 Broccoli Sprout vs Vegetable 
In addition to their findings that SFN is a powerful inducer of endogenous 
antioxidant enzymes and Phase 2 detoxification enzymes,28 the Johns Hopkins 
group found that the 3-day germinated broccoli seed contained 10-100 times 
more of the bioactive precursor glucoraphanin than the mature broccoli 
vegetable.169  It was this finding that enabled the design of trials which could 
achieve clinically-relevant SFN effects with small practical doses of dried broccoli 
sprouts. 
Of all vegetables, the cruciferous vegetables are the ones for which most 
evidence exists for a cancer-preventive effect.180  Early research on SFN focused 
on its potential in prevention and to a lesser extent as therapy against cancer.  
Several of the effects of SFN are directly related to the initiation and progression 
of the cancer process but as described above, Nrf2 activation is only one aspect 
of SFN’s pleiotropic role in this context.157   
4.4 Sulforaphane – Structure, Properties and Mechanism of Action 
The structure of this small lipophilic molecule (M.W. 177.29), confers upon SFN 
some unique advantages not afforded other phytochemicals such as the 
polyphenols which are structurally large and essentially hydrophilic.181  One of 
the major advantages for SFN is its higher bioavailability which is a consequence 
of its structure (Figure 4.2) 
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4.4.1 Bioavailability 
SFN has been demonstrated as having an absolute bioavailability of around 
80%182 and has been shown to peak in the bloodstream around 1 hour following 
ingestion.183 By comparison, the polyphenols typically exhibit bioavailability184 at 
around 1-8%.  SFN can therefore be considered as having at least one of the key 
properties necessary to be considered for development as a nutraceutical 
compound. 
4.5 The SFN-Nrf2 Relationship 
The essence of a very complex biochemical process147 is that in its basal state, 
Nrf2 is sequestered to Kelch-like ECH-associated protein 1 (Keap-1) and 
associated with cytosolic actin filaments; however, when Keap-1 detects a 
stressor which may threaten the cell’s integrity, activation of the complex leads to 
a dissociation of Nrf2 from Keap-1.185  Hereafter, it translocates to the nucleus 
where it  may induce expression of its many target genes, aligning with the ARE 
in the promoter region of these genes.  The ARE is a cis-acting enhancer 
sequence that is upstream of many Phase 2 detoxification and antioxidant 
genes.33  (Figure 4.3) 
Loss of the Nrf2-ARE function in mice has been shown to increase 
susceptibility186 to acute toxicity, inflammation and carcinogenesis due to the 
inability to mount adaptive responses. The elucidation of this process showed 
that activation of Nrf2-ARE induces a large battery of cytoprotective enzymes.187 
 
 
 
Figure 4.2   Sulforaphane (C6H11NOS2) – molecular structure of sulforaphane 
(4-methylsulfinylbutyl isothiocyanate)  
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Cellular Nrf2 levels are under strict control by multiple mechanisms but the best-
characterised is the one which is mediated by interaction with (Keap-1.)188  Keap-
1 not only binds Nrf2 to actin filaments in the basal state but it also acts a sensor, 
especially of subtle redox changes in the cell.  Very recently, it has been reported 
that the regulation of Keap-1/Nrf2/ARE is more complex than previously thought, 
with other mechanisms including epigenetic regulation of Nrf2 now known to be 
involved.149 
The chemistry of sulfur plays an integral role in Nrf2 activation and subsequent 
modulation of gene expression.  All Nrf2 activators react with thiol groups.  Keap-
1 is rich in sulfur-rich cysteine residues187 and is under oxidation-reduction (and 
alkylation) control via its highly reactive thiol groups.  
 
 
 
 
 
 
 
 
Figure 4.3   Mechanism by which an inducer affects expression of Phase 2 
detoxification genes 
An inducer such as SFN activates the Nrf2-Keap-1 complex, with sulfur chemistry playing an 
important role.  The presence of sulfur in Keap-1 and Nrf2 inducers is illustrated.187 
4.5.1 The Significance of the Nrf2-SFN Relationship 
Nrf2 is ubiquitously expressed with the highest concentrations (in descending 
order) in the kidney, muscle, lung, heart, liver, and brain.146  Because SFN is 
readily-bioavailable, such universal Nrf2 tissue distribution enhances SFN’s 
potential to modulate systemic gene expression.  In this context Nrf2189 has been 
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described as a ‘master switch’ involved in the induction of cytoprotective genes 
by some chemopreventive phytochemicals.   
4.5.2 Multiple Gene Targets and the Nrf2 /ARE Pathway 
It has been suggested that in excess of 500 genes have been identified as being 
activated by sulforaphane via the Nrf2/ARE pathway190,191,192 and it is likely that 
this under-estimates the number as others are being discovered. 
The large battery of upregulated cytoprotective genes includes those coding for 
the endogenous enzyme and non-enzyme antioxidants as well as Phase 2 
detoxification enzymes.168  Nrf2 plays a crucial role in the coordinated induction 
of those genes encoding many stress-responsive and cytoprotective enzymes 
and related proteins.193  These include NAD(P)H:quinone reductase-1 (NQO1), 
haemoxygenase-1 (HO-1), glutamate-cysteine ligase (GCL), glutathione-S-
transferase (GST), glutathione peroxidase (GPX1), thioredoxin (TXN), 
thioredoxin reductase (TXNRD1)189 and PPAR-γ (PPARG).194    
When Zhang and colleagues27 of the Johns Hopkins group had been 
investigating chemoprevention in the early 1990s, they had been working on 
cytoprotective genes including those coding for the Phase 2 detoxification 
enzymes NQO1 and the GST families; the discovery that these genes were 
significantly induced by broccoli sprout-derived SFN provided the foundation for 
the rapid interest in research in this field. 
Of the available SFN clinical trials associated with genes induced via Nrf2 
activation, many demonstrate a linear dose-response (Table 4.1).  More recently, 
it has become apparent that SFN can behave hormetically195 with different effects 
responsive to different doses and this is in addition to its varying effects on 
different cell types as outlined in 4.6. and tabulated in Table 4.2 
4.6 Published Clinical Trials 
At time of writingb there are 1592 published papers which appear in a PubMed 
search using the term, ‘sulforaphane’. However, a limited number of these are for 
clinical trials utilising either fresh or processed broccoli sprouts (Table 5.1 from 
                                            
b August, 2017 
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Chapter 5 and Table 4.1 here).  Not all trials quantitatively specify the bioactive 
content of the intervention material.  As a result, it is difficult to interpret their 
findings in a clinical context.  In considering SFN as a therapeutic intervention, 
some important questions to be asked are; ‘What quantity of starting material is 
needed to achieve a micromolar concentration which generates a significant 
clinical outcome?’  ‘How can a broccoli sprout raw material be produced which 
will be consistent in its composition?’ and ‘Is it possible to produce a broccoli 
sprout raw material that is a practical solution to consumer needs for a SFN-
yielding supplement?’   
4.7 The Clinician’s Dilemma in Applying Clinical Trial Data 
Unlike most of the products categorised by U.S. law as ‘dietary supplements’, the 
sub-groups of products claiming to be ‘nutraceutical supplements’ are typically 
standardised for their bioactivity; this may require that one or more bioactives is 
specified with each batch produced.  Of the various available supplements which 
include a dried broccoli sprout ingredient, the label disclosure is inconsistent; this 
is discussed in some detail later in this chapter and again in Chapters 5 and 6.  A 
consumer or a clinician intending to select an available SFN-yielding supplement 
on the basis of its dose compared with those used in the peer-reviewed 
published clinical trials will have great difficulty in doing so.   
This thesis explores the issues associated with the process of standardising label 
disclosure with a view to clarifying a dose-response relationship that can be 
compared with the currently available SFN clinical trial data.  In evaluating the 
available dose-response evidence, it may be concluded that it is simply too early 
in the process for clinicians to confidently make such recommendations.  Issues 
associated with dose-response considerations are addressed in some depth in 
Chapter 7.   
4.8 Valuable Contributions from Available Clinical Trial Data. 
Table 4.1 lists 33 of the 42 published clinical trials using SFN in a range of forms 
from pure chemical SFN to fresh sprouts, homogenised fresh sprouts and dried 
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sprout powder/capsules.c  These studies have been selected as each contributes 
significantly to the enhancement of our understanding of this phytochemical’s 
potential in human health and disease.  Although dose forms, study populations 
and endpoints are different across the selected trials, a pattern is emerging to 
show that clinical outcomes are achievable in conditions such as asthma196 with 
daily SFN doses of around 18 mg daily and from 27 - 40 mg in type 2 
diabetes.197,198  Positive outcomes were achieved at a lower SFN dose of around 
9-14 mg daily for the autism study by Singh et al.199  Reduction of Prostate 
Specific Antigen (PSA) doubling time after radical prostatectomy may require a 
higher 60 mg daily dose.200 Chapter 7 explores and analyses the dose-responses 
when considering an appropriate SFN dose for the gene expression study 
detailed in Chapter 8. 
                                            
c PubMed accessed 22nd July, 2017 
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Table 4.1   Selected Clinical Studies Investigating a Dose-Response for Sulforaphane, listed chronologically (2013 – 2017) 
The selected trials utilise various forms of intervention to provide a dose of SFN designed to positively affect the chosen endpoint(s).  These studies have 
been published subsequent to our Review paper (Chapter 5) which includes a more comprehensive list of published trials. 
 
Lead Author 
& Year of 
Publication 
Subject 
Number 
Intervention Endpoint Finding Dosage or Clinical Relevance 
Poulton et al. 
(2013)201 
24 
450 μmols SFN (~ 
80 mg) in broccoli 
sprout extract 
CYP3A4 induction 
in relation to drug 
adverse effects via 
the pregnane and 
xenobiotic receptor 
(PXR) 
SFN did not reduce 
CYP3A4 induction 
alone or as co-
treatment in co-
administration with 
drugs. 
A dose of 80 mg is significantly 
higher than available from 
foods or from practical intake 
from supplements. 
Singh; 2014199 44 
9 - 14 mg SFN 
based on body 
weight of a 
stabilised 
sulforaphane 
supplement. 
Validated 
questionnaire-
based disease 
markers for autism 
Positive responses in 
Aberrant Behaviour 
and Social 
Responsiveness.  
Reduced markers of 
redox imbalance and 
inflammation. 
Favourable effects at 18 weeks 
gradually trended towards 
baseline for further 4 weeks.  
Effect may not have plateaued 
at 18 weeks. 
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Lead Author 
& Year of 
Publication 
Subject 
Number 
Intervention Endpoint Finding Dosage or Clinical Relevance 
Egner et al.; 
2014202 
267 
262 mg GRN + 7 
mg SFN with MYR 
from daikon in juice 
Detoxification of 
Atmospheric 
pollutants via 
urinary excretion of 
the mercapturic 
acids of the 
pollutants, 
benzene, acrolein, 
and 
crotonaldehyde. 
Increased levels of 
excreted glutathione-
derived conjugates of 
toxins. 
Benzene-derived mercapturic 
acid was higher in participants 
who were GSTT1-positive than 
in the null genotype.  
Implications for polymorphism 
(SNP) screening in individuals. 
Heber et al.; 
2014203 
29 
18 mg SFN from 
GRN extract + 
daikon MYR in 
mango juice 
Nasal Allergic 
Response. White 
cell count (WBC) 
after exposure to 
diesel exhaust 
particles (DEP). 
85% increased WBC in 
nasal cells 24 hours 
after DEP exposure. 
Potential preventive therapy for 
those exposed to 
environmental inhaled 
toxins/particles. 
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Lead Author 
& Year of 
Publication 
Subject 
Number 
Intervention Endpoint Finding Dosage or Clinical Relevance 
Baier et al; 
2014204 
8 
Claimed to be 18 
mg SFN per gram 
fresh broccoli 
sprouts d at doses of 
34, 68 and 102 g. 
Activation of long 
terminal repeats 
(LTRs) as off target 
effects of SFN  
SFN increased LTRs 
dose-dependently, 
showing peak 10-fold 
increase at higher 
dose. 
May need to use caution with 
higher SFN doses. 
Brown et al.; 
2015203 
45 
18 mg SFN as GRN 
extract + daikon 
MYR in mango juice 
Reduction of 
symptoms in 
moderate asthma; 
redox and 
inflammation 
biomarkers 
SFN reduced airway 
resistance and 
reduced inflammatory 
markers. 
Potential benefit for asthmatics. 
                                            
d The SFN yield claimed by Baier et al is in stark disagreement with those stated by Myzak et al (2006) using the same fresh sprouts (Broccosprouts®).  Refer 
Chapter 7 for related discussion. 
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Lead Author 
& Year of 
Publication 
Subject 
Number 
Intervention Endpoint Finding Dosage or Clinical Relevance 
Cipolla et al.; 
2015200 
78 
60 mg SFN as 
stabilised SFN from 
seed extract 
PSA Doubling 
Time in mean with 
biochemical 
recurrence after 
radical 
prostatectomy 
SFN effects prominent 
after 3 months. PSA 
slopes were 
consistently lower in 
SFN group. 
Potential therapy following 
prostatectomy where PSA 
gradually increases. 
Atwell et al.; 
2015 
54  
SFN not specified. 
GRN supplement  
(180 mg daily). 
Breast Tissue 
Biopsy – presence 
of SFN and its 
mercapturic acid 
metabolites 
No change on breast 
tissue tumour 
biomarkers. SFN 
metabolites present. 
Confirmation of bioavailability 
in tissue of women with 
abnormal mammograms but 
query dose and SFN Yield. 
Doss et 
al.;2016205 
16 
SFN not specified.  
Broccoli sprout 
homogenate  
(50, 100, 150 g). 
Sickle Cell 
Disease – Nrf2 
activation 
Dose-dependent 
increase in Nrf2 target 
genes, NQO1, HBG1 
and HMOX1. 
Nrf2 is not maximally activated 
in sickle cell disease, thereby 
suggesting SFN as a 
therapeutic option. 
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Lead Author 
& Year of 
Publication 
Subject 
Number 
Intervention Endpoint Finding Dosage or Clinical Relevance 
Wise et al; 
2016206,207 
89 
Daily SFN at 4.4 mg 
and 26.6 mg. Whole 
broccoli sprout 
powder, described 
as a broccoli sprout 
extract (BSE). 
COPD – effects on 
two types of 
respiratory cells 
via Nrf2 
No change in Nrf2 
target genes at either 
dose. 
In diseases where Nrf2 is 
expressing maximally as a 
compensatory effect of the 
disease, Nrf2 activators may 
be ineffective. 
Axellson et 
al.;2017 
198(Supplement
ary material) 
97 
Daily SFN of 27 mg 
in a 5-gram powder 
dose. Whole 
broccoli sprout 
powder, described 
as a broccoli sprout 
extract (BSE). 
Type 2 diabetes 
biomarkers. 
Lowered fasting 
glucose, Inhibition of 
hepatic 
gluconeogenesis and 
lowered fatty liver 
index.  No effect in 
well-regulated 
diabetics. No effect on 
insulin resistance. 
Greater effect in patients with 
elevated HOMA-IR and in 
obese patients.  Potential 
treatment for those with poor 
glucose control. 
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4.9 Diversity of Effect of SFN in Various Cell Types. 
Part of the difficulty in the process of establishing an appropriate dose is that in vitro 
evidence clearly shows that effects are tissue-specific and more so, specific to 
different cell lines of the same tissue.  Table 4.2 illustrates this diversity and is also 
included in our published Review paper included in this thesis as Chapter 5.  For 
example, Ritz et al.208 showed that bronchial cells exposed to diesel extract in two 
bronchial cell lines responded differently to the same SFN concentration when 
measuring Nrf2-induced targets.    
Brooks et al.209 used six different prostate cell lines to show the broad diversity in 
effect of SFN.  Here, normal cells produced 1.35-fold induction of NQO1 at 0.1 µM 
SFN and 2.46 at 1 – 3 µM but in a prostate cancer cell line, 10 µM was required to 
produce 4.6-fold induction.  Interestingly, the group showed that simultaneous 
incubation with just 10 nM N-acetyl cysteine (NAC), a direct-acting antioxidant, 
abrogated all effects of SFN.  This may be significant because NAC is available as 
a dietary supplement and has recently been very actively promoted to non-
conventional clinicians who recommend it for a variety of off-label conditions 
associated with mental health.210-216 
An animal in vitro study investigating tissue- and organ-specific effects with SFN 
exposure suggested that there may be a need for prioritizing organs when 
considering the chemopreventive study of SFN.217 
These large variations are more clearly illustrated in Table 4.4 which shows the 
lowest effective SFN dose across a range of cell types and a brief summary of the 
effects. 
As in vitro studies, these data are not directly relevant to the in vivo environment.  
However, the data linking the intracellular SFN concentrations to a measurable 
effect is an important step moving such dose responses closer to prediction of 
clinical responses.  These in vitro findings are also essential in elucidating the 
mechanisms that underpin the observed effects. 
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Table 4.2.  Summary of effects of increasing sensitivity to SFN in different tissues or cell types (ascending order) 
Tissue or Cell Type Brief Summary of Effect  Lowest Effective 
SFN Dose (µM) 
Prostate cells, normal 
and cancer cell lines.209 
SFN increased activity of GSTP1, silenced in prostate 
cancer cells.  Also increased other Phase 2 enzymes in 
normal cells   
0.1 
Neural cortical cells.218 SFN protects against dopamine toxicity 0.1 
Aortic cells.219 Significant dose-dependent induction of Nrf2 target 
cytoprotective genes 
0.25 
Bronchial epithelial 
cells.208  
Upregulates Phase 2 enzymes and downregulates 
inflammatory cytokines 
0.3 
Brain – Substantia nigra 
cells.220 
 Significant increases in GSH and NQO1 at both doses 0 .5 
Bronchial epithelial 
cells.221 
Normal cells  significant increases in Nrf2 targets; no 
effects on cancerous cells 
0.5 
Retinal epithelial cells.222 Linear cytoprotective effects with increasing SFN dose 1.25 
Pancreatic β-cells.223 Protection against cytokine-induced cell death 2.5 
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Endothelial cells - arteries 
and veins.224 
SFN protective against endothelial lipase at lower dose  2.5 µM (arterial) 
10 µM (venous) 
 
Cardiomyocytes.225 Greatest effects with SFN exposure up to 48 hours 5 µM 
Prostate cancer cells.226 Strong Cell Cycle Arrest in Prostate Cancer 10 µM. (No effect at 
<3 µM) 
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4.10 Major Actions of SFN at the Cellular Level 
The major documented cellular actions SFN are listed in the non-exhaustive summary 
shown in Table 4.3 along with commentary on their clinical implications.  These upstream 
processes have significant downstream effects and are associated with the observed 
effects in clinical trials using SFN or a dietary source of SFN. 
 
Table 4.3 Summary of Clinically-Relevant Actions of SFN 
 ACTION CLINICAL IMPLICATIONS 
1. Increases synthesis of 
Glutathione.227 
 
This has implications for oxidative stress 
and detoxification as glutathione is the 
substrate for both pathways.  Glutathione 
is also an antioxidant in its own right. 
2. Inhibits some Phase 1 
detoxification enzymes that 
activate chemical 
carcinogens.228 
This reduces the level of toxic 
intermediates with carcinogenic potential.  
It also allows Phase 2 to ‘keep pace’ with 
Phase 1 processing. 
3. Increases activity of Phase 2 
detoxification enzymes.  
Sulforaphane is considered the 
most potent of the Phase 2 
inducing substances.27 
As a monofunctional inducer, 
sulforaphane is considered to be a 
significant component of the 
anticarcinogenic action of broccoli. 
4. Provides significant antioxidant 
activity, largely due to its ability 
to induce glutathione synthesis. 
Glutathione is a critical factor in 
protecting organisms against toxicity and 
disease.229  The ability of sulforaphane to 
upregulate glutathione synthesis is highly 
significant. 
5. Acts as a Histone Deacetylase 
inhibitor, providing DNA 
protection.230, 231, 232. 
Development of Histone Deacetylase 
inhibitors is a key avenue for cancer drug 
research. 
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6. Induces apoptosis, inhibits 
MMP-2 (metastasis), inhibits 
angiogenesis, cell cycle 
arrest40,158,233, 234 (interacts at 
several levels). 
Therapeutic interventions which exhibit 
several related actions targeting the 
same underlying defect are considered 
highly desirable. 
7. Limits pro-inflammatory effects 
of diesel chemicals by 
upregulation of Phase 2 
enzymes.208 
Environmental pollutants are known to 
contribute to various lung diseases.  
Removal of the toxins reduces tendency 
to disease. 
8. Induces Thioredoxin (Trx) as 
part of the ARE. 
Thioredoxin is implicated in 
cardioprotection by triggering several 
survival proteins.235  Sulforaphane may 
have beneficial effects in cardiovascular 
disease. 
9. Bactericidal against 
Helicobacter pylori and also 
blocks gastric tumour formation 
in animals.236 
Helicobacter is known to contribute to 
development of stomach cancer.  
Elimination of the organism without the 
use of typical antimicrobial Triple Therapy 
could protect the colonic microflora. 
10. Protects dopaminergic cells 
from cytotoxicity and 
subsequent neuronal death 
(cell culture).237 
Dopaminergic neurones are associated 
with Parkinson’s’ Disease.  
Pharmaceuticals to treat Parkinsonism 
are not without risk and the disease is not 
usually detected until more than 50% of 
the neurones have been lost.  A 
chemoprotective tool could prevent 
premature loss. 
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11. Increases p-53 (associated with 
tumour suppression) and bax 
protein expression, thereby 
enhancing cellular protection 
against cancer.238 
Sulforaphane is an attractive 
chemotherapeutic agent for tumours with 
a p53 mutation.157 
12. Limits effect of Aflatoxin on 
Liver Cells.38 
Interventions which can offer significant 
protection against environmental and 
food-borne pollutants could prevent the 
consequences of these factors.  
Appropriate doses of Sulforaphane-
yielding substances are yet to be 
determined. 
13. Enhances Natural Killer Cell 
activity and other markers of 
enhanced immune function.227 
The immune system is a critical part of 
the body’s defences against inflammatory 
as well as infectious diseases.  Most 
diseases benefit from enhancement to 
immune function. 
14. Suppresses NF-kB, a key 
regulator of inflammation.227   
NF-kB expression is 
downregulated by sulforaphane 
and as such downregulates 
inducible pro-inflammatory 
enzymes such as Cyclo-
oxygenase (COX-2) and NO 
synthase (iNOS). 
As an inhibitor of NF-kB as well as an 
activator of Nrf2, SF modulates many 
cancer-related events, including 
susceptibility to carcinogens, cell death, 
cell cycle, angiogenesis, invasion and 
metastasis.227 
 
15. Sulforaphane is not directly 
anti-oxidant.  Instead it exhibits 
a weak pro-oxidant effect.239 
Because sulforaphane is not directly 
antioxidant but exerts its antioxidant 
effect primarily by induction of glutathione 
and other antioxidant compounds, it is 
considered to exhibit an indirect 
antioxidant effect. 
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16. Potent inducer of HO-1, 
Haemoxygenase-1. 
Haemoxygenase-1 plays an important 
role in modulating the effects of oxidants 
in the lungs.240 
 
4.11 Cruciferous Vegetables, Composition and Bioactivity 
Cruciferous vegetables are known to contain high but variable levels of glucosinolates.241  
Glucosinolates (GSN) are not inherently bioactive but become so when enzymatically 
converted to their individual isothiocyanates (ITCs) in a hydrolysis reaction catalysed by 
the enzyme, MYR.242  GSNs found in the Brassica species exhibit their own 
characteristic properties; the broccoli-derived GRN is the best-known precursor to the 
bioactive compound, SFN but not the only one.26  Glucoerucin found in Rocket (Eruca 
sativa Mill) sometimes called ‘arugula’ is also a source of SFN.243 SFN is the ITC derived 
from GRN via a MYR-catalysed hydrolysis reaction.  Minimal quantities of GRN are found 
in several other Brassica species.26 
 
Figure 4.4   Conversion of Glucosinolates to Isothiocyanates in the presence of the 
enzyme, MYR.242    
In a hydrolysis reaction, glucose is cleaved from the glucosinolate and after a rearrangement, the 
ITC is produced.  GRN is the GSN from which SFN is derived. 
4.11.1 Stability of Bioactives and Effects of Cooking 
GSNs are compartmentalised in vacuoles within the plant cell and separated from the 
MYR which catalyses its hydrolysis.  In this way, the GSN remains inactive until the cell 
structure is disrupted.242  When the vegetable is cut, chewed or macerated in any way, 
the enzyme is released from its protective vacuole and immediately reacts with the GSN.  
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Figure 4.5   Effect of ESP on conversion of GRN to 
SFN and SFN Nitrile.1   
 
The resulting product is the bioactive ITC shown in Figure 4.4.  Once produced, the ITC 
is relatively unstable with a half-life of around 1.8 hours in humans.244    
Cooking and especially prolonged cooking denatures the enzyme.245,246  It becomes 
clear that for cruciferous vegetables to retain their bioactivity and maintain their efficacy, 
they must be handled carefully and with thorough understanding of the factors 
associated with their degradation.247,248 
MYR activity from broccoli vegetable has been reported to be thermolabile, with loss of 
approximately 90% activity after only 2 minutes of microwave cooking.246  Boiling and 
microwaving cause an initial loss of the MYR-inhibiting SFN nitrile, with a concomitant 
increase in SFN, followed by loss of SFN, all within 1 minute.249   By contrast, steaming 
enhanced SFN Yield between 1.0 and 3.0 min in some broccoli cultivars.249  
In contrast, it appears that MYR in broccoli sprouts and seeds is much less thermolabile 
than that of the mature vegetable250; nevertheless, the subtle differences in vegetable 
cooking method and times makes it virtually impossible for a consumer to be assured 
that MYR activity has been preserved. 
4.11.2 Effect of a MYR Inhibitor  
To compound the issue of variation in SFN Yield, broccoli seeds and the plants derived 
from them contain a thermolabile MYR inhibitor, Epithiospecifier protein (ESP)251,1 which 
converts a proportion of the GRN to a less active ITC, SFN nitrile (Figure 4.5).   
Measuring only GRN may lead to 
erroneous assumptions regarding the 
expected SFN Yield.   
A detailed knowledge of these 
processes is essential in the 
production of an enzyme-active 
broccoli sprout raw material to be used 
in clinical trials. 
In studies which use fresh or dried 
broccoli sprouts as the intervention, it 
is clearly essential to characterise the product for its SFN Yield and not just its GRN 
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content.  Failure to do so will impede the ability to interpret clinical findings; these issues 
are detailed in Chapter 5. 
4.11.3 Comparative Glucosinolate Quantity of Mature Broccoli vs the Sprout 
SFN is the most potent naturally-occurring monofunctional inducer of Phase 2 
enzymes209 and has been estimated to be around 10 times greater in its inducer activity 
than other GSNs.252  The highest source of SFN Potential has been found in the young 
germinated seedling of certain cultivars of Brassica oleracea italica (broccoli), with as 
much as 10 to100-fold the quantity of GRN per gram than found in the mature 
vegetable.169  
As the seedling matures, its levels of GRN proportionately diminish within the increasing 
plant volume,253 leading to substantial research interest in the young broccoli sprout.  A 
separate line of research has focused on the development of broccoli vegetable with 
higher GRN content; this has been developed by hybridisation and the vegetable has 
been subsequently commercialised.254  Broccoli sprouts as young as 3 days have been 
used to supply GRN in a number of studies and more recently MYR-inert, GRN-
containing extracts of broccoli seeds and sprouts have become commercially-available; 
the clinical relevance of the MYR-active and MYR-inactive forms is discussed in Chapter 
5 and 6. 
4.11.4 Variation in Composition of Glucosinolates in Mature Broccoli vs the Sprout  
GSNs can be classified into a number of chemical classes on the basis of their structural 
similarities.  The most extensively studied GSNs are the aliphatic, ω-methylthioalkyl, 
aromatic and heterocyclic (e.g. indole) forms, typical of those found in the Brassica 
vegetables.255  Individual Brassica plant species contain mixtures of GSN types and 
these vary significantly between and within species.255  Not all GSNs yield 
isothiocyanates with health-promoting properties.256   
The mature broccoli vegetable contains higher levels of a GSN, glucobrassicin which 
generates indole-3-carbinol (I-3-C).  I-3-C as a bifunctional inducer, upregulates Phase 1 
and to a very limited extent Phase 2 detoxification enzymes, whereas SFN as a 
monofunctional inducer, more significantly induces Phase 2 enzymes.257  The sprouted 
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broccoli seed contains high levels of GRN but little to no glucobrassicin, whereas the 
mature plant contains comparatively much less of the SFN precursor, GRN.253   
Significantly, the indoles are virtually absent in the broccoli sprout compared with their 
abundance in the mature vegetable.  More specifically, seeds or young sprouts of 
broccoli (Brassica oleracea var. italica) can contain 70±100 mmol total GSN per gram 
fresh wt., with <1% contributed by indole glucosinolates and the balance consisting 
almost entirely of the aliphatic GSNs, GRN, glucoerucin and glucoiberin.255 
4.11.5 Variability in Glucosinolate and Isothiocyanate Content and Effect 
Broccoli oleracea varieties are known to vary widely in their content of bioactives and 
inhibitor.256  The most commonly-consumed cruciferous vegetable is broccoli, Brassica 
oleracea var. italica.258  Within this classification are further sub-groups known as 
cultivars.  Analysis of the GRN and SFN Yield varies significantly between the 
cultivars.256,259   
A 2003 report showed that only 20% of the GRN in the Marathon cultivar is converted to 
SFN with 80% converting to the inactive sulforaphane nitrile.260  In other cultivars, 
conversion to the inactive SFN nitrile in each case was greater than 50%.251  At 
supermarket level, it is not possible for a consumer (or even the merchant) to make an 
informed choice without knowing what variety or cultivar is being offered. 
Some species contain high levels of other GSNs including the potentially thyrotoxic 
progoitrin which prevents the incorporation of iodine into thyroxine.261  Indole compounds 
such as indole-3-carbinol and 3–acetonitrile are formed from the hydrolysis of indole 
glucosinolates and these have the potential to form mutagenic N-nitroso compounds.262  
However, others suggest that the combined effects of the total GSN composition of a 
whole crucifer may be quite different from that of an isolated compound and that synergy 
has been demonstrated when assessing the effects of such combinations.253 
In considering cruciferous plants as suitable sources of medicinal compounds with 
clinical efficacy, these factors are among the more important to be considered. 
4.12 SFN – Its Potential Clinical Relevance 
4.12.1 Nrf2 and Endogenous Cellular Defence Mechanisms 
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The non-enzyme antioxidant GSH is a major contributor to cellular redox status and the 
rate-limiting enzyme for its synthesis, glutamate-cysteine ligase (coded by the gene GCL) 
can be induced by SFN.263  Antioxidants in general and glutathione in particular can be 
depleted rapidly under conditions of oxidative stress and this can signal inflammatory 
pathways associated with NF-kB.264  Nrf2 has been found to be the primary factor 
inducing the cell’s survival system under GSH depletion.265  Also of interest is the finding 
that Nrf2 transcriptional activity declines with age,266 leading to age-related GSH loss 
among other losses associated with Nrf2-activated genes.  This effect has implications 
too for decline in vascular function with age.267  
Some of the age-related decline in function can be restored with Nrf2 activation by 
SFN.268  Studies in aged mice showed that age-related changes in Th1 immunity could 
be restored using SFN as an intervention. This finding is compatible with the growing 
recognition of the importance of the Nrf2 pathway in innate immunity and has 
implications for human health.269  As Nrf2 targets, other cytoprotective enzymes such as 
HO-1 and Trx are also supportive of cellular redox modulation.  
4.12.2 Phase 1 vs Phase 2 Detoxification Pathways 
As long ago as 1993,171 it was determined that the ideal chemoprotective compounds are 
monofunctional inducers of Phase 2 detoxification enzymes. Monofunctional inducers 
function by upregulating Phase 2 detoxification pathways to metabolise the oxidative and 
carcinogen-activating products of the Phase 1 enzymes, without having any significant 
effect on Phase 1 activity itself.  Toxins presented to the Phase 1 enzymes produce 
intermediate compounds which are sometimes more toxic to cells than the initial toxin.270  
It is therefore important that Phase 2 is sufficiently active that the intermediate products 
cannot accumulate in the cellular environment.  Figure 4.6 illustrates the Phase 1 and 
Phase 2 detoxification pathways.271 The majority of chemical carcinogens require 
metabolic activation before they can initiate cancer.272  
As a monofunctional inducer, SFN has been described as an ideal detoxifier as its effect 
on Phase 1 is minimal compared with its significant activity on Phase 2.273  By 
comparison, many of the most potent of the synthetic SFN analogues274 are bifunctional 
inducers and not the monofunctional inducers having the most chemopreventive effect.  
Several synthetic compounds275 have been investigated for their chemopreventive 
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potential against lung cancer in smokers.175  Human cells are adapted to naturally-
occurring L-sulforaphane; they are not necessarily adapted to synthetic analogues.  
SFN’s role as the most potent inducer of the Phase 2 enzyme NADPH: oxido-reductase 
(NQO1) is discussed in detail in Chapter 6.   
 
Figure 4.6    Interaction of Phase 1 and Phase 2 metabolites in detoxification  
The process of cellular detoxification of both exogenous and endogenous factors entails two phases: 
Phase 1 (oxidative activation reactions), and Phase 2 (conjugative reactions), effected by several large and 
diverse gene families. 276 
 
4.12.3 Significance of Induction of Phase 1 and Phase 2 Detoxification Enzymes 
Not all Brassica-derived compounds are monofunctional inducers.  Indole-3-carbinol (I-3-
C) derived from the mature broccoli vegetable is a bifunctional inducer and as such may 
lead to the generation of highly toxic intermediate compounds which may overwhelm the 
capacity of the localised antioxidants to quench them or the Phase 2 processes to 
detoxify them.277  
By contrast, SFN selectively upregulates Phase 2 detoxification enzymes, minimising the 
risk of generating excessive amounts of reactive intermediates (Figure 4.6).276  As a 
consequence, although some I-3-C animal studies show an anticarcinogenic effect, other 
studies using I-3-C show it to have carcinogenic potential where comparable studies 
using SFN do not.278,279,280  It should be noted that the comparatively small quantity of I-
3-C generated from the GSNs in broccoli vegetable is unlikely to replicate the effects of 
isolated I-3-C concentrations used in cell culture studies.26 
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4.13 Exploring SFN’s Clinical Potential in Relation to Upstream Mechanisms 
With the knowledge that Nrf2 has broad upstream effects on endogenous cellular 
defence processes, it is to be expected that SFN’s clinical effects will be applicable to a 
broad range of conditions.  Endothelial dysfunction adversely affects circulation as 
described earlier and is known to be a major pathophysiological factor in type 2 diabetes 
(T2DM).  For this reason, T2DM has been selected to model the potential for SFN in 
chronic disease states underpinned by endothelial dysfunction. 
4.13.1 Type 2 Diabetes as a Model to Explore Putative Mechanisms  
The first clinical trial using quantified SFN as the intervention material in T2DM was 
published in 2011.197  An earlier 2004 study by another group examined markers of 
metabolic syndrome but did not quantify SFN in a fresh broccoli sprout intervention.37  A 
dose of 10 g of a 0.4% SFN-yielding broccoli sprout powder demonstrated beneficial 
effects in several cardio-metabolic biomarkers.  The trial did not investigate the 
mechanism to explain the effects but other researchers have hypothesised on the 
upstream etiological factors that closely link T2DM and cardiovascular disease 
(CVD).4,6,281   
Uncontrolled T2DM typically results in microvascular complications that significantly 
contribute morbidity and mortality, with one-third of patients with end-stage kidney 
disease being diabetic.282 
4.13.2 Effectiveness of Current Therapy 
Although the mainstay of diabetic treatment is in glucose-lowering, there is evidence to 
suggest that intensive glucose-lowering therapy has no significant effect on the rates of 
major cardiovascular events, death, or microvascular complications in T2DM patients 
with longstanding disease.283, 284 Intensive glucose-lowering may  potentially-harmful.285 
Intensive lifestyle modification as an intervention strategy has been shown to be at least 
comparable286 in its effect to the drug, metformin, typically the first pharmaceutical a 
patient will be prescribed.  Both metformin therapy and intensive lifestyle intervention 
reduced the risk of developing diabetes (by 31% and 58%, respectively, in comparison 
with placebo), showing that it may be possible to use a lifestyle-only approach to reduce 
the risk of T2DM. 
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4.13.3 Searching for an Upstream Etiological Factor  
 An evolving paradigm in the putative etiology of T2DM relates to oxidative stress as 
being the primary upstream factor4,6,3,287 from which all other manifestations of the 
disease ensue.  Furthermore, it has been stated288 that oxidative stress as the “root 
cause” underlies all aspects of the condition: i.e. the development of insulin resistance, 
beta-cell dysfunction, impaired glucose tolerance and T2DM itself (Figure 4.7). 
 
 
Figure 4.7   Oxidative Stress as a putative upstream cause of T2DM and its complications4.   
The primary causes, overnutrition and decreased physical activity create an oxidative environment which 
affects endothelial cells, muscle cells and adipocytes and pancreatic β-cells, each contributing to the 
disease presentation. 
4.13.4 Vulnerability of Endothelium and Pancreas 
At least six biochemical pathways contribute to oxidative stress in the pancreas and 
endothelia.289,290  Pancreatic beta-cells are equipped with about 50% of the SOD activity 
of liver cells.  GPx and Cat activity are even lower at 1%, making beta-cells highly 
susceptible to the effects of ROS.   
Glucose is transported291 between bloodstream and cells of both endothelium and 
pancreatic beta-cells via a concentration gradient and facilitated by insulin-independent 
transcription factors; GLUT-1 in endothelia and GLUT- 2 in beta-cells.  This process 
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being insulin-independent, both endothelia and beta-cells are exposed to high glucose 
levels during hyperglycaemia.  This is unlike the situation in muscles and adipose cells 
which use an insulin-dependent GLUT- 4 transporter and are better protected against the 
effects of ROS.292 
4.13.5 Influencing the Gene-Environment Interaction 
The completion of the Human Genome Project in 2003 led to a surge of interest in 
cataloguing genes associated with particular diseases. In 2007, it was thought that there 
were more than 50 genes known to be associated with T2DM, although these genes 
proved to be low-penetrance and not the high-penetrance genes that were expected to 
target the disease.293  In the last decade, other genes have been identified through gene 
expression studies and these more recent studies have reaffirmed the common upstream 
genetic associations between diabetic cardiovascular and renal complications.294  Much 
of the association is localised in the endothelium, such that endothelial dysfunction is a 
common upstream etiological event. 
A study295 using human microvascular endothelial (HMEC-1) cells showed that in the 
presence of hyperglycaemia, SFN was able to prevent biochemical dysfunction via 
multiple pathways.  SFN was shown to activate Nrf2 with consequent increases in the 
cellular enzymes, transketolase and glutathione reductase after a concentration of 4 
µmol/l-sulforaphane was added to the cells in the presence of 5 µmol/l glucose.  
4.13.6 Are Antioxidant Vitamin Supplements a Logical Therapy in T2DM Patients? 
Given that oxidative stress is emerging as the primary upstream factor in T2DM, 
antioxidants have been considered as likely therapeutic agents.  Perhaps surprisingly, 
these trials have been almost uniformly disappointing in their results.  A 2010 analysis296 
of major randomised placebo-controlled trials (98,886 subjects in total – Table 4.5) 
investigating the effects of antioxidant supplementation on prevention of diabetes or 
glucose homeostasis showed no effect from vitamin E, vitamin C, beta-carotene, 
selenium, zinc and combinations of these.  
Table 4.5   Major randomised placebo-control trials investigating the effects of antioxidant 
supplement on prevention of diabetes or glucose homeostasis.  (Table 1 from Chang and 
Chuang; 2010)296 
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4.14 Can Endogenously-generated Antioxidants Play a Role? 
Given the role of SFN in induction of Nrf2-dependent cytoprotective genes, SFN might be 
a useful candidate for modulation of upstream genes associated with the etiology of 
T2DM.  A 2016 review paper reaffirms the rationale for the ‘unifying hypothesis’ proposed 
by Brownlee in 2001281 in which generation of ROS is the key central theme linking the 
pathogenesis of T2DM and CVD.294  In further support of this hypothesis, Rask-Madsen 
and King reinforce the possibility that endogenous protective pathways could protect 
against vascular complications in T2DM.297 
The Nrf2-dependent target genes of possible relevance are those encoding synthesis of 
GSH, Trx, HO-1 and NQO-1.  Each has been shown to be induced by SFN in a variety of 
cell types, including endothelial cells.298,299  In addition, SFN has been shown to inhibit 
NF-kB in endothelial cells,300 an effect which may retard inflammation in these and other 
cell types.  A 2006 study174 using human aortic cells showed that activation of the Nrf2-
ARE pathway may represent a novel therapeutic approach for the treatment of 
inflammatory diseases such as atherosclerosis. 
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In support of this approach, a 2009 combined cell culture/animal study173 showed that 
shear stress in blood vessels keeps Nrf2 in an activated state and as such protects 
against endothelial function.  Activated by SFN, Nrf2 was shown to prevent endothelial 
cells from exhibiting a pro-inflammatory state via the suppression of p38–VCAM-1 
signalling, providing a novel therapeutic strategy to prevent or reduce atherosclerosis. 
In other tissues of the cardiovascular system, Nrf2 has been shown to regulate both 
basal and inducible ARE-controlled cytoprotective genes in cardiomyocytes.301  As with 
endothelia, Nrf2 is required for protection against glucose-induced oxidative stress and 
cardiomyopathy in the heart. 
4.14.1 Glutathione 
Disturbances of thiol-related mechanisms have been observed302 in diabetes, with 
plasma levels of protein-bound thiols lower in T2DM than in controls.  These thiols 
include GSH and Trx.  An animal study303 illustrates the relationship between depressed 
GSH and the development of atherosclerosis.  In this experiment4, the rate-limiting 
enzyme needed to synthesise GSH, (gamma-glutamyl cysteine synthetase) was shown 
to be downregulated early in the atherosclerosis process.  This effect preceded the 
appearance of lipid peroxidation products by several months.  The antioxidant enzyme, 
GPx was simultaneously downregulated.   
The researchers suggest that “depressed glutathione generation is a key early event and 
may lead to oxidative alterations involved in the development of coronary artery disease. 
This suggests that glutathione depression is a contributory factor in oxidative stress 
rather than a consequence of increased cellular exposure to oxidant species.” 
In a study on spontaneously-hypertensive rats, SFN (0.05±1 µmol/l) induced significant 
and concentration-dependent increases in cellular GSH levels304, HO-1 protein content 
and activities of GSH-reductase and GPx in vascular smooth muscle cells.  Whether this 
SFN concentration would have the same effect in humans is yet to be determined. 
Erythrocyte levels of GSH have been shown to change depending on the stage of the 
diabetic process of the individual.305  Australian research306 has shown that compared to 
controls, pre-diabetic patients exhibit a significant lowering of GSH.  As the disease 
progresses to diabetes and later to diabetes with cardiovascular complications, GSH 
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levels rise; however, they don’t reach the levels of controls.  The variability in GSH levels 
depending on the stage of the disease makes it difficult to use GSH as an effective 
biomarker to measure change in clinical trials. 
An infusion of GSH as an intervention in a clinical trial307 was shown to reverse 
endothelial dysfunction by strongly potentiating the effect of acetylcholine-mediated 
vasodilation via enhanced nitric oxide activity.  Because GSH as a tripeptide molecule is 
degraded by gastric proteolytic enzymes, it is not suitable as an oral therapeutic.308  If 
sulforaphane can be shown to induce GSH in endothelial cells, this may provide an 
alternative means of enhancing GSH levels in endothelial and pancreatic beta-cells with 
a view to reducing the complications of T2DM. 
4.14.2 Thioredoxin – Protection from Elevated Blood Glucose 
Thioredoxin (Trx) is a potent protein disulfide that participates in many thiol-dependent 
cellular reductive processes and plays an important role in antioxidant defence, signal 
transduction and regulation of cell growth and proliferation.  As a cellular thiol, Trx has 
been shown281 to be associated with the development of diabetic complications.  Like 
GSH, Trx has been shown to protect cells against high ambient glucose.309   Trx is at its 
highest levels in metabolically active tissues like the heart and it is critical for normal 
heart function. 
The thioredoxin system (Figure 4.8) consists of thioredoxin, thioredoxin reductase and 
NAD(P)H. Like GSH, Trx contributes to the cellular thiol pool310 with the thioredoxin 
system shown to exhibit cardio-protective effects.311  The pentose phosphate pathway 
which generates reducing equivalents in the form of nicotinamide adenine dinucleotide 
phosphate (NADPH) can alleviate much of the oxidative stress created by excess 
glucose.  By upregulating Trx, SFN contributes to cardioprotection by this additional 
mechanism. 
Figure 4.8.  The thioredoxin system and its relationship with glucose metabolism in the 
pentose phosphate cycle. 312 
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The pentose phosphate cycle generates reducing equivalents which are transferred along a series of 
cycling redox reactions.  Induction of Trx and Trx reductase by SFN enables glucose to be metabolised as 
an alternative to the synthesis of superoxide radical, thereby alleviating much of the metabolic stress 
associated with T2DM. 
 
There are few studies to associate SFN with heart disease but significant 
cardioprotection was demonstrated in an animal study235 using fresh broccoli 
homogenate. Changes included improved post-ischaemic ventricular function, reduced 
myocardial infarct size and decreased cardiomyocyte apoptosis after the rats were 
sacrificed.  These findings correlated with increased levels of Trx as well as HO-1, with 
the function of the latter discussed in relation to SFN in 4.14.7. 
A 1997 study313 investigating the role of thioredoxin in vascular biology describes the 
induction of mitochondrial MnSOD by Trx.  The researchers also comment that Trx 
reduces and protects the function of several classes of proteins during oxidative stress.  
These include proteins important in cell homeostasis and intermediary metabolism such 
as glyceraldehyde-3-phosphate dehydrogenase(GADPH),6 an enzyme which has a 
‘gatekeeper’ function in glucose regulation.  In addition, Trx influences hormones such as 
insulin as well as glucocorticoid receptors and other proteins such as endothelial nitric 
oxide synthase (NOS) and signalling proteins such as transcription factors.  The findings 
of a Phase 1 clinical trial37 demonstrated that 100 g of fresh broccoli sprouts over a 7-day 
period provided cardiovascular benefits which included favourable changes in blood 
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lipids as well as reduction in biomarkers of oxidative stress.  This study however did not 
assay the broccoli sprouts for their sulforaphane yield, limiting its usefulness. 
4.14.3 Quinone Reductase 
NQO1, often described simply as Quinone reductase (or QR) is emerging as an Nrf2-
induced enzyme with broad cytoprotective properties.  A paper314 published almost two 
decades ago claims that an extensive body of evidence supports the conclusion that 
catalysing obligatory two-electron reductions of quinones to hydroquinones, (NQO1) 
protects cells against the deleterious effects of redox cycling of quinones and their ability 
to deplete glutathione.  The same researchers30 have since published again on this topic 
discussing what they describe as a multifunctional antioxidant enzyme and exceptionally 
versatile cytoprotector.  They suggest too that NQO1 with cytoprotective roles which 
extend well beyond its catalytic function could be considered as a ‘marker cytoprotective 
enzyme’.  Further, they state that NQO1 is one of the most consistently and robustly 
inducible genes among members of the cytoprotective proteins.   
 
 
 
 
 
 
 
 
Figure 4.9. Induction of the chemoprotective enzyme NQO1 by phytochemicals in cell 
culture. 
The comparatively much higher induction by SFN against popular plant-derived supplements is evident.32 
NQO1’s antioxidant capacity extends to scavenging superoxide directly,315 albeit not as 
efficiently as does SOD.  As well as its antioxidant properties, NQO1 is also a key Phase 
2 detoxification enzyme, capable of being induced by SFN.  It has been claimed here and 
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elsewhere that sulforaphane is the most potent naturally-occurring inducer of of this 
enzyme (Figure 4.9).32,316  
4.14.4 Other Functions of NQO1 
NQO1’s other functions extend to the maintenance of quinones, Coenzyme Q 10 
(Ubiquinone) and vitamin E in their reduced active forms.30,317  Induction of NQO1 by 
SFN also co-ordinately induces168 genes encoding cellular NADPH-regenerating 
enzymes such as glucose-6-phosphate dehydrogenase, 6-phosphogluconate 
dehydrogenase and malic enzyme.  NADPH in turn assists in maintaining GSH in its 
reduced state.  NQO1, a highly-inducible enzyme provides major antioxidant functions by 
virtue of its two-electron reduction mechanism; this diverts quinones from participating in 
oxidative recycling and production of ROS.30   
4.14.5 Pharmacokinetics of NQO1 Following Induction by SFN 
(a)  Sulforaphane and its metabolites Women were given a single serve of broccoli 
sprout homogenate containing 200 μmols SFN one hour before reduction 
mammoplasty.183    
Figure 4.10 shows that SFN peaks in the blood at around 1 hour, with a subsequent peak 
at 12 hours and then declining until 48 hours, in both plasma and tissue.   Knowledge of 
these relationships contributes valuably to the determination of a dose-response for SFN 
in various tissues and under different conditions.   
(Special Note:  It would appear that the units on the right y axis are incorrect in listing 
pmol/mg; with respect to the left y axis, the correct units are more likely to be pmol/g.) 
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Figure 4.10   Plasma and tissue dithiocarbamate levels over time following 
sulforaphane ingestion. 183 
The pharmacokinetics of the SFN plasma dithiocarbamate (DTC) levels are shown in μM concentrations on 
the left vertical axis and the tissue pmol DTC concentrations on the right vertical axis, illustrating the 
significantly lower concentrations available to cells. 
(b) Transcripts of NQO1 and Haemoygenase-1 (HO-1).    In the same study, NQO-1 
and HO-1 transcripts both peaked at around 12 hours, declining until around 48 hours 
(Figure 4.11) 
 
 
 
 
 
 
Figure 4.11.   Plasma and tissue NQO-1 and HO-1 transcripts over time following SFN 
ingestion.318 
Both NQO-1 and HO-1 transcripts reached their maxima at 12 hours.  However, HO-1 transcripts remained 
more elevated than NQO-1 at 12 hours. 
(c) NQO1 activity Maximal induction of NQO-1 occurs at around 24 hours, declining 
over time.  This peak represents an approximate 2.8-fold induction (Figure 4.12). 
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4.14.6 The Effect of NQO1 Polymorphisms  
The relationship between the risk of NQO1 C609T polymorphisms and carotid artery 
atherosclerosis in patients with type 2 diabetes has been investigated.319  The major 
finding of the study was that the NQO1 C609T polymorphism is associated with carotid 
atherosclerosis in patients with T2DM. The gene coding for NQO1 has a genetic 
polymorphism320 (C → T) at nucleotide position 609.  This polymorphism was shown to 
reduce NQO1 enzyme activity, thereby diminishing the protection provided by NQO1.  
Whether diminished NQO1 activity can be influenced nutrigenomically in individuals with 
one variant allele is not known.  Nevertheless, knowledge of the NQO1 genotypic 
presentation in clinical trials could be useful, given the consequent variation in protein 
expression.   
In a later chapter, the role of the better-known GST family of polymorphisms in relation to 
SFN metabolism are explored. 
4.14.7 Haemoxygenase-1 (HO-1) 
HO-1 is an inducible isoform of the first and rate-controlling enzyme of the degradation of 
haem into iron, carbon monoxide, and biliverdin, the latter being subsequently converted 
into bilirubin.321  HO-1 is considered to have potent cytoprotective effects which include 
 
 
 
Figure 4.12   NQO-1 activity over time following sulforaphane ingestion.183 
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antioxidant and anti-inflammatory properties in cardiovascular and other tissues.  It has 
been suggested that cytoprotection may be due to bilirubin directly inhibiting NADPH 
oxidase activity, thereby reducing superoxide generation.322 
Although the mechanism for the anti-inflammatory effect of HO-1 has not been fully 
elucidated, there are known associations between HO-1 and a number of cytokines.  The 
5’-ﬂanking region of the HO-1 gene contains binding sites for the transcription factors that 
regulate inﬂammation, including NF-κB and Activator Protein-1 (AP1).323  Leukocyte HO-
1 gene expression is significantly lower in patients with and without diabetic 
microangiopathy compared with control subjects and normalisation of blood glucose 
results in a reduction in HO-1 antigen in the cytoplasm of mononuclear leukocytes.324 
Hyperglycaemia is known to increase the formation of advanced glycation end products 
(AGEs).  In endothelial cells, the interaction of the AGE with its receptor, (RAGE) induces 
generation of ROS, NF-kB translocation and expression of several pro-inflammatory and 
pro-coagulatory molecules.325  In normal cells, RAGE is present at low levels but is 
increased in the endothelia of diabetics.322 
Both NQO-1 and HO-1 are upregulated in response to AGEs.326  Both are products of 
Nrf2 induction and may provide an effective endogenous defence mechanism in diabetes 
and other vascular diseases.  Given the effect of SFN on induction of both genes as 
discussed in 14.4.5, a further mechanism to explain the observed beneficial effects of 
SFN in T2DM may be associated. 
4.14.8 8-OH-2-deoxy-guanosine (8-OHdG) 
Because rising levels of oxidative stress play an important role in the pathogenesis of 
T2DM, it is useful to have a marker which can detect individuals who are at risk.  As 
diabetes progresses from normal through pre-diabetes to diagnosed type 2 diabetes, 
DNA damage increases.  Superoxide anions which are elevated in hyperglycaemic 
states cause DNA strand breakage with a consequent increase in 8-OHdG.  A 2010 
study327 showed a significant and progressive increase in 8-OHdG in prediabetics and 
diabetics compared to controls.  Because markers such as GSH may again increase in 
later stages of disease following an initial drop,306 measurement of 8-OHdG may be a 
more reliable marker for the early detection of diabetic risk and or a tool for monitoring 
treatment. 
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4.15 The Role of Selenium in Sulforaphane Chemistry   
Although identified 200 years ago, selenium continues to be recognized as an essential 
element in biology and medicine.328  Its biochemistry resembles that of sulfur, yet differs 
from it by virtue of both redox potentials and stabilities of its oxidation states.329  
Selenium can substitute for the more ubiquitous sulfur of cysteine and as such plays an 
important role in more than a dozen selenoproteins.  These proteins include the Nrf2-
induced GSH, GPx, Trx and Trx reductase. 
4.15.1 Selenium Dietary Requirement 
Selenium is an essential trace element with most diet-derived organic forms being highly-
bioavailable at > 90%.330  By contrast, inorganic selenium, typically sodium selenite, is 
only about 50% bioavailable.  Compared with populations in the United States, 
Australians tend towards selenium deficiency due to the nature of the local soils331 and 
soil levels appear to be further declining.  Australians average an intake of 57-87µ 
selenium/day with the Recommended Dietary Intake (RDI)  listed as 85 µ per day.332   
4.15.2 Potential Selenium Toxicity  
There is increasing evidence linking selenium status to cancer risk and immune 
dysfunction but blood levels are poorly correlated to tissue levels.333,334  The eight-fold 
gap between the estimated average requirement and the upper limit of safe intake is 
relatively narrow.335  For this reason, supplements in Australia are closely regulated to 
limit the daily intake from supplements to 150 µg.336  Selenium is representative of a 
micronutrient for which the dose-response is hormetic; both low and high doses exhibit 
adverse effects in human cells.337  The concept of hormesis is very relevant to 
consideration of the dose-response and is further addressed in later chapters. 
4.15.3 Synergy Between Sulforaphane and Selenium 
The activation of Nrf2/Keap-1 by SFN results in the induction of several selenoproteins 
each of which contains an ARE in its promoter region. Translational realisation of the 
enhanced transcripts depends on adequate selenium supply, which explains the 
synergism of Nrf2 activators and selenium.338   
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If selenium incorporation at the active site of the enzyme is the rate-limiting step, then 
less than optimal levels of the enzyme will be synthesised.  Synergy between SFN and 
selenium in the induction of Trx-1 reductase requires both transcriptional and 
translational modulation.339  A cell culture study using human hepatocytes340 investigated 
the induction of Trx reductase-1 due to a SFN-yielding broccoli sprout material and 
selenium separately and then combined.  The results showed that induction by SFN at 
1.6-8 µM ranged from 1.7 to 2.2-fold. When the cells were co-treated with selenium (0.2 
– 1 µM), the enzyme activity was high in the range from 3.0 to 3.3-fold, demonstrably 
greater 
Another study338 using a human endothelial cell line, EAhy926, showed that the 
combination of selenium and SFN produced an increase in Trx-1 reductase expression 
that was significantly greater than that achieved when each agent was added alone.  The 
study also showed that SFN increased Trx-1 reductase but not GPx and in doing so 
conferred protection against oxidative damage in vascular endothelial cells. In contrast to 
these cell culture findings, a long-term (7.7 years) selenium supplementation study341 on 
individuals with T2DM showed that 200 µg daily of selenium does not seem to prevent 
disease risk and in fact, may increase risk.  Further investigation of these findings is 
warranted, especially in the context of the use of isolated nutrients as intervention 
materials.  Such study protocols may be more suited to a pharmaceutical intervention 
than a nutrient intervention. 
4.16 Implications for Type 2 Diabetes as a Representative Chronic Disease 
4.16.1 Oxidative Stress – Is It the Common Upstream Factor Linking CVD and T2DM? 
It is widely-accepted that we are in the midst of a global epidemic of T2DM. It has been 
estimated that up to 70% of patients with acute myocardial infarction have either diabetes 
or impaired glucose tolerance.342  Diabetes-specific microvascular disease is a leading 
cause of blindness, renal failure and nerve damage with diabetes-accelerated 
atherosclerosis leading to increased risk of myocardial infarction, stroke and limb 
amputation.281   
The observation that these seemingly-unrelated conditions are all manifestations of 
prolonged hyperglycaemia in certain individuals has led to a search for a common 
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upstream factor to provide an etiological mechanism.  It has been proposed4,343 that 
oxidative stress is the pathogenic mechanism linking insulin resistance with dysfunction 
of both beta-cells and endothelium, eventually leading to overt diabetes and 
cardiovascular disease. 
4.16.2 Pancreatic Beta-Cell and Endothelial Cell Vulnerability 
The beta-cells of the pancreas and those of the endothelium are particularly susceptible 
to the effects of oxidative stress.289  As the first line of protection for the vascular wall and 
occupying a strategic position between the blood and underlying tissues, endothelial cells 
appear very susceptible to glucose toxicity.344  This is especially so when compared with 
regulation of glucose uptake via glucose transporters by smooth muscle cells.291  
Several metabolic pathways which link hyperglycaemia in the endothelia to clinical 
diabetes are associated with oxidative stress.6,345  Recent studies demonstrate that a 
hyperglycaemia-induced process of overproduction of superoxide by the mitochondrial 
electron transport chain seems to be the ﬁrst and key event in the activation of all other 
pathways involved in the pathogenesis of diabetic complications.3 
4.16.3 Antioxidant Vitamins as Therapy? 
Although it might appear that classical antioxidants such as vitamins C, E and beta-
carotene would play a role in reducing oxidative stress in diabetes, they have been 
generally unsuccessful346 and there would seem to be a significant disconnect when 
comparing the findings of epidemiological and intervention studies.347  Furthermore, it 
appears that megadoses of vitamin antioxidants may impair induction of endogenous 
antioxidant enzymes and other cytoprotective compounds.348  This may help to explain 
some of the negative findings of studies using doses of vitamins well in excess of 
reasonable dietary intake. 
4.16.4 Exploring Nutrigenomic Strategies 
Investigation into alternative redox-regulating strategies continues.  The catalytic effect of 
antioxidant enzymes such as SOD provides greater potential to reduce oxidative 
stress121 than do antioxidants acting stoichiometrically.  SOD-mimetics, as introduced in 
Chapter 2,  have been used experimentally to show that quenching excessive superoxide 
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anion reduces endothelial dysfunction.349  Since epidemiological studies350 show that a 
diet high in fruits and vegetables confers protection against disease, various non-nutrient 
compounds of plant origin are also under consideration as suitable agents to prevent 
oxidative stress-induced cell damage. 
Polyphenolic compounds from plant foods have significant in vitro antioxidant potential 
but their low bioavailability351,352 limits their clinical usefulness as systemic antioxidants.  
On the other hand, SFN derived primarily from broccoli and with absolute 
bioavailability182 of around 80%, shows promise as a nutrigenomically-active compound 
capable of increasing several endogenous antioxidant compounds via the transcription 
factor, Nrf2.168   
These cytoprotective compounds28 which include NQO1 can protect the vascular wall 
against inflammatory processes.174   There is evidence353 to suggest that strategies to 
increase antioxidant activity of GSH and GPx in particular within the pancreatic islet cell 
may protect it against glucose toxicity.  Substantially reduced levels of erythrocyte GSH 
occur in the pre-diabetic stage306 rising with disease progression for 6-10 years after 
diagnosis.  Estimates suggest that 40-50% of individuals with pre-diabetes will develop 
type 2 diabetes within 10 years354 and this highlights the value of early detection of 
glucose dysregulation.  As SFN is known to be a potent inducer182, 355,301 of Nrf2 and has 
shown promise in clinical trials related to diabetes and its complications, this may 
indicate that SFN might play a preventive and therapeutic role in this disease epidemic. 
295,172 ,173, 356, 357, 198 
To more fully elucidate the Nrf2-dependent and Nrf2-independent mechanisms that 
underpin the observed effects of SFN, further investigation will be required.  Better 
understanding of these mechanisms may extend the clinical application for SFN, 
especially those associated with redox imbalance.  
4.17 DIRECTION OF FUTURE SFN RESEARCH  
4.17.1 The potential for SFN to be Used in Conjunction with Pharmaceuticals 
The diverse properties of Nrf2 are such that it is being increasingly considered as a novel 
drug target with potential applications across a broad range of conditions.  Interestingly, 
the Nrf2-activating properties of SFN have been experimentally used in conjunction with 
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pharmaceuticals.   As one example, SFN’s effect on Nrf2 has been investigated in this 
context as a means of minimising the nephrotoxicity which typically limits the use of the 
chemotherapeutic drug, cisplatin.358    
A further very recent example illustrates the effects of combining members of the 
chemotherapeutic taxane drug family with SFN.359  Taxanes are widely-used 
chemotherapeutic drugs for triple negative breast cancer (TNBC) which is unresponsive 
to more common receptor-targeted therapies. Taxane therapy typically targets only 
differentiated cancer cells without exerting any beneficial effect on the disease-promoting 
cancer stem cells (CSCs).  More significantly, taxanes may result in expansion of the 
breast CSC population. 
Because SFN has been shown to eliminate CSCs in some cancer cell types, it was 
trialled in conjunction with taxane.  Where taxane enhanced inflammatory cytokine 
production in TNBC cell lines, SFN reduced production of IL-6, IL-8, and NF-kB activity to 
inhibit CSCs.  These newer studies wherein SFN is tested in combination with an existing 
therapy provide numerous avenues for further SFN research. 
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CHAPTER 5 
Sulforaphane: Translational Research from Laboratory Bench to Clinic 
This chapter was published in Nutrition Reviews as Review – Special Article. The 
abbreviations, formatting and referencing of this document have been altered slightly to 
more closely reflect the formatting of other chapters and published work in this thesis.  
Section 5.11 has been updated to include reference to studies comparing the differing 
effects of SFN on normal and cancer cells. 
A pdf version of the published manuscript is attached as Appendix B. 
 
Houghton CA, Fassett RG, Coombes JS. Sulforaphane: translational research from 
laboratory bench to clinic. Nutr Rev. Nov 2013;71(11):709-726. 
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5.0 Abstract 
The chemopreventive benefits of cruciferous vegetables in human health are widely 
acknowledged but these vegetables are not generally consumed at levels which effect 
significant change in biomarkers of health.  Because consumers have embraced the 
notion that dietary supplements may prevent disease, this review considers whether an 
appropriately validated sulforaphane-yielding broccoli sprout supplement may deliver 
clinical benefit.  The crucifer-derived bioactive phytochemical, sulforaphane is a 
significant inducer of Nrf2 (nuclear factor erythroid 2-related factor 2), the transcription 
factor which activates the cell’s endogenous defences via a battery of cytoprotective 
genes. For a broccoli sprout supplement to demonstrate in vivo bioactivity, it must retain 
both the sulforaphane-yielding precursor compound, glucoraphanin and the activity of its 
intrinsic MYR enzyme.   Many such supplements are MYR-inactive but current labelling 
does not reflect this.  For the benefit of clinicians and consumers, this review summarises 
in vitro and clinical trial findings, interpreting these in the context of clinical relevance.  
Standardisation of sulforaphane nomenclature and assay protocols will be necessary to 
remove the inconsistency and ambiguity in the labelling of currently available broccoli 
sprout products.  
Key Words sulforaphane, broccoli sprout, myrosinase-active, bioactivity, bioavailability, 
glucoraphanin, broccoli seed extract 
5.1 Introduction  
The cruciferous vegetable family includes broccoli, cauliflower, cabbage, kale and 
others and consumption is associated with reduced cancer risk.180,360  As foods, 
crucifers are a significant source of micronutrients including folate and vitamin C but 
perhaps more significant is their nutrigenomic potential.361   This potential is due to 
generation of a family of bioactive compounds, known as isothiocyanates (ITC).  
Broccoli-derived ITCs for example, are not present in the plant cell but produced when 
the cell wall is ruptured, resulting in an enzymatic reaction between the MYR enzyme 
and an inert precursor, glucoraphanin.  The well-researched broccoli-derived ITC is 
sulforaphane (SFN) and it is this compound which appears to be responsible for the 
larger part of the plant’s health-promoting and cancer-preventive properties beyond its 
nutrient content.362,363,364  Whereas many plant-derived nutraceutical supplements 
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contain extracts of the major identified bioactive compound(s), the intrinsic 
instability365,366 of the naturally-occurring SFN molecule presents a challenge for which 
a manufacturing solution has yet to be found; SFN per se is simply not sufficiently 
stable to enable production as a supplement.  Alternative means of addressing this 
challenge are discussed herein. 
Given the prevalence of diet-related chronic disease and the evidence that many 
consumers have accepted a role for complementary medicines in their personal health 
management, there may be a place for a validated bioactive plant-derived SFN-
yielding supplement capable of modifying biochemical and physiological risk factors for 
disease.   It is against this background that this review investigates the possibility of 
delivering such supplements with significant clinical potential.   
5.2 The Emergence of Nutrigenomics 
Described in 2004367 as the ‘next frontier in the post-genomic era’, nutritional genomics 
(more commonly ‘nutrigenomics’) harnesses multiple disciplines and rests at the 
interface between the nutritional environment and cellular/genetic processes.368  
Understanding the relationships between phytochemicals and their ability to affect an 
individual’s gene expression underpins the principle of an evolving model of 
‘personalised nutrition’.369   Where pharmacogenomics370 describes the individual effects 
of pharmaceuticals on a patient’s genome, nutrigenomics describes similar responses to 
bioactive molecules in foods.371  Plant biomolecules as components of the human diet 
take on a new significance as the relevance of their roles in intracellular signalling and 
nutrigenomic modulation of gene expression continue to unfold.372   
As a weak pro-oxidant, SFN is a phytochemical with demonstrable nutrigenomic 
potential, activating the expression of a battery of cytoprotective genes via the 
transcription factor, Nrf2 (nuclear factor erythroid 2-related factor 2).373  Nrf2 co-ordinates 
the regulation of over 200 genes in humans and animals,192,194,219 largely related to 
mechanisms of endogenous cellular defence and survival.374 Nrf2 has been variously 
described as, ‘the master redox switch’,151 an ‘activator of cellular defence 
mechanisms150 and ‘a guardian of health span and gatekeeper of species longevity’.152   
As a mediator for amplification of the mammalian defence system against various 
stressors, Nrf2 sits at the interface between our prior understanding of oxidative stress 
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and the endogenous mechanisms cells use to deal with it.  The knowledge that a weak 
pro-oxidant such as SFN can initiate a sequence of events culminating in increased 
expression of endogenous anti-oxidant molecules such as glutathione, thioredoxin and 
hemoxygenase suggests that we re-examine the premise that dietary antioxidant 
supplements are generally beneficial to human health.34,375   
5.3 Nutrigenetics 
Where nutrigenomics investigates the effects of food nutrients and bioactive food-derived 
compounds on gene expression, nutrigenetics identifies and characterises gene variants 
associated with differential responses to nutrients, relating this variation to disease 
states; both aim to unravel diet-genome relationships.376  Nutritional epidemiology 
investigates the association between patterns of food consumption and disease risk, with 
nutrigenetics asserting that the effects of particular foods or food components may vary 
with genetic differences that affect the metabolic makeup of the individual.377  
Furthermore, nutrigenetics helps to explain why the findings of epidemiologic trials are 
often inconsistent, since to express their bioactivity, phytochemicals may need to be 
metabolised by enzymes with known single nucleotide polymorphism (SNP) 
variants.378,379   
5.4 Differential Responses Due to Nrf2-Target SNPs 
Glutathione S-transferases (GST) constitute a large multigene family of Phase 2 
enzymes involved in detoxification of potentially genotoxic chemicals.378  The bioactive 
ITCs of cruciferous vegetables are metabolised via the mercapturic acid pathway to form 
a GSH conjugate, catalysed by GST enzymes.379  Polymorphisms in these enzymes 
have a significant nutrigenetic impact on overall ITC metabolism, affecting SFN 
bioavailability, so that in some cases cruciferous vegetable intake confers greater 
chemoprevention in those with certain GST polymorphisms; in other studies, the opposite 
is observed.380-382  It has been reported that the differing effects of phenotypic expression 
of GSTM1 on SFN metabolism is such that GSTM1 null subjects excreted almost 100% 
of ingested SFN.383  In a later study, Gasper et al showed that there were apparent 
thresholds of intracellular SFN concentration below which gene expression did not 
occur.384  This could have implications for dietary recommendation to consume more 
cruciferous vegetables because it has been shown that some fresh broccoli purchased 
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from retail stores yielded very low SFN, even consumed raw and even when ingested 
repeatedly.385  The same study in humans consuming 300mls of liquidised commercially-
available raw broccoli florets achieved peak plasma SFN level of just 0.07 μM.  A later 
study386 which compared the peripheral SFN exposure in volunteers consuming a single 
serving of lightly-cooked fresh broccoli with lightly-cooked frozen broccoli showed an 
approximately 10-fold difference in plasma concentration, ~ 0.2 μM for the fresh vs ~ 
0.02 μM for the frozen.   Moreover, the lower physiological concentrations observed after 
ingestion of the frozen vegetable were described as being below the threshold required 
to cause a range of responses in cellular models.  GSTM1 on SFN metabolism is such 
that GSTM1 null subjects excreted almost 100% of ingested SFN.  In a later study, 
Gasper et al showed that there were apparent thresholds of intracellular SFN 
concentration below which gene expression did not occur.  This could have implications 
for dietary recommendation to consume more cruciferous vegetables because it has 
been shown that some fresh broccoli purchased from retail stores yielded very low SFN, 
even consumed raw and even when ingested repeatedly.   
 
Wide variations exist in glucosinolate content among varieties of the Brassica oleracea 
seeds387 from which broccoli sprouts are grown.  This would suggest the likelihood of 
marked variation in the quantities of isothiocyanates derived from hydrolysis of their 
glucosinolates (GSNs) from which broccoli sprouts are grown.  This would suggest the 
likelihood of marked variation in the quantities of isothiocyanates derived from hydrolysis 
of their GSNs.  A 27-fold difference between the highest and the lowest levels of 
glucoraphanin has been observed.256  As a consequence, for a nutraceutical supplement 
to demonstrate consistent responses, it will be essential for a MYR-active plant powder 
to contain a standardised content of glucoraphanin, with selection of an appropriate seed 
cultivar an important consideration.  
 
GST polymorphisms can be prevalent in the population, with up to 50% of people 
exhibiting the null genotype for the GSTM1 isoenzyme.382  Such a genotype may confer 
an advantage to GSTM1-null individuals because their reduced GST activity could result 
in slower elimination and longer exposure to ITCs after cruciferous vegetable 
consumption.388  The GST-null phenotypes have been associated with reduced risk of 
breast, prostate and colon cancers, adding support to SFN’s potential as a 
chemopreventive and cytoprotective agent25,389,390,391 but not all studies show that the 
 Page 81 of 308 
 
null genotype confers such protection.392  A study in which human hepatocytes were 
treated with the hepatocarcinogen Aflatoxin B1 after pre-exposure to SFN at doses from 
10-50 μM were investigated for their ability to resist DNA adduct formation; reduction in 
DNA adduct formation occurred at both doses, with greater reduction at the higher 
concentration.393   Analyses of gene expression in the SFN-treated hepatocytes 
demonstrated that SFN greatly decreased cytochrome P450 (CYP3A4) mRNA but did 
not induce the expression of GSTM1, suggesting that GST induction is but one means by 
which SFN exerts chemoprevention.  The effects of SFN on CYP3A4 are discussed in 
more depth in a later section.387  
5.5 Sulforaphane’s Diverse Modes of Chemoprotection 
A number of cell defects have been observed in cancer cells.394  Among such defects, 
mutation of the p53 suppressor gene occurs in about 50% of all cancers.395  
Accumulated and varied defects in the cell’s intrinsic cytoprotective mechanisms 
gradually weaken these defences.  The most common molecular genetic change in 
prostate cancer involves silencing of the expression of the gene which codes for GSTP1, 
a critical enzyme of carcinogen defence.209  This change occurs early in prostate 
carcinogenesis because it is found in virtually all cases of intraepithelial neoplasia (PIN) 
and is a near universal finding in clinical prostate cancers regardless of the grade or 
stage.209 
Normal GST function is required to detoxify potential carcinogens; without it, prostate 
cells are exposed to the damaging effects of endogenous and exogenous toxins.  
Fimognari396 showed that SFN is capable of offsetting the effects of a mutated p53 gene 
by virtue of its various modes of action, providing evidence that SFN confers 
chemoprotection even when genetic defects are already apparent, a finding of 
considerable clinical significance.  These findings reaffirm the value of cruciferous 
vegetables in human diets. 
Whether it is possible to develop a clinically efficacious supplement based on the 
nutrigenomic potential and the pharmacokinetic properties of phytochemicals like SFN is 
a key question posed by this review.397,398  A close investigation of many of the 
phytochemical-derived supplements popular with consumers reveals that many of these 
exhibit poor bioavailability, in contrast to that of SFN.399,400,41  As a result, it is doubtful 
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that some of the bioactive compounds which demonstrate impressive effects in highly-
publicised in vitro studies exist in sufficient systemic concentration to exhibit a clinical 
effect.401   
5.6 Developing an Evidence-Based Sulforaphane Supplement 
The finding that SFN is both a potent32 and a bioavailable41 inducer of Nrf2 places it in 
a category distinct from most other supplemental phytochemicals, especially the 
polyphenols.352  Cell culture studies are a valuable starting point in dose determination 
and various human cell types have been investigated as substrates for SFN 
intervention studies.402  Of particular value are the studies which reveal the 
biochemical effect of a specific micromolar concentration of SFN.318,402  These data 
can then be reviewed in relation to the SFN Yield from a specified oral dose.   
Whereas the primary bioactive component of many phytochemicals is extracted and 
the standardised extract used in the manufacture of a nutraceutical supplement, the 
intrinsic instability of the SFN molecule prevents this method of delivery.366  As such, 
broccoli-derived foods or supplements require the hydrolysis of the glucoraphanin 
precursor in the presence of the MYR enzyme; typically, this occurs when the fresh 
plant cell is ruptured or when a dry whole powder becomes moist.  In short, SFN must 
be formed close to the time of ingestion.  The challenge for the manufacturer of a 
SFN-yielding supplement lies in the ability to retain both the glucoraphanin and the 
MYR enzyme during the processing from fresh whole plant to powder; this aspect is 
explored in more detail later. 
5.7 Sulforaphane Yield vs Sulforaphane Content 
Broccoli sprouts yield more SFN than any other known plant and contain10-100 times 
the concentration of glucoraphanin (the major glucosinolate in broccoli)  of the mature 
broccoli vegetable.32,169  The broccoli seed therefore contains more glucoraphanin per 
gram than does the sprout or the vegetable of the same seed. The higher level in 
broccoli seeds compared to young sprouts is apparently due to the fact that there is no 
significant net synthesis of the glucosinolates over the few days following 
germination.169,403  As the maturing plant becomes established and is exposed to 
environmental factors including the influence of herbivorous predators, additional 
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glucosinolates can be synthesised as part of the plant’s defence against predators.404  
Nevertheless, the very young broccoli sprout is typically a far more significant source 
of SFN on a weight basis compared with the vegetable and it is for this reason that the 
sprout is chosen as a source of sulforaphane-yielding precursors in many clinical trials. 
In addition, different cultivars of Brassica oleracea contain varying levels of 
glucoraphanin, further establishing the wide variation in glucosinolate content between 
broccoli sprout and the broccoli vegetable.387  Importantly however, the plant does not 
contain any SFN, instead producing it during the hydrolysis of glucoraphanin in the 
presence of MYR.27   As a result, broccoli sprouts are correctly described as    As a 
result, broccoli sprouts are correctly described as releasing, generating or yielding but 
not containing SFN.  The ideal broccoli sprout ingredient contains separately 
compartmentalised glucoraphanin and MYR which react at, or close to the time of 
ingestion.387  The absence of MYR in a broccoli sprout food powder or supplement 
renders the product unable to produce SFN on ingestion.398    
5.8 Role of Epithiospecifier Protein (ESP) 
The presence of a pH-sensitive modifier protein, ESP affects the amount of SFN 
produced on hydrolysis.405  In broccoli, the primary glucosinolate glucoraphanin, can 
be converted to two principal products, SFN and SFN nitrile, the latter being several 
orders of magnitude lower in Nrf2-activating potency than SFN.253  The importance of 
this finding is that, whereas SFN has been shown to have anticarcinogenic properties, 
SFN nitrile has not.406  Because ESP is temperature-sensitive, heating broccoli sprouts 
to 60 degrees C decreases the formation of SFN nitrile.251  A challenge for 
manufacturers of a SFN-yielding supplement lies in deactivating the ESP without 
simultaneously deactivating the MYR enzyme or degrading the glucoraphanin. 
5.9 Presence of Erucic Acid in Broccoli Seed Lipid Fractions 
Erucic acid is a lipid found in broccoli seeds as well as in other members of the 
Brassicaceae family.  Its toxic effects in animals consuming rapeseed (another 
member of the Brassicaeae family) are well-known and include myocardial lipidosis, 
myocardial necrosis, and impaired oxidative phosphorylation.407  Concerns regarding 
its possible effects in humans are sufficiently important that erucic acid in rapeseed is 
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regulated in the U.S.408  Broccoli seeds contain about 28% lipid but broccoli sprouts 
contain only about 1%.   Therefore, as further described by West et al (2002), one 
gram of broccoli seed may contain approximately 120mg of erucic acid but 28 g of 
broccoli sprouts contains 90mg of erucic acid407 ; this would indicate that the seed 
contains around 37-fold more than the sprout.  They calculate that 35 g per week of 
broccoli seeds could equal the estimated maximum allowable amount of erucic acid, 
extrapolating from FDA requirement to limit the content of erucic acid in canola oil to a 
level not exceeding 2% of the component fatty acids.  Although it is unlikely that an 
individual would consume 35 or more g of broccoli seed per week, it is not impossible; 
consumption of supplements derived from broccoli seeds is therefore not 
recommended.408   
The production of an aqueous broccoli seed extract provides a way of removing the 
erucic acid; however, this process also activates the enzymatic conversion of 
glucoraphanin to SFN, which exhibits relatively high reactivity,387 making SFN 
unsuitable as a compound for direct fortification of foods or supplements.   A number 
of MYR-inactive broccoli seed extracts are commercially-available; these products are 
a source of glucoraphanin but are devoid of the MYR necessary to convert it to SFN 
on ingestion.397 
5.10 Sulforaphane’s Effects on Target Genes 
The more than 200 identified Nrf2 target genes can be classified194 broadly as those 
which code for a range of cytoprotective proteins, including antioxidants (enzyme and 
non-enzyme), drug-metabolising enzymes, drug-efflux pumps, heat shock proteins, 
NADPH regenerative enzymes, growth factors, growth factor receptors, heavy metal 
binding proteins and various transcription factors including PPAR-γ as well as for Nrf2 
itself.409  
An illustrative study318 investigated the effect of a single oral dose of 200 µmols of pure 
SFN in women immediately before undergoing reduction mammoplasty.  This dose 
can be calculated to be equivalent to 35 mg SFN, given that 5.7 µmols SFN is equal to 
1mg SFN (M.W. = 177.29).  Two important biomarkers in this study were 
hemoxygenase-1 (HO-1), a cytoprotective enzyme expressed following Nrf2 induction 
of the target gene410 and NAD(P)H:Quinone oxido-reductase (NQO1), a Nrf2-inducible 
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Phase 2 detoxification enzyme253 exhibiting a range of other cytoprotective properties.  
The dose selected was based on an earlier study411 which showed that SFN 
dithiocarbamate metabolites were detected at 15 minutes in the plasma and peaked at 
2.00 ±0.3 µM one hour after ingestion, indicating rapid uptake.   
A maximal 12-fold induction of NQO1 transcripts was observed in the mammary gland 
12 h after dosing, with significant induction as early as 2 h.  A biphasic pattern of HO-1 
transcript induction was observed, with an initial peak at 2 h followed by a subsequent 
peak at 12 h, indicative of the delayed effect of SFN conversion to dithiocarbamates 
(DTCs). The minimal time to statistically-significant HO-1 induction was 1 h.   
Cornblatt’s study183 is significant in providing a guide to the expected micromolar 
concentration for a given quantity of ingested SFN.  A dose of 35mg SFN (200 µmols) 
appears to be achievable from a MYR-active broccoli sprout powder, provided such a 
powder is able to yield 1% SFN per gram of powder.  As such, a supplement weight of 
3.5 g is within a practical human dose range, ingested either as a powder or as several 
capsules.   
5.11 Relevance of in vitro Studies 
Much of the preclinical research on SFN examines its effect in various cell types and 
at varying micromolar concentrations.  It soon becomes clear that different tissues 
respond differently to a specified dose.  Even different cell types in the same organ 
can respond differently.208   
The expression of Nrf2 target genes such as NQO1 occurs at lower SFN 
concentrations, whereas other effects appear to require much higher intracellular 
concentrations.157   SFN exhibits effects beyond its ability to activate Nrf2; these 
effects include HDAC (Histone Deacetylase) inhibition,412 apoptosis,159 anti-
angiogenesis413 and anti-metastasis414 in cancer cells.   Induction of NQO1 in the rat 
colon is 3-fold higher than it is in the liver for the same dose.415  Clearly, an effect 
detected in one tissue cannot be extrapolated to others.  This may also suggest that 
the beneficial effects from both dietary crucifers and supplements may be greater in 
organs such as the digestive tract and bladder than in organs reached only 
systemically.  A recent study416 showed that SFN levels measured in the stomach and 
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bladder are higher than for the other organs measured.  It is possible that tissue 
uptake of SFN is highest in the stomach due to direct exposure but the levels are seen 
to decline rapidly in the descending gastrointestinal tract, possibly a result of metabolic 
conversion.416,417  Paradoxically, induction of GST and NQO1 are relatively modest in 
the stomach; the authors state that the reason for high gastric uptake of SFN but low 
induction of GST and NQO1 remains unexplained.  An earlier study by the same 
researchers showed that SFN tissue uptake level in the bladder was second only to 
that in the stomach.  There would appear to be remarkably high exposure of the 
bladder epithelium to dietary SFN, with a peak at 6 h after dosing and levels 64–5509 
times higher than in the plasma.416  Unlike the relatively low extent of enzyme 
induction observed in the stomach, significant induction of GST and NQO1 occurred in 
bladder cells.416 This may have clinical implications for patients with bladder cancer.418 
It would seem too that the doses required for disease prevention are far lower than 
those required to effect change in established disease.  A study419 on men at risk of 
prostate cancer showed that increasing intake of cruciferous vegetables from one 
serve per week to more than three serves per week (presumably cooked) was enough 
to provide 41% decreased apparent risk.  Data shown in Table 5.1 review a number of 
in vitro studies208,209,218-226 which evaluated the effect of SFN in different tissue and cell 
types.  Notably but not surprisingly, the micromolar concentrations to effect change are 
highly variable across cell types and it has also been shown that the time during which 
the cells were exposed to SFN markedly altered the response.  In cardiomyocytes 
exposed to hydrogen peroxide (H2O2), a 5 μM SFN dose for 6 hours maintained 45% 
cell viability but when exposed for 24 and 48 hours, cell viability increased to 82% and 
92% respectively.225  How the findings of such cell culture studies translate to the 
human in vivo situation is not yet known. 
The examples shown in Table 5.1 are a cross-section of the many published in vitro 
SFN trials of this type.  The data show that in some cell types, the required 
biochemical changes could be readily achievable by supplementation of a MYR-active 
standardised broccoli sprout supplement.  It is equally likely that in some cells and in 
certain conditions, such supplementation may not provide the required micromolar 
concentration.  For example, inhibition of transcription factor, NF-κB and induction of 
transcription factor, Nrf2 appear to be achievable at micromolar concentrations much 
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lower than for the induction of HDAC inhibition, cell cycle arrest or anti-angiogenesis in 
cancer cell lines.232,420  As an example, where low SFN doses between 0.1 and 3 μM 
activate Nrf2-related cellular defences in prostate cells,209 higher doses of 10 μM for 
DU145 cells and 30 μM  for LNCaP cells are necessary to induce cell cycle arrest and 
apoptosis.226    
As a further consideration, when comparing the effects of SFN in normal and cancer 
cells, SFN has been shown to exhibit different behaviours.  A study comparing the 
effect of SFN on three tumour cell lines and a normal cell line showed differing abilities 
of SFN to induce apoptosis and arrest the cell cycle for the three tumour cell lines; 
more significantly, in the normal cell line, SFN was shown to be less toxic than to the 
tumour cell lines.421   In a separate study investigating effects on prostate cells, SFN 
was shown to exhibit a different pattern of chemoprevention-related gene expression 
when comparing normal and cancer cells.422  These effects extend beyond  
comparison of cancer and normal cells, so that  in a rheumatoid arthritis model, SFN 
induces the cytoprotective transcription factor Nrf2 in naïve synoviocytes, whereas it 
induces apoptosis in inflamed synoviocytes.423
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Table 5.1    Studies showing the diversity of effects in different cell types when varying µM SFN and incubation time.  
 
Lead Author & 
Year of 
Publication  
Tissue SFN µM Conc. Cell Type & Effect Finding 
Brooks et al. 
(2001)209 
 
Prostate 0.1 – 15 µM  6 prostate cancer cell lines 
+ normal cells.  Effect of 
SFN evaluated – including 
effect on GSTP1 silencing 
• Normal cells:  SFN after 48 hours 
1.35-fold NQO1 induction at 0.1 µM and 
2.46 at 1 – 3 µM 
• LNCap cells:  SFN  4.6-fold induction 
at 10 µM  
• Modest induction of GST isoforms to 
1.7-fold in all cell lines 
• All effects of SFN completely abrogated 
by 10 nM NAC 
Gao et al. 
(2004)222 
 
Retinal 
epithelium 
1.25 – 5 µM  Human adult retinal pigment 
epithelial cells (ARPE-19). 
 
Challenged with UV light + 
all-trans retinaldehyde on 
photo-oxidative damage 
• Increased cell survival with increasing 
SFN doses; linear cytoprotective effect 
with dose 
• Where only 9.4% of cells survived, pre-
incubation with SFN raised survival 3-
fold to 27.4% at SFN = 5 µM  
Cho et al. Prostate 10 µM Effect of SFN on prostate • Strong cell cycle arrest (G2/M phase) 
and apoptosis at SFN = 10 µM.  No 
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Lead Author & 
Year of 
Publication  
Tissue SFN µM Conc. Cell Type & Effect Finding 
(2005)226 
 
Cancer cancer cell line DU145 effect at < 3 µM 
• LNCaP cells required SFN > 30 µM for 
arrest 
• Effects of SFN completely abrogated by 
NAC 
Ritz et al. 
(2007)208 
 
Bronchial 
epithelium 
0.3 – 10 µM Effect of SFN on bronchial 
cells exposed to diesel 
extract in two cell lines 
BEAS-2B and NHBEC 
• All doses induced GST, NQO1 but to 
different degree in each cell line 
• SFN at 5 µM  15-fold increase in 
NQO1 in BEAS-2B cells 
• GST increased 1.9-fold in NHBEC at 
SFN = 1.25 µM  1.43-fold increase in 
BEAS-2B 
• Expression of inflammatory cytokines, 
IL-8, IL-1β and GM-CSF were all 
significantly reduced at SFN = 0.625 µM 
Zhu et al. 
(2008)219 
 
Aorta 0.25 – 5 µM  Effect of SFN in aortic cell 
cytoprotection in rat aortic 
smooth muscle cells (A10 
cell line) 
• Significant dose-dependent induction of 
cytoprotective Nrf2 target genes at SFN 
as low as 0.25 µM. 
• SFN at 0.25 µM  25% increase in 
GST and 66% increase in NQO1. 
• SFN at 0.5 µM   33% increase in GSH 
levels. 
• SFN protected against toxicity of 
superoxide, H2O2, acrolein and 
peroxynitrite. 
Angeloni et al. Cardiac 5 µM Effect of SFN on • Greater effects when pre-dosing for 48 
hours 
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Lead Author & 
Year of 
Publication  
Tissue SFN µM Conc. Cell Type & Effect Finding 
(2009)225  tissue cardiomyocyte cell viability 
in presence of reactive 
oxygen species (ROS) over 
6-48 hours 
• H2O2 reduced cell viability to 40% 
• SFN at 5 µM for 6 hours  45% viability 
• SFN at 5 µM for 12 hours  75% 
viability 
• SFN at 5 µM for 24 hours  82% 
viability 
• SFN at 5 µM for 48 hours  92% 
viability 
Song et al. 
(2009)223 
 
Pancreatic    
β-cells 
 
0.1 – 10 µM Effect of SFN in protecting 
β-cells (RIN cell line) 
against oxidative damage, 
restoring insulin secretion 
and preventing type 1 
diabetes in STZ-treated 
mice 
• ~ Linear response in Nrf2 target genes 
to induction by 2.5, 5.0 and 10.0 µM 
SFN. 
• Protection against cytokine-induced β-
cell death by SFN. 
• Cytokines reduced cell viability to ~54%.   
• SFN at 10 µM increased viability to 
~96%. 
• SFN at 5.0 µM increased viability to 
~92%. 
• SFN at 2.5 µM increased viability to 
~80%. 
Kivela et al. 
(2010)224 
 
Endothelial 
cells or 
arteries and 
veins 
Human 
Umbilical 
Endothelial 
Cells (HUVEC)   
Effect of SFN on Endothelial 
Lipases (EL) and TNF-α 
expression in HUVEC and 
HAEC cells 
• SFN at 10 µM inhibits EL in HUVECS 
venous cells  
• SFN at 2.5 µM inhibits EL in HAEC 
arterial cells 
• EL activation occurs through classical 
(canonical) NF- κB pathway 
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Lead Author & 
Year of 
Publication  
Tissue SFN µM Conc. Cell Type & Effect Finding 
0 - 10 µM  
Human arterial 
endothelial cells 
(HAEC) 0 - 10 
µM 
 
Mas et al. 
(2011)220 
 
Brain – 
Substantia 
nigra 
0 .5 - 5 µM Dopaminergic human 
neuroblastoma cells (SK-N-
SH cells). 
Potential for SFN to protect 
against ox stress-induced by 
anti-psychotics 
• 2.5 µM and 5.0 µM  60% and 140% 
increase in GSH. 
• 2.5 µM and 5.0 µM  175% and 250% 
increase in NQO1 activity. 
• Doses > 5 µM reduced cell viability. 
• 2.5 µM and 5.0 µM maintained normal 
lipid peroxidation in the presence of 
Haloperidol. 
• SFN at these doses protects 
dopaminergic cells from the oxidative 
stress-induced by antipsychotic drugs, 
including Haloperidol at a dose to 
reduce cell viability by 80%. 
Tan et al. 
(2010)221 
Bronchial 
epithelium – 
normal and 
0.5 – 2.0 µM Normal human bronchial 
epithelial cells (NHBE)  
• NHBE cells:  SFN  ~ 4-fold increase in 
NQO1 at 0.5 and 1.0 µM at 24 hours 
and 11.8-fold at 6 days 
• HBEC cells:  SFN  7.5-fold increase in 
NQO1 at 2.0 µM, only at 48 hours 
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Lead Author & 
Year of 
Publication  
Tissue SFN µM Conc. Cell Type & Effect Finding 
 cancerous & Immortalised human 
bronchial epithelial cells 
(HBEC) 
Malignant lung 
adenocarcinoma cells (A549 
cells) 
• A549 cells:  SFN  no change at the 
doses tested 
• No toxicity at 10 µM SFN 
Vauzour, D et al. 
(2010)218 
 
Neural cortex 0.1 – 1.0 µM Cortical neurones.  
Protection against dopamine 
toxicity 
• SFN  maximum protection (~ 30%) at 
0.1 µM and ~ 24% at 1.0 µM 
• No toxicity at 10 µM SFN. 
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5.12 Data from Clinical Studies  
A summary of twenty-two published clinical studies using a variety of intervention 
materials is tabulated in Table 5.2.37,38,41,197,245,318,383-385,397-399,412,424-432  These 
materials include mature broccoli vegetable (raw and cooked), fresh broccoli sprouts, 
MYR-inactive broccoli extract beverage,  MYR-inactive powdered broccoli sprout 
extract (BSE), MYR-active broccoli sprout powder and capsules made from MYR-
inactive broccoli extract.  Several of the studies38,397,398,430 confirm the necessity for 
MYR in optimising SFN Yield, citing cooking and extraction as being the primary 
processes leading to loss of activity. confirm the necessity for MYR in optimising 
SFN Yield, citing cooking and extraction as being the primary processes leading to 
loss of activity.424,245,399  The SFN bioavailability399 from raw broccoli was shown to 
be 10-fold higher than for cooked broccoli.   Plasma SFN peaked at about 1.6 hours 
after ingesting raw broccoli but peaked later at around six hours after cooked 
broccoli. Also apparent in the MYR-inactive materials was that inter-individual 
variability in SFN concentration was considerably higher in those taking the MYR-
inactive material.430  The SFN bioavailability from raw broccoli was shown to be 10-
fold higher than for cooked broccoli.   Plasma SFN peaked at about 1.6 hours after 
ingesting raw broccoli but peaked later at around six hours after cooked broccoli. 
Also apparent in the MYR-inactive materials was that inter-individual variability in 
SFN concentration was considerably higher in those taking the MYR-inactive 
material.    
Others425,428,433,434 demonstrate the bactericidal effect on the Helicobacter pylori 
organism associated with gastric reflux and cancer.  Forty-eight H pylori-infected 
subjects were given 70 g fresh broccoli sprouts daily.428  Three markers of H pylori 
infection declined within eight weeks to below the diagnostic cut-off point.  However, 
once the intervention had stopped, the levels of H pylori returned to baseline levels 
after 8 weeks. 
In evaluating the effect of 25 to 200 g of a 1:4 fresh broccoli sprout homogenate, a 
dose-escalation study41 found that there was a safe and effective induction of Phase 
2 enzyme expression in the upper airways in a dose-dependent manner.  At the 
highest intake, there was a 200% increase in NQO1 activity.  This study is valuable 
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in that it demonstrates the dose required to double activity of NQO1 in tissues of the 
human airway; more importantly, it shows that such doses are achievable through 
diet. 
HDAC inhibition is an epigenetic phenomenon associated with chemoprotection.  
SFN was shown to act as an HDAC inhibitor412 in a mechanism unrelated to its 
activation of Nrf2.  In this study, a single dose of 68 g of broccoli sprouts (claimed to 
yield 105mg SFN) “inhibited HDAC activity significantly in peripheral blood 
mononuclear cells 3 and 6 hours following consumption”.  The effect lasted 24-48 
hours.  
 An important question a clinician might ask relates to the possibility that the 
beneficial effects bestowed upon normal cells by SFN might also protect cancer 
cells.  To be certain that SFN as a therapeutic intervention is both safe and clinically-
relevant, a recent cell culture study compared the effects of SFN on cancer cells and 
normal cells.435  Using four cell types in a prostate model, normal (PrEC), cancer 
(LnCaP and PC3) and benign prostatic hypertrophic (BPH1) cells were subjected to 
15 µM SFN for varying time periods.  The results showed that SFN selectively 
targets benign hyperplastic cells and cancerous prostate cells whilst leaving the 
normal prostate cells unaffected.  These findings hold clinical significance, 
highlighting the potential of SFN as a non-toxic chemopreventive agent readily 
incorporated into the diet as an uncooked vegetable or taken as a MYR-active 
supplement.
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Table 5.2   Clinical studies investigating Sulforaphane (2000 – 2012) 
 
Lead Author 
& Year of 
Publication  
Subject 
Number 
Intervention Endpoint Finding Dosage Relevance 
Conaway et 
al. (2000)424 
 
12 200g fresh or 
steamed 
broccoli 
vegetable– 
single dose 
Compare 
metabolic fate 
of steamed vs 
fresh broccoli 
Bioavailability of 
isothiocyanates from fresh 
broccoli is approximately three 
times greater than that from 
cooked broccoli. 
• Total isothiocyanate plasma 
metabolites peaked between 1 
and 8 hours 
• Total urinary excretion of total 
isothiocyanate equivalents (esp. 
SFN-NAC) occurred at 2-12 
hours 
Galan et al. 
(2004)425 
 
9 14, 28, 56 g 
fresh broccoli 
sprouts twice-
daily for 7 
days 
Can orally 
consumed 
broccoli 
sprouts 
eradicate 
Helicobacter 
pylori 
infection? 
Consumption of oral broccoli 
sprouts was temporally 
associated with eradication of 
H pylori infection in three 
subjects. 
No data provided on sprout 
composition or SFN Yield 
Murashima 
et al. 
(2004)37 
 
12 100 g daily 
fresh broccoli 
sprouts for 7 
days 
Markers of 
oxidative 
stress and lipid 
metabolism in 
healthy males 
and females 
Improved lipid parameters and 
reduced oxidative stress 
markers.  HDL increased only 
in females. 
No data provided on sprout 
composition or SFN Yield 
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Lead Author 
& Year of 
Publication  
Subject 
Number 
Intervention Endpoint Finding Dosage Relevance 
Kensler et al. 
(2005)38 
 
200 Hot water 
infusions of 3 
day-old 
broccoli 
sprouts 
nightly for 2 
weeks 
Could MYR-
inactive 
infusion alter 
the disposition 
of aflatoxin 
and 
phenanthrene, 
predisposing 
to hepatic 
carcinoma 
Significant inter-individual 
differences in bioavailability but 
no overall difference between 
intervention arms was 
observed. 
• Each dose contained 400 µmol 
SFN 
• Inter-individual variability 
between 1-45% of dose 
• DTC (Dithiocarbamate) 
excretion = 49 µmol/12 hours 
 
Gasper et al. 
(2005)383 
 
16 3-phase 
crossover 
dietary trial of 
standard 
broccoli 
vegetable, 
super 
broccoli 
vegetable, 
and water 
Comparison of 
sulforaphane 
metabolism in 
GSTM1-null 
and GSTM1-
positive 
subjects in 
different 
broccoli types 
GSTM1 genotypes have a 
significant effect on the 
metabolism of sulforaphane 
derived from standard or high-
glucosinolate broccoli - greater 
protection that GSTM1-positive 
persons. 
• GSTM null subjects excreted ~ 
100% of urinary metabolites 
• GSTM positive subjects 
excreted ~ 70% SFN 
Shapiro et al. 
(2006)426 
 
12 as 3 
groups of 4.   
3:1 active to 
21 doses for 
7 days of 
glucoraphani
n or SFN 
Evaluation of 
safety, 
tolerance and 
metabolism 
No significant or consistent 
subjective or objective 
abnormal events (toxicities) 
associated with any of the 
sprout extract ingestions were 
Non-toxic at well in excess of any 
practical dose 
 Page 97 of 308 
 
Lead Author 
& Year of 
Publication  
Subject 
Number 
Intervention Endpoint Finding Dosage Relevance 
placebo  observed. 
Cornblatt et 
al. (2007)318  
8 Single dose 
oral broccoli 
sprout 
delivering 
200 µmol 
SFN ~ 1 hour 
pre-surgery 
Evaluation of 
plasma DTC 
concentration 
at ~ 100 
minutes after 
ingestion 
Approx 40-fold increase in 
urine SFN metabolites and a 
90-fold increase in plasma 
SFN metabolites. 
200 µmol oral SFN  2µM in 
breast tissue 
 
Rungapames
try et al. 
(2007)245 
 
12 Single meal 
broccoli 
vegetable 
Comparison of 
beef meal 
composition on 
150g lightly-
cooked or 
broccoli or 
broccoli seed 
with 3 g 
mustard 
SFN Yield 3-fold higher after 
lightly-cooked than fully-
cooked.  No effect of meal 
matrix, only with cooking. 
No effect of meal matrix on SFN 
bioavailability.  Complete cooking 
more destructive than light 
cooking which is more destructive 
than raw 
Gasper et al. 
(2007)384 
 
16 3-phase 
crossover 
dietary trial of 
standard 
broccoli, 3-
fold higher 
glucosinolate 
Comparison of 
gene 
expression in 
gastric mucosa 
6 hours after 
consuming 
broccoli 
Only one gene upregulated by 
more than 1.5-fold in standard 
broccoli. Several genes 
upregulated in the high-
glucosinolate broccoli. 
Apparent threshold for doses of 
SFN influencing gene expression 
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Lead Author 
& Year of 
Publication  
Subject 
Number 
Intervention Endpoint Finding Dosage Relevance 
broccoli, and 
water 
vegetable of 
varying 
glucosinolate 
content 
Traka et al. 
(2008)427 
 
22 Broccoli 
vegetable-
rich diet over 
6 months 
(400 g 
broccoli per 
week) 
Does broccoli 
alter 
expression of 
GSTM1 to 
perturb 
oncogenic 
signalling in 
prostate? 
Broccoli interacts with GSTM1 
genotype to result in complex 
changes to signalling. 
pathways associated with 
inflammation and 
carcinogenesis in the prostate. 
Only the broccoli-rich diet 
influenced expression of genes in 
the androgen receptor pathway, 
insulin signalling TGF-β and EGF 
(Epidermal Growth Factor) 
receptors 
Vermeulen et 
al. (2008)399 
 
8 200 g 
broccoli 
vegetable, 
raw and 
cooked 
Determine the 
bioavailability 
and kinetics of 
sulforaphane 
Broccoli eaten raw 
(bioavailability of 37%) versus 
cooked (3.4%).  
SFN absorption delayed when 
cooked broccoli was 
consumed (peak plasma time - 
6 h) versus raw broccoli (1.6 
h). 
10% greater bioavailability from 
raw vs cooked 
Myzak et al. 3 68 g broccoli 
sprouts 
Effect of SFN 
on HDAC 
Strong inhibition of HDAC 
activity 3-6 hours after 
• 68 g fresh sprouts  105mg SFN 
• Human HDAC activity reduced to 
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Lead Author 
& Year of 
Publication  
Subject 
Number 
Intervention Endpoint Finding Dosage Relevance 
(2007)412 
 
containing 
approx 105 
mg 
sulforaphane 
activity in 
peripheral 
blood 
mononuclear 
cells 
ingestion. Trend towards 
increased histone acetylation. 
~65% after 3 hours - lasted 24-48 
hours 
Riedl et al. 
(2009)41  
 
65 Dose-
escalation 
from 25 g to 
200g fresh 
broccoli 
sprouts 
Effect of SFN 
on the 
expression of 
GSTM1, 
GSTP1, 
NQO1, HO-1 
in the upper 
airway of 
human 
subjects 
Safe and effective induction of 
mucosal Phase 2 enzyme 
expression in the upper airway 
of human subjects, in a dose-
dependent manner. 
• 125 g dose (64 µmol SFN)  > 
50% in NQO1 activity 
• 200 g dose   > 200% NQO1 
activity 
Yanaka et al. 
(2009)428  
 
48 
H. pylori-
infected 
patients 
70 g/day 
broccoli 
sprouts for 8 
weeks 
(glucoraphani
n 420 
µmol/day) vs 
alfalfa 
sprouts 
Effect of SFN 
on gastric H. 
pylori infection 
Markers of H. pylori diminished 
in the broccoli sprout group 
only, remaining low for 8 
weeks after cessation. 
• HO-1 increased 2 to 3-fold 24 
hours after single 50 g dose of 
sprouts 
• 3 markers of H. pylori infection 
declined to below cut-off after 8 
weeks 
• Levels returned to baseline 8 
weeks after end of study 
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Lead Author 
& Year of 
Publication  
Subject 
Number 
Intervention Endpoint Finding Dosage Relevance 
Hanlon et al. 
(2009)385 
 
6 Single and 
repeated 
intake of raw 
broccoli 
vegetable. 
(Noted lower 
than 
expected 
SFN Yield in 
the 
commercial 
broccoli) 
Pharmacokinet
ic study of 
SFN 
Sulforaphane was rapidly 
absorbed with peak plasma 
levels within 1.5h, 
characterised by a long 
terminal elimination phase.  No 
impact of repeated intake, nor 
accumulation. 
• Rapid decline in plasma levels to 
50% after ~ 3 hours, whether as 
single or repeated doses 
• Fresh broccoli from retail sources 
generates very low SFN, even 
when raw 
Kumar et al. 
(2010)429 
 
85 3 diet groups 
to include 
different 
dietary 
glucosinolate
s over 4 
weeks 
Develop a 
method to 
measure 
isothiocyanate 
albumin 
urinary 
adducts 
Hb and albumin adducts are a 
useful marker of isothiocyanate 
intake. 
• More stable adducts for easier 
quantification 
Egner et al. 
(2011)430 
 
50 2 groups over 
7 days. 2 
broccoli 
sprout-
derived 
beverages, 
Comparison of 
bioavailability 
and tolerability 
of SFN from 
beverages with 
and without 
Bioavailability of MYR-active 
SFN-rich beverage = 70% vs 
5% for glucoraphanin-rich 
MYR-inactive beverage. 
• Inter-individual variability in 
excretion was considerably lower 
with SFR than with GRR 
beverage 
• Bioavailability SFR=70% vs GRR 
5% 
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Lead Author 
& Year of 
Publication  
Subject 
Number 
Intervention Endpoint Finding Dosage Relevance 
one 
glucoraphani
n-rich (GRR 
= 325 µmol 
glucosinolate/
g powder) 
and the other 
SFN-rich 
(SFR 
(Sulforaphan
e)= 202 µmol 
SFN/g) 
 
MYR • Taste preference significant for 
GRR 
• 34% null for GSTM1 genotype 
• 51% null for GSTT1 
• SFR better bioavailability and 
more rapid uptake 
• GRR more stable but 
unpredictable and overall poor 
bioavailability 
Clarke et al. 
(2011)397 
 
12 40 g broccoli 
sprouts for 4 
weeks vs 6 x 
broccoli 
sprout MYR-
inactive pills 
(equiv. 3g 
dried sprouts) 
To compare 
glucosinolate 
metabolites 
SFN and 
erucin in MYR-
active broccoli 
sprouts and 
MYR-inactive 
pills 
Broccoli supplements devoid of 
MYR activity do not produce 
equivalent plasma 
concentrations of bioactive 
isothiocyanate metabolites 
compared to broccoli sprouts.   
• Plasma level ~ 2.3 µM from 
sprouts 
• 7-fold higher peak conc. from 
sprouts 
• 74% recovery from fresh sprouts 
vs 19% from MYR-inactive pills 
• Significant inter-individual 
variability 
• SFN and another isothiocyanate 
erucin (ERN) are inconvertible 
but effect is variable between 
subjects 
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Lead Author 
& Year of 
Publication  
Subject 
Number 
Intervention Endpoint Finding Dosage Relevance 
Cramer et al. 
(2011)398  
 
4 42 g fresh 
broccoli 
sprouts (74 
µmol SFN);  
2 g of MYR-
inactive 
broccoli 
sprout 
powder (120 
µmol SFN) 
Can MYR-
active broccoli 
sprouts 
enhance SFN 
Yield of a 
glucoraphanin-
rich MYR-
inactive 
broccoli sprout 
powder? 
The 24 h urinary SFN-N-
acetyl-cysteine recovery was 
65, 60 and 24 % of the dose 
ingested from combination, 
broccoli sprout and GRN 
(Glucoraphanin) powder 
meals, respectively. 
• Enhanced conversion to SFN 
when MYR-inactive powder is 
combined with MYR-active whole 
sprout powder 
• Synergistic effect of combination 
• Fresh sprouts + MYR-inactive 
powder enabled earlier SFN 
conversion 
Bahadoran et 
al. (2011)197  
81 x Type 2 
diabetic 
patients 
10 g and 5 g 
daily of a 
MYR-active 
broccoli 
sprout 
powder 
Can a MYR-
active broccoli 
sprout powder 
reduce 
biomarkers of 
oxidative 
stress in type 2 
diabetes? 
Significant decrease in MDA, 
ox. LDL cholesterol, Oxidative 
Stress Index, and significant 
increase in TAC. No effects 
were found on Total Oxidant 
Status.  Greater effects for 
higher dose. 
• 5g dose    112 µmol SFN 
• 10g dose  225 µmol SFN 
• Higher dose  9% lower MDA, 
~5% lower Ox-LDL, ~16% higher 
TAC 
• Lower dose  4.6% lower MDA, 
no change in ox-LDL and 10.3% 
higher TAC 
   
Clarke et al. 
(2011)431 
 
24 68 g broccoli 
sprouts for 4 
weeks vs 6 x 
broccoli 
sprout MYR-
inactive pills 
Metabolic 
comparison 
between fresh 
broccoli 
sprouts and 
MYR-inactive 
Broccoli sprout supplement 
results in significantly lower 
excreted isothiocyanate 
metabolites, compared to fresh 
sprout. (5-fold lower excretion 
of SFN metabolites). 
• Fresh sprouts demonstrate 
HDAC activity 
• Supplement did not show HDAC 
activity  
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Lead Author 
& Year of 
Publication  
Subject 
Number 
Intervention Endpoint Finding Dosage Relevance 
(equiv. 3g 
sprout 
powder in 
glucoraphani
n content: 
~220µmol) 
supplements.  
Comparison of 
HDAC effects 
Conversion of SFN metabolites 
to ERN metabolites.  HDAC 
findings inconclusive. 
Bahadoran et 
al. (2012)432 
81x type 2 
diabetic 
patients 
5 and 10g 
MYR-active 
broccoli 
sprout 
powder daily 
for 4 weeks 
Cardiovascular 
Risk 
parameters 
At the 10g dose, significant 
decrease in serum 
triglycerides, oxidised LDL: 
LDL and Atherogenic Index of 
Plasma (AIP).   
Required 10g daily dose to 
achieve statistically-significant 
change 
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5.13 Characterisation of the Intervention Material 
The intervention material used in some of the published SFN studies is not well-
characterised, making it difficult in some cases to attribute relevance.  For a food to 
be considered within the realm of medicine as either a functional food or a 
nutraceutical, the properties and effects of its bioactive constituents on human 
cellular function must be well understood.  As described earlier in relation to GST 
polymorphisms, such an understanding should allow for the variable effects in 
individuals in whom gene variants impacting on the relevant pathways demonstrate a 
different response.381,383  Development of a plant-derived medicine or supplement 
requires the knowledge that a certain concentration of the bioactive will result in a 
measurable change at the cellular level.  In the case of studies using broccoli sprouts 
as the intervention material, it is essential that the factors responsible for generating 
bioactive SFN are assayed and quantified.   Such characterisation should include at 
least the level of the precursor, glucoraphanin and the quantity of SFN released.  
Additional assays to quantify the MYR enzyme and ESP, as a modifier of SFN 
release may also be performed but are not essential if yield of SFN and perhaps the 
other broccoli sprout bioactive ITCs, erucin and iberin is known.436  In the presence 
of ESP, variable amounts of glucoraphanin are enzymatically converted to the 
relatively inactive SFN nitrile,253 so removal of ESP is a desirable goal in optimising a 
broccoli sprout ingredient for SFN. If such an ingredient is to be used as a 
nutraceutical, it must be standardised to one or more of the bioactives in order to 
provide within tolerance, clinical predictability.  In a clinical trial, the outcome is less 
meaningful if the data do not exist to draw a relationship between the intervention 
material and the observable effects.  
In a 2004 study, Murashima37 used 100 g fresh sprouts in 12 subjects over seven 
days and reported positive outcomes in a number of parameters related to lipid 
metabolism.  Sprouts vary widely in their composition387,437 due to a range of factors; 
because the sprouts in this study had not been characterised, the study is of limited 
value as a basis from which to extrapolate its findings in the development of an 
efficacious supplement.  Subsequent studies using fresh sprouts have more fully-
characterised the intervention material.  A study397 which compared fresh sprouts 
against a MYR-inactive sprout powder in tablet form measured the plasma 
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concentration of SFN after a dose of 40 g fresh sprouts containing 150 μmols 
glucoraphanin; SFN Yield of the sprouts was not specified.  An earlier unrelated 
study438 using 68 g of fresh sprouts had shown that this dose released 105 mg SFN, 
so that 40 g of fresh sprouts may proportionately yield around 62 mg SFN. 
The effect of a MYR-active broccoli sprout powder was investigated in type 2 
diabetics.432  Eighty-one patients were randomised to receive placebo, 5 g or 10 g 
powder daily over four weeks.  The manufacturer of the powder specified it as 
yielding 22.5 µg/ gram but this was not confirmed by assay as part of the trial.  Using 
these values, subjects received respectively 112 and 224 µmols SFN daily.  The 10-
gram dose resulted in a 9% reduction in markers of oxidative stress as measured by 
malondialdehyde (MDA) and ~ 16% increase in total antioxidant capacity (TAC).  
The lower dose resulted in 4.6% lower MDA values and 10.3% higher TAC.   Effects 
on lipid peroxidation parameters were seen only with the higher dose.  Fasting blood 
glucose dropped by 11.3% at the higher dose and 4.9% at the lower dose.   
In a dose-escalation study41 investigating the effects of SFN in nasal cells in the 
upper airways, subjects were given from 25 – 200 g of fresh sprout homogenate 
daily.  Increased Phase 2 enzyme expression in nasal lavage cells occurred in a 
dose-dependent manner, with maximal enzyme induction observed at the highest 
dose.  The sprouts used in the study claimed a glucosinolate content of 6 µmol/ 
gram.  The SFN levels of the 175g and 200g doses were assayed at 89 and 102 
µmols, respectively.  At doses yielding > 51 µmol SFN (by calculation), a significant 
dose-response in Phase 2 enzyme expression was observed.  At the highest dose 
(102 µmols SFN), there was a 200% increase in NQO1 activity with a 50% increase 
at the dose yielding 64 µmols SFN.  These findings may imply a protective effect of 
SFN in diseases of the airways such as asthma and chronic obstructive pulmonary 
disease and also in countering the effects of airborne pollutants. 
5.14 What Micromolar Concentrations are Possible? 
Based on the available, albeit limited clinical data, we have estimated the micromolar 
concentration which may be possible using a MYR-active whole broccoli sprout 
supplement.  These data are based on the effects of single doses and so do not 
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adequately reflect the clinical situation and the significant effect of cellular 
accumulation of SFN and its metabolites.439 
Ye et al411 and Cornblatt183 showed that 200 µmols SFN was capable of producing a 
2 µM concentration in breast cells.  A dose of 200 µmols corresponds to ~ 35 mg 
SFN.  Our lab’s own unpublished tapped density data on a whole sprout powder 
show that a Size ‘00’ capsule is capable of holding 700mg of powder, with allowance 
for a small quantity of encapsulation processing aids.440  Bahadoran’s 2011 study on 
type 2 diabetics showed that 5 g of their powder contained a dose of 112.5 µmols 
SFN, or 19.7 mg SFN (3.94 mg per gram or 0.4% SFN Yield).197  Had they used 
capsules instead of powder in their study, each subject would have needed more 
than 12 x 700 mg capsules daily to supply 35 mg SFN, a number which is not 
clinically practical. 
To provide 35mg SFN, 8.9 g of the grade of broccoli sprout powder used by 
Bahadoran would be required.  Therefore, to achieve ~2 µM using Bahadoran’s 
powder in human breast cells, around 13 capsules would be required, again 
impractical.  It is likely that other grades of MYR-active broccoli sprout powder 
contain higher levels of glucoraphanin and yield more SFN; in such cases, fewer 
capsules would be required to achieve the same outcome.  If a daily dose of 4 
capsules is practical and a powder with a 1% SFN Yield were available, an 
intracellular concentration of around 2.0 µM may be achieved.   
Clarke et al used 68 g of fresh sprouts, which they claim contained 105 mg SFN.397  
With a drying ratio typically of ~12:1, the fresh sprouts would be calculated to be 
equivalent to ~5.7 g of powder.   For comparison and (unrealistically) assuming no 
processing losses, SFN Yield of such a powder could be 18.4 mg SFN per gram 
(~1.8 % SFN Yield).  The powder used in Bahadoran’s trial yielded 0.4%, so that 
Clarke’s fresh sprouts could have provided around 4-fold more SFN.  There are not 
sufficient available data to make similar calculations for other cell types represented 
in Table 5.1 but it is clear that there can be wide variability in the SFN Yield from 
different forms.  Clarke et al compared their fresh sprout product against a MYR-
inactive broccoli seed extract capsule to demonstrate the marked contrast in SFN 
Yield between the two.397  They conclude that their findings have implications for 
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people who purchase supplements devoid of MYR, believing incorrectly they are 
receiving a dose equivalent to that of fresh broccoli sprouts. 
5.15 Toxicity Issues 
Many of the in vitro studies (Refer Table 5.1) show that micromolar concentrations of 
SFN in various cell types needed to activate cellular defences via Nrf2, range from 
0.2 – 5 µM.209,222,208,219,225,220,221,218  In vitro studies using endothelial cells show that 
SFN is cytotoxic to these cells at concentrations of 20-40 µM and that such 
cytotoxicity is mediated through death receptors and apoptotic signalling.295 These 
levels are well in excess of anything that can be achieved through diet or indeed via 
the broccoli sprout supplements currently available.441  Toxicology studies utilising 
32 different haematology and chemistry tests in human subjects have supported the 
safety of MYR-active broccoli sprouts.426 
5.16 Detoxification Interactions  
As phytochemicals have grown in popularity as supplements, the issue of drug-
phytochemical interactions must be considered.442  In particular, phytochemicals 
which modulate detoxification pathways can have unpredictable adverse effects on 
patients by either increasing or decreasing the available concentration of prescribed 
pharmaceuticals.443  As an added complication, the patient may fail to inform the 
attending medical practitioner that one or more supplements is being ingested 
concomitantly.442   
The Cytochrome P450 (CYP P450) family are drug-metabolising enzymes involved 
in the activation and detoxification of a large number of pharmaceuticals, with the 
CYP3A sub-family involved in the metabolism of more than 50% of all therapeutic 
drugs in clinical use.444  Perhaps surprisingly, naturally-occurring chemicals, at 
dietary levels of intake, can modulate the hepatic and extra-hepatic expression of 
cytochrome P450 levels, resulting in marked changes in the metabolism of 
pharmaceutical drugs.443  Once thought to be relatively benign in their effects on 
drug metabolism, phytochemicals can potentially increase the risk of an adverse 
drug reaction.   
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A well-studied example of such drug-phytochemical interactions is Hypericum 
perforatum (commonly known as St John’s Wort) which can adversely affect the 
immunosuppressant effect of the drug cyclosporine, thus potentially putting the well-
being of the transplanted patient at risk.442 
Similarly, grapefruit and its bioactive component, naringenin have been known for 
over 20 years to inhibit CYP3A4 and patients are often advised to avoid its 
consumption when taking pharmaceuticals.445,446  To illustrate the uncertainty 
associated with trying to classify these phytochemical-drug responses, a series of 
reviewed clinical studies were unable to verify green tea’s known potent in vitro 
inhibition of CYP3A4.447 
If the metabolism of a pharmaceutical is significantly inhibited, it can accumulate to 
higher levels than intended, thereby providing a greater than expected dose.  
Phytochemicals have the potential to both elevate and suppress cytochrome P450 
activity, so that both over- and under-dosing effects can be observed.442    Coupled 
with CYP3A4 inhibition, there are other documented effects of phytochemical-drug 
reactions; the effects on the rate or amount of absorption and interaction with ATP-
dependent transporters can modify the clinical response.  Adding to the complexity is 
the fact that genetic polymorphisms and environmental factors have been shown to 
alter CYP activities, resulting in inter-individual differences in drug effects.448 
If the degree of inhibition is significant, the clinical implications may be relevant for 
the many patients chronically ingesting commonly-prescribed pharmaceuticals such 
as statins, benzodiazepines, antihypertensives, antimicrobials and numerous 
others.445     
Whilst SFN can be an inhibitor of the Phase 1 enzyme CYP3A4, it is also a potent 
inducer of the Phase 2 detoxification enzymes, including GST and NQO1.449  SFN 
typically does not induce Phase 1 enzymes but does induce Phase 2; this is thought 
to retard the activation of a presenting toxin to its more toxic intermediate, enabling 
metabolic conversion to excretable non-toxic compounds via the Phase 2 
enzymes.391 
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There are limited data on the extent to which SFN inhibits CYP3A4.   However, a 
series of experiments using both broccoli extracts and SFN evaluated CYP3A4 
protein levels in human hepatocytes; there was a reduction of CYP3A4 protein to 33 
± 5% and 37 ± 8% for the 10 and 25 μM SFN concentrations respectively.393  The 
authors consider whether it is possible for SFN to reach a concentration in the liver 
sufficient to inhibit CYP3A4 expression following dietary exposure, given that a 
single dose of 200 μmols (35 mg SFN) has been shown to be necessary to achieve 
a plasma level of 2 μM.411  They comment that substantially higher peak 
concentrations are likely to be seen in the liver because of extensive first pass 
clearance of SFN by the liver.393  SFN in this study was shown to reduce DNA 
adduct formation following exposure to aflatoxin B1.  Where repression of genes 
involved in CYP3A4 gene activation can lead to undesirable interactions with 
pharmaceuticals, such repression can also have beneficial effects; in this case, 
reduction of aflatoxin B1 bioactivation with subsequent reduction in DNA damage.  In 
a tissue culture study using Caco-2 cells, Lubelska et al. recently described the 
variable effects of different concentrations of SFN in combination with several 
pharmaceutical drugs; SFN was shown to alter the metabolism and transport of the 
drug. How this might translate to the in vivo situation is not known.450 
Clearly, this complex area is in need of much more investigation and clinicians 
should be aware that when any phytochemical supplement is ingested in conjunction 
with a pharmaceutical, the patient’s response should be monitored with a view to 
modifying dosages if necessary.  
5.17 Anticoagulants Reliant on Vitamin K1 Inhibition  
The pharmaceutical drug, coumadin (Warfarin) is an anti-coagulant drug with a 
narrow therapeutic index.  As such, too much or too little of the drug can lead to 
either haemorrhage or formation of vascular blood clots.  Its principal mechanism is 
reliant on inhibition of endogenous synthesis of vitamin K-dependent clotting factors.  
Because vitamin K is found abundantly in plant foods and especially green leafy 
vegetables including crucifers, patients taking this drug are typically advised to avoid 
consuming these vegetables and to ensure that such intake is consistent.451  In 
considering whether or not to recommend a broccoli sprout supplement to a patient 
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prescribed coumadin, the effect of such a supplement on the drug’s vitamin K-related 
metabolism is of clinical relevance. 
Where a standard 80 gram (1/2 cup) serve of broccoli vegetable contains around 
110 µg of vitamin K,452 a 28 gram (½ cup serve) of fresh sprouts contains ~ 38 µg.453  
Since no direct data are available regarding the vitamin K content of dried whole 
broccoli sprouts, hypothetically assuming no losses, an estimate could be made as 
follows:  A half cup of fresh sprouts is equivalent to about 2.3 g of powdered broccoli 
sprout, assuming a typical 12:1 drying ratio.  In most instances, a daily dose of the 
powder would be less than 2.3 g, providing less than one-third of the vitamin K found 
in a single serve of broccoli vegetable.   
A dose-response study examined the effect of broccoli vegetable on the stability of 
oral anti-coagulant treatment in healthy adults.454   The relative bioavailability of 
vitamin K from broccoli was 29% compared with that of vitamin K supplements, 
illustrating the unlikelihood that vegetables consumed in dietary quantities would 
adversely affect coagulation.454  Furthermore, it was shown that the threshold dose 
causing a statistically-significant lowering of the International Normalised Ratio (INR) 
occurred at a dose of 150 μg daily.   
It is not known how the bioavailability of dried whole broccoli sprouts compares with 
fresh sprouts or fresh mature broccoli vegetable.  Even though it might appear that 
an amount of less than 38 µg obtained from less than 2.3 g of broccoli sprout powder 
might be unlikely to destabilise the activity of the drug, the evidence does not exist 
and further investigation is needed.   
As a separate issue, any biochemical which induces the expression of CYP2C9 can 
increase warfarin clearance, thereby reducing the antithrombotic response to a given 
warfarin dose.  Whereas watercress-derived phenyl-ethyl isothiocyanate (PEITC) 
can inhibit CYP2C9, it is not clear if SFN does the same.455    Given the growing 
popularity of broccoli sprouts as functional foods and supplements, knowledge of the 
relationship between regular consumption of the dried sprouts and possible 
interactions with pharmaceuticals including coumadin is of clinical importance. 
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5.18 Thyroid Dysfunction 
A toxic effect of certain glucosinolates on livestock has been known for 
decades261,456 and animals consuming rapeseed meal as a major food source have 
been especially susceptible to the adverse physiological effects of various 
degradative products of glucosinolates.  In humans, such products can block iodine 
uptake by the thyroid gland and retard synthesis of T3 and T4 hormones in the 
gland; hypothyroid goitre may be the outcome.457  Just how significant this is in 
humans regularly consuming broccoli or other crucifers is not clear.   A study on 
thyroid cancer-prone Melanesian women concluded that relatively high crucifer 
intake of ~ 70 g/day increased the risk of thyroid cancer only in those women who 
were moderately iodine deficient (daily iodine intake below 96 µg/day).458 The same 
effect was not demonstrated in European women. 
Clinicians tend to be mindful of the need for caution when counselling ‘thyroid 
patients’ about the consumption of cruciferous vegetables457; however, little is known 
about the threshold levels requiring such caution.  It may be that at risk individuals 
unnecessarily avoid cruciferous vegetables which could provide more benefits than 
risk.459  In the absence of more definitive guidelines, it would seem prudent to 
consider the possibility of iodine deficiency. 
In a mechanistic study, it was recently shown that the administration of thyroid 
hormone, T3 to rats triggers a redox-mediated translocation of Nrf2 from the cytosol 
to the nucleus in rat liver.460  This may represent a cytoprotective mechanism of T3 
to counter electrophile toxicity.  The induction of Nrf2 in this rat model was blocked 
by pre-treatment with NAC.  This has clinical implications since NAC is being 
consumed with increasing frequency as a dietary supplement promoted as providing 
a precursor compound for GSH synthesis.  Such negative implications of NAC are 
not just relevant to thyroid function but also to the numerous cytoprotective 
compounds generated in response to Nrf2 activation. 
5.19 Classical ‘Antioxidant’ Supplements 
It may not be intuitive to consider that vitamins A, C and E could counter the effects 
of Nrf2-activating phytochemicals.   However, several lines of evidence converge on 
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the notion that modulation of the intracellular redox environment by use of 
supraphysiological doses of ‘antioxidant’ vitamins significantly interferes with Nrf2 
signalling mechanisms.36,461-463  That the results of numerous clinical trials using 
‘antioxidant’ vitamins have been disappointing is well-known.464  The mechanism to 
explain this failure is not yet certain but it would seem reasonable to hypothesise that 
interference with Nrf2 signalling may offer one possible explanation.461  It could be 
hypothesised that SFN-initiated gene expression of cytoprotective genes via 
activation of Nrf2 can be inhibited by altered redox state due to the presence of 
direct-acting antioxidants.  How this translates to the clinical environment is not 
known but may signify the need for caution when combining supplements.  In the 
context of a SFN-yielding broccoli sprout supplement, concomitant ingestion with 
supraphysiological doses of redox-modulating supplements such as vitamins A, C, E 
and NAC might negate the potential benefits of the broccoli sprout supplement. 
5.20 Criteria for a Sulforaphane-Releasing Supplement - both preventive and 
therapeutic  
For a broccoli sprout supplement to be suitable as a preventive and/or therapeutic 
agent, it must meet a number of criteria.  These criteria include demonstrating 
retention or presence of both glucoraphanin and MYR in quantifiable amounts, 
elimination of factors which favour SFN nitrile formation over SFN, standardisation 
for a specified glucoraphanin content and/or SFN Yield, a potency capable of 
significantly activating Nrf2, low residue of particulate seed matter and oil, 
compliance with specified microbiological species/concentration for supplements and 
it must maintain stability for a period of at least 24 months. 
5.21 Current Status of Broccoli Sprout Supplements 
A number of broccoli-derived supplements are already commercially-available and 
fall into several categories, each with its own properties.    
5.21.1 Broccoli Sprout/Seed Extracts Delivered as Powders 
An extract is a common delivery form for phytochemical supplements.  To produce a 
powder, typically only the fibrous plant material and water are removed, with or 
without added solvent(s).  Although extraction is a time-honoured method of 
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concentrating bioactive compounds, in the case of cruciferous plants, extraction is 
not appropriate.   Because the reaction between the precursor glucoraphanin and 
the enzyme MYR is initiated in the presence of moisture, the conversion to SFN may 
be complete before the extraction process is finished.  Although glucoraphanin is 
stable over a long period, SFN is not.365  Consequently, the final extract is not likely 
to contain the bioactive components.   
To avoid total loss of glucoraphanin content in producing an extract, MYR in the 
broccoli sprout material must be completely deactivated prior to extraction.465  The 
product of this process is a water-soluble glucoraphanin-rich powder devoid of MYR 
and as such has no intrinsic ability to generate SFN on ingestion.  Such products 
abound in the market where the label typically specifies a quantity of ‘sulforaphane 
glucosinolate’.  However, ‘sulforaphane glucosinolate’ is not a scientific term and 
consumers and clinicians alike understandably but erroneously assume that the 
quantity of the material shown on the label refers to SFN, when in fact, it refers to 
glucoraphanin.466  Any reference to ‘sulforaphane’ is inappropriate for extracts, 
especially given the fact that no SFN is present in any broccoli sprout powder; it is 
generated only with the addition of water and then only in a MYR-active powder.   
MYR-inactive products such as extracts claim to rely on the uncertain composition of 
the colonic microflora to produce limited quantities of SFN.467,387  It is claimed 
extracts have the advantage of being water-soluble and have a milder flavour than a 
whole sprout powder.466  
5.21.2 Broccoli Seed or Minimally-sprouted Powders  
Some products labelled as ‘broccoli sprout powder’ are derived from minimally-
sprouted seed (less than 3 days’ sprouting).  These powders appear yellow-brown, 
coarse and contain a high proportion of particulate matter including visible seed 
husks.  Such products tend to contain a high proportion of oil, making the finely-
milled sprout powder difficult to handle if it is to be used for manufacturing ingestible 
capsules.  Because this oil may also be a source of potentially toxic erucic acid, such 
seed powders are unsuited to production of encapsulated supplements.  Seed 
powders are sometimes marketed as food supplements where bioactives are not 
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named or quantified.  These powders typically retain both glucoraphanin and MYR, 
although these values are typically not assayed. 
5.21.3 Broccoli Whole Sprout Powders  
Although whole broccoli sprout products have been developed with the aim of 
optimising SFN Yield, there are other bioactive substances in the broccoli plant with 
similar and supporting activities.468 The value of a wholefood supplement has been 
highlighted by studies that compare the SFN Yield of a whole sprout with that of an 
extract. The recent work by Clarke et al.397 comparing the in vivo effects of SFN ITCs 
in whole sprouts versus those in a MYR-inactive supplement in humans not only 
reaffirms that erucin and SFN are capable of interconversion but also provides 
further evidence that the bioavailability of SFN and erucin is dramatically lower when 
subjects consume MYR-inactive broccoli supplements versus fresh broccoli sprouts. 
Although there do exist some whole broccoli sprout powders retaining both 
glucoraphanin and MYR, they are not as widely-available as are the extracts.  Their 
appearance is typically more olive-green than yellow-brown and they may or may not 
be finely-milled.  Most are available as unspecified food powders, although some 
manufacturers produce higher-grade finely-milled material, optimised for SFN 
bioactivity.  These ingredients are much better suited to medicinal applications.   The 
dilemma for the clinician is in identifying those commercially-available supplements 
capable of delivering the required clinical outcomes. 
5.21.4 What Can a Clinician Expect of a MYR-active Supplement? 
Clinicians are aware that there are many factors which can prevent the patient from 
adopting changes in eating behaviour; failure is common.   If a patient simply does 
not consume the recommended diet, is there a case for appropriate 
supplementation, not just of nutrients but also of phytochemicals such as SFN, 
known to enhance cellular defences?   
At this incomplete stage of SFN research, clinical trial data regarding therapeutic 
interventions are limited.  Nevertheless, a large body of epidemiological evidence 
shows that even several serves per week of (presumably cooked) broccoli vegetable 
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may confer measureable cytoprotection.419  Therefore, even small amounts of a 
MYR-active broccoli sprout supplement may offer at least the same degree of 
protection.  As a preventive, especially in those whose poor vegetable intake is 
unresponsive to clinical advice, appropriate SFN supplementation may be indicated. 
However, for therapeutic purposes, a relevant therapeutic dose is much more difficult 
to determine. Examining the in vitro data shown in Table 5.1 and the in vivo data 
shown in Table 5.2, it is clear that there is wide variability in the response to SFN in 
different tissue types.  For example, the neural cortex is protected against dopamine 
toxicity at intracellular SFN concentrations as low as 0.1 µM.218  Pancreatic β-cells 
respond to slightly higher doses, with SFN at 2.5 µM increasing cell viability to ~80% 
under conditions of oxidative stress.223  Aortic levels of GSH and NQO1 levels 
increased 25% and 66% respectively at just 0.25 µM.219  However, cardiomyocytes 
required a SFN level of 5 µM to retain 92% cell viability over a 48-hour period.225  
Table 5.3208,209,218-226 summarises the effects of increasing sensitivity to SFN in 
different tissues or cell types.    
Doses required for HDAC inhibition and direct cancer cell kill appear to be much 
higher.  Tan et al221 showed that malignant lung adenocarcinoma cells were 
unresponsive to doses up to 2 µM, even though normal lung cells showed up to a 
7.5-fold increase in cytoprotective NQO1 at this dose.  Inhibition of HDAC activity 
required 15 µM in prostate epithelial cells.232 
5.21.5 Clinically-relevant Doses 
The earlier estimate indicated that ~ 0.6 µM SFN could be achieved in breast cells 
with 4 capsules daily of the powder used in Bahadoran’s trial.  This may be sufficient 
for cytoprotection in pancreatic β-cells, neurons, aortic cells and other cell types. 
Table 5.1 shows that induction of cytoprotective genes coding for NQO1 and GST 
can occur at low intracellular concentrations in a range of tissues.  This should be 
readily achievable with modest intake of a whole sprout powder supplement.  
However, SFN has been shown to accumulate in cells and to conjugate with GSH so 
that both SFN and its metabolites are bioactive.  Accumulation can lead to millimolar 
concentrations.193   Ye and Zhang417 show that Area Under Curve (AUC) calculations 
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based on multiple doses over an extended period may better correlate with inducer 
capacity than that derived from a single dose.  In this way, multiple dosing in a fixed 
time period may enhance induction by some ITCs with initially low activity.  This is 
clinically-relevant in that multiple dosing has a different effect from the single doses 
used in many in vitro studies.    
5.22 Future Research 
Development of a pharmaceutical is a multi-faceted, complex, protracted and 
expensive process.  Many of the same steps are essential in the development of a 
functional food or nutraceutical supplement but since the FDA does not formally 
approve a supplement prior its market release,469 a consumer or a clinician cannot 
be assured of either its quality or the potential efficacy. 
There is a popular perception470 that dietary supplements are inherently safer than 
pharmaceuticals and in 1994, the U.S.  Congress enacted the Dietary Supplement 
and Health Education Act (DSHEA)471 to authorise the regulation of such 
supplements.  The implementation of DSHEA however has led to considerable 
confusion for manufacturers and marketers.  Aware of the growing consumer interest 
in supplements together with the burgeoning costs of delivering health care to the 
community, the FDA recently released proposed guidelines which, if implemented, 
will significantly affect the supplement industry.472  The guidelines specify that new 
ingredients in supplements must be proven to be safe, a situation likely to incur 
considerable extra manufacturing costs.469  However, if inexpensive dietary 
supplements are found to be safe and effective, the requirement for additional 
research could yield significant community cost savings as well as health benefits.473 
The number of published clinical trials for SFN is comparatively small, although 25 
planned or in-process  studies are currently listed with the U.S. National Institutes of 
Health.474  Consideration of the existing SFN clinical trial data against a background 
of epidemiological and in vitro data for cruciferous vegetables and SFN itself would 
seem to indicate that an appropriately-produced MYR-active broccoli sprout 
supplement is safe and could have preventive and clinical value.  In order to give 
clinicians the confidence they need to recommend such supplements, 
standardisation of both nomenclature and assay protocols is essential.   
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Not only is labelling of the currently available broccoli sprout supplements 
inconsistent but there is no reliable way for a clinician or consumer to know if the 
product will yield SFN on ingestion.   The ability to influence cell function is entirely 
due to the yield of SFN and other ITCs, so that reporting other parameters is largely 
irrelevant. 
5.23 Conclusion 
Nutrition professionals and public health authorities encourage individuals to 
consume a diet with the appropriate proportion of plant foods; however, clinician 
experience and large-scale survey data continue to show that adherence to such 
recommendations is generally poor.  Even though no supplement can replace the 
value of a balanced and varied diet, a SFN-yielding supplement capable of 
nutrigenomically inducing the expression of cytoprotective genes may provide a 
health benefit not achievable with the more popular ‘antioxidant’ vitamin 
supplements. A MYR-active SFN-yielding standardised whole broccoli sprout 
supplement may make the health-promoting benefits of the unpopular cruciferous 
vegetable more widely and conveniently available.  
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CHAPTER 6 
Sulforaphane and other Nutrigenomic Nrf2 Activators:  can the Clinician’s 
Expectation be Matched by the Reality? 
This chapter was published in Oxidative Medicine and Cellular Longevity as a 
Review Article.  The abbreviations, formatting and referencing of this document have 
been altered slightly to more closely reflect the formatting of other chapters and 
published work in this thesis.   
A pdf version of the manuscript is attached as Appendix C. 
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6.0 ABSTRACT 
The recognition that food-derived non-nutrient molecules can modulate gene expression 
to influence intracellular molecular mechanisms has seen the emergence of the fields of 
nutrigenomics and nutrigenetics.  The aim of this review is to describe the properties of 
nutrigenomic activators of transcription factor Nrf2 (nuclear factor erythroid 2-related 
factor 2), comparing the potential for SFN and other phytochemicals to demonstrate 
clinical efficacy as complementary medicines.  Broccoli-derived SFN is emerging as a 
phytochemical with this capability, with oral doses capable of favourably modifying 
genes associated with chemoprevention. Compared with widely-used phytochemical-
based supplements like curcumin, silymarin and resveratrol, SFN more potently 
activates Nrf2 to induce the expression of a battery of cytoprotective genes.  By virtue of 
its lipophilic nature and low molecular weight, SFN displays significantly higher 
bioavailability than the polyphenol-based dietary supplements that also activate Nrf2.  
Nrf2 activation induces cytoprotective genes such as those playing key roles in cellular 
defence mechanisms including redox status and detoxification.  Both its high 
bioavailability and significant Nrf2-inducer capacity contribute to the therapeutic potential 
of SFN-yielding supplements. 
KEYWORDS:  glucoraphanin, myrosinase, nutrigenomics, antioxidant, oxidative stress. 
6.1 INTRODUCTION 
Whilst early 20th century nutrition science resolved issues related to micronutrient 
deficiency states and the latter part focused more on macronutrient excesses,475 the first 
decade of the 21st century has already seen old paradigms challenged and new theories 
proposed.  The recognition that food-derived non-nutrient molecules can modulate 
intracellular molecular mechanisms has seen the emergence of the fields of 
nutrigenomics and nutrigenetics, disciplines derived from the interweaving of the 
sciences of nutrition, biochemistry, molecular biology and genomics.  It has been 
estimated that there are more than 5000 different phytochemicals present in food476 and 
our current knowledge is limited to a reasonable understanding of the function of just a 
few.   
Against this background sits the quest to identify biomolecules with significant 
nutrigenomic potential.  A growing body of research highlights one such biomolecule, 
SFN, an isothiocyanate (ITC) derived from the cruciferous vegetable family and in 
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particular from Brassica oleracea.477  Although the plant kingdom is the source of 
thousands of phytochemicals, little is known about the way in which food-derived 
phytochemicals support the maintenance of human health and especially those 
associated with cellular defence mechanisms.  As the science of nutrigenomics evolves 
and our understanding of the many interactions between phytochemicals and 
endogenous cytoprotective mechanisms grows, the significance of plant foods in human 
health becomes clearer.   
A critical review of the formulations of some available supplements reveals numerous 
flaws, shedding doubt on their potential efficacy.478  There are few published clinical 
trials using phytochemicals as the intervention material and only a small number of 
these withstand scientific scrutiny.  However, even when benefit for a compound has 
been demonstrated, it is common for a commercial product to include the ingredient at a 
dose many-fold lower than that shown to be efficacious in either clinical trials or as it 
was traditionally employed by cultures of the past.  As a further trap for the unwary 
consumer or uninformed clinician, supporting commentary may include citations for in 
vitro and animal studies, giving the reader a false impression of the product’s likely 
efficacy as a supplement for humans. 
Because it appears that many consumers have accepted a role for complementary 
medicines in their personal health management, it is important to review the evidence 
on whether plant-derived supplements can assist in modifying various biochemical and 
physiological risk factors for disease.  The aim of this review is to describe the properties 
of nutrigenomic activators of Nrf2, focusing on the potential for SFN and other activators 
of gene expression to demonstrate clinical efficacy as complementary medicines.  
 
6.2 BEYOND NUTRITIONAL DEFICIENCIES AND EXCESSES  
6.2.1 Nutrigenetics and Nutrigenomics   
The interlinked sciences of nutrigenetics and nutrigenomics provide the clinician with a 
more targeted opportunity to personalise a patient’s treatment programme,369 revealing 
those genetic polymorphisms which may compromise individual biochemical function.  
Even without access to sophisticated genome profiling, a clinician’s knowledge that 
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potent food-derived biomolecules can interact with intracellular signalling pathways 
provides another dimension to clinical management and disease prevention processes.   
The realisation that food-derived molecules are in constant conversation with complex 
intracellular control systems via signalling pathways, has unveiled the role of food as so 
much more than a source of micro- and macro-nutrients.479  What becomes immediately 
apparent in this model is that no multi-nutrient supplement can substitute for the 
enormous diversity in phytochemicals present in a balanced human diet.  Also evident is 
that the health benefits of the popular polyphenolic phytochemicals such as those found 
in green tea, grape seed, red wine, curcumin, pomegranate and olives are unlikely to be 
due to direct-acting antioxidant effects demonstrated by these molecules in numerous in 
vitro studies.480,481  Polyphenols are typically large bulky molecules which are poorly 
absorbed and poorly-bioavailable,184 so that it is unlikely that the intracellular micromolar 
concentrations necessary to scavenge free radicals can be achieved.  Polyphenols can 
also behave as either antioxidants or pro-oxidants depending on the experimental 
conditions.482  In addition, newer evidence suggests polyphenols and other 
phytochemicals may function hormetically, whereby dose-response is characterised by 
low dose stimulatory response and high dose inhibition.483   
In a bioactive-specific approach, a recent comprehensive review of phytochemicals 
indicated for cardiovascular disease, focused on both preclinical and clinical beneficial 
effects of four commonly-supplemented compounds.484  The review concluded that 
there are few definitive trials in this area and in some studies the exact dose used is not 
clear.  However, the authors confirm the findings of others in that the use of a very high 
dose is associated with the most protective effects for a few phytochemicals, whereas 
the lowest dose turns out to be the most effective for other compounds. 
As with vitamin ‘antioxidants’, the notion that ingested polyphenol supplements act as 
‘antioxidants’ in human cells is called into question.480 Emerging evidence suggests that 
polyphenols or their metabolites exert their systemic intracellular effects not as direct 
‘antioxidants’ per se but as modulators of signalling pathways.  
6.2.2 Cruciferous Vegetables Harbour Nutrigenomic Potential    
The classification, cruciferous vegetables (crucifers) includes species predominantly 
from the Brassicaceae family and the more common members are cultivars of the 
Brassica oleracea genus including broccoli, cabbage, cauliflower, Brussels’ sprout and 
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kale but also of the Raphanus genus which includes various types of radish.  Although 
these vegetables are good sources of micronutrients, their value to human health would 
seem to be at least partly due to the nature of the phytochemicals they contain and in 
particular the glucosinolates,485 the enzymatic hydrolysis products of which are capable 
of modifying gene expression.486  Although vegetables such as broccoli are not popular 
dietary choices,258 the unique health-promoting value of crucifers continues to be 
reaffirmed.487  A recent review488 investigating the effect of crucifers on total and 
cardiovascular mortality, found that several prospective studies showed no association 
for total vegetable consumption but did show a significant inverse association for 
cruciferous vegetable consumption.  The potential benefits of green leafy vegetables in 
general and cruciferous vegetables in particular are not limited to their effects in cancer 
and cardiovascular disease.  In a 27-year prospective cohort study on cognitive decline 
in ageing women (n=15,080), those in the highest quintile of cruciferous vegetable 
intake declined more slowly than those in the lowest quintile, with a linear dose-
response evident.489  Those in the highest quintile of green leafy vegetable intake also 
experienced slower cognitive decline.  The association did not change when data for 
participants with cardiovascular disease and diabetes were excluded. 
Most research on crucifers has focused on broccoli, Brassica oleracea (both vegetable 
and sprouts) as a source of bioactive compounds with nutrigenomic potential.  The last 
two decades have seen accelerating interest in the role of broccoli in human health 
following evidence that induction of detoxification enzymes might be responsible for the 
majority of the observed health benefits of vegetables.27,490  After isolating broccoli-
derived SFN, Zhang’s group showed that SFN was a major and very potent Phase II 
enzyme inducer.  The group of induced enzymes includes NAD(P)H:NQO1 (quinone 
reductase) and the family of GSTs, both of which are required for the detoxification of 
steroids and the ubiquitous environmental toxin, benzo(a)pyrene.491-493  Zhang et al. 
concluded that the induction of detoxification enzymes by SFN may significantly 
contribute to the anticarcinogenic action of broccoli.  The way that SFN demonstrably 
increased target enzymes is indicative of a nutrigenomic effect, even though the precise 
mechanism to explain such gene expression was not known at the time.  It would be 
another two years before the mechanism to explain the effect of SFN would be 
elucidated.146 
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6.3 INFLUENCING SIGNALLING PATHWAYS  
6.3.1 Nrf2 as ‘Master Regulator’ of Cell Defence  
Although SFN interacts in a number of mammalian biochemical pathways, its effect on 
the redox-sensitive transcription factor, Nrf2 (nuclear factor erythroid 2-related factor 2) 
appears to be responsible for its greatest clinical potential when administered at 
practical oral doses.494  Reference to Nrf2 first appeared in the scientific literature in 
1994 and has subsequently been the subject of over 5,500 MEDLINE published 
papers.146  In the ensuing two decades, Nrf2 has emerged as a key modulator of the 
cell’s primary defence mechanism, countering many harmful environmental toxicants 
and carcinogens.495  Considerable research has focused on Nrf2’s role in preventing the 
activation of carcinogens to toxic metabolites, especially by induction of the Phase II 
detoxification enzyme, NAD(P)H:Quinone reductase (NQO1).496 
The elucidation of the mechanism by which Nrf2 acts as a cytoplasmic ‘switch’ to 
activate a battery of cytoprotective genes arguably heralds a new paradigm in nutrition 
science.  Identification of Nrf2 gave the first real clue that bioactive diet-derived 
compounds like SFN had the potential to co-ordinately influence large banks of function-
specific genes.497 
Nrf2 has been variously described as an activator of cellular defence mechanisms,150 
the master redox switch151 and a guardian of health span and gatekeeper of species 
longevity.152   As a mediator for amplification of the mammalian defence system against 
various stressors, Nrf2 sits at the interface between our prior understanding of oxidative 
stress and the endogenous mechanisms cells use to deal with it.  What has become 
clear is that although attempts to counter oxidative stress by ‘antioxidant’ vitamin 
supplementation have been disappointing,34 many phytochemicals have the capacity to 
activate Nrf2 and thereby induce genes192 which collectively regulate much of the cell’s 
endogenous defence system, enhancing its survival.498  This finding may be clinically 
significant in that diseases known to be underpinned by oxidative stress may prove to 
be more responsive to such amplification of cellular defences via Nrf2 activation than by 
the administration of direct-acting antioxidant supplements.154 
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6.3.2 Sulforaphane - an Inducer of Nrf2 Target Genes    
Notably and perhaps surprisingly, given its significant cytoprotective potential, SFN does 
not exhibit a direct antioxidant effect; instead it is weakly pro-oxidant.499  As further 
evidence to support the critical role of redox signalling in cellular defence mechanisms, 
the ability of SFN to induce NQO1 and cell cycle arrest in prostate cancer cell lines was 
shown to have been completely abrogated by pre-treatment with the glutathione (GSH) 
precursor, N-acetyl-cysteine.209,226  This finding has implications for the regular ingestion 
of readily-available supplements of NAC. 
Sulforaphane [1-isothiocyanato-(4R)-(methylsulfinyl) butane: CH3S(O)(CH2)4 -N =C =S] 
is a small (M.W. = 177.29) aliphatic lipophilic organosulfur molecule which is not present 
in cruciferous or other plants (Supplementary Data; Figure 1).  Instead, plants of the 
Brassica genus contain a biologically inactive precursor compound, glucoraphanin 
(GRN) which is contained within a plant cell vacuole together with an enzyme, MYR 
which is separately compartmentalised.500   It is when the plant cell ruptures and the 
GRN  and MYR come into contact that SFN is enzymatically produced.501 
(Supplementary Data; Figure 2).   Compared with its stable GRN  precursor, the 
resulting SFN aglycone is relatively unstable366;  this has implications for culinary 
applications of broccoli and other cruciferous vegetables.  Broccoli is not the only 
crucifer which yields SFN but it yields the highest amounts, with its GRN content around 
75%431  of total glucosinolates.  Notably, glucosinolate-containing plants contain variable 
quantities of both precursor and enzyme.502  As a result, the yield of SFN and other 
isothiocyanates can vary widely.  
Cutting, chewing or otherwise disrupting the broccoli plant cell structure initiates the 
synthesis of SFN which, compared to its stable GRN precursor, begins degrading soon 
after synthesis.365  For consumers to take advantage of the cytoprotective benefits of 
broccoli and other crucifers, steps must be taken to conserve the integrity of the SFN 
released.   
SFN belongs to one of nine identified classes of chemical Nrf2 activator.503  Structurally 
varied, the only property shared by all inducers is their ability to react with sulfhydryl (-
SH) groups.  Nrf2 therefore is intimately tied to sulfur chemistry and provided dietary 
protein is adequate, a balanced diet should furnish sufficient sulfur.  However, there are 
concerns that sulfur intake in many may be marginal,504 with some researchers 
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suggesting that deficiency of sulfur amino acids can compromise GSH synthesis to a 
greater extent than for protein synthesis in both the presence and absence of 
inflammatory stimuli.505  Whilst vegan diets may provide significant levels of 
phytochemicals,506 there may be a need for vigilance regarding sulfur adequacy, given 
that the sulfur-containing amino acids are least abundant in plant proteins and that 
vegans typically consume about half of the sulfur consumed by those consuming a 
mixed balanced diet.504 
6.3.3 Broccoli Sprout vs. Broccoli Vegetable  
Much of the clinically-relevant Brassica research relates to broccoli sprouts169 rather 
than to the mature vegetable, with most of the early work in this field done by a group at 
the Johns Hopkins University beginning in the early 1990s.  The group found that 3-day-
old sprouts of cultivars of certain crucifers contained 10–100 times higher concentration 
of GRN than the corresponding mature plants.169  With a focus on identifying plants with 
cancer chemopreventive properties, they found that the sprouts were highly effective in 
reducing the incidence, multiplicity and rate of development of mammary tumours in 
dimethylbenz(a)anthracene-treated rats.  Broccoli sprouts also had the added 
advantage of containing mostly the methylsulfinylalkyl glucosinolate (75% of the total) 
and very little of the indole glucosinolate found in the mature plant and which is a 
potential tumour promoter.278  Their realisation that small quantities of broccoli sprouts 
may protect against cancer as effectively as much larger quantities of the vegetable 
stimulated subsequent research. 
6.3.4 How Nrf2 Activators Influence Gene Expression   
Although the complexity of Nrf2- pathways has not yet been fully elucidated, the 
principal elements are depicted in Figure 6.1.252  Essentially, Nrf2 is sequestered in the 
cytoplasm by the actin-bound cytosolic repressor Keap-1 (Kelch-like ECH-associated 
protein 1), a cysteine-rich protein which also acts as a sensor of variations in 
cytoplasmic redox status.  When the appropriate signal is detected by cysteine thiols 
within Keap-1, its ability to bind and retain the transcription factor Nrf2 in the cytoplasm 
is lost.  Keap-1 typically responds to an electrophilic or oxidative stress signal.252  
Thus released, Nrf2 translocates to the nucleus where it aligns with a short nucleotide 
base sequence in the promoter region of its target genes; this sequence is commonly 
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known as the Antioxidant Response Element (ARE) or the Electrophilic Response 
Element (EpRE), the latter considered a more correct descriptor, although the terms are 
used interchangeably.507  To bind, Nrf2 dimerises with other basic leucine zipper (bZIP) 
proteins such as small Maf proteins (MafG) to form a transactivation complex that binds 
to AREs.508 
 
 
Figure 6.1   The mechanism by which Nrf2 activation increases the expression of 
genes with an ARE in their promoter regions.   
Human Keap-1 contains 27 cysteine residues providing sulfhydryl groups (-SH) which act as sensors 
of ARE inducers including oxidative stress.509   Small Maf proteins are essential for Nrf2 function.510  
Figure adapted from Kensler, 2003 with permission.50 
 
When an electrophilic or oxidative stressor challenges the cell, Keap-1 senses the 
disturbance to its cytoplasmic redox equilibrium.   After release from Keap-1, Nrf2 levels 
rapidly rise in the nucleus, upregulating a battery of cytoprotective genes, each 
containing at least one ARE.  Of significance is the effect of Nrf2 on induction of the 
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rate-limiting enzyme for (GSH) synthesis, γ-glutamyl-cysteine synthetase, thereby 
elevating tissue GSH levels.511 
For the Nrf2-Keap1 pathway to such a play a key role in cytoprotection, its activity must 
be capable of being regulated in tandem with the ever-changing cellular environment.  
Under basal non-stressed conditions, Nrf2 is continuously degraded via the ubiquitin-
proteasome pathway.512  With a half-life of around 20 minutes,513 Nrf2 is maintained at a 
low cellular level.514 Exposure to stressors inactivates Keap1 by direct modification of 
cysteine thiol residues, thereafter releasing Nrf2 in a derepression-type stress 
response.515 
The clinical significance of this mechanism is apparent when considering the 
hepatotoxic effects of acetaminophen, a drug responsible for considerable drug-induced 
liver injury.516 Excessive doses of this common analgesic/ antipyretic drug rapidly 
deplete intracellular GSH reserves.  However, the cell activates an adaptive response 
whereby Keap-1 senses the acetaminophen metabolite, N-acetyl-p-benzoquinoneimine 
(NAPQI), subsequently activating Nrf2.517  GSH is synthesised rapidly along with a 
battery of other Nrf2 target genes. This mechanism may not be adequate to increase 
GSH levels in an acute care setting, given that translation times for protein synthesis of 
various Nrf2 target genes can take hours.  A study investigating the effect on gene 
expression of cytoprotective hemoxygenase-1 (HO-1) in neurons after subarachnoid 
haemorrhage showed that Nrf2 levels increased ~ 4-fold at 12 hours, peaking at > 4.5-
fold at 24 hours, with HO-1 levels increased to >3-fold at 12 hours and peaking at >4.5-
fold at 24 hours.518 
6.3.5 Phase II Enzymes and the Detoxification Mechanisms  
The mechanisms that cells use to detoxify potentially-harmful compounds, often 
carcinogens,157,271 can involve a Phase I component associated with monoamine 
oxidases of the Cytochrome P450 family and a Phase II component where the 
intermediate compound produced by Phase I is metabolised in a way that permits ready 
excretion.  A compound which activates Phase I and Phase II enzymes is known as a 
bifunctional inducer; however, if it activates only Phase II enzymes, it is a 
monofunctional inducer.519   Phase II enzymes are induced by Nrf2 and as such are 
integral to this discussion.  For safe and efficient detoxification, a toxin will ideally 
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undergo a relatively slow Phase I reaction followed by a more rapid Phase II; this tends 
to prevent accumulation of the Phase I metabolite which can be more toxic than its 
precursor.13   
Therefore, for an optimal cellular detoxification environment, Phase II reactions should 
be at a rate which prevents intermediate products of Phase I from accumulating.  
Aliphatic SFN acts as a monofunctional inducer, whereas the indole ITCs from mature 
broccoli are bifunctional inducers derived from the glucosinolate glucobrassicin.169  Of 
clinical significance is the finding that Phase II enzymes have a relatively long half-life, 
so that upregulated expression of these proteins can remain for several days.  In a study 
using human adult retinal pigment epithelial cells (ARPE-19), NAD(P)H:Quinone 
reductase remained active for more than 5 days.520  
6.4 INDUCERS OF Nrf2 TARGET GENES 
Nrf2 can be activated by a variety of inducers, not all of which are obtained orally. For 
example, the pro-oxidant signals generated by the ROS released during exercise521 or 
from inhaled environmental chemicals522 are capable of upregulating the cellular 
endogenous defences, provided exposure is sufficiently modest that it does not 
overwhelm the cell’s defences.   
6.4.1 Diet-derived Nrf2 Inducers  
Although a number of phytochemicals have been investigated in relation to their Nrf2-
inducer ability, the mechanistic studies to explain the nature of the induction are limited.   
A 2008 review paper which focused on molecular mechanisms of phytochemicals in 
chemoprevention listed a number of natural and synthetic Nrf2 inducers; many others 
are known.  The authors showed that a number of these have been mechanistically 
investigated but the mechanisms are not known for all.  Of the three naturally-occurring 
molecules they discuss, only SFN, carnosol and quercetin have been mechanistically 
investigated on the basis of their Nrf2 nuclear accumulation.  Furthermore, they state 
that only SFN has been studied for its roles in multiple mechanisms.509   
 
Given the more extensive literature on SFN, we hereafter consider its potential as a 
supplement of clinical significance and where the data exist, comparing its potential with 
that of popular and widely-available phytochemical supplements.  
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6.4.2 Sulforaphane – in Vitro Effects 
SFN is a potent Nrf2 inducer with consequent induction of cellular defences.168  The 
effect is rapid in cell culture with activation by SFN occurring within 30 minutes in human 
bronchial epithelial BEAS-2B cells.523   Using microarray analysis to investigate the 
effect of SFN in the wild-type murine liver, Hu et al. showed that expression levels of 
1725 genes were increased after 3 hours’ exposure and 3396 genes were changed 
after 12 hours.192 Comparing expression patterns at different time points, they also 
showed that maximal change occurred 12 hours after a single administration of SFN, 
based on fold changes greater than 2-fold.  The identified Nrf2 target genes can be 
classified broadly as those coding for a range of cytoprotective proteins, including 
antioxidants (enzyme and non-enzyme), drug-metabolising enzymes, drug-efflux 
pumps, heat shock proteins, NADPH regenerative enzymes, growth factors and growth 
factor receptors, heavy metal binding proteins and various nuclear receptors including 
PPAR-γ as well as for Nrf2 itself.192  
Vitamin D’s protective effects on human cells are well-recognized524; it may be 
nutritionally significant that the vitamin D receptor (VDR) is a Nrf2 target gene inducible 
by SFN525; in turn, vitamin D can increase Nrf2 expression.526  To further illustrate this 
diversity, Nrf2 target genes include those coding for β-defensin-2 (HBD-2), an 
antimicrobial peptide associated with innate immunity, protecting the intestinal mucosa 
against bacterial invasion.  HBD-2 can be induced by SFN525 and was shown in a cell 
culture study using human Caco-2 cells to be significantly induced 1.6-fold at 24 hours 
and 2-fold at 48 hours by SFN concentrations of > 5 µM.  These results may have 
relevance in disorders of the intestinal epithelium but systemically, an intracellular 
concentration of 5 µM is probably higher than can be readily achieved by diet or even 
via practical doses of available oral SFN-yielding supplements. 
The downstream enzyme products of Nrf2 target genes are efficient and versatile.  They 
include those which constitute the glutathione and thioredoxin systems, the major 
cellular reducing systems in the body.191  Several reasons explain their efficiency and 
versatility:28  1) they are not consumed stoichiometrically, as are direct-acting 
antioxidants such as ascorbate and tocopherols; 2) their duration of action is long with 
half-lives measured in days, so their induction need not be continuous; 3) they restore 
the endogenously-produced direct-acting antioxidants like coenzyme Q10 and the 
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tocopherols by returning them to the reduced state (in particular via NQO1 because 
both coenzyme Q10 and tocopherols are quinones).  Major products of Nrf2 target 
genes and their roles in cytoprotection are listed in Table 6.1. 
Table 6.1    Major Products of Nrf2 Target Genes 
PRODUCTS OF Nrf2-TARGET 
GENES 
ROLE IN CYTOPROTECTION 
Glutathione (non-enzyme) 
(GSH) 
Abundant intracellular sulfur-containing direct 
antioxidant – predominant intracellular thiol.264  
Essential in function of Glutathione peroxidase 
and GST for redox balance and detoxification.264   
Haemoxygenase-1  
(HO-1) 
Redox-regulating, broad protection against 
oxidative stress.527   Metabolises haem, also 
producing bilirubin which scavenges peroxyl 
radicals.  Anti-inflammatory and immune-
modulating properties. 528  
Thioredoxin (Trx) (non-enzyme) Ubiquitous intracellular sulfur-rich protein. 
Singlet oxygen quencher and hydroxyl radical 
scavenger.529  
Thioredoxin reductase  
(TrxR) 
An oxido-reductase which regenerates Trx and 
GSH.530  
Glutathione-S-transferase  
(GST) 
A Phase II detoxifying enzyme with broad 
spectrum of activity, depending on subclass.28  
Quinone reductase 
NAD(P)H:Quinone oxido-reductase 
(NQO1) 
A multifunctional redox-regulating and 
detoxifying enzyme, including protection against 
oestrogen quinone metabolites.531   Directly 
scavenges superoxide but less efficiently than 
SOD.315  Stabilises the p53 tumour suppressor 
protein,30 especially under exposure from γ-
irradiation or other oxidative stress. Protective 
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against dopamine cytotoxicity where SOD and 
Catalase were not.532 
Ferritin Binding of free iron to prevent its reaction with 
superoxide to produce hydroxyl radical.533   
Metallothionein Removal of heavy metals such as mercury and 
cadmium.534  
Peroxisome proliferator-activated 
receptor 
(PPAR-γ) 
Regulator of adipogenesis and central integrator 
of glucose metabolism, energy homeostasis and 
skeletal metabolism.535  
Nuclear factor erythroid 2-related 
factor 2  (Nrf2) 
Nrf2 induces its own synthesis.409    
NADPH regenerative enzymes Restores reducing equivalents and reduces 
oxidised GSH to its reduced form.30 
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6.7 QUINONE REDUCTASE (NQO1) – A TOOL TO EVALUATE INDUCER 
CAPACITY 
Initially considered as an Nrf2-activated Phase II enzyme associated with detoxification 
pathways, the function of NQO1 is now considered to be much broader30.   NQO1 has 
been described as a “quintessential cytoprotective enzyme” and is coded by what is 
considered ‘one of the most consistently and robustly inducible genes within its class’.30  
Furthermore, its activity declines with age whilst upregulation of its activity by Nrf2 
induction is described as an avenue for maintaining cellular defences with advancing 
age.152  Furthermore, animal studies show significant decline in Nrf2 activity between 
youth and old age.536-538  Humans genetically deficient in NQO1 are more susceptible to 
the carcinogenicity of benzene exposure.314  NQO1 is highly active in pulmonary 
tissues539 as well as in epithelial and endothelial cells in general,494 suggesting that it 
could act defensively against compounds absorbed via the airways, gut and 
bloodstream.  NQO1 activity is used as a rapid screening procedure and a biomarker of 
the anticarcinogenic activity of phytochemicals.253,503   The assay490 uses cells defective 
in Phase I function to provide the means for selectively distinguishing monofunctional 
inducers that elevate Phase II enzymes.540 
6.7.1 The CD Value as a Comparative Marker 
The term ‘CD value’ describes the concentration required to double NQO1 activity in 
murine hepatoma cells.541  A CD value is also useful for comparing the potential in vivo 
nutrigenomic effect of an ingestible bioactive compound.  The CD value has also been 
used 27,253  to classify Brassica spp. according to their relative ‘anti-cancer potential’.  
When several crucifers were compared for their Nrf2-inducer effect,542  ITCs of cabbage, 
kale and turnips exhibited less NQO1 inducer capacity than broccoli-derived SFN.   SFN 
returned ~33,000 units NQO1 inducer activity/g fresh weight for broccoli, cabbage 
returned ~11,000 units, kale ~10,000 units with turnip ~2,000 units.  This property may 
partly explain why broccoli is researched more extensively than are other Brassica spp. 
6.7.2 Clinical Significance of CD Value 
In data from studies comparing CD values of well-known phytochemicals, SFN showed 
the highest potency, with a concentration as low as 0.2 µM required to double the 
activity of NQO1.27,541  The comparative CD values of other phytochemicals have been 
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documented by others, 32,543-545  with lower micromolar concentrations representing 
those with the higher inducer activity. (Figure 2) 
CD values are available for phytochemicals used in common oral supplements 
32,253,543,544,546: SFN (0.2 µM), andrographolides (1.43 µM), quercetin (2.50 µM), β-
carotene (7.2 µM ), lutein (17 µM), resveratrol  (21 µM ), indole-3-carbinol from mature 
broccoli vegetable (50 µM), chlorophyll (250 µM), α-cryptoxanthin (1.8 mM) and 
zeaxanthin (2.2 mM),  An earlier study conducted in a different laboratory546 had shown 
curcumin (2.7 µM), silymarin (3.6 µM ), tamoxifen (5.9 µM), genestein (16.2 µM ), 
epigallocatechin-3-gallate (EGCG)  (>50 µM ) and ascorbic acid (>50 µM ).  The 
comparative NQO1 inducer activity of these phytochemicals is: SFN> 
andrographolides> quercetin> curcumin> silymarin> tamoxifen> beta-carotene> 
genestein> lutein> resveratrol> I-3-C> chlorophyll> α-cryptoxanthin > zeaxanthin.   
Notably, the CD value of SFN is 13.5-fold greater than that of curcumin, 18-fold greater 
than silymarin and 105–fold greater than resveratrol, all phytochemicals which are 
extensively promoted for their claimed health-promoting properties.  It may be useful for 
relevant oral supplements to be evaluated in relation to the CD value of their primary 
ingredient(s), given that an internet search will readily reveal many self-select and 
clinician-recommended supplements claiming to ‘enhance detoxification’ and ‘promote 
longevity’, even though supporting evidence is not apparent.  Many such supplements 
claiming to target ‘detox’, are based on ingredients such as chlorophyll and vitamin C, 
both of which have comparatively low NQO1 inducer capacity. 
It is also important to note that the CD values discussed above are generated from in 
vitro cell culture data and that both the ranking and the magnitude of these values can 
change substantially when the same compounds are investigated in an in vivo 
environment.  When considering the clinical relevance of such findings, it is useful to do 
so in the context of bioavailability as discussed later in 6.10. 
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Figure 6.2   CD Values of popular phytochemicals used as supplements and a 
commonly-prescribed pharmaceutical.  
CD Values refer to the concentration of a compound required to double the activity of the Phase II 
detoxification enzyme, Quinone reductase.32,253,543,544,546  
6.7.3 Comparing Effects of Indole Glucosinolates 
Indole-3-carbinol (I-3-C), the ITC found in mature broccoli vegetable (but not significantly 
in the sprout) required > 50 µM to double NQO-1 activity253.  In vivo, I-3-C must be 
dimerised in the acidic environment of the stomach to 3,3’-diindolymethane (DIM) to be 
active.547  This has certain clinical implications as synthetic molecules of both I-3-C and 
DIM are available as supplements.  With significantly lower inducer capacity than 
SFN,546 it bears mention that DIM is also a bifunctional inducer of the detoxification 
pathway, thus limiting its cytoprotective potential.  Early research on broccoli sprouts 
suggested potential limitations to the use of indole glucosinolates such as I-3-C as 
chemoprotectors in humans.169  Not only are they weak inducers of Phase II enzymes 
but as bifunctional inducers, they simultaneously activate Phase I enzymes.  They may 
also have estrogen receptor binding activity, adding to their potential as tumour 
promoters.169   
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Interestingly, DIM is sometimes recommended clinically for patients with compromised 
estrogen metabolism, the theory being that DIM inhibits CYP1B.  Inhibition of CYP1B1 
shifts estrogen metabolism towards 4-hydroxyestrone, a metabolite which can 
contribute to carcinogenesis.531  Not all data agree; a 2007 cell culture study analysed 
gene expression using microarray profiling and quantitative real-time–polymerase chain 
reaction in MCF7 breast cancer cells treated simultaneously with estradiol and  DIM.548  
CYP1B1 was upregulated with a fold-change of 3.93 ± 0.25.  Such findings would tend 
to suggest that DIM may not protect against the metabolism of estrogen to the 4-
hydroxy metabolites.  Such conflicting data indicates that clinical trials are required to 
establish the in vivo effects of such an intervention when using a clinically-relevant dose 
of a readily-available supplement. 
To illustrate the differences in potency between SFN and I-3-C in a study using a 
prostate cell line, it was found that both compounds inhibited the proliferation of the 
prostate cancer cells in a dose-dependent manner but the inhibitory concentration of 
SFN required was just 10% that of I-3-C.549  They may also be safety issues which 
require caution in the recommendation of I-3-C supplements, available at many times 
the quantity of I-3-C achievable from broccoli vegetable consumption.  Although I-3-C 
administered one-week after the last dose of the carcinogen has been shown in rats to 
result in a latency delay of mammary tumour formation, it did not alter tumour incidence 
or multiplicity among survivors.550  Any research showing a preventive benefit of this 
compound must be considered against the risk that it may promote liver and colon 
cancer.550 
6.8 OTHER MODES OF ACTIVATING Nrf2  
Although our focus is to compare the inducer capacity of phytochemicals, Nrf2 in human 
cells is activated by a range of stressors, not all of which are chemical in nature.  The 
diverse nature of Nrf2 activators is highlighted in the three examples which follow.  We 
use several examples of pharmaceuticals with pleiotropic Nrf2-inducing effects.  
Furthermore, we illustrate that when pharmaceutical Nrf2 activation occurs at 
supraphysiological levels, the outcome may be unexpected, indicating that the 
significantly lower inducer capacity of diet-derived Nrf2 activators may represent a 
hormetic effect.551 
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6.8.1 Mechanical Effects 
The mechanical effect of blood flow in regions where arteries are exposed to high shear 
stress are protected from inflammation and atherosclerosis.  By contrast, low-shear 
regions are susceptible and this effect has been shown to be due to the effect of Nrf2 in 
reducing activation of the endothelium at atherosusceptible sites.173     
6.8.2 Pharmaceutical Drugs 
The pharmaceutical tamoxifen, commonly-prescribed to women following treatment for 
breast cancer is an NQO1 inducer but its CD value is 30–fold lower than that for SFN.552  
Nrf2 inducer activity may play some role in this drug’s therapeutic profile in addition to its 
primary role as a selective estrogen receptor modulator (SERM).552  These comparative 
data may be clinically significant when considering the potential value of a drug or 
supplement with cytoprotective potential.   A number of other pharmaceuticals activate 
Nrf2.  The redox-modulating activity of the frequently-prescribed statins and Angiotensin 
Converting Enzyme (ACE) inhibitors has been attributed to their Nrf2-inducer ability.553  
Similarly, gold salts, once the mainstay of treatment for rheumatoid arthritis, are Nrf2 
inducers.554  Indomethacin, now seldom used in reducing the symptoms of inflammatory 
joint diseases has Nrf2-inducing properties, illustrating that non-steroidal anti-
inflammatory drugs (NSAIDs) exhibit properties other than their anti-inflammatory 
effects.555   
A relatively new pharmaceutical, Bardoxolone Methyl (BARD) was shown to enhance 
estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease, a 
disease characterised by significant oxidative stress.556,557,558  BARD is a synthetic 
analogue of oleanolic acid, a triterpenoid found extensively in edible plants559 and with 
broader cytoprotective properties attributed to Nrf2 induction.179   The Phase 3 BEACON 
Trial560 was halted in October 2012 following adverse events including 57 deaths out of 
2185 participants in the BARD arm.561  In comparing the inducer activity of BARD with 
that of SFN, a 2005 study comparing a range of triterpenoids showed that BARD was 
230-fold more potent than SFN as a NQO1 inducer.562   The adverse effects 
demonstrated by the synthetic triterpenoid analogue in the BEACON trial may be 
representative of a hormetic response at the upper end of a bifunctional dose-response. 
By contrast, phytochemicals at the doses provided by foods are typically non-toxic.551 
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6.8.3 Exercise 
Exercise is associated with an increased flux of glucose and oxygen through the 
mitochondria, a process which increases levels of ROS such as superoxide.  An 
essential role for exercise-induced ROS formation in activating transcription factors and 
co-activators has been proposed.119  Ristow et al demonstrated that typical exercise-
related changes in gene expression were almost completely abrogated by daily 
ingestion of supplements of vitamins C and E at doses of 1000 mg and 400 IU 
respectively.   
A review highlighted 23 studies showing that antioxidant supplementation interferes with 
exercise training-induced adaptations.463  An emerging theme375 supports the view that 
because Nrf2 is activated by a mild pro-oxidant signal, high doses of antioxidant 
supplements may blunt signals required to activate endogenous defences.563,564  
Ristow’s assertion that antioxidant supplementation blocks many of the beneficial effects 
of exercise is supported by such evidence. 
6.9 OTHER ACTIONS OF NQO1 WHICH CAN BE INFLUENCED BY 
SULFORAPHANE 
NQO1 exhibits broad substrate specificity extending well outside its better-known role as 
a Phase II inducer; its other roles as described in the following section may contribute to 
its cytoprotective capacity.   Its actions include: 1.) Protection against benzene-derived 
quinones such as benzo(a)pyrene, a carcinogen found commonly in petrochemical 
exhaust gases and in barbecued meats 565;  2.) NQO1 can reduce catechol estrogen 
quinones to catechol estrogens, a process associated with lowering breast cancer risk 
due to elevated estrogen metabolites.566 3.) NQO1 can scavenge superoxide, albeit at a 
lower order of magnitude than does SOD.567  4.) NQO1 stabilises p53, the tumour 
suppressor gene30; 5.) NQO1 restores oxidised coenzyme Q10 (ubiquinone) and the 
tocopherols to their reduced forms.30 
Several NQO-1 polymorphisms exist and these have been associated with risk of 
carcinogenesis. The C609T gene variant is one of very few common SNPs known to 
almost completely eliminate enzymatic activity; consequently, NQO1 is attracting 
considerable research attention given its multiple effects in cellular defences.568  
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6.9.1 Other Mechanisms – Animal Studies 
Although a large volume of the published SFN research is associated with its Nrf2-
inducer potential, some studies point to other mechanisms.  A recent study used 
broccoli sprout juice as the intervention material in stroke-prone spontaneously-
hypertensive rats to investigate possible effects on renal damage.569  After 4 weeks, the 
animals were shown to have been largely protected against renal damage.  
Mechanistically, the effect was shown to be independent of systemic blood pressure but 
to parallel stimulation of the AMPK/SIRT1/PGC1a/PPARa/UCP2 axis.  Whether this can 
be replicated in humans at practical doses has not yet been investigated. 
6.10 THE ISSUE OF BIOAVAILABILITY 
6.10.1 Comparative Effects of Popular Phytochemical Supplements 
Aside from wide variation in Nrf2 inducer capacity, a second barrier to clinical efficacy is 
bioavailability.  When bioavailability is low, cell culture studies may significantly over-
estimate the intracellular concentration that ingestion of such a compound can achieve, 
being unlikely to demonstrate the expected clinical benefit indicated by the in vitro 
work.570,571  In considering the potential clinical efficacy of a phytochemical, the active 
compound and/or any of its active metabolites must reach the cells of the target 
organ(s) in appropriate concentration.  Oral bioavailability of polyphenols is typically < 
10%, ranging between 2 and 20%,572 with many closer to 1%; cooking and processing 
significantly reduce polyphenol content.352   By comparison, a pharmacokinetic animal 
study showed that SFN was rapidly absorbed with its absolute bioavailability 82%.573 
Many phytochemical-containing supplements contain polyphenolic molecules such as 
curcumin (turmeric), catechins (green tea), resveratrol (grapes), and ellagic acid (berries 
and pomegranate), hydroxytyrosol and oleuropein (olives).  Much of the evidence used 
to promote these supplements is either from in vitro or animal studies, with limited 
clinical evidence to support the assertions.  Supplements of these phytochemicals 
frequently bear an ‘antioxidant’ claim, even though the amount of polyphenol reaching 
the circulation or target cells is seldom adequate to alter redox status,480,574 gene 
expression studies have helped in quantifying likely systemic responses.  Preclinical cell 
culture or animal studies may involve very high doses of an isolated polyphenol.  Such 
doses are seldom clinically practical, considering average dietary intake of mixed 
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polyphenols in food is approximately 1gram per day of poorly-bioavailable 
compounds.181  
 
   Figure 6.3. Comparative Bioavailability of Phytochemicals commonly used in 
supplements.182,545,575-578 
 
Curcumin, resveratrol and silybin are examples of popular polyphenol supplements for 
which preclinical findings cannot be readily extrapolated to the clinical environment.  
Figure 6.3 compares the  bioavailability of several polyphenols with that of SFN [native 
curcumin at ~ 1%,575 resveratrol < 1%,577 and silybin ~ 0.73% 576].   In each case, the 
systemic bioavailability compares the plasma concentration of an oral dose to an 
intravenous dose and is expressed as a percentage, where F = Bioavailability.545    
F oral = (AUC oral/Dose oral) / (AUC i.v./Dose i.v.) × 100% 
The high intracellular concentrations of polyphenols required to replicate in vitro findings 
are difficult to achieve in humans with practical oral doses.   
There is some evidence to suggest that the activity of some polyphenols may instead 
reside in their metabolites,579  so that small quantities absorbed intra-cellularly act as 
signalling molecules and may act synergistically with other biomolecules.580  It is likely 
that any direct antioxidant effects occur only within the lumen of the gut and not 
systemically. 482,581  
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Quercetin naturally found in onions, watercress, tea and other plants, is a popular oral 
supplement typically promoted as an ‘antioxidant’ or ‘anti-inflammatory’ agent.  Some 
studies suggest that quercetin may have anti-cancer potential582 but other studies 
describe potential for risk,583 given that quercetin may exhibit pro-oxidant effects, 
especially in a GSH-depleted cellular environment.584 
Specifically, quercetin can exert an inhibitory effect on the metabolism of catechols via 
the catechol-O-methyltransferase enzyme (COMT).585  This may have implications in 
estrogen-related disorders where inappropriately-metabolised estrogens can form DNA 
adducts.531  Whether oral doses of quercetin have these effects in humans is not known 
but the issue has been flagged as ‘concerning’ since readily-available quercetin 
supplements represent up to 100 times the quantity typically available in a Western 
diet.586  
6.10.2 Curcumin 
Curcumin is regarded as having in vitro anti-inflammatory activity by virtue of its ability to 
inhibit the transcription factor, NF-κB.587  In a study investigating inflammation in human 
tenocytes, high concentrations of 5–20 µM were required to inhibit IL-1β-induced 
inflammation.588  However, very high oral doses in humans (up to 8 g) yielded curcumin 
peak intracellular levels of only 0.5 – 2.0 µM, clearly not attaining a concentration of the 
same order; commonly-recommended supplemental doses of up to 180 mg were 
undetectable in plasma.589,590  Laboratory findings demonstrating an impressive and 
diverse array of cytoprotective effects for curcumin may not generally apply to practical 
oral doses in humans.591   
By contrast, there is evidence for an effect in gastrointestinal tissue, where transport 
occurs across a single enterocyte membrane.592,593  Patients with colorectal cancer 
were administered doses up to 3.6 g curcumin daily.594  M1G, a marker of DNA damage, 
decreased 38% in the colorectal tissue, showing that a dose of 3.6 g daily achieves 
pharmacologically efficacious levels in colonocytes but with negligible distribution 
outside the gut, confirming its poor systemic bioavailability.   
When considering both CD value and bioavailability, native curcumin with bioavailability 
of ~ 1% would appear to be less clinically-relevant than SFN which shows both high 
inducer activity and high bioavailability.  Even enhanced forms of curcumin with ~ 7-fold 
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higher bioavailability still exhibit comparatively low bioavailability.595  Investigating 
physiologically-achievable doses of curcumin, Lao et al, administered from 500 - 12,000 
mg of a curcumin powder; no curcumin was detected in any of 74 participants taking up 
to 8,000 mg; low serum levels in the ng/ml range were detected only for doses > 
8,000mg, with doses below 4,000 mg barely detected.596  Similarly, curcumin was not 
detected in normal liver or colorectal liver metastases in patients receiving 3.6 g/d for 1 
week.594 Howells et al conclude that in vitro studies with curcumin in the high 10 μmol/L 
range or below might have human physiological relevance but that its role as a 
chemopreventive agent may lie primarily within the gastrointestinal tract.590 
6.10.3 Resveratrol 
Resveratrol achieved international acclaim after studies in mice and lower organisms 
indicated that it was responsible for a longevity effect.597 Only mice administered 
resveratrol from birth lived longer; those started at middle age had no longevity 
benefit.598  The benefit appeared due to enhanced expression of survival genes, a 
number of which are also expressed during caloric restriction.599 
The longevity effect has never been tested in humans, so an appropriate dose is not 
known nor even if a longevity benefit is likely.600,601  Although well-absorbed, resveratrol 
displays low bioavailability; at least 70% of an oral 25 mg dose in human subjects was 
shown to appear as resveratrol metabolites in plasma, with most of the oral dose 
subsequently recovered in the urine.577  Like curcumin, resveratrol is readily absorbed 
by enterocytes/ colonocytes,578 showing potential benefit to intestinal tissues.  A daily 
resveratrol dose of 3000 mg administered to overweight or obese men with non-
alcoholic fatty liver disease (NAFLD) over 8 weeks, did not significantly improve any of 
the features of NAFLD over placebo.602   
A review of 3650 publications on resveratrol concluded that the evidence is not 
sufficiently strong to justify a recommendation for resveratrol to humans beyond the 
dose which can be obtained from dietary sources, estimated to be ~ 4mg daily for 
adults.603   
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6.10.4 Silymarin 
Silymarin, the major flavonoid complex in Silybum marianum has a long history of 
traditional use in liver disorders.604  Silymarin supplements claiming to target human liver 
detoxification mechanisms are readily-available.  Silibinin, the most bioactive of the 
complex is insoluble in water, not lipophilic and with low bioavailability of 0.73% in 
rats.576  Its CD value ranks next below curcumin and third after SFN.  Where optimising 
Phase II detoxification is the desired outcome, there may be value in considering both 
CD values and bioavailability.  Such evidence sheds considerable doubt on the likely 
efficacy of many such phytochemicals at doses typically found in commercially-available 
supplements.  Nevertheless, published trials show that silymarin exhibits hepato-
protective properties in humans, indicating that other mechanisms may be 
responsible.604,605 
6.10.5 Sulforaphane 
SFN’s lipophilic nature and low molecular weight readily enable passive diffusion into 
cells.573  It is rapidly absorbed, peaking in plasma as early as 1 hour after ingestion.318 
Predictably, dose-dependent pharmacokinetics in rats reveals that bioavailability 
decreases with increasing dose.573  The doses corresponded to ~ 0.5mg, 1.0 mg and 
5.0 mg/kg of pure SFN, a relatively high for humans who typically consume a Brassica 
vegetable and not pure SFN.  It is unlikely that humans, through diet would ingest such 
high quantities of SFN.  By calculation, a MYR-active whole broccoli sprout supplement 
yielding 1% SFN could deliver 10 mg SFN per gram of powder, corresponding to ~ 12 g 
of fresh broccoli sprouts (dried powder retains ~ 8% moisture).  Administering 5.0 mg/kg 
of SFN to a 70 kg human at the upper end of the animal dose range represents an 
intake of 350 mg or 35-fold the quantity that a human might reasonably ingest from 
dietary the fresh sprouts.  Clearly, these quantities are not a practical means of 
providing a broccoli sprout supplement for human use. 
6.10.6 Dose Considerations in Humans 
An indication of what might be practically achievable with supplementation is illustrated 
by several human studies.  Ye et al. showed that after a single 200 µmol oral dose of 
SFN, both SFN and its metabolites were detected in plasma and erythrocytes in just 15 
minutes, peaking in all four subjects at ~ 2.00 µM after 1 hour and declining with first-
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order kinetics, with a mean half-life of 1.77 ± 0.13 hours.411  To investigate effects in 
systemic tissue, Cornblatt et al. showed that one hour after a single 200 µmol oral dose 
of SFN administered to 8 women, metabolites were detected in resected left and right 
breast tissue at concentrations of 1.45 ± 1.12 and 2.00 ± 1.95 pmol/mg tissue 
respectively.  (Section 4.14.5 queried the validity of the units shown here; more likely, 
the correct units were pmol/g.)  This proof-of-principle study observed a significant 
induction of NQO1 enzymatic activity in the same tissue.318  In another example, a 
dose-escalation placebo-controlled study investigated Phase II gene expression in 
human airways mucosa, showing that a 200 gram broccoli sprout homogenate 
delivering 102µmol of SFN increased NQO1 mRNA expression by almost 200%.41 
Given that oral doses appear capable of increasing NQO1, we consider whether it may 
be possible that a SFN-yielding broccoli sprout powder might deliver a plasma 
concentration of ~ 2.00 µM.  By calculation, a 1% powder yields 56.4 µmol SFN per 
gram.  Ye et al. showed that a single 200 µmol dose resulted in a peak plasma 
concentration of ~ 2.0 µM after 1 hour.   As Ye411 et al. had shown that a 200 μmol oral 
dose had resulted in a plasma concentration of ~ 2.0 µM and Riedl41 had shown that 
102 μmol had increased NQO1 mRNA expression by ~ 200%, these orders of 
magnitude could be achievable with a SFN-yielding broccoli sprout powder.  
Theoretically and by calculation, an individual could consume around 2 g of a 1% SFN-
yielding broccoli sprout powder to achieve what Riedl et al. achieved with 200 g broccoli 
homogenate and 4 g to achieve what Ye et al, achieved with a single 200 µmol dose. 
6.11 FACTORS GOVERNING SULFORAPHANE YIELD 
6.11.1 The Role of MYR 
Glucosinolates as Brassica-derived precursor compounds are converted to their 
bioactive forms only under the action of MYR because GRN has no inherent bioactivity.  
Investigating the metabolic fate of ingested broccoli phytochemicals, Shapiro et al. 
showed that MYR-inactivated broccoli resulted in 10-20% lower conversion to ITCs.  
When the colonic microflora were reduced, recovery of ITCs in a MYR-free environment 
was negligible.  It may be inferred that MYR is essential for SFN synthesis and that the 
colonic microflora may exhibit MYR-like activity. 
 Page 144 of 308 
 
The colonic microflora appear capable of limited MYR activity, with conversion to the 
bioactive ITC varying from 1% to 40% of the dose.606  Several genera of human 
microflora such as Bifidobacterium, Lactobacillus and Bacteroides have been reported 
to possess MYR-like activity 607 but with wide variability in their population, the ability to 
hydrolyse glucosinolates cannot be reliably estimated.  So unpredictable is this factor 
that a large clinical trial using a MYR-inactive BSE could not achieve statistical 
significance.38   Many available broccoli sprout supplements are MYR-inactive extracts 
which claim their clinical benefit is due to the alleged conversion to SFN by the colonic 
microflora.  Neither consumers nor clinicians have any way of knowing if an individual 
harbours MYR-active microflora. 
6.11.2 The Nitrile Factor 
Among crucifers, broccoli contains significant amounts of Epithiospecifier protein (ESP), 
a non-catalytic inhibitor of MYR activity.251  ESP produces inactive SFN nitrile. Under 
certain conditions, the nitrile pathway is favoured, with the hydrolysis product 
constituting as much as 75% nitrile (Figure 6.4).   The colonic microflora also support 
nitrile formation, thereby further limiting the potential of a MYR-inactive supplement608  
ESP deactivation can significantly enhance SFN Yield, illustrating that broccoli and 
broccoli sprout products cannot be meaningfully evaluated on the basis of their GRN 
content alone.   
It is likely that clinical trials using either fresh or powdered broccoli sprouts may give 
conflicting results when the presence or absence of nitrile has not been considered. The 
presence of ESP means that assayed measurement of the SFN Yield is critical in order 
to estimate the real efficacy of a broccoli sprout powder intended for a supplement; 
measurement only of GRN and MYR does not allow for the effect of ESP on enzyme 
activity.  
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Figure 6.4   Epithiospecifier protein (ESP), an inhibitor of myrosinase enzyme 
The presence of Epithiospecifier Protein (ESP) prevents complete conversion of glucoraphanin to 
sulforaphane.  Instead, part of the glucoraphanin is converted to inactive sulforaphane nitrile.  As 
much as 75% of the product of MYR activity on glucoraphanin can be sulforaphane nitrile. 
6.12 CLINICAL IMPLICATIONS 
6.12.1 Cruciferous Vegetable Consumption 
The presence of unquantified amounts of ESP in raw broccoli has clinical implications; 
as a salad vegetable, raw broccoli may not be an efficient means of obtaining the 
benefits conferred by SFN.  Similarly, cooking has been shown to destroy the enzyme in 
as little as 3 minutes of steaming.609.  Five minutes of microwave cooking resulted in 
74% loss of glucosinolates from broccoli florets with high-pressure cooking and boiling 
leading respectively to 33% and 55% losses.253    
Even consumers and clinicians conscious of the importance of cruciferous vegetables in 
the diet may be unaware that open-air storage of broccoli as occurs during transport 
and in retail environments may lose 55% of its glucosinolates after 3 days and storage 
in plastic bags at 22 degrees C may result in similar losses over 7 days.253 
Also of significance is the fact that broccoli cultivars for vegetable production are not 
selected on the basis of their SFN Yield.  It is possible that the cultivars available to 
consumers are not good sources of cruciferous bioactives.  Until Food Law allows 
appropriate health claims to be associated with cruciferous vegetables, there is no 
incentive for growers to select higher yielding cultivars.  In short, neither a clinician nor a 
consumer has the information needed to make an appropriate choice.  
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6.12.2 Supplements Derived from Cruciferous Vegetables 
Similarly, it is not generally known if a producer of broccoli sprout powder as a 
supplement ingredient has deactivated the ESP.  If two supplements contain high levels 
of GRN but one has had the ESP deactivated, the comparative SFN Yield from these 
broccoli sprout powders may be markedly different.  Ideally, a SFN-yielding supplement 
would be characterised on the basis of the various determining factors; the presence of 
quantifiable GRN, active MYR together with the inhibitory ESP.  
These concerns are reflected in a recent study which compared a commercially-
available supplement labelled as containing 30 mg ‘sulforaphane glucosinolate’ per 
dose with a quantity of fresh sprouts containing the same amount of GRN.397 The study 
showed that consumption of a MYR-devoid broccoli supplement when compared with 
broccoli sprouts produced 7-fold lower plasma concentrations of the bioactive ITC 
metabolites in the subjects. Clarke et al concluded that these findings have implications 
for people who consume the recommended dose of such a MYR-inactive broccoli 
supplement believing they are obtaining equivalent doses of ITCs.  This is significant in 
that the available broccoli sprout supplements are dominated by the MYR-inactive 
‘extracts’, even though MYR-active whole broccoli sprout supplements do exist. 
There is a further strong case for a whole food broccoli sprout supplement on the 
grounds that although GRN is the primary glucosinolate found in broccoli and broccoli 
sprouts, it is not the only one; erucin (ERN) and iberin comprise most of the remaining 
25% of the glucosinolate content of broccoli.  Although it has been known for two 
decades that ERN and SFN are interconvertible610, Clarke’s more recent study 
suggested that the clinical effects are likely to be due to the combined effects of all the 
glucosinolate hydrolysis products.397   
6.13 STANDARDISATION 
To compound the difficulties associated with determining the clinical potential of a SFN-
yielding supplement, variations in nomenclature add to the problem.  The term, 
‘sulforaphane glucosinolate’ which has recently appeared in the scientific literature is 
now associated with and specified for commercially-available MYR-inactive extracts 
derived from broccoli seed or sprout extracts.144,397  Since ‘sulforaphane glucosinolate’ 
describes only the quantity of ‘glucoraphanin’, this nomenclature could erroneously lead 
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both clinicians and consumers to believe that the material will deliver SFN when 
consumed. 
6.13.1 Commercial Assay Protocols 
Various methods to describe a SFN supplement are commonly used in industry.  To 
evaluate and compare different broccoli sprout powders intended as supplements or for 
use in clinical trials, assay methodologies must be standardised.  There are several 
common practices for reporting the SFN derived from a broccoli sprout sample but 
because the assay protocol is almost never specified for a commercial product there is 
no way to reliably compare these values from one product to another. 
6.13.2 Sulforaphane Potential 
SFN Potential is a calculated value by measuring GRN and then assuming 100% 
conversion to SFN, whether or not MYR has been retained after processing.  Based on 
relative molecular weights, the measured amount of GRN is multiplied by 0.406 to arrive 
at a SFN Potential.  No provision is made for the presence or absence of either MYR or 
ESP.  Where ESP has not been fully deactivated, calculating SFN Potential will over-
estimate the amount of SFN that could be produced on ingestion. Broccoli sprout 
powdered ingredients or supplements which claim SFN Potential and for which the ESP 
has not been deactivated may yield limited SFN.  
6.13.3 Sulforaphane Yield with Addition of Exogenous MYR 
By adding enough exogenous MYR to ensure full conversion of GRN to SFN, this 
method overcomes the possibility that the starting material may contain only GRN and 
may be completely or partially MYR-inactive.  The assay results may not specify that 
exogenous MYR was added, so that the reader may incorrectly conclude that the 
material will yield SFN on ingestion.   
6.13.4 Sulforaphane Yield Due to Endogenous MYR 
This method more closely resembles the in vivo situation after ingestion of the 
supplement, in that conversion to SFN is entirely dependent on the quantities of ESP 
and MYR retained after processing.  It may provide a lower SFN value when compared 
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with the other methods, even though it may be the method which most reliably 
approximates SFN’s metabolic fate in human physiology. 
The same supplement assayed by each of these procedures is likely to produce quite 
different results and more importantly, only supplements which have retained MYR 
activity are likely to demonstrate in vivo effects.  Methods which assess SFN’s inducer 
capacity in cell culture may more reliably evaluate the clinical potential of a supplement 
or enable comparison of supplements.  RT-qPCR-array and pathway analysis studies 
provide gene expression data which is another step closer to establishing the clinical 
effects of a supplement.611 
6.14 CONCLUSION 
The evolving science of nutrigenomics is in many ways legitimising the important role of 
plant foods in human health, not just as sources of nutrients but as a huge library of 
phytochemicals capable of interacting with intracellular biomolecules to influence gene 
expression.  Of the many thousands of phytochemicals in the food supply, SFN exhibits 
properties which may make it an ideal cytoprotective biomolecule, deliverable in 
practical doses as a whole food supplement.  Attempts to produce SFN-releasing 
supplements have resulted mostly in forms with little or no bioactivity, such as extracts 
of the seed or sprout, rather than as MYR-active whole food products.  When compared 
with other phytochemicals widely-used in dietary supplements, SFN is significantly more 
bioavailable than polyphenols such as curcumin, resveratrol and silymarin.  It is also 
significantly more able to induce NQO1, a Phase II enzyme essential in the metabolism 
of a number of exogenous toxins, oxidised nutrients and endogenous metabolites.  
Such comparative findings call into question the clinical efficacy of many of the 
supplements popular among consumers.  Alleged benefits of such supplements appear 
to require much higher intracellular concentrations than can be achieved with 
reasonable oral intake. 
Initial attempts to produce high-potency pharmaceutical Nrf2 inducers have so far been 
unsuccessful.  Given the prevalence of diet-related disease and the evidence that many 
consumers have accepted a role for complementary medicines in their personal health 
management, appropriately validated SFN-releasing supplements may provide another 
avenue for supporting human health.  Such supplements will need to demonstrate 
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sufficient nutrigenomic potential that they can modify key biochemical and physiological 
risk factors for disease. 
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CHAPTER 7 
Methodological Considerations in Investigating 
the Effects of Sulforaphane on Gene Expression 
-  referencing the EASYGENEX Study 
7.0 BACKGROUND 
The EASYGENEX Study (Effect of a Sulforaphane-Yielding supplement on Gene 
Expression) was initially planned by the candidate to investigate the effect of a SFN 
supplement on a population of otherwise apparently healthy type 2 diabetic men not 
using insulin replacement.  As discussed in Chapter 2, type 2 diabetes has been 
mechanistically associated with perturbed cellular redox status in human cells 
including pancreatic beta-cells.6,281  It seemed reasonable that because antioxidant 
vitamin supplements had not been shown overall to favourably change the course of 
disease progression,5,612 it may be possible to help restore redox status and related 
disease biomarkers by supplementing with a phytochemical Nrf2 activator such as 
SFN.  Induction of Nrf2 target genes is known to generate a range of cytoprotective 
compounds including antioxidant enzymes and non-enzymic biomolecules such as 
glutathione and thioredoxin. 
Interest in type 2 diabetes was partly influenced by Bahadoran’s 2011 trial197 and 
subsequent publications432,613 in which her group had used a manufacturer-specified 
0.4% SFN-yielding whole broccoli sprout powder to demonstrate positive changes in 
metabolic syndrome/ cardiovascular biomarkers.  Their study used large dose 
volumes of an unpleasant-tasting powder, making this clearly impractical as a 
recommendation for regular use by individuals when compared to a standard Size 
‘00’ capsule of the same material which can contain no more than 700 mg.  By 
calculation, the 5- and 10-gram powder doses would have yielded daily SFN doses 
of approximately 20 and 40 mg respectively.  Bahadoran showed some benefits from 
a 5-gram daily dose and greater benefits from a 10-gram dose.  In a low-density 
powder with a tapped density of around 0.4e, 10 g occupies a volume of 25 millilitres, 
clearly impractical for long-term regular therapeutic use. 
                                            
e Typical tapped density measured on the samples used in our university laboratory from sprouts 
grown using Caudill seed stock.  http://www.caudillsprouting.com/Seeds/index.html  
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As the powder used in the EASYGENEX trial had been separately assayed by an 
independent commercial laboratoryf to yield around 1.8% SFN, it was postulated that 
the higher yield would enable supplementation with just a few daily capsules as a 
more practical option.  A small pilot study using real-time quantitative polymerase 
chain reaction (RT-qPCR Array) had been planned to investigate gene expression in 
a range of around 40 redox and inflammation-sensitive genes expected to be 
relevant in individuals with type 2 diabetes as well as to investigate plasma SFN 
metabolites and relevant disease biomarkers. Thereafter, the plan had been to 
review the PCR gene expression findings in conjunction with the polymorphisms 
obtained separately for each participant for a number of the same genes on the PCR 
test panel.  In a further step, the plan had been to investigate protein levels for 
several of the genes showing greatest expression. 
Originally named the EASYDIAB2 Study, it was planned to recruit around six 
participants for this pilot study, expecting that the outcomes would provide 
pharmacokinetic and dose-response relationship data that would inform a larger 
study. 
It later became apparent that in order to select as homogeneous a population as 
possible, the selected exclusion criteria were so narrow that it was difficult to recruit 
suitable individuals to the study.  Consequently, the study design was modified to 
investigate the effect of similarly high SFN-yielding broccoli sprout capsules on a 
population of twenty healthy young men.  To broaden the potential findings of the 
study by accessing a larger gene set, it was decided to utilise microarray instead of 
the more restrictive RT-qPCR platform, even though it is well-established that 
microarrays tend to generate a significant noise-to-signal ratio.614   The detailed 
methodology for the EASYGENEX Study is described in Chapter 8. 
7.1 DESIGNING A STUDY TARGETING Nrf2 MODULATION 
A recent Special Issue editorial615 highlights the role of Nrf2 as an emerging 
therapeutic target.  A number of small-scale clinical trials utilising SFN as the 
intervention compound in various doses and forms have shown positive outcomes, 
                                            
f Eurofins Supplement Analysis Center. http://www.eurofinsus.com/food  
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with authors typically describing the observed responses being associated with 
activation of the transcription factor Nrf2. (Table 7.1) 
In conducting these trials, other known Nrf2 activators and modulators must be 
considered and ideally excluded.  Typically excluded are dietary glucosinolates from 
cruciferous and related plant foods, phytochemical supplements such as green tea, 
pomegranate or turmeric and other polyphenols,200 antioxidant vitamin supplements 
which may attenuate SFN’s weak Nrf2-activating pro-oxidant signal,616 medications 
known to activate Nrf2 such as statins617 and metformin618 and environmental 
stressors such as cigarette smoke.619  The one significant and likely Nrf2 activator 
that had not been excluded is exercise and this factor is addressed in some detail 
later as it appears that the failure to exclude regularly-exercising individuals may 
have impacted the expected findings of the EASYGENEX Study. 
7.2 DOSE CONSIDERATIONS 
What has emerged in recent years is the fact that Nrf2 activation appears to act 
hormetically in that whilst low Nrf2 activity can compromise normal cellular function, 
persistently high Nrf2 activity can also be detrimental to cells.620,621  The latter aspect 
has been harnessed in chemotherapy in which specific pharmaceuticals have been 
developed to inhibit Nrf2 activity in cancer cells, since it is now known that cancer 
cells too can take advantage of the cytoprotective properties of Nrf2 activation.622,166  
Pharmaceutical Nrf2 activation in non-cancer cases must be equally considered with 
caution; the failed Bardoxolone methyl trial561 in patients with chronic kidney disease 
acts as stark warning that attempting to exceed normal physiological limits can have 
serious and sometimes fatal consequences.  As discussed in Chapter 6, the trial had 
to be stopped prematurely when increased number of heart failure events including 
some deaths became apparent.  Chapter 6 referred to the fact that Bardoxolone 
methyl has more than 200-fold greater ability to activate Nrf2 than does SFN.560 
Therefore, what becomes of critical importance in clinically utilising the beneficial 
effects of Nrf2 activators is that an appropriate dosage range can be established for 
both preventive and therapeutic applications.  The review material in Chapters 4, 5 
and 6 addresses many of the issues associated with the significant variability in Nrf2 
inducer potential by phytochemicals as well as the large observed differences in 
bioavailability when attempting to translate in vitro effects into in vivo responses.  
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SFN has been shown to be a potent inducer of Nrf2 as well as being highly-
bioavailable, especially when compared to some popular phytochemical 
supplements.153   
In Chapter 6, it was suggested that it may not be possible that oral dosing of existing 
SFN-yielding supplements could achieve the high intracellular concentrations 
described in the various in vitro studies or in those using large daily quantities of 
fresh broccoli sprouts or sprout homogenates.623  More recently, some supplements 
have been shown to yield higher levels of SFN, such that it may be important to 
more cautiously consider supplement dosage.  Holmstrom et al. highlight similar 
cautions in the conclusion to their paper investigating the role of Nrf2 in 
mitochondrial function by suggesting that both “insufficient and persistently high Nrf2 
activity can have detrimental consequences”.621  SFN has been shown to induce 
Nrf2 in cancer cells as well as in normal cells, highlighting the need for further in vivo 
investigation, since Nrf2 activation is just one of multiple synergistically-acting 
mechanisms by which SFN may confer chemoprotection.157    
7.2.1 EASYGENEX Study – Selecting the Dose 
Because it is well-established that SFN is a potent activator of Nrf2, in most clinical 
trials in which SFN is the intervention material, pathways and outcomes associated 
with Nrf2 activation are the primary focus.  Even so, SFN’s pleiotropic nature has 
been noted in a range of other less well-understood cellular events.157  In this 
context, SFN is also known to exhibit epigenetic effects which include post-
translational histone modification, DNA methylation and post-transcriptional gene 
expression regulation by non-coding microRNAs.163 
A number of in vitro studies have used microarray analysis as their platform for 
investigating gene expression via Nrf2.  A relatively recent study used human retinal 
pigment epithelial cells to examine the effect of SFN on the expression of oxidative 
stress-related genes.  The study found that 10μM SFN was the optimal dose needed 
to enable the cells to counter the oxidative assault.  Mechanistically, SFN was shown 
to activate Nrf2 and induce a number of its target genes.624  
In determining the dose for the EASYGENEX Study, consideration of the range of 
doses utilised in in vitro studies played little part.  Instead, the focus was on the more 
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relevant doses used in the published clinical trials in which SFN has been used as 
the primary intervention.  Comparison was difficult due to the variety of forms in 
which SFN had been administered; some studies used the synthetic form, others 
generated SFN in situ by combining GRN with a plant source of MYR, whilst others 
used fresh broccoli sprouts, an aqueous homogenate of fresh sprouts or a powder of 
dried whole sprouts.  One study claimed to be using a broccoli sprout BSE but the 
Supplementary Materials describing the material showed that it was, in fact a dried 
whole broccoli sprout powder.198  Daily doses of SFN in these studies ranged from 
4.4 mg daily as the lower dose in the chronic obstructive pulmonary disease (COPD) 
study by Wise et al. to 105 mg in the prostate xenograft study by Myzak et al. in 
2007, with others studies selecting doses in between (Table 7.1). 
Where fresh sprouts or their minimally-processed derivatives are used, SFN is not 
the only bioactive compound being investigated, even though it is the most 
abundant.  Other isothiocyanates (ITCs) and a range of other phytochemicals and 
micronutrients may all impact gene expression.  The second most abundant ITC 
generated from MYR hydrolysis of broccoli sprouts is erucin which has been shown 
to readily interconvert with SFN.  When a whole broccoli sprout or whole plant 
derivative is used as the intervention material, converted erucin may contribute to the 
total SFN yield and subsequent effect on gene expression.397 
Table 7.1 Selection of clinical trials utilising various forms of broccoli sprouts or 
sulforaphane as the primary intervention to evaluate their effect on disease 
biomarkers. 
Disease 
and/or 
Biomarker 
Daily Dose Form Reference 
Metabolic Syndrome SFN not specified 
Fresh sprouts    
(100 g) 
Murashima et al.; 
200437 
Helicobacter pylori 
infection 
14 – 56 g fresh sprouts 
(SFN not specified)  
Fresh broccoli sprouts  
(14-56 g) 
Galan et al.; 
2006425 
Prostate xenograft – 
HDAC activity in 
PBMCs 
68 g fresh broccoli 
sprouts, yielding 105 mg 
SFN (as a single dose) 
Fresh broccoli sprouts (68 
g as a single dose) 
Myzak et al; 
2007438 
SFN metabolite 
effects in female 
breast tissue 
35 mg SFN 
Fresh sprout extract + 
daikon MYR 
Cornblatt et 
al;2007183 
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Chronic Obstructive 
Lung Disease 
19 mg SFN 
Broccoli sprout 
homogenate 
Riedl et al.; 200941 
Type 2 diabetes 
40 mg SFN 
(calculated) 
Broccoli sprout powder 
Bahadoran et al.; 
2011and 
2012197,432,613 
Autism 
9 - 14 mg SFN based on 
body weight 
Stabilised SFN supplement Singh; 2014199 
Detoxification 
(Atmospheric 
pollutants) 
262 mg GRN + 7 mg 
SFN 
GRN + daikon MYR in juice 
Egner et al.; 
2014202 
Nasal Allergic 
Response 
18 mg SFN  
GRN extract + daikon MYR 
in mango juice 
Heber et al.; 
2014203 
Off target effects of 
SFN and HDAC 
inhibition 
Claimed to be 18 mg 
SFN per gram fresh 
sprouts g 
Fresh broccoli sprouts  
(34, 68 and 102 g) 
Baier et al; 2014204 
Asthma 18 mg SFN  
GRN extract + daikon MYR 
in mango juice 
Brown et al.; 
2015203 
Prostate – PSA 
doubling time 
60 mg SFN  
Stabilised SFN from seed 
extract 
Cipolla et al.; 
2015200 
Breast tissue 
(biopsied) 
SFN not specified. SFN 
metabolites measured 
GRN supplement  
(180 mg daily) 
Atwell et al.; 2015 
Sickle Cell Disease SFN not specified 
Broccoli sprout 
homogenate  
(50, 100, 150 g) 
Doss et al.;2016205 
COPD – effects on 
two types of 
respiratory cells via 
Nrf2 
Daily SFN at 4.4 mg and 
26.6 mg 
SFN extracted from fresh 
broccoli sprouts 
Wise et al; 
2016206,207 
Type 2 diabetes – 
hepatic glucose 
production 
Daily SFN of 27 mg in a 
5-gram powder dose 
Whole broccoli sprout 
powder, described as a 
broccoli sprout extract 
(BSE) 
 
Axellson et 
al.;2017198 
(Supplementary 
material) 
                                            
g The SFN yield claimed by Baier et al is in stark disagreement with those stated by Myzak et al 
(2006) using the same fresh sprouts (Broccosprouts®).  Myzak et al. claim that 68 g fresh sprouts 
yield 105 mg SFN, whereas Baier et al. claim that their sprouts yield 18 mg/ gram fresh weight.  It is 
unlikely that Baier et al are correct when comparing their values with those used in other studies.  
Baier et al state later in their paper that their dose is similar to that available in a BroccoMax® 
supplement that lists one serving of the product to contain ‘30 mg sulforaphane glucosinolate’.  Baier 
et al. don’t comment that such a supplement is devoid of myrosinase and is therefore not equivalent 
to a supplement that yields 30 mg sulforaphane. 
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The highest daily dose used in the studies listed in Table 7.1 is 102 g of fresh 
broccoli sprouts.  If it is assumed that Baier’s stated SFN Yield is incorrect (explained 
in Footnote g above) and instead use Myzak’s stated SFN Yield for fresh 
commercially-available sprouts carrying the same brand name, then Baier’s highest 
dose of 102 g fresh sprouts would then have been equivalent to 158 mg SFN.  
Myzak’s stated SFN Yield from fresh broccoli sprouts is in agreement with the order 
of magnitude stated by Riedl et al41 in their study which used a homogenate of fresh 
broccoli sprouts. 
Myzak and Baier both use HDAC inhibition as their outcome measure.  Two earlier 
cell culture studies by Myzak et al230,232 showed that 15 µM SFN significantly 
inhibited HDAC in human embryonic kidney cells, colorectal cancer cells and three 
different prostate epithelial cell lines.  The group’s working hypothesis was that it was 
not so much SFN itself that was responsible for the observed HDAC inhibition but 
more the SFN metabolites produced through the mercapturic acid pathway; the 
EASYGENEX Study therefore includes measurements of the SFN metabolites. 
Chapter 5 queried whether it is possible to achieve the higher intracellular levels 
shown to be associated with HDAC inhibition in tissue culture.  In 2002, Ye et al411 
reported that in four human volunteers, a single total ITC dose of 200 µmols (~ 35 
mg, most of which is likely to be SFN) from a MYR-hydrolysed extract of 3-day 
broccoli sprouts resulted in 0.943 ± 2.27 µmol/l in plasma, serum and erythrocytes at 
one hour after feeding.  They further comment that peak plasma levels reached 2 
µM. The authors of the study comment that the ITC and ITC metabolite levels in 
erythrocytes contained only low micromolar concentrations in contrast to the much 
higher millimolar concentrations that can accumulate in tissue culture studies.625  
They suggest that this is because most of the ITCs in the blood were in the form of 
conjugates rather than as free ITCs, given that most conjugates are absorbed very 
slowly in tissue culture studies compared with the rapid absorption of ITCs.   
In the EASYGENEX Study, participant blood samples were collected at 0, 7 and 14 
days of continuous twice daily dosing, whereas the pharmacokinetic study by Ye et 
al discussed above used a single dose with sampling at several time points within 
hours of dosing.  The participants were expected to accumulate SFN and its 
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metabolites over the extended time frame of the study, increasing the likelihood that 
the intracellular concentrations in the EASYGENEX Study would be higher.  
Accumulation of metabolites has been shown to be particularly cytoprotective in 
epithelial cells lining the gut626 (especially the stomach) and the urinary bladder.627  
In both types of epithelia, a single membrane is the only barrier to SFN absorption 
into these cells.  In the urinary bladder, concentration of SFN metabolites in the urine 
for extended time periods prior to voiding may explain the observed cytoprotective 
effects of SFN in this organ.628  
Myzak et al.629 report that HDAC inhibition was apparent in murine colonic mucosa 
and peripheral mononuclear cells, suggesting that dietary SFN is capable of 
inhibiting HDAC in vivo.  It is worth noting that in general, HDAC inhibitors exhibit 
greater effects on cancer cells than on normal cells,630 raising the possibility that 
such differential effects may provide an opportunity to utilise SFN in cancer therapy 
as well as in prevention.   
Where in vitro HDAC studies typically employ 15μM SFN, the human retinal pigment 
epithelial cell culture study referred to in 3.1 used the lower 10μM SFN 
concentration.   
A concentration of 10μM SFN was found to be the optimal dose needed to enable 
the cells to counter an oxidative assault.  Mechanistically, SFN was shown to 
activate Nrf2 and induce of a number of its target genes.624  Whether a lower 5μM 
more typical Nrf2-activating dose would have also been effective in modulating gene 
expression in these cells is not known. 
In practice, there are fewer in vivo opportunities to study the concentrations of SFN 
and its metabolites in cells compared with those of the in vitro situation, so that the 
available evidence for intracellular SFN concentrations is limited.  Muscle biopsy is 
one mode of investigating such concentrations following SFN dosing but the 
procedure carries enough risk as well as participant discomfort that it is not often a 
test method of choice.   Cornblatt et al,183 in a proof-of-principle pilot study of eight 
women, were able to show the presence of SFN and its metabolites in 
epithelial/stromal-enriched mammary tissue excised during reduction mammoplasty 
60-90 minutes after a 200 µmol (35 mg) SFN dose of a freeze-dried powder.   Where 
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the pre-dose plasma metabolite concentration was 0.01µM ± 0.02, the post-dose 
dose level was much higher at 0.92µM ± 0.72.  The post-dose level shown here is in 
agreement with the peak plasma SFN concentration shown by Ye et al as 0.943µM ± 
2.27. 
To demonstrate that the metabolites had significantly accumulated in urine at the 
same time as plasma was sampled post-surgery, urinary metabolite concentrations 
were assayed.  The pre-dose metabolite concentration was shown to average 
4.07µM ± 5.22, with the post-dose level much higher at 158.85µM ± 93.89.  The 
accumulation of SFN metabolites in the urinary bladder is considered to provide a 
cytoprotective environment for the prevention of bladder cancer.  The potential for 
SFN as a therapy in the context of bladder cancer prevention is discussed in some 
detail in a recent review paper.628 
Overall, review of the published literature on SFN shows that the doses required for 
Nrf2 induction are lower than those for HDAC inhibition and a number of other 
putative cytoprotective processes.157  When considering the higher dose levels, one 
must consider the potential for toxicity.  Although Shapiro et al.426 showed that SFN 
is safe and generally well-tolerated in humans, a more recent study631 raised the 
question of safety in comparing desirable and potentially toxic cellular effects of SFN 
in Hepa1c1c7 cells.  When comparing increasing intracellular concentrations of SFN 
with curcumin, quercetin and resveratrol on this hepatic cell line, it was found that 
only SFN and curcumin significantly increased NQO1 protein expression and activity 
without triggering G2/M cell arrest or mitotic catastrophe.  Quercetin was found to 
disrupt mitosis at a concentration 100-fold higher than that required to induce NQO1.  
Since quercetin has been a popular dietary supplement over many decades, one 
might question whether this in vitro study is applicable to the in vivo situation.  
Nevertheless, it highlights the need for caution when using doses much higher than it 
is practically possible to obtain from food, especially of isolated compounds 
extracted from their whole plant sources. 
7.2.2 The Dose Employed in the EASYGENEX Study 
Having considered the range of doses used in studies focused separately on Nrf2 
induction and HDAC inhibition, a dose in the higher range but in keeping with other 
studies was selected for the EASYGENEX Study.   Myzak showed in a human study 
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that 68 g of fresh broccoli sprouts yielding 105 mg SFN strongly inhibited HDAC 
activity in PBMCs 3 and 6 hrs following consumption.438  Two dose levels were 
selected, with the highest dose of capsules approximating the SFN Yield of Myzak’s 
68 g of fresh broccoli sprouts.   
The EASYGENEX Study participants were therefore administered 4 capsules (~ 50 
mg daily SFN Yield) in the first week and 8 capsules (~ 101 mg daily SFN Yield) in 
the second week.  The capsules had been produced from whole fresh dried broccoli 
sprouts using the same seed stock used by Myzak et al. as described in Footnote g. 
7.2.3 Ingestion of dried broccoli sprouts from powder vs capsules 
The reaction between GRN and MYR is so rapid that SFN is released in the mouth 
when a SFN-yielding broccoli sprout powder is ingested.  As a result, supplementing 
with such a powder may generate different in vivo responses from supplementing 
with a capsule containing exactly the same quantity of the same powder.  An 
innovative study632 used an in vitro digestion model to compare, among other things, 
the conversion and bioaccessibility of SFN in the mouth, stomach, and small 
intestine.  In minimally-steamed (one minute) broccoli vegetable, approximately 30% 
as much SFN was generated in the mouth as in the stomach and with only around 
23% as much SFN nitrile produced in the mouth. 
The capsules typically used in phytochemical supplements are manufactured from 
vegetable cellulose.  The Size ‘00’ Vcaps selected for the EASYGENEX Study and 
described in 8.2.2 are specified by the manufacturer as disintegrating in no more 
than 30 minutes (NMT < 30 mins).  As a consequence, studies where powder has 
been used are likely to reveal different levels of SFN conversion and absorption from 
those where a capsule is the intervention dose form. 
7.3 THE ROLE OF EXERCISE IN Nrf2 ACTIVATION 
When designing the EASYGENEX Study, the role of exercise as a significant 
contributor to Nrf2 activation had not been considered; in retrospect, it should have 
been listed for exclusion along with dietary factors, particular supplements and 
pharmaceuticals, especially since the participants recruited were young, healthy men 
predominantly from the university’s School of Human Movement and Nutrition 
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Sciences.  As described in Chapter 8, the participants were in the habit of 
undertaking significant regular aerobic and resistance exercise sessions.  When the 
differential gene expression microarray data from baseline to day 7 and day 14 was 
reviewed, the expected induction of the Nrf2 target genes was not detected.  
However, plasma analysis showed that there were significant levels of SFN and its 
metabolites in the samples, confirming that the intervention material did yield SFN in 
situ.  What appeared to be the study’s major response was related to inhibition of 
inflammation-related genes associated with the Nuclear Factor-kappa B (NF-κB) 
network. 
In reviewing what might have led to failure to demonstrate Nrf2 activity, consideration 
should have been given to whether the participants at baseline and throughout the 
study had already optimised their Nrf2 activity in some other way; the effect of 
exercise seemed the most likely possibility 
7.3.1 Known Association Between Exercise and Nrf2 Activation 
When reviewing the literature on the relationship between Nrf2 and exercise, it was 
apparent that although there were limited human data to quantify such a relationship, 
there were, nevertheless many peer-reviewed publications that focused on relevant 
mechanistic aspects.  Aerobic exercise in particular increases respiration which 
results in greater generation of the stressor, superoxide anion.  Since such stressors 
are the signal detected by Keap-1 to release Nrf2, it should not have been surprising 
that these participants at baseline might already have been exhibiting significant 
expression of the Nrf2 target genes.  If Nrf2 had already been maximally activated in 
these young men, the addition of another weak stressor in the form of SFN would not 
have changed the status quo.  Two of the EASYGENEX participants had lower 
exercise output than the average of the study group (but still averaged 30 minutes of 
moderate intensity walking daily).   When considering if they might have displayed a 
different response to SFN, no difference could be demonstrated.  
Although the relationship of exercise to Nrf2 activation has not been extensively 
reported in humans or in animals, a recent review paper633 summarises what is 
known about the effects of acute and regular exercise on Nrf2 activity and 
downstream targets of Nrf2 signalling.  The authors raise the possibility that because 
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some phytochemicals have also been shown to activate Nrf2, there may be 
synergistic effects between exercise training and ingested phytochemicals.  
The authors highlight human studies which showed that the response to exercise 
differed significantly between younger and older individuals, between the trained and 
untrained and between acute bouts of exercise and regular exercise.  In addition, 
even where Nrf2 had been activated, some Nrf2 target genes and their protein 
expression products did not always respond as expected.  Of significance when 
considering the results of the EASYGENEX study, the authors state that there are no 
studies to date that investigate the role of exercise intensity and Nrf2 activation.   
Some of the salient points which emerge from the review by Done et al. are these: a) 
regular exercise in rodent models consistently results in Nrf2 signalling and protein 
abundance across multiple tissues.  b) more active older individuals had significantly 
greater Nrf2 protein and a higher Nrf2/Keap-1 ratio in muscle tissue, suggesting that 
there is the potential to restore Nrf2 signalling in older age. c)  short, intense bouts of 
exercise as in interval training deliver repeated shifts in redox balance, differentially 
affecting the frequency of Nrf2 activation. d) both animal and human studies in this 
area are almost exclusively on males. e) nuclear accumulation of Nrf2 was 
demonstrated only in younger men, showing that ageing is associated with 
impairment to nuclear import of Nrf2. f) Nrf2 mRNA was increased 2 hours after 
acute exercise in middle-aged women who were regular exercisers but not in 
sedentary women who showed no change in Nrf2 or its target genes. g) there may 
be an upper limit to the stimulatory effects of exercise. h) there may be a synergistic 
effect when combining exercise with Nrf2-activating dietary supplements. i) direct-
acting antioxidant vitamin supplements may attenuate the beneficial effects of 
exercise. 
Overall, Nrf2 activation varied with acute vs regular exercise, with age, with fitness 
status and possibly with sex.  What becomes immediately apparent is that there is a 
dearth of research on the role of exercise in Nrf2 signalling.  The ability to quantify 
this effect would contribute greatly to our understanding of how to more effectively 
apply exercise prescriptions. 
In the EASYGENEX Study, wherein the participants were young males, most of 
whom exercised regularly, it may not have been possible to detect differential gene 
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expression across the two one-week trial periods because these young men had 
already achieved maximal Nrf2 activation. Nevertheless, the study did show that a 
range of other genes not associated with Nrf2 activation were differentially-
expressed.  It is likely that gene expression in these networks may have been 
substantially altered by the effect of exercise on other transcription factors and their 
downstream pathways, perhaps limiting the ability to detect the real effect of the SFN 
intervention. 
It is likely that a potential weakness in some other studies may have been uncovered 
and where exercise is not typically considered in the list of exclusion criteria when 
considering the effects of a dietary intervention on Nrf2.  Just one peer-reviewed 
published SFN-based study could be located (also conducted by a Nutrition and 
Exercise Science department) wherein those engaged in vigorous activity for more 
than 6 hours per week were excluded.397 
7.3.2 Immune-related Effects of Exercise. 
Brief bouts of exercise are widely-known to lead to robust increase in circulating 
PBMCs in humans634 but it is not known whether this might impact on the 
simultaneous effect of SFN.  An acute bout of exercise can cause tissue injury and 
the release of both pro- and anti-inflammatory cytokines, whereas regular physical 
activity seems to promote an anti-inflammatory environment in the body, attenuating 
the inflammatory effect.635  T-lymphocytes are sometimes grouped as T helper-1 
(Th1) cells or T helper-2 (Th2) cells; Th1 cells are primarily pro-inflammatory in their 
actions whilst Th2 cells are anti-inflammatory.  This is significant in the context of the 
EASYGENEX Study because the Th1-Th2 balance is largely determined by NF-κB 
activity which was shown to be significantly downregulated by SFN. Clinically, this 
may also be relevant in that Th1-dominated responses are involved in the 
pathogenesis of organ-specific autoimmune disorders but in contrast, allergen-
specific Th2 responses are responsible for atopic disorders in genetically susceptible 
individuals.636 
The effect of exercise is also affected by sex and pubertal phase.  A study637 
investigating the effect of brief bouts of exercise on young, healthy individuals 
showed that the genes commonly regulated by exercise in all tested groups are 
related to growth, apoptosis, inflammation and tissue repair.  Using the same 
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Affymetrix U133 + 2.0 arrays for gene expression that was selected for the 
EASYGENEX Study, the group identified 894 genes significantly altered by exercise 
in PBMCs.  They also noted distinct gene alterations likely to affect monocytes in an 
anti-inflammatory, anti-atherogenic pathway, including downregulation of TNF-α and 
TLR4.  SFN is also known to downregulate TLR4, an effect in common with that of 
exercise and discussed further in Chapter 8.638 
7.4 NF-κB INFLAMMATION-RELATED PATHWAYS 
Of the exercise-related studies, there is extensive reference to the mechanistic 
relationship of exercise to inflammation and as such to the transcription factor, NF-
κB.   In relation to its observed anti-inflammatory activity, SFN has been shown to 
modulate the activity of the transcription factor NF-κB, well-known for its role in the 
immune system.  Whereas SFN directly activates cytosolic Nrf2, its action on NF-κB 
is to inhibit NF-κB binding to the DNA.639  Such anti-inflammatory mechanisms are 
suggested to contribute to SFN-mediated cancer chemoprevention.  Since the 
EASYGENEX Study detailed in Chapter 8 highlights the effect of SFN on 
downregulating in the NF-κB network, the next section describes relationships and 
pathways that may be relevant to the study’s findings. 
7.4.1 Regulation of NF-κB     
Members of the NF-κB family of transcription factors function as dominant regulators 
of inducible gene expression in virtually all cell types in response to a broad range of 
stimuli, with particularly important roles in coordinating both innate and adaptive 
immunity.640  NF-κB is controlled by various mechanisms of post-translational 
modification and subcellular compartmentalisation as well as by interactions with 
other cofactors or corepressors.641  The NF-κB family of transcription factors includes 
RelA (p65), RELB and others and as a complex, NF-κB mediates immune responses 
to cellular challenges that include bacterial and viral infection and inflammation.188  
These transcription factors play critical roles in both adaptive and innate immunity, 
inflammatory responses, cell differentiation, proliferation and apoptosis.  The 
EASYGENEX Study identified RELB as one of the significantly downregulated genes 
in the NF-κB network.  The activity of NF-kB is tightly regulated at multiple levels, a 
factor that may be associated with its influence on the expression of numerous 
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genes.642  Nuclear translocation of NF-κB is primarily controlled by signalling 
associated with IkB kinase (IKK) in two related pathways associated respectively 
with the NF-κB classical (canonical) and alternative pathways. 
Among the most potent NF-κB activators are tumour necrosis factor (TNF-α), 
interleukin (IL)-1β and bacterial lipopolysaccharide (LPS), with TNF-α activation 
being one of the best-characterised of the NF-κB signalling pathways.643  
Furthermore, several cross-talk relationships associated with NF-κB have been 
identified and three clinically-relevant relationships are described below. 
7.4.2 Cross-talk Between Nrf2 and NF-κB.   
Given that SFN is associated with cellular defences via the essentially opposing 
mechanisms of Nrf2 and NF-κB, it is not unexpected that molecular cross-talk 
between these transcription factors has been reported.188  Imbalance between Nrf2 
and NF-κB is associated with a significant number of diseases across various body 
systems and these relationships are the subject of extensive research in cancer 
biology.644   
Although the complex interplay between Nrf2 and NF-κB has been highlighted, there 
remains much to be explored in order to understand how such relationships may 
impact on disease pathophysiology at the molecular level.  As part of the cross-talk 
between these two transcription factors, NF-κB has been shown to regulate Nrf2-
mediated ARE expression.  Several mechanisms exist by which p65 (the canonical 
NF-κB subunit) can exert negative effects on ARE-linked gene expression.645  It 
would seem that the cross-talk between Nrf2 and NF-κB enables cells to more finely 
regulate their responses to cellular stressors. 
7.4.3 Cross-talk Between NF-κB and CEBPB 
CCAAT-enhancer-binding proteins (C/EBPs) are activated by a high-fat diet or a diet 
especially when high in the fatty acid palmitic acid.  C/EBPβ governs a network of 
genes crucial for dietary-driven inflammatory activity and insulin resistance.646  
C/EBPβ overexpression induces NF-κB DNA binding, JNK activation and pro-
inflammatory cytokine expression but when C/EBPβ expression is downregulated, 
(as in murine C/EBPβ -/- knockdown), palmitic acid-induced inflammation was 
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inhibited.  C/EBPβ is known to be central to the pathogenesis of several 
inflammatory and metabolic disorders.646  The two families of transcription factor, 
NF-κB and C/EBPβ have been considered as a complex that may act 
synergistically.647  More recently, C/EBPβ overexpression has been shown to 
promote cardiomyocyte hypertrophy and that C/EBPβ knockdown protects these 
cells from hypertrophy via inhibition of NF-κB transcriptional activity.648   
7.4.4 Cross-talk Between NF-κB and Phase 1 Detoxification. 
Other forms of molecular cross-talk have been investigated with the NF-κB RELB 
subunit closely interacting with the Acyl hydrocarbon receptor (AhR).  Numerous 
exogenous compounds have been shown to bind to activate the AhR.649  The 
ArH/Rel B dimer can bind to DNA response elements as well as NF-κB.  RELB has 
been implicated in breast cancer and is also a critical factor in the function and 
differentiation of dendritic cells.  Furthermore, AhR can regulate the generation of 
regulator T cells (Treg) or pro-inflammatory T cells, positioning it as a key factor in the 
immune system.649   
The AhR plays a key role in the cellular defence mechanisms in that it regulates a 
number of the CYP450 genes, particular CYP1A1, CYP1B1 and CYP1A2 which 
respectively encode the Cytochrome P450 enzymes 1A1, 1B1 and 1A2.  Many 
substrates for CYP1 enzymes are AhR ligands.650  These reactions occur not only in 
Phase 1 detoxification of environmental toxicants but also in the metabolism of 
endogenous compounds such as steroid hormones.651  The product of the Phase 1 
reaction may be a compound with greater carcinogenicity than the initial CYP450 
substrate.  Many of the enzymes active in the subsequent Phase 2 detoxification 
reactions are products of Nrf2 target genes, such as NQO1, GST and UDP-
glucuronosyl transferase (UGT), linking Nrf2, NF-κB and the AhR in the initial stages 
of detoxification.531   
7.4.5 NF-κB and clinical implications of dysregulation 
As the relationship between NF-κB and AhR has been only recently known, there is 
as yet, little data to support the relationship. Several observations by Vogel et al 
(2009) suggest that RELB contributes to cancer cell survival and tends to be 
overexpressed in the inflammatory breast cancer phenotype, the form with highest 
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metastatic potential.  Perhaps surprisingly, the AhR binds to the NF-κB consensus 
site, suggesting that the AhR may affect the canonical NF-κB pathway.  This 
suggests that the AhR may function not only on AhR signalling but also NF-κB 
signalling that is activated by classical NF-κB inducers such as LPS.649  In addition, 
RELB has been shown, by inducing manganese superoxide dismutase (MnSOD) to 
act as a major cancer cell survival factor by conferring radiation resistance and by 
inhibiting cancer cell apoptosis.652   
7.5 MICROARRAY vs RT-qPCR PLATFORMS IN STUDYING GENE 
EXPRESSION 
Any study investigating gene expression must select the most appropriate platform 
on which to do so.  When it had been initially planned to use SFN to investigate 
differential gene expression in type 2 diabetes, the RT-qPCR platform was chosen 
as it is considered most accurate when expression of a relatively small number of 
specific process-related genes is under investigation.  This technique is generally 
considered the ‘gold standard’ in precision when quantifying gene expression.653  
The plan had been to use probes associated with around 40 Nrf2-target genes, 
including those coding for antioxidant/detoxification enzymes, non-enzymic 
glutathione and inflammation biomarkers because their roles in the redox imbalance 
associated with glucose dysregulation has been well-documented.  Given what may 
now be presumed to be the effect of exercise in the EASYGENEX Study, it is 
fortuitous that this platform was not adopted, as none of the Nrf2-target genes was 
differentially-expressed by the SFN intervention. 
Instead, an oligonucleotide microarray platform, the Affymetrix HG U133 plus 2.0 
Genechip was selected to enable investigation of a large number of human genes. 
The manufacturerh describes this chip as “a single array representing14,500 well-
characterised human genes that can be used to explore human biology and   
disease processes.”  Although microarrays permit the simultaneous investigation of a 
very large number of genes, they lack the precision of RT-qPCR.  Microarray is a 
multi-stage process in which the accuracy of each step may influence the gene 
expression estimates.654  The weakness of microarrays is generally considered to be 
                                            
h www.affymetrix.com/support/technical/datasheets/human_datasheet.pdf  
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their low accuracy, precision and specificity655 and have been criticised as a method 
that fails to identify clinically-relevant information.654     
Their usefulness in the EASYGENEX Study lay in the ability to identify genes and 
pathways which may not have been expected.  In Chapter 8, the steps needed to 
enhance the signal-to-noise ratio are described as a way of providing more 
meaningful data.  Having identified that the genes expressed in the EASYGENEX 
Study were primarily related to the NF-κB network, a further study might utilise RT-
qPCR as the platform to focus on the role of SFN in attenuating inflammation in 
human cells. 
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CHAPTER 8 
Effect of a Sulforaphane-Yielding supplement on Gene Expression in 
Healthy Young Exercising Men; a Microarray Analysis 
(THE EASYGENEX STUDY) 
8.0 Abstract 
The broccoli-derived phytochemical, sulforaphane (SFN) has been extensively 
studied for its beneficial effects on human health, exerting many of its known effects 
by activation of the transcription factor, Nrf2.  Its additional Nrf2-independent effects 
are of increasing interest. A primary aim of this study was to investigate SFN gene 
expression using two SFN dose levels with the expectation that Nrf2-dependent 
genes would express at the lower dose and that Nrf2-independent genes would also 
express at the higher dose.  SFN is metabolised extensively by the gut microflora 
with GSTP1 genotypic differences largely determining the nature and extent of the 
metabolites produced.  A further aim of this study was to investigate the effects of 
the two doses of a broccoli sprout-containing supplement on plasma SFN and its 
mercapturic acid metabolites and to determine if the responses in plasma SFN and 
metabolites vary between participants with different GSTP1 genotypes. An open-
label dose-escalation study was conducted with 21 young, healthy, physically-active 
men.  Plasma was collected before and after consuming encapsulated whole 
broccoli sprout supplements over two 7-day continuous periods (53 g SFN/day 
during week 1 and then 106 g SFN/day in week 2). Genotypes were identified from 
buccal swab samples. Liquid chromatography with tandem mass spectrometry was 
used to measure plasma SFN and its metabolites. Gene expression analysis was 
conducted using Ingenuity Pathway Analysis on PBMCs using a microarray platform. 
The presence of significant levels of plasma SFN and its metabolites confirmed that 
SFN had been generated in situ by ingestion of the broccoli sprout capsules, with 
SFN reaching 0.08 μM in those carrying the wild-type genotype and 0.02 μM in those 
with polymorphisms for GSTP1. The SFN-NAC metabolites reached 0.03 μM in wild-
type GSTP1 genotypes and 0.06 μM in those with polymorphisms.  Over the 14-day 
supplementation period there was a significant downregulation of the NF-kB network. 
There were 10 upregulated and 26 downregulated genes, 8 of which have not 
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previously been associated with SFN (DDC, ACSM2A, HERC6, PDIA4, ZBTB2, 
IGF2B2, DDX3X and GK5).  All 36 differentially-expressed genes can be broadly 
grouped into 6 overlapping categories related to their cellular functions; immune 
modulation (anti-inflammatory), metabolism (adipogenesis, glucose metabolism, 
insulin sensitivity), neurotransmitter synthesis, cytoprotection, cardioprotection and 
redox modulation.  
This study provides evidence that whole MYR-active broccoli sprout capsules yield 
significant SFN and that in the study population, the intervention resulted in 
significant differential expression of Nrf2-independent genes only.  
8.1 Introduction 
Epidemiologically, cruciferous vegetable consumption is associated with reduced 
cancer risk,180 whilst vegetables in general are associated with chronic disease 
prevention.656  In the last 25 years, interest in the chemopreventive properties of 
broccoli-derived SFN has grown significantly, such that it has been employed as the 
intervention compound in a number of human clinical trials.  The range of disease 
processes targeted in these clinical trials is diverse, providing evidence that the 
application of bioavailable SFN is potentially much broader than chemoprevention; 
the nature of these studies and the range of forms and doses employed were 
discussed in Chapter 7. 
When reviewing the available clinical trials utilising different forms of SFN 
intervention, it is clear that some of these may not be appropriate for practical daily 
dosing, even though studies using fresh sprouts and their homogenates or powdered 
forms have demonstrated significant clinical responses.  One of the goals in 
designing the current study was to gain greater insight into SFN’s dose-response in 
healthy individuals ingesting an encapsulated SFN-yielding dietary supplement.  In 
working with nutraceuticals and functional foods as interventions, one must be 
mindful that the techniques being utilised are largely designed for pharmaceuticals 
rather than for foods and that there are important differences that are not easy to 
separate and appropriately quantify.657 
What is emerging is that diseases known to be underpinned by redox imbalance and 
uncontrolled inflammation are proving to be more responsive to amplification of 
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cellular defences via Nrf2 activation than to administration of direct-acting antioxidant 
supplements.154,35   Cellular Nrf2 levels are under strict control by multiple 
mechanisms, the best-characterised of which is mediated as described in Chapter 4 
by interaction with Kelch-like ECH-associated protein 1 (Keap-1).188 
The greater focus of SFN research has been on its nutrigenomic role as a potent 
activator of the transcription factor Nrf2 (coded by the gene NF-E2-related factor 2), 
even though it is known to participate in other cellular processes.157  Where many 
studies have focused on plasma disease biomarkers and clinical disease outcomes, 
others employ gene expression platforms as a means of discovering more about 
mechanistic aspects of Nrf2 activation and its downstream targets as well as to 
search for novel processes and molecular pathways. 
Nrf2 and its target genes can be activated at the lower end of the SFN dose 
continuum631 but other effects such as HDAC inhibition are thought to require higher 
intracellular concentrations; the SFN concentration reported in in vitro HDAC 
studies39,412,435 is typically 15μM but there is limited information on how this might 
compare with oral doses required in human populations.658  Similarly, the doses 
required to modulate inflammation via NF-kB are poorly-defined.  A PubMed search 
on the grouped terms ‘sulforaphane’ and ‘NF-kappa B’, at time of writing returned 
more than 80 publications but when the limit, ‘clinical trial’ is applied, there are none. 
Further confounding the ability to quantify a dose-response relationship, it has been 
long known that polymorphisms in genes of the GST families of Phase 2 
detoxification enzymes modulate SFN metabolism in vivo but the effect appears to 
be inconsistent.659,660  The primary route of in vivo metabolism of SFN and other 
ITCs is by the mercapturic acid pathway, a major pathway for elimination of many 
xenobiotics, ultimately via the urine.661  Of the three major human GST families, 
cytosolic GSTs form the largest of the seven classes.662   The most efficient GST 
isozyme catalysts of ITC metabolism are GSTM1-1 and GSTP1-1.663   
Polymorphisms of GSTP1 are common but are not distributed equally by ethnicity.  
In a study664 reviewing GSTP1 polymorphisms across population groups, the wild-
type GSTP1 (Ile/Ile) was represented in 47% of Europeans, 61% of Asians and 50% 
of Indians.  Additionally, the GSTP1 heterozygote (Ile/Val) was carried by 43%, 34% 
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and 44% of these ethnic groups respectively, with the homozygote (Val/Val) carried 
by just 10%, 5% and 6% of the same groups. 
Human GSTP1 enzyme catalyses thioether conjugation of reduced glutathione 
(GSH) with potentially toxic electrophile reactive intermediates, acting as a 
detoxifying enzyme.665  A key enzyme in the Phase 2 detoxification pathways, the 
GSTP1 enzyme selectively detoxifies the toxic epoxide of benzo(a)pyrene, a highly 
carcinogenic metabolite of polycyclic aromatic hydrocarbon (PAH).  The role of the 
GST in its various forms plays a key role in protecting cells from a wide range of 
endogenous and exogenous potentially toxic chemical entities.664 
This fact highlights an important aspect of the GSTP1 gene and its enzymatic 
product in human health.666  Furthermore, it is overexpressed in tumours following 
chemotherapy and has been associated with poor prognosis in breast cancer.  A 
recent study identified a novel regulatory function of GSTP1 in which it modulates 
Estrogen Receptor-alpha (ERα) signalling events in a non-enzymatic manner, 
thereby closely associating it with estrogen-dependent cancers such as breast, 
uterine and prostate cancer.667 
As discussed in some detail in Chapter 5, SFN has been identified as a molecule 
with potential as an effective chemopreventive for bladder cancer by multiple 
mechanisms including its ability to induce genes of the GST family, even though not 
all studies agree on whether GST polymorphisms are generally cytoprotective.   
In a 2011 study considering bladder cancer susceptibility in relation to GST 
polymorphisms, it was shown that patients carrying the GSTP1 homozygous 
genotype were at increased risk for developing high-grade and muscle invasive 
bladder cancer.668  Another meta-analysis two years later confirmed this by 
concluding that the presence of the homozygous GSTP1 polymorphism is a strong 
predisposing risk factor for bladder cancer.669  Contrary to these findings, a more 
recent 2016 meta-analysis showed no association between GSTP1 polymorphisms 
and bladder cancer susceptibility.670   
SFN’s effects are pleiotropic such that it is not known to what extent GSTP1 
contributes to its observed chemopreventive effects. Interestingly and in support of 
SFN’s chemopreventive potential, a very recent 2017 review article suggested that, 
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based on available evidence from epidemiological, in vitro, preclinical, and early 
phase trials, phytochemicals such as ITCs and specifically SFN, represent a 
promising potential chemopreventive agent in bladder cancer.628   
Clearly, many factors are involved and to further confound opportunities to draw any 
definitive conclusions, it has been suggested that genotypes associated with more 
favourable handling of carcinogens may be associated with less favourable handling 
of phytochemicals.659 
Knowing that SFN is a substrate for the gut microflora which produce SFN 
mercapturic acid metabolites, a further aim was to determine if the responses in 
plasma SFN and metabolites vary between participants with different GSTP1 
genotypes.  Usually considered as a key Phase 2 detoxification enzyme, GSTP1 
codes for the glutathione-S-transferase enzyme, known also to be pivotal to SFN 
conjugation.   
It was anticipated that the findings might be clinically-relevant in that individuals 
known to carry GSTP1 polymorphisms could expect a higher levels of plasma SFN 
and its metabolites in response to SFN supplement from those expressing the wild-
type GSTP1 gene.   
Whether or not regular consumption of broccoli vegetable as the primary dietary 
source of SFN is sufficient to achieve the higher doses indicated by in vitro studies 
and preliminary clinical trials continues to be a key research consideration.384,671,672  
Broccoli sprouts as a more concentrated source of broccoli bioactives are commonly 
the intervention material in this context.  The EASYGENEX Study selected a SFN-
yielding broccoli sprout capsule as its intervention; a detailed rationale for the 
selected form and dosage is discussed in Chapter 7.   
Chapter 7 also describes the way in which SFN has been shown to exhibit anti-
inflammatory effects which are at least in part due to its ability to modulate the 
activity of the transcription factor NF-kB, well-known for its role in immune function.  
Unlike its direct activation of Nrf2, SFN has no direct effect on release of NF-kB from 
its complex with the IκB kinase enzyme (IKK) but instead acts to inhibit the binding of 
NF-kB to the DNA.639 
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Microarray techniques provide an avenue to investigate gene expression and in 
some cases, to discover hitherto unknown target genes and their related pathways.  
This study therefore utilised a microarray platform as its means of investigating the 
effects of SFN on gene expression in young, healthy men.   
8.1.1 The Aims of the EASYGENEX Study 
The primary aim of this dose-escalation study was to investigate two doses of SFN 
on gene expression, with the second dose double that of the first.  A further aim was 
to determine if the responses in plasma SFN and metabolites vary between 
participants with different GSTP1 genotypes.  As detailed in Chapter 7, the higher 
dose has been used in other studies utilising broccoli sprout forms other than orally-
ingestible capsules.  Since other studies have shown that SFN induces expression of 
Nrf2-dependent target genes, it was expected that this would similarly occur in the 
EASYGENEX Study.   
Furthermore, there was the expectation that Nrf2-independent genes would also be 
expressed at the higher dose and that the higher dose would reveal different and 
more quantitatively significant effects. The study’s hypothesis extended to 
consideration that genes associated with HDAC inhibition and inflammation might be 
negatively expressed. SFN is also known to be associated with other processes like 
cell cycle regulation, apoptosis, angiogenesis, metastasis and microtubule 
disruption673 and so it was considered that the expression of these genes might be 
modulated by the intervention. 
8.2 MATERIALS AND METHODS 
8.2.1 Study Design 
The study was an open-label dose-escalation clinical trial conducted in accordance 
with the ethical guidelines laid down by the Declaration of Helsinki, 1975 and 
approved by the Ethics Committee of the University of Queensland (Clearance 
Number: 2013000222).   
Healthy, non-medicated, young adult men with BMI in the normal range and of 
average age 25 ± 4 years were recruited by advertisement from the university 
campus and neighbouring areas.  Prospective participants were excluded if they 
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were female, aged under 18 or over 35, a smoker or regularly took dietary 
supplements considered to potentially interfere with the treatment.  This intervention 
study was conducted over the period from 14th September, 2016 to 7th October, 2016 
in two 7-day blocks with the intervention for the second week at double the dosage 
administered in the first week.  Following a 3-day washout period during which 
cruciferous vegetables, other known Nrf2 activators and redox-modulating foods and 
supplements were excluded from the diet, participants attended the university 
laboratory in the fasted state for collection of baseline anthropometric data, blood 
and buccal swab sampling; questionnaires were used to collect details of each 
participant’s usual dietary intake and physical activity.  Items for the Active Australia 
Survey were used to quantify physical activity in METmins This self-report approach 
has been shown to be valid.674 Details appear with Table 8.1 which also lists 
participant anthropometric data, participant ethnicity and GSTP1 genotype. 
Participants were given a 14-day diary in which to record daily details of diet and 
sleep as well as any adverse effects.  Each participant was given sufficient capsules 
for the following 7 days with instructions that these be taken as two capsules in the 
morning and two capsules in the evening (a total of 28 capsules).  The dietary and 
other exclusions undertaken during the 3-day washout period were to be continued 
throughout the 14-day intervention period.  Participants returned in the fasted state 
on the 7th day for blood sample collection and to return any unused capsules. 
Sufficient capsules to cover Day 7 to Day 14 with instructions to take 4 capsules 
night and morning were provided (a total of 56 capsules).  On Day 14, the final 
fasting blood sample was taken.  Any remaining capsules were collected and 
counted for the Day 7 and Day 14 visits respectively.  On Day 14, participants were 
asked to provide feedback on the treatment, including any adverse or other effects 
experienced.  Adherence to the protocol was assessed through interview and by 
counting the number of capsules returned at the end of the study. 
8.2.2 The Intervention Material 
The broccoli sprout powder used to make the capsules was supplied by Cell-Logic 
Pty Ltd (Queensland, Australia).  The sprouts had been grown, dried and milled to a 
fine powder, suitable for encapsulation.  The material (Batch EUCAPE 00080573) 
was assayed by Eurofins Supplement Analysis Center, 1365 Redwood Way, 
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Petaluma CA. 94954, USA to contain 3.77 ± 0.52% GRN and to yield 1.89 ± 0.30 % 
SFN per gram.  The SFN assay was specified to be performed without the addition 
of an exogenous source of MYR, so that the SFN Yield is determined only on the 
basis of the endogenous presence of both glucoraphanin (GRN) and MYR.  The 
powder was stored in a sealed foil bag in a dark, low-temperature, low-humidity 
environment.  Size ‘00’ vegetable capsules purchased from CapsuGel® in Sydney 
Australia were used to produce the study capsules, using the Cap-M-Quik hand-
filling device. (Cap-M-Quik.com. 40950 Bouvier Court, Murrieta, CA 92562).  Each 
capsule contained on average 700 ± 11 mg of broccoli sprout powder.  By 
calculation, each capsule contained 26.4 mg GRN and would yield 13.2 mg SFN.  
Assuming full conversion of GRN to SFN, participants in Week 1 of the study 
ingested 52.8 mg SFN daily and in Week 2, ingested 105.6 mg SFN daily. 
8.2.3 Sample Collection  
Blood samples from 21 apparently healthy human donors were obtained after 
informed consent was given.   Blood used for RNA extraction was collected in 
PAXgene (Qiagen) tubes and frozen at −80°C after a 2 h incubation at room 
temperature.  Serum and plasma samples were obtained after centrifugation of blood 
collected in vacutainer tubes (with and without EDTA).   
8.2.4 Plasma Extraction for Metabolite Analysis 
Plasma was first defrosted and 200µL transferred to a 1.5mL micro centrifuge tube. 
To this, 50µl of the internal standard solution (sulforaphane-d8 in methanol) was 
added followed by vortex mixing. To this solution, trifluoracetic acid (50µL) (TFA) 
was added to precipitate plasma proteins in the sample followed by brief vortex 
mixing and centrifugation at 11,600 x g for 10 min. 100µL of the resulting 
supernatant was removed and 10µL injected for analysis. Throughout the extraction 
process, samples were kept at 4°C. 
8.2.5 SFN Metabolite Assay Using LC–MS–MS  
An assay of plasma SFN and its metabolites was undertaken to establish the 
absorption and subsequent metabolism of the intervention material to its major 
metabolites and the difference in these concentrations at two dose levels.   
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Chromatographic separation was carried out on an Agilent 1260 Infinity HPLC 
system (Agilent Technologies, CA, USA) using a Kinetex 5µm C18, 250 x 4.6mm 
with an AQ C18 4 x 3mm Security Guard cartridge, all purchased from Phenomenex, 
Unit 35, 2-6 Chaplin Drive, Lane Cove West, NSW, 2066 Australia. The mobile 
phase consisted of solution A: distilled water with 0.1% formic acid, and solution B: 
75% acetonitrile, 25% methanol and 0.1% formic acid run with a gradient with a flow 
rate of 1mL/min. Starting with 10% solution B and increasing to 50% over the first 6 
minutes. This flow was held for 2 minutes before increasing to 90% solution B at 10 
minutes and holding for 2 minutes. The flow was returned to 10% solution B by the 
end of the run at 13 minutes. The column temperature was maintained at 30°C and 
the analytes were quantified with an Agilent 6460 triple quad mass spectrometer with 
transitions as follows: sulforaphane 179.2→115.2; sulforaphane-d8 187.2→123.2; 
sulforaphane NAC 342.0→179.0; sulforaphane glutathione 487.0→136.0; 
sulforaphane-cysteine 301.0→136.0. This method is based on and modified from a 
previously-published SFN method675 and an Agilent protocol for curcumin extraction 
and analysis.i      
8.2.6 RNA Extraction 
RNA was isolated from whole blood collected in PAXgene tubes using the 
PreAnalytiX PAXgene blood RNA kit (Qiagen) according to the manufacturer’s 
instructions. RNA was eluted in RNase-free water.  RNA quality was determined by 
spectrophotometry and by using the RNA 6000 NanoChip kit on an Agilent 2100 
Bioanalyzer (Agilent Technologies). RNA passing quality control criteria were used 
for further analysis.  Samples were shipped on dry ice to the Ramaciotti Centre for 
Genomics (The University of New South Wales) for microarray analysis. 
8.2.7 Reverse Transcription 
Reverse transcription reactions were performed using the AffinityScript QPCR cDNA 
Synthesis kit from Agilent Technologies and following the manufacturer’s 
instructions. 
                                            
i  Obtained from Agilent and accessed 18th May, 2017. 
https://www.agilent.com/cs/library/applications/5991-3340EN.pdf  
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8.2.8 Microarray Procedures   
Microarray analysis was performed in the Ramaciotti Centre for Genomics (The 
University of New South Wales) using the Affymetrix Human Genome U219 Array 
Plate.  Microarray data were analysed for each of the 3 times points of the study 
(Day 0, Day 7 and Day 14) using R (v3.4.0) (R Development Core Team 2005) and 
Bioconductor.676 The ‘.CEL’ data file was imported using the ‘affy’ package 
(v1.54.0).677  Custom microarray probe set definition (v21), updated according to the 
latest genome sequence and gene annotations, were used to map each probe to its 
corresponding gene.678  The data were normalised using the Robust Multi-array 
Average (RMA) function679 from the affy package. The quality of the normalised data 
were assessed using the ‘arrayQualityMetrics’ package (v3.32.0)680 and any outliers 
identified were excluded from subsequent analyses. Three samples were identified 
as outliers based on the gene expression distances between microarrays; these 
samples include participant 6 day 7, participant 5 day 14, and participant 20 day 0. 
Principal component analysis was performed using the ‘arrayQualityMetrics’ package 
and the ‘mixOmics’ package.681  The heat map was drawn using the ‘iheatmapr’ 
package (https://github.com/AliciaSchep/iheatmapr).  Information regarding the 
repeated measure of the subjects across the three time points was included as 
factors in all differential gene expression and unwanted variation analyses. 
Unwanted variations from the microarray data were identified using the remove 
unwanted variation (ruv) package (v0.9.6).682 Unwanted variations were identified 
from a set of negative control genes for which expression is not known to change 
with respect to the biological factor of interest.683  In this study, negative control 
genes were identified empirically from a preliminary analysis of significantly 
differentially-expressed genes, using the ‘limma’ package (v3.32.2).684  The 1,402 
empirical negative control genes consisted of those commonly found among the 30% 
least significant genes from all pairwise time points comparisons (day 0 – 7, day 7 – 
14, and day 0 – 14).  The 1,402 empirical negative control genes consisted of those 
commonly found among the 30% least significant genes from all pairwise time points 
comparisons (day 0 – 7, day 7 – 14, and day 0 – 14).  
The optimum number of unwanted factors was identified using the ‘getk’ function; 
there were 13 for unwanted factors for day 0 – 7 and 14 unwanted factors for both 
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day 7 – 14 and day 0 – 14. The ‘ruv4’ function was used to identify the top 14 
unwanted factors. The unwanted factors were removed using the linear model during 
a subsequent ‘limma’ analysis and significantly differentially-expressed genes were 
identified for each pair of time. The log fold-change in gene expression was 
calculated as the difference between the latest date and the earliest date. The p-
values were adjusted using the Benjamini-Hochberg procedure and a gene was 
deemed significantly differentially-expressed if the adjusted p-value was < 0.05.  
Two samples from participants who reported being unwell between Day 0 and Day 7, 
participants #21 and #23, were suspected of having a viral infection since they 
showed an increased expression of genes involved in response to viral infection. 
Since removing these two samples would have decreased the number of 
significantly differentially-expressed genes across all time points, it was decided to 
focus the analyses on the comparison of day 0 versus day 14.  
8.2.9 Ingenuity Pathway Analysis (IPA)  
Significantly differentially-expressed genes were analysed using the IPA software 
(Ingenuity Systems Inc., Redwood City, CA). IPA was used to identify enriched 
canonical pathways and to identify significantly differentially-expressed genes in the 
context of the IPA Global Molecular Network. All 17,684 genes defined by the 
custom CDF file were used as the background gene set for the analysis of enriched 
canonical pathways.  
8.2.10 Buccal Swab Collection and Analysis 
Sample collection kits for analysis of polymorphisms of genes associated with 
cellular redox and cytokines were purchased from Fitgenes Pty Ltd who supplied the 
Isohelix T-Swabs manufactured by Cell Projects Limited.   
Samples collected using these kits were analysed by DNAiQ Genetic Testing 
Laboratories, using the following procedure. For DNA extraction & quality control, 
Genomic DNA from buccal swabs was extracted and purified using a paramagnetic 
particle automated method according to the manufacturer’s instructions (Maxwell 16 
instrument and AS1020 DNA purification kit, Promega). The DNA concentration and 
260/280 absorbance quality ratio for all samples extracted was determined using 
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spectrophotometry according to the manufacturer’s instructions (Nanodrop One 
instrument, Thermofisher). Samples with DNA concentration >=35 ng/μL and purity 
>=1.7 were used in the study. DNA was either diluted with RT-PCR grade water or 
evaporated to obtain a final concentration in the range of 50ng/μL. DNA was stored 
at -20C until use.    
For real-time PCR, genotyping from purified DNA was determined using a real-time 
PCR and fluorescence detection method according to the manufacturer’s instructions 
(QuantStudio 12k instrument Life Technologies). Each SNP was targeted using 
TaqMan SNP genotyping assay probes (ThermoFisher Scientific) in an OpenArray 
Genotyping plate format (Life Technologies). Standard cycling conditions were 
configured for SNP genotyping assays on an OpenArray Genotyping format 
according to the manufacturer’s instructions (QuantStudio 12k instrument Life 
Technologies). 
8.2.11 Data Analysis 
Analysis of the microarray data has been included in each relevant section above. 
The plasma SFN and metabolite concentration data were first checked for normality 
using the Shapiro-Wilk test. If data were not normally distributed, they were log-
transformed and rechecked. SFN data were normally distributed. The metabolite 
data were normally distributed after log transformation. A 2-way (group*time) 
repeated measures multivariate analysis was used to assess main effects (group 
and time) and any interaction. Statistical analysis was done with SPSS (version 24) 
                                                                                                                                                                                                        
8.3 RESULTS 
8.3.1 Study Flow, Adherence and Supplement Tolerance 
A total of 23 men gave written consent and were enrolled in the study. Figure 8.1 
shows the flow of participants through the study, in which three were subsequently 
withdrawn, two were unqualified (Participants #3 and #4) by not meeting the age 
criterion of 18 years and the other (Participant # 1) dropping out after 7 days, citing 
abdominal discomfort due to the supplement as the reason.   
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Figure 8.1 EASYGENEX Study Flow Chart 
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Most participants took capsules as instructed; however, there were exceptions; 
participants # 6, 9 and 25 each missed one dose, with #9 missing the last evening 
dose before the end of the study. Nevertheless, over the two 7-day periods, the 
overall amount ingested approximated the specified dosages, with the exception that 
the timing of the missed dose by #9 may have affected his final plasma metabolite 
level.   
Furthermore, participant # 18 exercised at the gym before attending for his 7-day 
blood sample collection and failed to fast for the second blood test.  Four participants 
reported that the capsules caused bloating, one reported that this eased in the 
second week and one reported nausea if the capsules were taken on an empty 
stomach.  Reported adherence with dietary exclusions appeared to be very good 
apart from one participant who reported a single occasion during which he 
consumed mustard, a food from the ‘excluded foods’ list.  However, plasma SFN 
data as described later in 8.6 indicated that actual adherence appeared to be 
different from reported adherence. 
From the Outlier Detection for Distances between Arrays (Table 8.2), 3 outlier 
samples were identified, these were participant 20 in day 0, participant 6 in day 7, 
and participant 5 in day 14.  Outlier samples were not included in the analyses of 
significantly differentially expressed genes. Table 8.3 classifies all participants as to 
their inclusion or exclusion from the final datasets analysed. 
8.3.2 Participant Characteristics  
Baseline data was collected for each participant with the demographic characteristics 
of the 20 men shown in Table 8.1.  The results of the genotyping analysis for GST 
polymorphisms is also recorded in Table 8.1. 
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Table 8.1.  Individual Participant Characteristics 
Anthropometric data, average physical activity output and GSTP1 genotype. 
Participant 
# 
Age 
(years) 
Height 
(m) 
Weight 
(kg) 
BMI Ethnicity 
Average 
Daily 
Exercise 
Physical 
Activity 
(METMins) a 
GSTP1 Genotype 
 
Wild-type (Normal)  
+313AA 
Homozygous Variant 
+313 GG  
Heterozygous Variant 
+313 A>G (Ile105V) 
1 25 1.72 73 24.7 Caucasian N/A N/A 
2 24 1.81 74.5 22.7 Asian 407  
3 17 
     
N/A 
4 17 
     
N/A 
5 30 1.78 78 24.6 Caucasian 1067 
 
6 20 1.81 88 26.9 Caucasian 467 
 
7 28 1.7 73 25.3 Asian 270 
 
8 20 1.8 95 29.3 Asian 643 
 
9 20 1.77 65 20.7 Caucasian 259 
 
10 31 1.7 74.8 25.9 Caucasian 150 
 
11 25 1.74 77 25.4 Caucasian 285 
 
12 28 1.67 72 25.8 Asian 764 
 
13 20 1.75 51 16.7 Asian 433 
 
14 23 1.7 70 24.2 Asian 120 
 
15 23 1.69 69 24.2 Asian N/A 
 
16 25 1.78 73 23.0 South Asian 1131 
 
17 23 1.8 90 27.8 Caucasian 694 
 
18 22 1.94 94 25.0 Caucasian 154 
 
19 29 1.86 83 24.0 South Asian 370 
 
20 31 1.78 78 24.6 South Asian 345 
 
21 30 1.85 86 25.1 Caucasian 360 
 
22 28 1.82 79 23.8 Caucasian 424 
 
23 29 1.65 65 23.9 Asian 287 
 
a 1 MET = the resting metabolic rate, equivalent to oxygen uptake of 3.5 mL/kg/hr.674  Walking and 
moderate activities were defined as having an energy expenditure rate equivalent to 3.5 METs and 
vigorous activities as 9.0 METs.  According to the Australian government recommendations, adults 
are recommended to undertake at least 500 MetMINs per week or total time (150 minutes of 
moderate activity).   2012 Development of Evidence-based Physical Activity Recommendations for 
Australian Adults (18-64 years) www.health.gov.au/internet/main/publishing.../DEB-PAR-Adults-18-
64years.pdf  
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8.3.3 RNA Sample Integrity  
The measured RNA Integrity Number (RIN) for all samples was above 7.5, 
demonstrating that the RNA integrity was not ideal but satisfactory for analysis. 
Table 8.2 shows that in 3 samples, RNA had been degraded; these samples were 
Day 0 for participants # 10 and 12 and on Day 14 for participant # 20.  Insufficient 
RNA had been extracted for two samples (Participant #5 on Day 7 and Participant # 
7 on Day 7).  As a consequence, not all participants have data for all 3 time points.   
 
Table 8.2 RNA Quality by Sample at each Time Point. 
Collection data participant at each time point showing missing data points, low RNA concentration 
and degraded samples. 
 
8.3.4 Microarray Data Quality Analysis 
The arrayQualityMetrics tool generated a heatmap image that demonstrated 
Distance between Arrays Figure 8.2, with subsequent detection of outliers for the 
distances between arrays, Figure 8.3. 
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Figure 8.2 Distances between arrays  
This figure shows a false colour heatmap of the distances between arrays. The colour scale is chosen 
to cover the range of distances encountered in the dataset. Patterns in this plot can indicate clustering 
of the arrays either because of intended biological or unintended experimental factors (e.g. batch 
effects). The distance between two arrays a and b (dab) is computed as the mean absolute difference 
between the data of the arrays (using the data from all probes without filtering). Outlier detection was 
performed by looking for arrays for which the sum of the distances to all other arrays, Sa = Σb dab 
was exceptionally large.  Three such arrays were detected, and they are marked by an asterisk* as 
25, 41 and 47. (Shown lower left – both axes) 
 
8.3.5 Outlier Detection for Distances Between Arrays 
The heatmap shown in Figure 8.2 highlighted the three arrays, 25, 41 and 47 as 
being outside the determined threshold of 21.1 for outlier analysis.  Figure 8.3 
identifies the participant and time period which classifies them as outliers. 
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Figure 8.3 Outlier Detection for Distances between arrays.  
This figure shows a bar chart of the sum of distances to other arrays Sa, the outlier detection criterion 
from Figure 8.2. The bars are shown in the original order of the arrays. Based on the distribution of 
the values across all arrays, a threshold of 21.1 was determined, which is indicated by the vertical 
line.  Three arrays exceeded the threshold and were considered outliers.  
The following three samples were identified as the outliers: Participant 6 day 7; Participant 5 day 14; 
Participant 20 day 0  
8.3.6 Principal Component Analysis (PCA) 
PCA is an method for grouping the samples based on their similarity in the 
expressions of all the transcripts.  To explore genes for which expression changed 
due to SFN in two different doses from baseline, genome-wide expression profiles 
for the two dose levels were investigated.  The PCA data, illustrated graphically in 
Figure 8.4 do not show a visually-apparent PCA relationship.  The absence of 
clusters indicates that there were few significantly differentially-expressed genes 
across the time periods Days 0 – 7 and Days 7-14.    
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Figure 8.4 Principal Component Analysis.  
This figure shows a scatterplot of the arrays along the first two principal components, reflecting the 
overall data (dis)similarity between the arrays, with the larger points indicative of the outliers.   
8.3.7 Number of Differentially-expressed Genes  
Overall, when comparing the numbers of genes significantly differentially-expressed 
from Day 0 to Day 14, 36 genes with adjusted p-values <0.05 were identified; 10 of 
these genes were upregulated and 26 were downregulated.  For the positively-
expressed genes, the fold-change ranged from 1.1 to 1.3 and for the negatively-
expressed genes from 0.8 to 0.9. 
The results of the study appear to have been confounded by the presence of viral 
infection in two of the participants (#21 and #23) during Week 1.  Had the outliers 
and the subjects carrying the Day 7 viral load data been removed, there would have 
been an overall decrease in the number of significantly differentially-expressed 
identified genes. (Refer Table 8.4) 
Participants for whom one or two data points were missing were retained in this set 
of analyses.  This is illustrated in Table 8.3 and Figure 8.1, showing that the final 
sample number for each time period was 18.   
Review of the data overall and consideration of the sparseness of the differentially-
expressed genes shown by the Volcano Plots for each of the time periods confirmed 
the need to focus on the period Day 0 – Day 14. 
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Table 8.3 Samples that are included in this analysis. 
Of the 23 enrolled participants, 18 at each time point were included in the data analysis 
Time Point (Days) Participants  Number of Samples 
0 1, 2, 5, 6, 7, 8, 9, 11, 13, 14, 
15, 16, 17, 18, 19, 21, 22, 23 
18 
7 1, 2, 8, 9, 10, 11, 12, 13, 14, 
15, 16, 17, 18, 19, 20, 21, 22, 
23 
18 
14 2, 6, 7, 8, 9, 10, 11, 12, 13, 
14, 15, 16, 17, 18, 19, 21, 22, 
23 
18 
 
Table 8.4 shows the list of significantly differentially-expressed genes comparing two 
time points with baseline.  These three periods are: Day 14 versus Day 0, Day 14 vs 
Day 7 and Day 7 vs day 0.  The study’s primary focus as explained earlier is on the 
Day 0-Day 14 period. 
Table 8.4 The number of significantly differentially-expressed genes based on viral 
load. 
The numbers of differentially-expressed genes were reduced when the subjects with viral infections 
were included or excluded. (adjusted p-value <0.05).  The fold-change for positively-expressed genes 
ranged from 1.1 to 1.3 and the fold-change for negatively expressed genes ranged from 0.7 to 0.9.  
Refer Table S 8.1 for data.   
Comparisons 
Number of Genes 
with Positive 
fold-change 
Number of genes 
with Negative fold-
change 
Excluding the outliers 
Day 7 vs Day 0  17 83 
Day 14 vs Day 0  10 26 
Day 14 vs Day 7 36 90 
Excluding the outliers and subjects (virus) 21 and 23 from Day 7 
Day 7 vs Day 0  10 64 
Day 14 vs Day 0  8 13 
Day 14 vs Day 7 8 15 
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8.3.8 Revised PCA With Outliers Excluded 
After removal of outliers, the revised Ingenuity PCA data are graphed below wherein 
Figure 8.5a represents PCA of samples with the subject ID indicated. The first PCA 
plot showed that samples from the same subject tend to have similar gene 
expression and were clustered close together in the graph.  Figure 8.5b represents 
the PCA of samples with the sample collection day indicated.  
 
Figure 8.5 Principal component analysis (PCA) of the microarray data without outliers.  
There were no clearly defined clusters for Day 0- 7and Day 7-14, so that comparison of gene 
expression between the individual time periods is not expected to generate reliable data. This 
suggested that there were few significantly differentially expressed genes when comparing the gene 
expression from different time points. 
Review of the two principal components on the x and y axes respectively, showed 
that there was an absence of distinct clusters when considering the samples from 
Days 0, 7, and 14. This suggests that there were few significantly differentially-
expressed genes across Days 0 – 7 and Days 7-14.    
Each point in the scatter plot represents one microarray sample. Samples that have 
similar gene expression profiles will be close to each other. Figure 8.5a shows that 
for participant #17, the samples for all three time points had similar gene expression 
profile and where therefore close together on the PCA plot.  Some other participants 
a b
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also have their samples from different time points clustered closer together (e.g. #18, 
#9, and #13 as examples). This suggests that for the most part, the gene expression 
profile from different time points for the same person are similar. 
8.3.9 Summary of Microarray Quality Analysis Data 
The various quality control measures described above reaffirm that there are 
relatively few significantly differentially-expressed genes across the two 7-day time 
points. 
8.4 ANALYSIS OF SIGNIFICANTLY DIFFERENTIALLY-EXPRESSED GENES   
8.4.1 Day 0 – Day 14 Heatmap 
Figure 8.6 Heat map showing the expression level of the significantly differentially-
expressed genes for the 23 sets of participant data for Day 0 - Day 14.  
The rows represent the significantly differentially-expressed genes and the columns represent the 
identification numbers of the participants. Each cell of the heat map represents the gene expression 
values normalised using the RMA algorithm, in which red represents high gene expression, blue 
represents low gene expression and white represents medium expression. The bar on the right side 
of the heat map represents the significantly differentially-expressed genes, red = significantly 
increased expression, light blue = significantly decreased expression. The bar below the heat map 
indicates the number of days of SFN treatment, grey = 0 days and black = 14 days. The bottom left 
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region of the heat map highlighted a group of genes which had significantly increased expression in 
day 0 as compared to day 14. It also highlighted another group in the top right region of the heat map, 
showing genes with statistically significantly increased gene expression from Day 0 to Day 14. 
8.4.2 Further Confirmation of Differential Gene Expression via Volcano Plot. 
To further illustrate significant differential expression from Day 0 to Day 14, the R 
statistical programming language was used to generate a Volcano Plot (Figure 8.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.7 Volcano plot showing the significantly differentially-expressed genes when 
comparing changes from Day 0 to Day 14.  
The y-axis represents the negative log adjusted p-values and the x-axis represents the log fold-
change, visually separating upregulated and downregulated genes.  Blue dots = significantly 
differentially-expressed genes (adj. p-value < 0.05) and Red dots = other genes.  
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8.4.3 Differentially-expressed Genes Day 0 – Day 14 
Table 8.5 Significantly differentially-expressed genes when comparing Day 0 to Day 
14.  (adjusted p < 0.05)  
Those marked as BOLD, are indicated as significant within the Ingenuity Network #1. 
Gene 
Symbol 
Log 
Fold-
change 
Fold-
change 
Adjusted 
p-value 
Description 
Increased Gene Expression at Day 14 compared with Day 0  
ARL17B 0.43 1.3 0.047 ADP ribosylation factor like GTPase 17B 
ANKRD52 0.30 1.2 0.030 ankyrin repeat domain 52 
RPS15A 0.26 1.2 0.016 ribosomal protein S15a 
ACSM2A 0.23 1.2 0.041 acyl-CoA synthetase medium-chain family member 2A 
GPC1 0.22 1.2 0.045 glypican 1 
TMEM132E 0.22 1.2 0.037 transmembrane protein 132E 
DDC 0.18 1.1 0.041 dopa decarboxylase 
CCDC82 0.16 1.1 0.042 coiled-coil domain containing 82 
BGN 0.15 1.1 0.037 biglycan 
C14orf2 0.14 1.1 0.045 chromosome 14 open reading frame 2 
Decreased Gene Expression at Day 14 compared with Day 0 
TMEM176B -0.39 0.8 0.037 transmembrane protein 176B 
ZFPM1 -0.37 0.8 0.004 zinc finger protein, FOG family member 1 
RELB -0.28 0.8 0.037 RELB proto-oncogene, NF-kB subunit 
NTAN1 -0.28 0.8 0.047 N-terminal asparagine amidase 
IGF2BP2 -0.28 0.8 0.037 insulin like growth factor 2 mRNA binding protein 2 
GK5 -0.28 0.8 0.041 glycerol kinase 5 (putative) 
HERC6 -0.25 0.8 0.038 
HECT and RLD domain containing E3 ubiquitin protein 
ligase family member 6 
TICAM1 -0.24 0.8 0.037 toll-like receptor adaptor molecule 1 
ZNF142 -0.24 0.8 0.038 zinc finger protein 142 
GAR1 -0.22 0.9 0.016 GAR1 ribonucleoprotein 
CFD -0.21 0.9 0.037 complement factor D 
SEC61A1 -0.21 0.9 0.041 Sec61 translocon alpha 1 subunit 
CEBPB -0.20 0.9 0.037 CCAAT/enhancer-binding protein beta 
GSR -0.19 0.9 0.045 glutathione-disulfide reductase 
ZBTB2 -0.19 0.9 0.044 zinc finger and BTB domain containing 2 
HSP90B1 -0.18 0.9 0.041 heat shock protein 90 beta family member 1 
ETF1 -0.18 0.9 0.037 eukaryotic translation termination factor 1 
PDIA4 -0.17 0.9 0.045 protein disulfide isomerase family A member 4 
EXOSC10 -0.16 0.9 0.045 exosome component 10 
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Gene 
Symbol 
Log 
Fold-
change 
Fold-
change 
Adjusted 
p-value 
Description 
SURF4 -0.16 0.9 0.037 surfeit 4 
CPVL -0.16 0.9 0.044 carboxypeptidase, vitellogenic like 
SETD2 -0.15 0.9 0.037 SET domain containing 2 
RPN1 -0.14 0.9 0.037 ribophorin I 
GSTP1 -0.14 0.9 0.041 glutathione S-transferase pi 1 
CSNK1G1 -0.14 0.9 0.041 casein kinase 1 gamma 1 
DDX3X -0.14 0.9 0.037 DEAD-box helicase 3, X-linked 
 
8.4.4 Differentially-expressed Genes for Periods Day 0 – Day 7 and Day 7 – Day 14 
The Supplementary Materials contain the tables of differentially-expressed genes for 
the periods Day 0 to Day 7 and Day 7 to Day 14.  These data have been removed 
from the Results section as they failed to meet the criteria for significance; even so, 
for completeness, they are included as supplementary material because elements of 
these data form part of the Discussion section in 8.7.  
8.5 NETWORK ANALYSIS 
8.5.1 Network #1 - NF-kB Interactive Network 
Based on the input dataset, the IPA library of canonical pathways identified the NF-
kB network as the most significant network, illustrated in the interactive network 
diagram in Figure 8.8.  Chapter 7 discussed in some depth the NF-kB network and 
its cross-talk relationships with both Nrf2 and the Aryl hydrocarbon receptor, the 
latter being integral to the Phase 1 detoxification pathway.   
Of the genes identified as interactive in the NF-kB pathway, IPA highlights RELB,685 
a component of the NF-kB sub-family and CEBPB,686 both of which are 
downregulated in the EASYGENEX Study.  The two aforegoing literature references 
suggest that the NF-kB complex also regulates RELB and CEBPB.   What this study 
has identified is possibly evidence of a negative feedback mechanism, wherein NF-
κB requires CEBPB and RELB subunit to function whilst NF-κB is a regulator of 
RELB and CEBPB expression.   
This is further evidenced in that a cross-talk relationship between NF-κB and CEBPB 
has been identified showing that these transcription factors can act synergistically.647  
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These transcription factors acting together have been shown to mediate the 
expression of the major acute phase reactant, serum amyloid A2 via IL-1 and IL-6.  
Downregulated CEBPB has been shown to protect cardiomyocytes from hypertrophy 
via inhibition of p65-NF-κB, further highlighting the close inter-relationships between 
these transcription factors.648    
These relationships are considered to be clinically significant in that a diet high in 
saturated fat, especially palmitic acid directly activates CEBPB protein expression in 
liver, adipocytes and macrophages, providing a putative link between dietary fat and 
the known inflammatory state associated with adiposity and type 2 diabetes.646   
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Figure 8.8 NETWORK 1.  The highest scoring interaction network comparing Day 0 to 
Day 14 highlighted a possible negative feedback mechanism for the activity of the NF-
kappa B (NF-kB) complex.  
Genes that have significantly increased expression are highlighted in red and genes with significantly 
decreased expression in Day 14 are highlighted in green. The shape of each node in the network 
references the following: trapezium = transporter; diamond = enzyme; concentric circles = protein 
complex; square = cytokine; triangle = phosphatase; tall rectangle = ion channel; long rectangle = 
ligand-dependent nuclear receptor; tall ellipse = transmembrane receptor; long ellipse = 
transcriptional regulator. Genes in this network are known to be involved in cell death and survival, 
protein synthesis, and inflammatory response. The network highlights the decreased expression of 
genes whose protein product is known to interact in the NF-kB complex. 
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8.5.2 Canonical Pathways 
IPA generated the Top 15 Enriched Canonical Pathways across the two 7- day 
periods and the overall 14-day period.  The Canonical Pathway for Day 0 - 14 
complements Network #1 by identifying the pathways highlighted by the statistically-
significant degree of enrichment above a -log (adjusted p-value) threshold.  For each 
of the Figure 8.9 enriched pathways expressed as -log(p-value), seven are 
significant and above the threshold.  
IPA identifies the relevant genes in the canonical pathway which had significantly 
increased gene expression compared to the average level of all genes but because 
these are expressed as grey bars, there is insufficient data to determine whether 
expression is up- or downregulated.  Those pathways for which the ratio was low 
(i.e. less than 0.1) are indicative of too few statistically-significant differentially-
expressed genes compared with the ratio to the total number of genes in the 
canonical pathway. Table 8.6 identifies the genes contributing to the pathways. 
Figure 8.9 Enriched canonical pathways for day 0 vs day 14 comparison.  
The left y-axis represents the significance of the canonical pathways as shown as the -log adjusted p-
value; the right y-axis represents the enrichment ratio.   The enriched canonical pathways are shown 
as labels on the x-axis. The bars represent the significance of each of the pathways and the threshold 
represents the adjusted p-value level of < 0.05. The enrichment ratio (orange line) represents the 
proportion of genes in the canonical pathways that are also the query genes.  
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Table 8.6 The five top Canonical Pathways identified by IPA for Day 0 - Day 14.   
Those pathways shown in bold and above the threshold are significant, with the higher bars indicating 
greater enrichment. 
The expression column represents the up- or downregulated genes, indicated in Table 8.5. 
Ingenuity Canonical 
Pathways 
-log 
(p-value) 
Ratio z-score Genes Expression 
Glutathione Redox 
Reactions I 
3.17 0.11 
NaN GSR, GSTP1 ↓ 
Serotonin and Melatonin 
Biosynthesis 
2.07 0.25 
NaN DDC ↑ 
Catecholamine 
Biosynthesis 
2.07 0.25 
NaN DDC ↑ 
Glutathione Redox 
Reactions II 
2.07 0.25 
NaN GSR ↓ 
Glycerol Degradation I 1.97 0.2 
NaN GK5 ↓ 
 
8.5.3 IPA Interpretive Summaries 
IPA provides summaries of the microarray data, grouped to include Top Canonical 
Pathways and Top Networks.  The highlighted networks for Day 0 – 14 are listed as 
relating to processes associated with the inflammatory response, cell death and 
survival, protein synthesis, cell-to-cell signalling, haematological system function, cell 
cycle, replication, recombination and repair, connective tissue, cancer, endocrine 
and gastrointestinal disorders.  The top up- and downregulated molecules are 
identified in this context; however, review of the literature reveals that limited data 
exist for a number of those genes and their molecular products.   
Of those Network #1 genes for which data is more extensive, a number bear 
mention, especially in relation to their differential expression following the 
intervention in this study.   
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8.5.4 Differentially-expressed Genes  
Of the significantly differentially-expressed genes across the Day 0 – Day 14 period, 
two upregulated and eleven downregulated genes have been listed in Table 8.7.  As 
each is described in the scientific literature in relation to its known function in 
humans, it has been selected for more detailed discussion. 
Table 8.7 Differentially-expressed genes from Network #1 and their key properties and 
functions 
Gene Properties and Functions 
Key Upregulated genes (Defined in Table 8.5) 
DDC 
DDC is required for synthesis of dopamine as well as epinephrine 
and norepinephrine.  DDC can also decarboxylate 5-
hydroxytryptophan to produce serotonin.687 
ACSM2A 
ACSM2A belongs to a family of mitochondrial Acyl-CoA synthetase 
enzymes essential for de novo lipid synthesis, fatty acid catabolism 
and remodelling of membranes.688 
Key Downregulated genes 
RELB 
The NF-kB or Rel protein family plays critical roles in adaptive and 
innate immunity, inflammation, cell differentiation, proliferation and 
apoptosis.  RELB is overexpressed in various cancers.649   
CEBPB 
Plays an essential role in cell proliferation (pro- or antiproliferative), 
differentiation and growth arrest in specific cell types, including 
adipocyte differentiation.689   
HERC6 
HERC proteins are key components of a wide range of cellular 
functions – neurodevelopment, DNA damage repair, cell growth 
and immune response.690   
TICAM1 
TICAM1 is an adaptor protein in TLR3 and TLR4 signalling 
pathways that mediate pro-inflammatory cytokine and interferon 
(IFN) responses.691  
PDIA4 PDIA4 inactivation restores a classical mitochondrial apoptosis 
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pathway.692 
ZBTB2 
A potential proto-oncogenic master control gene of the p53 
pathway.693   
IGF2BP2 
Associated with decreased insulin secretion and type 2 
diabetes.694  
DDX3X 
The helicases are nucleic acid-dependent ATPases, which unwind 
and remodel DNA or RNA695     
GSR 
GSH homeostasis is regulated by de novo synthesis (via GPX1) as 
well as the status of the GSH:GSSG redox couple (GSR).  Both 
GSR and GPX are Nrf2-dependent genes.696  Downregulation of 
GSR was observed but GPX was not. 
GSTP1 
Codes for a key Phase 2 detoxification enzyme which uses SFN 
as a substrate for the synthesis of mercapturic acid metabolites.  
Polymorphisms are associated with cancer susceptibility.697 
GK5 
Active in triacylglycerol biosynthesis and glycerol degradation 
pathways, especially high in hepatocytes but limited in adipocytes 
under normal conditions.698,699   
 
8.5.5 Enriched Canonical Pathway Comparisons. 
Figures 8.9, 8.10 and 8.11 illustrate the marked differences in the canonical 
pathways generated across the 3 study periods.  Although the Day 0 – Day 7 and 
Day 7 – Day 14 periods indicate there was significant differential expression, the 
enrichment ratio representing the proportion of query genes within the total number 
of genes in the canonical pathways is limited (orange line).  Furthermore, Day 7 - 
Day 14 shows the likely possibility that the significantly enriched canonical pathways 
such as Integrin Signalling and Vascular endothelial growth factor (VEGF) signalling 
were the result of viral infection in Participants #21 and #23 rather than the effect of 
the intervention.  Figure 8.12 shows the genes with significantly decreased gene 
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expression involved in response to viral infection as well as their upstream regulatory 
partners (IPA generated image). 
8.5.6 Day 0 – Day 7.  Top 15 Canonical Pathways 
IPA classifies the identified pathways as being related primarily to the signalling 
processes of fundamental cellular functions; movement, function and maintenance, 
development, growth and proliferation are compromised.  Since the enrichment ratio 
is low (i.e. ratio less than 0.1) for the canonical pathway query genes, no significance 
can be attached for this period. 
Figure 8.10 illustrates a number of downregulated pathways within the initial 7 days 
of the study.  Since all participants were included in the analysis, it is not possible to 
differentiate the observed effects of SFN or viral burden.  However, several of the 
identified pathways are known to be SFN targets. Of the four signalling pathways 
listed below (Integrin, ERK/MAPK, Extravasation and VEGF) and shown in Figure 
8.10, for three of these, SFN is already known to interact; these pathways are 
included for this reason.   
 
 
 
 
 
 
 
 
 
Figure 8.10 Day 0 – Day 7. Top 15 enriched canonical pathways  
For each, the left y-axis represents the significance of the canonical pathways shown as -log adjusted 
p-value; the right y-axis represents the enrichment ratio and the enriched canonical pathways are 
shown as labels on the x-axis. The bars represent the significance of each of the pathways and the 
threshold represents the adjusted p-value level of < 0.05. The enrichment ratio (orange line) 
represents the proportion of genes in the canonical pathways that were also the query genes. 
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8.5.7 Day 7 – Day 14.  Top 15 Canonical Pathways 
Day 7 vs day 14 analysis: As with the Day 0 – Day 7 period, the data for the IPA 
Enriched Canonical Pathway are not sufficiently robust to be considered significant. 
Reference to this period has been made as it reflects the effect of the virus in two 
participants on the entire dataset for this period.  The strong negative z-score 
identifies significant enrichment in Interferon Signalling but the ratio of query genes 
to the total for this pathway prevents us from drawing any conclusion.   It is likely that 
the significantly decreased downregulation of interferon was due to resolution of the 
virus and not related to SFN.  The analysis of the regulator effects supports the 
decreased expression of genes involved in response to viral infections (Figure ).  
Heat map analysis (not shown) indicated that two samples, subjects 21 and 23 from 
day 7, had increased expression of known viral infection-related genes as described 
earlier.  Although Participant #2 was suspected to have had a viral infection during 
the study, the expression of genes involved in response to viral infection were 
comparatively low for subject 2. 
  
Figure 8.11 Day 7 – Day 14. Top 15 enriched canonical pathways. 
Interferon signalling was highlighted as being significantly downregulated during the second 7-day 
period of the study. The enrichment ratio (orange line) represents the low proportion of genes in the 
canonical pathways that were also the query genes. 
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8.5.8 Viral Infection – a Possible Confounder 
Our rationale for considering that two of the study participants exhibited symptoms of 
infection as well as changes in gene expression was described earlier.  IPA identified 
the genes MX1, IFITM3, OAS1, PLSCR1 and OAS3 as being downregulated due to 
the presence of a virus.  Downregulation was due to their upstream regulatory 
partners, USP18, IFNL1, IFNA2 and EIF2AK2. 
 
Figure 8.12 Genes with significantly decreased gene expression involved in response 
to viral infections and their upstream regulatory partners.  
The shape of each node in the network references the following: tall diamond = enzyme; long 
diamond = peptidase; square = cytokine; octagon = biological process.  
 Page 202 of 308 
 
8.6 PLASMA SFN AND ITS MERCAPTURIC ACID METABOLITES. 
Participants #2, #8 and #9 had baseline SFN levels well above the average of 3.19 ± 
5.3 ng/ml indicating that they had not adhered to the study instructions. Data from 
these 3 participants was removed; all three carry the normal GSTP1 gene. Table 8.8 
lists plasma concentrations of SFN and its mercapturic acid metabolites of the 
remaining participants across each time period expressed in ng/ml as measured. 
The standard deviations of each of these indicated very large inter-individual 
variability.  
 
Table 8.8. Plasma concentrations of SFN and its mercapturic acid metabolites of all 
participants mean ± SD.  
SFN = sulforaphane; SFN-NAC = sulforaphane N-acetyl cysteine metabolite; SFN-GSH = 
sulforaphane glutathione metabolite; SFN-CYS = sulforaphane-cysteine metabolite.  High levels for 
SFN at baseline are a likely indicator that dietary exclusions were not followed by Participants #2, #8 
and #9. 
 
 
 
 
8.6.1 Presentation and Analysis of the Data according to Genotype 
The data for all participants were separated according to the nature of GSTP1 
genotype (derived from Table 8.1) and expressed initially as nanograms per millilitre 
(ng/mL) (Table 8.9) and later converted to micromolar concentrations (µM). (Utilised 
in Figures 8.13, 8.14 and 8.15) for ease of comparison with other studies.   
 
 
 
 
 
Day 
SFN  
(ng/ml) 
SFN-NAC 
(ng/ml) 
SFN-GSH 
(ng/ml)  
SFN-CYS 
(ng/ml) 
0 10.36 ± 19.7 13.62 ± 12.7 3.57 ± 7.3 0.60 ± 0.4 
7 37.25 ± 68.7 64.05 ± 83.9 3.77 ± 3.8 4.98 ± 9.8 
14 64.50 ± 65.1 97.15 ± 147.4 8.32 ± 21.2 7.52 ± 16.1 
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Table 8.9. Plasma SFN Concentrations via genotype 
Plasma concentrations of SFN and its metabolites considering GSTP1 genotype in accordance with 
the 3 time periods for which samples were collected.  SFN data is reported as Mean ± Standard 
Deviation with data for the three metabolites reported as Median Values with their Interquartile Range.   
SFN and SFN metabolite levels during the trial for all 
participants and according to GSTP1 polymorphism 
Metabolite 
Gene or 
Variant 
0 days 7 Days 14 days 
SFN 
(ng/ml)  
All 14.8± 22.3 53.2 ±77.3 82.3±65.9 
Normal 22.7 ± 26.9 36.0 ±38.7 78.2±56.8 
Homo/Hetero 4.2 ± 6.1 76.2±111.1 87.6±82.0 
SFN-NAC 
 (ng/ml) 
  
All 0.93 [0.50] 1.48 [1.27] 1.58 [1.14] 
Normal 0.88 [0.29 0.82 [1.30] 1.52 [1.01] 
Homo/Hetero 1.22 [0.72] 1.81 [0.64] 1.73 [1.74] 
SFN-GSH 
 (ng/ml) 
  
All 1.79 [0.85] 1.60 [3.52] 2.04 [2.34] 
Normal 1.91 [0.81] 1.54 [3.46] 1.81 [3.97] 
Homo/Hetero 1.69 [1.64] 1.78 [6.53] 2.58 [1.03] 
SFN-CYS 
 (ng/ml) 
  
All 0.52 [0.41] 0.86 [4.55] 0.52 [1.73] 
Normal 0.41 [0.45] 0.53 [2.77] 0.38 [6.48] 
Homo/Hetero 0.67 [0.36] 4.3 [21.95] 0.66 [1.96] 
 
8.6.2 Summary of Findings 
Overall, there was a significant (p<0.05) effect of time for SFN, SFN-NAC and SFN-
CYS. There were no significant (p>0.05) effects of group (wild type vs homo/hetero) 
and no significant group*time interactions. There was a trend for a group effect in 
SFN-NAC (p=0.09) indicating a greater number of participants would be needed to 
find a significant group effect.  
Figures 8.13, 8.14 and 8.15 show the differences in the micromolar concentrations 
and proportions of SFN and the measured metabolites, SFN-NAC, SFN-GSH and 
SFN-CYS.  Of the metabolites, SFN-NAC was significantly the highest of the three 
and in those carrying polymorphisms, SFN-NAC was higher than SFN itself.  
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Figure 8.13   Plasma SFN and mercapturic acid metabolites (μM) for all participants, 
combining wild-type, homozygous and heterozygous polymorphisms, with error bars 
indicating standard deviation. 
 
 
Figure 8.14  Plasma SFN and mercapturic acid metabolites (μM) for participants with 
wild-type GSTP1 genotype, with error bars indicating standard deviation. 
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Figure 8.15 Plasma SFN and mercapturic acid metabolites (μM) for participants with 
combined homozygous and heterozygous GSTP1 polymorphisms, with error bars 
indicating standard deviation. 
 
8.7 DISCUSSION 
SFN is the primary bioactive compound generated from broccoli sprouts following 
the enzymatic hydrolysis of GRN by MYR.  As a food-derived nutraceutical, the 
human genome is adapted to this readily-bioavailable low M.W. lipophilic molecule.  
Both SFN-yielding and GRN supplements are available to consumers, even though 
the dose-response for each form is not fully-characterised.  The broccoli sprout form 
utilised in this study provides the convenience of a capsule, designed to be taken 
daily over extended periods, thereby more closely approximating the regular dietary 
intake of a cruciferous vegetable.  As a whole food ingredient and not an extract of a 
specific bioactive compound, this intervention is more likely to provide the full 
spectrum of micronutrients and other phytochemical bioactives naturally-occurring in 
broccoli sprouts.   
In this study, a microarray platform was utilised to investigate the differential gene 
expression at two dose levels of a SFN-yielding encapsulated supplement.  The 
advantage of using a microarray platform lies in the ability to simultaneously evaluate 
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the effect of a specific intervention on many hundreds of genes.  The results of this 
study are intended to highlight important directions for future research in this field. 
SFN derived from food and supplements is best-known for its role in Nrf2-dependent 
effects associated with the induction of a large battery of cytoprotective genes.  
Clinical trials using SFN and broccoli sprouts have generally shown Nrf2-dependent 
effects. However, SFN also exhibits other effects for which gene expression data 
and related mechanistic findings are emerging.157,204  Surprisingly, there was no 
observed expression of Nrf2-dependent genes; instead, the study highlighted a 
series of Nrf2-independent effects, some of which may give preliminary indication of 
SFN’s involvement in new clinically-relevant areas such as neurotransmitter 
synthesis.  
8.7.1 Lack of Nrf2-dependent Effect on Differential Gene Expression 
The lack of an Nrf2-dependent effect in this study is hypothesised as being related to 
the fact that the participants in the intervention group were all young, healthy and 
physically-active.  Therefore, it might be expected that inflammation and other 
disease markers at baseline would already be in the normal range, potentially 
limiting any changes due to the intervention.  In Chapter 7, some of the beneficial 
effects of physical activity on human health were discussed, highlighting the fact that 
little has been published on the role of exercise on Nrf2 and in particular that there is 
no quantitative data for comparative consideration.  
Others have reported lack of effect of other phytochemical interventions under 
similar conditions to ours in that the trial participants were healthy.700 A study using 
the isolated phytochemical quercetin ± antioxidant vitamins in a healthy population 
failed to observe the expected response on cardiovascular lipid and coagulation 
markers, even though blood levels of quercetin were as expected.701   By contrast, 
they observed the predicted benefits of quercetin when health status was 
compromised by hypertension in a different study population. 
Other SFN studies showed that participants with chronic obstructive airway disease 
(COPD)206,207 and asthma702 failed to respond to SFN.  Here, it was postulated that 
upregulation of Nrf2 may have already been present at baseline as a compensatory 
mechanism for the disease process itself, making it difficult to further stimulate Nrf2 
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with SFN.  In these cases, SFN had been shown to be well-absorbed using 
measurement of SFN and its metabolites in plasma, just as demonstrated in the 
EASYGENEX Study. 
Similarly, SFN was not effective on glucose control biomarkers in metabolically well-
regulated animals on a high-fat diet compared to its positive effects on obese 
metabolically-dysregulated animals on the same diet, indicating that responses may 
differ between normal and abnormal states.198   
Chapter 7 described the process for determination of dosage in the EASYGENEX 
Study.  In summary, histone deacetylation (HDAC) is known to be inhibited by an 
Nrf2-unrelated mechanism and typically responds to higher doses than for Nrf2 
activation.  As such, it was expected that HDAC inhibition would be observed at the 
higher of the dosage levels as administered during the Day 0 – Day 14 period.  
However, little is known about the effect of exercise on HDAC inhibition.  A 2009 
study showed equivocal findings on the effect of 60 minutes of cycling on HDAC 
inhibition in human skeletal muscle tissue.703  During the Day 7 – 14 period, HDAC 
downregulation with a fold-change of 0.9 at the higher dose was observed but this 
effect was not seen in comparing Day 0 with Day 14.  As a consequence, it was not 
possible to determine whether failure to demonstrate significant HDAC inhibition was 
due to lack of effect of SFN or whether this group of young, healthy, regularly-
exercising men might already have optimised HDAC activity.   
Considering these data together with the known effects of exercise on Nrf2 
activation, the effect of the intervention in this study might therefore be more difficult 
to detect than had an older, less healthy, less active study population been selected. 
8.7.2 SFN’s Effect on Differential Gene Expression  
This study revealed relationships between SFN and a number of genes for which 
there are no reports in the scientific literature.  Notably are the genes DDC, 
ACSM2A, HERC6, PDIA4, ZBTB2, IGF2B2, DDX3X and GK5. 
From consideration of all the differentially-expressed genes across Day 0 – Day 14, 
a picture emerges of interactions in intricate signalling associated with many core 
cellular processes, particularly those associated with immune dysregulation.  In 
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addition to downregulation of pro-inflammatory processes, others appear to be 
related to inhibition of cancer cell development by downregulating genes associated 
with angiogenesis and metastasis and by protecting tumour suppressor genes such 
as p53 and p21, (RELB, HERC6, ZBTB2). 
Two of the genes negatively expressed (IGF2BP2 and CEBPB) may impact on 
glucose metabolism, potentially reducing changes that contribute to insulin 
resistance and adiposity.  These effects of SFN are already known; however, this 
study has uncovered specific genes not previously associated. These genes can be 
broadly grouped into 6 overlapping categories with some genes known to exhibit 
multiple effects:  immune modulation (anti-inflammatory), metabolism (adipogenesis, 
glucose metabolism, insulin sensitivity), neurotransmitter synthesis, cytoprotection, 
cardioprotection and redox modulation. 
8.7.3 Immune Modulation (Anti-inflammatory Effects) 
IPA highlighted the NF-kB Network as the most significant during Day 0 – Day 14, 
with the NF-kB subunit, RELB significantly downregulated.649  NF-kB subunits are 
known to strongly act in synergy with members of the C/EBP family of transcription 
factors704 and this study showed that both were downregulated.   
Toll-like receptor (TLR4) pathways mediate pro-inflammatory cytokine and interferon 
responses, with the adaptor protein TICAM1 essential in stopping TLR-mediated IFN 
production.691  SFN has been shown in a thiol-dependent manner to suppress TLR4 
oligomerization, an event that is critical to TLR4 activation in inflammation.  SFN’s 
suppression of TLR4 oligomerization was shown to downregulate NF-kB 
activation,705 potentially further regulating inflammation.  Saturated fatty acids are 
known to act as ligands for toll-like receptor 4 (TLR4) in macrophages and 
adipocytes, with these signals in turn regulating various pro-inflammatory 
transcription factors.646  IPA’s Network #1 shows TICAM1 to be downregulated by 
the SFN intervention, thereby highlighting the possibility that SFN was responsible 
for dysregulation in the expression of genes in the TLR4 pathway and consequently 
limiting a possible inflammatory response. 
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8.7.4 Dopamine Expression and its Little-Known Effect on Immune Function 
A lesser-known effect of dopamine is that it may inhibit cytokine production706 and is 
an endogenous regulator of inflammasome activation, bridging the nervous and 
immune systems.706  It was shown that SFN upregulated DDC, so that it may 
contribute an anti-inflammatory effect by this additional mechanism.  Substantial 
synthesis of neurotransmitters including dopamine occurs in the gastrointestinal 
tract707 but it is not known whether SFN might exhibit anti-inflammatory or other 
effects here by this mechanism. 
8.7.5 Metabolism – Adipogenesis, Glucose Metabolism, Insulin Sensitivity 
Our study showed upregulation of CEBPB, a gene associated with adipogenesis. 
Activation of an associated transcription factor PPARγ, in turn activates expression 
of adipogenic genes.689  SFN (20 μM) has been shown to decrease the expression of 
CEBPB and PPARγ during early stage adipogenesis in a cell culture model.708  An 
animal study concluded that  SFN may induce anti-obesity activity by inhibiting 
adipogenesis through downregulation of PPARγ and C/EBPα and by suppressing 
lipogenesis through activation of the AMP-activated Protein Kinase (AMPK) 
pathway.709   The study’s data did not identify PPARγ.   
Upregulation of ACSM2A was observed; this is a gene that codes for the 
mitochondrial Acyl-CoA synthetase enzymes abundant in human liver and specific 
for medium-chain triglycerides (MCT).  MCTs are known to fuel the lipid β-oxidation 
and ATP-generating pathway to induce thermogenesis and reduce de novo lipid 
synthesis.710  SFN was shown here for the first time to upregulate ACSM2A.  How 
this might impact regulation of adiposity is not known but since several association 
studies have linked ACSM2A polymorphisms to traits of insulin resistance.711, this 
may be an avenue for further investigation of the properties of SFN, especially given 
that SFN has already been shown to have positive effects in patients with type 2 
diabetes.197,432  ACSM2A is also associated with enhanced glycine conjugation in 
detoxification of xenobiotics like benzoate, ibuprofen and aspirin.712  The possible 
role of SFN in this context deserves further investigation.  
Another metabolically-related gene, IGF2BP2 is associated with decreased insulin 
secretion but effects on type 2 diabetes risk of its polymorphisms are unclear.694  It 
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was hypothesised that SFN’s observed downregulation of IGF2BP2 may assist in 
restoring insulin secretion. 
SFN was shown to downregulate GK5.  Glycerol is a primary factor determining 
plasma glucose,713 with catecholamines inducing lipolysis, thereby increasing the 
release of free fatty acids and glycerol from fat into the bloodstream.714 This study 
showed upregulation of DDC, inferring enhanced catecholamine synthesis with a 
possible tendency towards lipolysis; it is not possible to say whether downregulation 
of GK5 was in response to SFN. Aberrant function of the glycerol kinase enzyme has 
implications for adiposity and insulin resistance but as this study investigated 
PBMCs, its significance in relation to broader physiological function is not known. 
A recent in vitro study investigating brown vs white adipocytes showed that SFN 
enhanced glucose uptake and oxidative utilisation, lipolysis and fatty acid oxidation 
together with adipocyte ‘browning’ in an Nrf2-related manner.715  Another study 
showed that SFN stimulates lipolysis via a decrease in energy-sensitive AMPK 
signalling.716  However, the genes identified in these studies were not differentially-
expressed in the EASYGENEX Study.  Clearly, SFN is affecting a number of 
adipose-related genes although the mechanisms are as yet poorly-characterised. 
8.7.6 Neurotransmitter Synthesis and Neuroprotection.   
The effect of an increase in Dopa Decarboxylase activity (DDC) may have 
implications for neuropsychiatric effects related to upregulation of synthesis of 
neurotransmitters dopamine, serotonin, epinephrine, norepinephrine and melatonin 
(a downstream product of serotonin).  The relationship to neurotransmitter synthesis 
is reflected in the IPA Enriched Canonical Pathway (Figure 8.9) which shows 
Serotonin, Melatonin and Catecholamine pathways as enriched.  This is the first time 
a relationship between SFN and DDC has been reported, although SFN’s effect on 
dopamine is anti-glycative717 and in other ways neuroprotective in an Nrf2-dependent 
manner718.  SFN can prevent oxidation of dopamine in cells of the substantia nigra of 
the brain, with implications for patients with Parkinson’s Disease.   
In relation to neuroprotection, the Day 7 – 14 canonical pathway data highlighted the 
Methylglyoxal Degradation I pathway which is close to the threshold for significance 
but for which the activity pattern is not known.  Methylglyoxal is the most potent 
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precursor of the AGEs, oxidant molecules that contribute to the etiopathogenesis of 
various neurodegenerative diseases. In a 2015 study, high levels of methylglyoxal 
have been found in the cerebrospinal fluid of Alzheimer patients.719  In the same 
study, SFN was shown to enhance the methylglyoxal detoxifying system, increasing 
the expression and activity of GLO1 (glyoxalase -1) in a glutathione-dependent 
manner.  As SFN demonstrated a protective anti-glycative effect in that study, one 
might postulate that the direction of expression of the Methylglyoxal pathway in the 
EASYGENEX Study was downregulation.   
In Day 7 – 14, GLO1 was shown to be downregulated with a fold-change of 0.9.  A 
related gene, GLOD4 was also downregulated to a similar degree during Day 7 – 14.  
However, these genes were not present in the Day 0-14 data listed in Table 8.5. 
8.7.7 Cytoprotection 
This study highlighted a number of downregulated genes associated with cancer.  
The role of CEBPB in relation to adiposity overlaps its role in cancer.  Increased 
CEBPB expression is implicated in development of some tumours with expression 
correlated with invasive activity.720  Similarly, IGF2BP2 described earlier in relation to 
insulin secretion has been shown also to contribute to colorectal carcinogenesis.721   
Loss of function of the tumour suppressor protein p53 is known to be a frequent and 
early event in cancer.722  ZBTB2 is a potential proto-oncogenic master control gene 
of the p53 pathway, potently repressing the cell cycle arrest genes, p21 and the 
tumour suppressor gene p53.693  The EASYGENEX Study showed for the first time, 
downregulation of ZBTB2, further illustrating the known cytoprotective effect of SFN 
by reducing or removing the suppression of p53.157 Response to chemotherapy has 
been shown to be associated with polymorphisms in the GST gene family, including 
GSTP1.723  Knowledge of an individual patient’s GST polymorphisms may inform  
dose determination when administering these highly potent pharmaceuticals.  
Downregulation of HERC6 was observed and there is currently no published 
association between SFN and HERC6.  Small HERCs such as HERC6 are related to 
male fertility, antiviral responses and cancer development.  Where HERC2 regulates 
BRCA1 stability during the cell cycle and regulates p53 signalling, much less is 
known of the physiological functions of the small HERCs (3-6).690   
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For the first time SFN’s effect in downregulating DDX3X was observed; this gene 
that can promote metastasis with worse overall survival in patients with high DDX3X 
expression in metastatic tissue.724  DDX3X regulates the NF-kB pathway but its 
interaction with NF-kB in cancer is controversial.695,725 
There is no published relationship between SFN and PDIA4, a gene downregulated 
in this study.  The protein disulfide isomerases are a superfamily of oxidoreductases 
localised in the endoplasmic reticulum (ER), nucleus, cytosol, mitochondria and cell 
membrane.   PDIA4 is intimately tied to the switch between pro-survival and pro-
death pathways during ER stress, with PDIA4 shown to play dual roles.  This effect 
has been demonstrated in secretory cells such as pancreatic beta-cells, B-
lymphocytes, hepatic cells and osteoblasts.  Failure of this pathway to restore ER 
homeostasis results in the activation of apoptotic pathways.726  Such PDIA4 
inactivation restores a classical mitochondrial apoptosis pathway, suggesting a 
possible association with chemoresistance.692  How this relates to the observed 
PDIA4 downregulation is not known but is likely to be associated with redox-related 
disulphide chemistry. 
Dopamine can suppress systemic inflammation.706,727  As it was shown that SFN 
upregulated DDC to increase dopamine synthesis, this may also contribute to 
cytoprotection because low DDC mRNA has been correlated to poor tumour 
prognosis in head and neck cancers.728   
8.7.8 Cardioprotection 
CEBPB may participate in cardiac hypertrophy with CEBPB knockdown protecting 
cardiomyocytes from hypertrophy via inhibition of p65-NF-kB.648  As discussed in 
some detail in the previous chapter, NF-κB and C/EBPβ have long been known to 
function synergistically as a complex.647  The significance of the observed 
downregulation of SFN in this context is not known. 
8.7.9 Redox-related Effects 
IPA identified Glutathione Redox Reactions as being significant overall for Day 0 – 
Day 14, highlighting two genes GSR and GSTP1.  GSR is one of two Nrf2-
dependent genes associated with GSH homeostasis;696 the other is GPX1. Together, 
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the enzymes for which these two genes code are responsible for maintaining the 
GSH:GSSG couple, often used as a marker for oxidative stress.  Here, GSH is 
oxidised by GPx and GSSG is returned to its reduced state by GSR.729  The study 
showed downregulation of GSR but did not identify GPX.  The reason that GSR was 
downregulated in this study is not clear, given that in a resting cell, the molar 
GSH:GSSG ratio exceeds 100:1730 and it might be expected that upregulated GSR 
would tend to maintain this ratio.   
Since Nrf2 is typically activated by SFN, GSTP1 too might be expected to be 
upregulated.  Here it is downregulated at Day 14.  When the participants with a viral 
burden were excluded, GSTP1 remained downregulated.  Decrease in GSTP1 gene 
expression in PBMC may be specific for these cells, since other studies have 
reported a reduction in GSTP1 on mRNA and protein level in dietary intervention 
studies. PBMCs may be also adversely affected by cryopreservation.731   
Juge et al673 in their comprehensive review of SFN in cancer refer to a similar 
glutathione-related counter-intuitive finding in that glutathione reductase (GSR) 
needed for the regeneration of glutathione was consistently inhibited by SFN in 
several cell culture lines.732  Nevertheless, this study showed that the intervention 
resulted in increased plasma GSH conjugates, the presence of which is dependent 
on the action of enzymes of the glutathione-S-transferase family of which GSTP1 is 
one member.  One might question whether this anomalous finding might be resolved 
by closer examination of the simultaneous effect of exercise in the young, healthy 
study population and the use of a different cell type for gene expression analysis.   
8.7.10 Review of Day 0 – Day 7 and Day 7 – Day 14 Canonical Pathways 
Although IPA identified a number of pathways by degree of enrichment in the study’s 
sub-groups, there were proportionately few genes representative of this pathway.  
Even so, SFN-related processes possibly deserving further investigation are 
highlighted later. 
8.7.11 Integrin Signalling Pathway: Day 0 – Day 7 
The Integrins are a family of transmembrane proteins expressed in almost every cell 
type that mediate attachment to the extracellular matrix.  They are important 
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regulators of cell survival, proliferation, adhesion and migration with established 
relationships in cancer.733  In an in vitro study on renal carcinoma cells, SFN was 
shown to downregulate integrins, demonstrating reduced tumour growth and 
proliferation in a drug resistance model.734  Integrins form numerous cellular 
signalling relationships, some of which are associated with metabolism.  A recent 
review described integrins being interwoven in a network of interdependent 
regulatory pathways with cell metabolism, highlighting the emerging control of cell 
physiology by metabolic cues.733   Integrins are also intimately associated with viral 
penetration of cells, being physiologically important receptors that have been 
usurped by viruses for attachment and/or cell entry.735 
8.7.12 ERK/MAPK Signalling Pathway: Day 0 – Day 7 
The molecular events linking cell surface receptors to activation of ERKs are 
complex and are closely linked to the process of metastasis in cancer, implicating 
SFN in the inhibition of cell motility.  Various cellular stresses, as well as pro-
inflammatory cytokines such as IL-1β and TNFα, can activate multiple MAP kinase 
signalling pathways which then play major effector roles in numerous cellular 
responses.736   Small GTP-binding proteins activate MAP kinase kinase kinases 
(MAP3K) and the phosphorylation reactions which activate the MAP kinases (MAPK) 
to elicit cellular responses. Inhibitors of these pathways are effective in preventing 
induction of pro-inflammatory genes.737   
In a cell culture model, SFN inhibited glioblastoma cell migration and invasion.738  
SFN (20 µM) reduced the formation of cell pseudopodia by phosphorylating ERK1/2 
in a sustained way, contributing to the downregulated MMP-2 (matrix 
metalloproteinase) expression and activity associated with metastasis. 
As with the Integrin signalling pathway, viruses interact with and hijack some of the 
cell’s core defence mechanisms.  The influenza viral infection modifies the signalling 
pathways, ERK-MAPK, NF-kB, MAPK and others important for viral entry, viral  
replication, viral propagation and apoptosis.739  Activation of the NF-kB pathway is a 
primary requirement for influenza virus infection and its efficient replication.739  SFN 
and viruses impact some of the same pathways but the expression data revealed in 
this study are insufficient for any conclusion to be drawn. 
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8.7.13 VEGF: Day 0 – Day 7 
VEGF is a potent angiogenic factor which is known to be suppressed by SFN, 
thereby limiting the spread of cancer.740 Still below the threshold for significant 
enrichment, this study also highlighted inhibition of Leukocyte Extravasation 
Signalling which does not appear to be hitherto related to SFN.  Leukocyte 
extravasation is a critical step in the inflammatory response, involving the migration 
of leukocytes from the bloodstream towards target tissues. The process promotes 
the rapid influx of leukocytes to inflammatory foci without compromising the integrity 
of the endothelial barrier741; no conclusions can be drawn. 
In a 2007 review paper, SF showed time- and concentration-dependent inhibitory 
effects on expression of VEGF and two angiogenesis-associated transcription 
factors on human endothelial cells (HUVECs) in a concentration range of 0.8–25 
mM; this is higher than the concentrations typically employed in cell culture 
studies.157 
8.7.14 Acetyl-CoA III Biosynthesis (from Citrate):  Day 7-14  
Although no activity pattern for the pathway shown as Acetyl-CoA III Biosynthesis 
(from citrate) is available, it is above the threshold for significance and the ratio of the 
query genes to the total in this pathway is significantly higher than for other identified 
pathways.  The ATP Citrate Lyase gene (ACLY), essential for synthesis of Acetyl-
CoA from citrate produced in the Kreb’s Cycle was shown to have been 
downregulated.  The lack of significant data for this pathway prevents any conclusion 
but given the central role of Acetyl-CoA in many aspects of metabolism, it would be 
of interest to explore this further in relation to the SFN intervention. 
8.8.15 SFN and Plasma Mercapturic Acid Metabolite Data Quality 
An initial review of the Table 8.8 data on SFN and its metabolites reveals an 
anomaly.  It would be expected that the Day 0 SFN levels shown in Table 8.8 would 
be close to zero, given that the 3-day washout period was intended to remove SFN 
and its metabolites from the system before the introduction of the capsules.  
The plasma data showed that three participants had relatively high plasma SFN 
levels at baseline, indicating either likely failure to adhere to the dietary exclusions 
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during the preliminary washout period or that our list of Dietary Exclusions had 
overlooked a significant contributor; the participant dietary intake diaries did not 
clarify the issue.  It is not possible to say whether this had any significant effect on 
the overall outcome, especially if the participants had continued to consume the food 
or foods and thereby still enabling detection of a differential effect of the intervention 
from their baseline.  These participants were removed from the analysis, further 
limiting the opportunity to observe the effect of the GSTP1 polymorphism on SFN 
metabolism. 
8.8.16 Comparison of SFN Metabolite Data with Other Studies 
There are several limitations associated with quantification of SFN metabolites and 
described by Al Janobi et al.675  These limitations are related to rapid plasma 
clearance, the potential for irreversible reactions with plasma proteins and possible 
instability of the metabolites during sample processing. 
In addition, it is difficult to compare our metabolite data with that from other studies, 
most of which examine the effect of a single dose on the pharmacokinetics over 
several hours, to record peak values.  Al Janobi et al675 showed in their validation 
study that SFN and its metabolites all peaked between 1 and 2 hours with SFN’s 
peak value of 0.8 μmol/L.  All samples declined rapidly to 6 hours from where they 
declined more slowly thereafter.   
In our study which involved twice-daily dosing over 14 days, we did not record 
measurements on time from last dose to blood collection, so that in our study no 
data on peak values are available for comparison.  The inclusion of a 
pharmacokinetic step in our study would have been useful in enabling comparison 
with data from other studies, especially in relation to the plasma peak SFN value and 
the time point at which SFN peaked. 
8.8.17 The Effects of GSTP1 polymorphisms in the EASYGENEX Study 
Of the 20 participants (of diverse ethnicity), one was found to be homozygote, six 
were heterozygote and the remaining 13 carried the normal GSTP1 gene showing 
that roughly one-third of participants carried a GSTP1 variant.  As described in the 
Introduction to this chapter, GSTP1 variants vary by ethnicity but the homozygote 
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form is the least prevalent across all ethnicities examined.664 Table 8.1 lists the 
EASYGENEX study population by ethnicity, grouping participants by Caucasian, 
Asians and Southern Asian. 
There was a significant effect of time on plasma levels of SFN and its NAC and CYS 
conjugate. In those with the GSTP1 variants, with the > 3-fold increase in the NAC 
metabolite greatest for the GSTP1 variant group at 14 days. Such an effect is 
considered in some studies to confer a chemopreventive advantage for those 
carrying either the homo- or heterozygote GSTP1 polymorphism.   
8.9 LIMITATIONS and FUTURE PERSPECTIVES. 
The EASYGENEX Study showed several limitations likely to have affected the 
outcome.  Participant numbers were initially small but reduced even further by the 
presence of a viral infection in some and degradation of RNA samples for others.  
The presence of the virus made it difficult to separate the effect of SFN from that of 
the virus.  Selection of a young, healthy, physically-active male population may have 
limited the potential for expression of genes also modulated by exercise.  By 
selecting this population, the study had inadvertently failed to exclude all significant 
Nrf2 activators; nor was any allowance made for sex differences which may or may 
not have had an effect.  Gene expression data were taken from PBMC cells which 
are not necessarily representative of all cells, even though this cell type is 
considered a satisfactory surrogate tissue in dietary investigations.  PBMCs are 
known to give less sensitive responses and reveal high inter-individual differences.  
They may also be adversely affected by cryopreservation.731  The nature of 
microarray studies is that they query large gene datasets but lack the accuracy of 
platforms such as RT-qPCR.  In a next step, it would be advantageous to select and 
investigate a number of the genes of interest from the EASYGENEX Study, using 
this more sensitive tool. 
This investigation of plasma SFN and its mercapturic acid metabolites confirmed that 
SFN had been generated in vivo after ingestion of the broccoli sprout capsules.  It 
was expected that participants would achieve steady state by taking these capsules 
over a number of days.  As no pharmacokinetic studies in the minutes and hours 
after ingestion of the capsules were undertaken, it was not possible to identify the 
peak plasma levels.  Given that two different doses were tested, it would have been 
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useful to have identified the peak plasma level for each dose.  This is a limitation in 
that it was not possible to draw any conclusions regarding a dose-response.  This 
further limited any ability to compare these findings with those of other studies where 
peak values and other pharmacokinetic markers had been recorded. 
A number of other identified genes did not reach statistical significance.  As some of 
these are known to be related to the functions identified in IPA Canonical Pathways, 
it would be advantageous to explore these further in relation to SFN but in a different 
population. The genes TNFSF8, IL6R, IFI6, IRS2, LDLR, HDL, ACLY and HLA-DRA 
are all directly clinically-relevant with relationship to inflammation and autoimmunity, 
lipid metabolism, glucose metabolism and energy synthesis. 
Future studies could further investigate these effects on a more sensitive platform 
such as RT-qPCR and might also select an older, less healthy population to study 
these and other effects on disease markers. 
8.10 CONCLUSION 
As a phytochemical, low molecular weight, lipophilic SFN is structurally quite 
different from the more extensively-researched higher molecular weight, bulky 
polyphenol molecules abundant in plant foods.  Where the polyphenols as a group 
are limited by their low bioavailability, SFN does not have this limitation.  As a result, 
there is greater likelihood that its in vivo effects will more closely approximate what is 
observed in in vitro studies.  The EASYGENEX Study showed that an ingested 
whole broccoli sprout capsule yielded sufficient SFN in situ to cross several 
membranes to be detected in white blood cells, the PBMCs.  This study also 
supported the known effect of GSTP1 polymorphisms on SFN metabolism. 
Furthermore, it was demonstrated that SFN differentially-modified the expression of 
genes associated with core cellular processes related to immune modulation (anti-
inflammatory), metabolism (adipogenesis, glucose metabolism, insulin sensitivity), 
neurotransmitter synthesis, cytoprotection, cardioprotection and redox-regulation; a 
number of genes is known to be associated with more than one process.  Of the 
differentially-expressed genes in this study, eight were identified for which no prior 
reference in association with SFN could be found.  This finding might reaffirm the 
known pleiotropic character of the SFN molecule, suggesting the requirement for 
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more targeted investigation of its nutrigenomic effects and their potential clinical 
significance. 
8.10 SUPPLEMENTARY MATERIALS 
Table S8.1   Significantly differentially-expressed genes on Day 0 compared to Day 7. 
(p<0.05) 
Gene 
Symbol 
Log 
Fold-
change 
Adjusted 
p-value Description 
Increased Gene Expression on Day 7, compared to Day 0 
SIGLEC1 0.40 0.0303 sialic acid binding Ig like lectin 1 
GDPD5 0.28 0.0419 
glycerophosphodiester phosphodiesterase domain 
containing 5 
C20orf173 0.27 0.0419 chromosome 20 open reading frame 173 
DYRK1B 0.24 0.0331 
dual specificity tyrosine phosphorylation regulated 
kinase 1B 
MEPE 0.21 0.0419 matrix extracellular phosphoglycoprotein 
RIC8B 0.21 0.0303 RIC8 guanine nucleotide exchange factor B 
CWC15 0.20 0.0392 CWC15 spliceosome associated protein homolog 
SYNDIG1L 0.19 0.0248 synapse differentiation inducing 1 like 
CENPX 0.18 0.0240 centromere protein X 
MLF1 0.17 0.0248 myeloid leukemia factor 1 
MT2A 0.17 0.0191 metallothionein 2A 
ATP6V1F 0.17 0.0232 ATPase H+ transporting V1 subunit F 
TGM2 0.16 0.0240 transglutaminase 2 
ATG9A 0.16 0.0400 autophagy related 9A 
CCDC82 0.16 0.0347 coiled-coil domain containing 82 
TUBA1B 0.13 0.0459 tubulin alpha 1b 
HDLBP 0.13 0.0347 high density lipoprotein binding protein 
Decreased Gene Expression on Day 7, compared to Day 0 
TNFSF8 -0.45 0.0050 tumour necrosis factor superfamily member 8 
F2RL1 -0.37 0.0255 F2R like trypsin receptor 1 
ZNF92 -0.32 0.0115 zinc finger protein 92 
CYP4F3 -0.30 0.0065 cytochrome P450 family 4 subfamily F member 3 
DUSP1 -0.29 0.0322 dual specificity phosphatase 1 
IL6R -0.28 0.0003 interleukin 6 receptor 
MAT2A -0.26 0.0065 methionine adenosyltransferase 2A 
HIST1H2AC -0.26 0.0111 histone cluster 1 H2A family member c 
CD46 -0.26 0.0017 CD46 molecule 
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PIK3IP1 -0.26 0.0068 phosphoinositide-3-kinase interacting protein 1 
IRS2 -0.25 0.0393 insulin receptor substrate 2 
EIF3L -0.25 0.0179 eukaryotic translation initiation factor 3 subunit L 
PHC2 -0.25 0.0069 polyhomeotic homolog 2 
ATP6V1A -0.25 0.0485 ATPase H+ transporting V1 subunit A 
PTTG1IP -0.24 0.0021 pituitary tumour-transforming 1 interacting protein 
CEACAM4 -0.24 0.0065 
carcinoembryonic antigen related cell adhesion 
molecule 4 
SRSF1 -0.24 0.0073 serine and arginine rich splicing factor 1 
TM6SF1 -0.21 0.0065 transmembrane 6 superfamily member 1 
ROCK1 -0.21 0.0395 Rho associated coiled-coil containing protein kinase 1 
VASP -0.21 0.0111 vasodilator-stimulated phosphoprotein 
LGMNP1 -0.21 0.0347 legumain pseudogene 1 
PRNP -0.20 0.0179 prion protein 
RAB6A -0.20 0.0471 RAB6A, member RAS oncogene family 
CSF2RA -0.19 0.0065 colony stimulating factor 2 receptor-alpha subunit 
IL7R -0.19 0.0232 interleukin 7 receptor 
PELI1 -0.19 0.0208 pellino E3 ubiquitin protein ligase 1 
EP300 -0.19 0.0322 E1A binding protein p300 
SACM1L -0.19 0.0234 SAC1 suppressor of actin mutations 1-like (yeast) 
DDX3X -0.19 0.0021 DEAD-box helicase 3, X-linked 
SGK1 -0.19 0.0155 serum/glucocorticoid regulated kinase 1 
CRK -0.19 0.0069 CRK proto-oncogene, adaptor protein 
USO1 -0.19 0.0287 USO1 vesicle transport factor 
TANGO2 -0.19 0.0155 transport and golgi organization 2 homolog 
RTN3 -0.18 0.0065 reticulon 3 
SURF4 -0.18 0.0065 surfeit 4 
SHOC2 -0.18 0.0391 SHOC2, leucine rich repeat scaffold protein 
ABTB1 -0.18 0.0232 ankyrin repeat and BTB domain containing 1 
CFL1 -0.17 0.0419 cofilin 1 
TPRG1L -0.17 0.0127 tumour protein p63 regulated 1 like 
HMGB1 -0.17 0.0322 high mobility group box 1 
RTN3P1 -0.17 0.0208 reticulon 3 pseudogene 1 
LBR -0.17 0.0234 lamin B receptor 
PRKAR1A -0.17 0.0239 
protein kinase cAMP-dependent type I regulatory 
subunit alpha 
CD82 -0.17 0.0322 CD82 molecule 
PTAFR -0.17 0.0355 platelet activating factor receptor 
SLBP -0.17 0.0232 stem-loop binding protein 
RPS6KA5 -0.17 0.0069 ribosomal protein S6 kinase A5 
CDC42SE2 -0.17 0.0419 CDC42 small effector 2 
POLR2C -0.17 0.0127 RNA polymerase II subunit C 
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NAP1L4 -0.17 0.0239 nucleosome assembly protein 1 like 4 
GRN -0.17 0.0347 granulin precursor 
SDCBP -0.17 0.0118 syndecan binding protein 
RAD21 -0.16 0.0347 RAD21 cohesin complex component 
ORAI2 -0.16 0.0419 ORAI calcium release-activated calcium modulator 2 
FBXL3 -0.16 0.0239 F-box and leucine rich repeat protein 3 
ACTB -0.16 0.0118 actin beta 
IFNGR1 -0.16 0.0207 interferon gamma receptor 1 
CAPZB -0.16 0.0303 capping actin protein of muscle Z-line beta subunit 
STAT3 -0.16 0.0322 signal transducer and activator of transcription 3 
TMEM154 -0.16 0.0069 transmembrane protein 154 
STX3 -0.16 0.0342 syntaxin 3 
RAB11FIP1 -0.16 0.0065 RAB11 family interacting protein 1 
VNN2 -0.16 0.0240 vanin 2 
RPN1 -0.16 0.0069 ribophorin I 
PTPRE -0.16 0.0234 protein tyrosine phosphatase, receptor type E 
SNAP23 -0.15 0.0240 synaptosome associated protein 23 
TOR1AIP1 -0.15 0.0322 torsin 1A interacting protein 1 
CLRN3 -0.15 0.0455 clarin 3 
CD164 -0.15 0.0347 CD164 molecule 
CRLF3 -0.15 0.0275 cytokine receptor like factor 3 
FPR2 -0.15 0.0248 formyl peptide receptor 2 
TAGLN2 -0.14 0.0370 transgelin 2 
NARS -0.14 0.0155 asparaginyl-tRNA synthetase 
TAB2 -0.14 0.0268 TGF-beta activated kinase 1/MAP3K7 binding protein 2 
AKIRIN1 -0.14 0.0148 akirin 1 
CAB39 -0.14 0.0419 calcium binding protein 39 
NT5C2 -0.13 0.0431 5'-nucleotidase, cytosolic II 
VMP1 -0.13 0.0337 vacuole membrane protein 1 
ARF4 -0.13 0.0347 ADP ribosylation factor 4 
ACTN1 -0.13 0.0303 actinin alpha 1 
TBL1X -0.12 0.0322 transducin beta like 1X-linked 
LAMP2 -0.12 0.0419 lysosomal associated membrane protein 2 
PPT1 -0.12 0.0419 palmitoyl-protein thioesterase 1 
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Table S8.2   Significantly differentially-expressed genes on Day 14 compared to Day 7. 
(p<0.05) 
Gene Symbol 
Log 
Fold-
change 
Fold-
change 
Adjusted 
p-value 
Description 
Increased Gene Expression on Day 14 compared to Day 7 
CYP4F3 0.29 1.2    0.0060 
cytochrome P450 family 4 subfamily F 
member 3 
RPS15A 0.27 1.2    0.0029 ribosomal protein S15a 
PIK3IP1 0.24 1.2    0.0039 
phosphoinositide-3-kinase interacting 
protein 1 
EIF3L 0.23 1.2    0.0193 
eukaryotic translation initiation factor 3     
subunit L 
IL7R 0.22 1.2     0.0058 interleukin 7 receptor 
IL6R 0.22 1.2     0.0019 interleukin 6 receptor 
USP10 0.22 1.2 0.0495 ubiquitin specific peptidase 10 
KLRG2 0.22 1.2 0.0228 killer cell lectin like receptor G2 
GOLGA8A 0.22 1.2 0.0435 golgin A8 family member A 
VCPKMT 0.21 1.2 0.0315 
valosin containing protein lysine 
methyltransferase 
SRSF5 0.20 1.1 0.0428 serine and arginine rich splicing factor 5 
CD46 0.20 1.1 0.0083 CD46 molecule 
CSGALNACT1 0.20 1.1 0.0264 
chondroitin sulfate N-
acetylgalactosaminyltransferase 1 
HAL 0.19 1.1 0.0427 histidine ammonia-lyase 
TM6SF1 0.19 1.1 0.0120 transmembrane 6 superfamily member 1 
DDX17 0.19 1.1 0.0040 DEAD-box helicase 17 
TNFSF14 0.19 1.1 0.0380 
tumour necrosis factor superfamily member 
14 
CD200 0.19 1.1 0.0482 CD200 molecule 
LAT2 0.18 1.1 0.0315 
linker for activation of T-cells family member 
2 
MME 0.18 1.1 0.0466 membrane metalloendopeptidase 
OXNAD1 0.18 1.1 0.0123 
oxido-reductase NAD binding domain 
containing 1 
SRSF1 0.18 1.1 0.0432 serine and arginine rich splicing factor 1 
CEACAM4 0.18 1.1 0.0131 
carcinoembryonic antigen related cell adhesion 
molecule 4 
SGK1 0.17 1.1 0.0228 serum/glucocorticoid regulated kinase 1 
LUC7L3 0.17 1.1 0.0266 LUC7 like 3 pre-mRNA splicing factor 
ARGLU1 0.15 1.1 0.0269 arginine and glutamate rich 1 
RB1CC1 0.15 1.1 0.0495 RB1 inducible coiled-coil 1 
MYO1F 0.15 1.1 0.0432 myosin IF 
ATG16L2 0.15 1.1 0.0315 autophagy related 16 like 2 
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TAB2 0.15 1.1 0.0206 
TGF-beta activated kinase 1/MAP3K7 
binding protein 2 
PTTG1IP 0.14 1.1 0.0459 
pituitary tumour-transforming 1 interacting 
protein 
NAP1L4 0.14 1.1 0.0334 nucleosome assembly protein 1 like 4 
ZNF791 0.14 1.1 0.0466 zinc finger protein 791 
CRLF3 0.13 1.1 0.0450 cytokine receptor like factor 3 
SPSB3 0.13 1.1 0.0495 
splA/ryanodine receptor domain and SOCS box 
containing 3 
TMEM154 0.11 1.1 0.0479 transmembrane protein 154 
     
 Decreased Gene Expression on Day 14 compared to Day 7 
Gene Symbol 
Log 
Fold-
change 
Fold-
change 
Adjusted 
p-value 
Description 
LAP3 -0.50 0.7 0.0019 leucine aminopeptidase 3 
PPIHP1 -0.49 0.7 0.0069 peptidylprolyl isomerase H pseudogene 1 
GDPD5 -0.49 0.7 0.0019 
glycerophosphodiester phosphodiesterase domain 
containing 5 
SERPING1 -0.46 0.7 0.0241 serpin family G member 1 
C12orf76 -0.45 0.7 0.0040 chromosome 12 open reading frame 76 
SIGLEC1 -0.42 0.7 0.0233 sialic acid binding Ig like lectin 1 
OAS3 -0.37 0.8 0.0083 2'-5'-oligoadenylate synthetase 3 
KLF10 -0.36 0.8 0.0466 Kruppel like factor 10 
IFITM3 -0.35 0.8 0.0019 interferon induced transmembrane protein 3 
CDKN1C -0.33 0.8 0.0281 cyclin dependent kinase inhibitor 1C 
ETFB -0.32 0.8 0.0459 electron transfer flavoprotein beta subunit 
RBBP8 -0.32 0.8 0.0466 RB binding protein 8, endonuclease 
ATP8B4 -0.32 0.8 0.0264 
ATPase phospholipid transporting 8B4 
(putative) 
ACSF2 -0.32 0.8 0.0083 acyl-CoA synthetase family member 2 
HERC6 -0.31 0.8 0.0040 
HECT and RLD domain containing E3 ubiquitin 
protein ligase family member 6 
VRK1 -0.31 0.8 0.0410 vaccinia related kinase 1 
GPR84 -0.31 0.8 0.0176 G protein-coupled receptor 84 
PFKM -0.31 0.8 0.0228 phosphofructokinase, muscle 
CENPU -0.30 0.8 0.0450 centromere protein U 
CDC42EP2 -0.30 0.8 0.0174 CDC42 effector protein 2 
RCBTB1 -0.29 0.8 0.0466 RCC1 and BTB domain containing protein 1 
IFI6 -0.28 0.8 0.0438 interferon alpha inducible protein 6 
NTAN1 -0.27 0.8 0.0380 N-terminal asparagine amidase 
LAG3 -0.27 0.8 0.0264 lymphocyte activating 3 
CHCHD4 -0.26 0.8 0.0495 
coiled-coil-helix-coiled-coil-helix domain 
containing 4 
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DDX60 -0.26 0.8 0.0241 DExD/H-box helicase 60 
OAS2 -0.25 0.8 0.0181 2'-5'-oligoadenylate synthetase 2 
ZFPM1 -0.25 0.8 0.0233 zinc finger protein, FOG family member 1 
LDLR -0.25 0.8 0.0113 low-density lipoprotein receptor 
MTMR2 -0.25 0.8 0.0019 myotubularin related protein 2 
OAS1 -0.24 0.8 0.0334 2'-5'-oligoadenylate synthetase 1 
C12orf75 -0.24 0.8 0.0241 chromosome 12 open reading frame 75 
IDH2 -0.23 0.9 0.0083 
isocitrate dehydrogenase (NADP(+) 2, 
mitochondrial 
CCDC162P -0.23 0.9 0.0435 
coiled-coil domain containing 162, 
pseudogene 
FUNDC1 -0.23 0.9 0.0280 FUN14 domain containing 1 
GBP4 -0.22 0.9 0.0046 guanylate binding protein 4 
PPIH -0.22 0.9 0.0148 peptidylprolyl isomerase H 
HEG1 -0.22 0.9 0.0147 
heart development protein with EGF like 
domains 1 
ATIC -0.22 0.9 0.0459 
5-aminoimidazole-4-carboxamide 
ribonucleotide formyltransferase/IMP 
cyclohydrolase 
NUP93 -0.21 0.9 0.0086 nucleoporin 93 
MX1 -0.21 0.9 0.0438 MX dynamin like GTPase 1 
CDKN1A -0.21 0.9 0.0255 cyclin dependent kinase inhibitor 1A 
ACLY -0.21 0.9 0.0123 ATP citrate lyase 
TTC9C -0.21 0.9 0.0227 tetratricopeptide repeat domain 9C 
NAGA -0.20 0.9 0.0065 alpha-N-acetylgalactosaminidase 
THYN1 -0.20 0.9 0.0228 thymocyte nuclear protein 1 
PLSCR1 -0.20 0.9 0.0327 phospholipid scramblase 1 
TUBA1B -0.20 0.9 0.0019 tubulin alpha 1b 
KIF1C -0.20 0.9 0.0315 kinesin family member 1C 
CHST12 -0.19 0.9 0.0450 carbohydrate sulfotransferase 12 
GLOD4 -0.19 0.9 0.0193 glyoxalase domain containing 4 
SCARB2 -0.19 0.9 0.0193 scavenger receptor class B member 2 
MT2A -0.19 0.9 0.0086 metallothionein 2A 
GPN3 -0.19 0.9 0.0269 GPN-loop GTPase 3 
TJP2 -0.19 0.9 0.0131 tight junction protein 2 
CIZ1 -0.19 0.9 0.0233 CDKN1A interacting zinc finger protein 1 
CEBPB -0.19 0.9 0.0206 CCAAT/enhancer-binding protein beta 
NDUFA8 -0.18 0.9 0.0450 
NADH:ubiquinone oxidoreductase subunit 
A8 
CD300C -0.18 0.9 0.0281 CD300c molecule 
RIC8B -0.18 0.9 0.0457 RIC8 guanine nucleotide exchange factor B 
ARPP19 -0.18 0.9 0.0435 cAMP regulated phosphoprotein 19 
TMEM41A -0.18 0.9 0.0427 transmembrane protein 41A 
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GLO1 -0.18 0.9 0.0457 glyoxalase I 
IL1RN -0.18 0.9 0.0450 interleukin 1 receptor antagonist 
FUCA2 -0.18 0.9 0.0233 fucosidase, alpha-L- 2, plasma 
RUVBL1 -0.17 0.9 0.0280 RuvB like AAA ATPase 1 
NEXN -0.17 0.9 0.0233 nexilin F-actin binding protein 
CTNNA1 -0.17 0.9 0.0311 catenin alpha 1 
ZBTB2 -0.17 0.9 0.0426 zinc finger and BTB domain containing 2 
HARS -0.17 0.9 0.0391 histidyl-tRNA synthetase 
HDAC1 -0.17 0.9 0.0438 histone deacetylase 1 
SAMD9 -0.17 0.9 0.0469 sterile alpha motif domain containing 9 
ZC3H4 -0.17 0.9 0.0450 zinc finger CCCH-type containing 4 
GAR1 -0.16 0.9 0.0264 GAR1 ribonucleoprotein 
GSE1 -0.16 0.9 0.0130 Gse1 coiled-coil protein 
TAOK3 -0.16 0.9 0.0130 TAO kinase 3 
DDX24 -0.16 0.9 0.0112 DEAD-box helicase 24 
EIF4EBP1 -0.16 0.9 0.0315 
eukaryotic translation initiation factor 4E 
binding protein 1 
MRPL51 -0.16 0.9 0.0365 mitochondrial ribosomal protein L51 
CDK5RAP2 -0.15 0.9 0.0438 
CDK5 regulatory subunit associated protein 
2 
RUNX3 -0.15 0.9 0.0450 runt related transcription factor 3 
SDF2L1 -0.14 0.9 0.0318 stromal cell derived factor 2 like 1 
ARSB -0.14 0.9 0.0162 arylsulfatase B 
LRRFIP2 -0.14 0.9 0.0495 LRR binding FLII interacting protein 2 
DTL -0.14 0.9 0.0438 
denticleless E3 ubiquitin protein ligase 
homolog 
RAB8A -0.13 0.9 0.0416 RAB8A, member RAS oncogene family 
ANO6 -0.12 0.9 0.0432 anoctamin 6 
HLA-DRA -0.12 0.9 0.0438 
major histocompatibility complex, class II, 
DR alpha 
SMAP1 -0.12 0.9 0.0428 small ArfGAP 1 
ELF4 -0.12 0.9 0.0499 E74 like ETS transcription factor 4 
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CHAPTER 9 
Thesis Conclusion 
9.0 Final Impressions 
The major focus of this work has been on Brassica-derived SFN but in exploring this 
bioactive phytochemical, a much broader base has been traversed, a base which 
has examined principles that apply to many phytochemicals.  This journey has 
highlighted controversies, investigated unresolved opposing views and has raised 
questions for which there are not yet answers; such are the challenges faced by a 
collaborative scientific community in any investigative endeavour. 
9.1 The Role of Serendipity in Science 
The clinical trials that were undertaken in delivering this thesis confirmed that there 
are no failed experiments in science; instead, these are valuable opportunities for 
enlightenment.  The Fatigue Study described in Chapters 3 highlighted the 
importance of assaying the raw material to be used as an intervention rather than 
relying on the specification provided by the supplier.  Had this been done, there 
would have been greater likelihood of determining whether the intervention had 
failed to provide a significant clinical response or instead that the enzyme-active 
intervention material simply did not meet its specification and as a result, failed to 
deliver the assumed bioactive content; an important lesson well-learned. 
The EASYGENEX Study in Chapter 8 provided a different type of learning 
opportunity in that the study failed to exclude all the factors capable of activating 
Nrf2.  Given that the intervention was expected to reflect similar findings to that of 
other studies investigating Nrf2 activation, this oversight had important ramifications.  
In reviewing the literature on exercise and Nrf2, it became apparent that, even 
though much is known about the health-promoting effects of exercise, little evidence 
exists to quantify its effect on Nrf2 activation.   
This revelation may provide a valuable avenue for future investigation, especially 
since supraphysiological doses of antioxidant vitamin supplements are frequently 
ingested by sportspeople of all ages, even though it has been found that such 
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supplements can abrogate the beneficial effects of exercise.119  It may be that 
quantifying the relationship between exercise and Nrf2 activation would more 
effectively deliver measurable benefit. 
Chapter 8 postulated that exercise and SFN may have had similar effects in 
activating Nrf2 in the young, healthy males investigated.  The genes differentially-
expressed in this study were representative of Nrf2-independent targets and it would 
be valuable to know how many of these are also modulated by exercise and to what 
extent; existing data are limited.  
9.2 Why Sulforaphane? 
Of the many thousands of identified phytochemicals, SFN is just one.  This single 
molecule is not the only Brassica-derived ITC with clinical potential but it is the one 
for which most evidence exists at this time, especially when few clinical trials have 
been conducted on other members.  There may in fact be advantages in more 
intensively investigating other ITCs because although preservation of MYR activity is 
important for all ITCs, not all MYR-active GSNs contain the ESP inhibitor.  Daikon 
radish for example does not contain ESP, whereas cabbage does.  Regardless of 
the specific GSN precursor, the presence of ESP will impact the generation of the 
associated ITC.406 
In the production of a SFN-yielding broccoli sprout raw material, the application of 
heat must be able to simultaneously retain MYR whilst degrading the ESP.  It is 
perhaps for this reason that the MYR-inert broccoli sprout and broccoli seed extracts 
have been developed as a way to avoid addressing this challenging issue.  A whole 
MYR-active broccoli sprout material is able to endogenously generate SFN, so that it 
is not reliant on the largely unknown and variable status of the gut microflora 
required to provide MYR-like activity when only GRN is ingested. 
The EASYGENEX Study showed that daily ingestion of capsules of MYR-active 
dried broccoli sprouts resulted in the presence of SFN and its metabolites in the 
plasma, confirming that SFN in this form is bioavailable.  It also confirmed that the 
presence of the metabolites was associated with the GSTP1 genotype of the 
individual, showing that those carrying either homo- or heterozygous polymorphisms 
had higher plasma levels of both SFN and its metabolites than those with the normal 
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genotype.  This may have implications for anticipating clinical responsiveness when 
employing SFN in both prevention and therapy. 
9.3 Sulforaphane Amidst a Sea of Polyphenols 
When comparing the clinical potential of SFN with other dietary phytochemicals such 
as the abundant polyphenols, SFN has clear advantages.  Chapters 5 and 6 
highlight the low bioavailability of the intact unmetabolised polyphenols as being a 
major barrier to their use systemically, even though they can function as direct-acting 
antioxidants in the gut, especially effective when consumed with carcinogen-
containing foods.  Figure 6.3 in Chapter 6 presents a comparison of SFN with the 
four polyphenols, andrographolides, quercetin, curcumin and silymarin, illustrating 
the far higher bioavailability of SFN over the four polyphenols, all of which are 
readily-available as dietary supplements.   
The possibility that the metabolites of the polyphenols are both bioactive and 
bioavailable has been explored by some.  However, the role of the gut microflora in 
producing an unpredictable range of possible metabolites is a largely unexplored but 
emerging research area.  Greater clarity on the underlying processes may help to 
explain why there exist a few clinical trials showing positive outcomes for 
polyphenolic interventions with very low bioavailability, even though in vitro studies 
show that the intact polyphenols could not be detected in tissues at such doses.  
SFN by contrast can be readily detected in micromolar amounts in various cell types. 
As a further significant difference, Figure 6.2 illustrates the superior capacity of SFN 
as an inducer of the cytoprotective Phase 2 detoxification gene NQO1 by comparing 
the CD value of SFN with other phytochemicals, not all of which are polyphenols.  
On both counts, SFN is not only a more potent inducer of the Nrf2-dependent NQO1 
gene but is also more bioavailable than others that have been investigated, 
establishing SFN as a candidate for further independent or comparative research 
with clinical endpoints. 
9.4 Sulforaphane and the Intricacies of Signalling 
The NF-κB network was the predominant Canonical Pathway discussed in Chapter 8 
and whilst some of the genes identified were already known to be associated with 
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SFN, others were not.  The microarray data showed that the intervention resulted in 
the differential expression of 8 genes not previously associated with SFN.  These 
genes are known to function in six overlapping pathways associated with a range of 
core cellular processes.  This finding is worthy of more targeted gene expression 
techniques such as RT-qPCR in order to reject or validate the gene expression 
relationship to SFN.  If one or more of these genes can be validated for its 
association with SFN, this may lead to new avenues for SFN research. 
When exploring the functions of the genes found to be significantly differentially-
expressed by SFN in this study, it becomes immediately apparent that there is 
substantial cross-talk and interactivity among their related biochemical pathways, 
such that each of these genes functions in multiple pathways.  By way of example, 
two of the downregulated genes, RELB and CEBPB are known to act synergistically 
in downregulating inflammation.  But CEBPB is also integral to the processes of 
adipogenesis, glucose metabolism and insulin sensitivity.  Furthermore, the role of 
CEBPB in adiposity overlaps its role in cancer because increased CEBPB 
expression is implicated in the development of some tumours with expression 
correlated with more invasive activity.   
Similarly, DDX3X as a member of the large DEAD-box protein family is known to 
regulate NF-kB, with dysregulation of this gene implicated in tumorigenesis.  SFN 
was shown in the EASYGENEX Study to downregulate this gene along with four 
other cancer-related genes, ZBTB2, HERC6, PDIA4 and IGF2BP2.  This suggests 
that there may be additional roles for SFN in chemoprevention. 
Chapter 8 referred to a more recent published discussion of cancer cell survival 
mechanisms involving a redox-related process wherein cancer cells can switch 
between survival and death pathways.  The EASYGENEX data showed for the first 
time that SFN may downregulate the PDIA4 gene.  Since PDIA4 expression is 
upregulated in a variety of tumour cell lines, its yet-to-be-confirmed downregulation 
by SFN may be indicative of alternative signalling mechanisms used by cells to 
determine whether and when a cancer cell switches from death to pro-survival 
signals or vice versa.  
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An upregulated gene with multiple functions and identified in this study was DDC, the 
gene coding for dopa decarboxylase. Dopamine is usually considered for its role as 
a neurotransmitter and as the precursor for other catecholamine neurotransmitters.  
However, dopamine also has a lesser-known role in modulating the inflammatory 
process; the IPA data highlighted its presence in the NF-κB Network.  If subsequent 
RT-qPCR and protein studies validate its induction by SFN, it would be intriguing to 
know whether this action is also applicable in neuropsychiatry and 
neurodegeneration.  SFN is known to inhibit dopamine oxidation and has already 
been investigated in relation to Parkinson’s Disease in which dopamine is both 
under-secreted and readily oxidised. 
9.5 The Emerging Dual Roles of Nrf2 – a Certain Dilemma 
Surely, one of the dilemmas of our time in this research field lies in attempting to 
unravel the dual role of Nrf2 activation in human cells.  Where such activation has 
been demonstrated to be protective of healthy cells, the same may be equally 
protective of cancer cells, giving these cells a distinct survival advantage; it has 
already been shown that resistance to chemotherapeutic drugs (chemoresistance) 
could result from such induction.  This leaves us to ponder how the observed 
positive clinical outcomes via Nrf2 activation can be reconciled against the potential 
adverse effects in individuals who may be in an undiagnosed preliminary stage of 
cancer cell progression. 
Cancer cells are known to upregulate their own Nrf2 pathway so that strategies that 
attempt to enhance the cell’s endogenous defences may not be advantageous in 
active disease.  Although the precise signalling that governs Nrf2’s pro-survival 
mode in cancer cells is not known, it is conceivable that induction of the Phase 2 
detoxification genes via Nrf2 might reduce the effective dose of the 
chemotherapeutic agent.  Pharmaceuticals designed to inhibit Nrf2 are already part 
of the cancer therapy armamentarium.   
So, on the one hand, there is evidence to support the chemoprotective effects of 
Nrf2 activation742 but on the other hand, Nrf2 inhibition is being already used to 
sensitise cancer cells to chemotherapeutic agents, thereby eliminating 
chemoresistance.743 
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9.6 So Many Questions – So Few Answers 
To put these issues into perspective, it is important to consider them against the 
larger body of epidemiological evidence which connects chemoprevention with diet.  
A number of questions invariably arise from such consideration: Is there any 
documented evidence that dietary consumption of Nrf2 activators such as broccoli 
promotes cancer or retards recovery?  Does a synthesised more potent Nrf2 
activator behave in the same way as SFN and other phytochemical Nrf2 activators?   
Is there any evidence that dietary intake of plant foods promotes cancer in 
established disease?  Could Nrf2 activation in healthy cells assist in restoring the 
endogenous mechanisms cells use to mount a successful challenge on a cancer 
cell? What does simultaneous activation of Nrf2 in healthy and cancer cells achieve? 
Is such plant food contra-indicated when a patient is undergoing chemotherapy?  
Does a diet high in plant food promote chemoresistance in such a patient? Do other 
benefits of a diet high in plant foods outweigh the possible adverse effects?   
Given that cancer patients in particular are known to search for alternative therapies 
in addition to their conventional treatments, it is imperative that the answers to at 
least some of these questions are found.  How do supplemental Nrf2 activators 
impact treatment with potent pharmaceuticals, many of which are designed to 
promote redox imbalance in the cancer cells? And if the answer to this question is 
not known, how should a medically- or even nutritionally-trained clinician advise a 
patient in relation to diet and/or particular supplements?   
9.7 Multiple Mechanisms – Which are at Play? 
One very important consideration is that Nrf2 is only one component of the cancer 
process and other mechanisms are known to modulate the process. Throughout this 
thesis, the pleiotropic nature of the SFN molecule has been highlighted and many of 
its Nrf2-independent effects are related to cancer.  Is it possible that a phytochemical 
like SFN can simultaneously engage some or all of its multiple signalling pathways in 
healthy cells to over-ride the cancer cell’s Nrf2 activation? Is there evidence that all 
of SFN’s anti-cancer effects are similarly active in the cancer cell? 
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9.8 Concluding Remarks 
This thesis set out to explore the role of phytochemicals in modulating intrinsic 
human cellular defence processes.  Even though the focus is primarily on SFN, it is 
cast against a backdrop of other phytochemicals more abundant in the human diet. 
This has enabled the differences between this low molecular weight lipophilic 
molecule to be compared and contrasted with the typically larger, bulkier 
polyphenolic molecules in terms of their relative clinical potential. 
An underlying theme running throughout this thesis is the awareness that the rapidly-
evolving science of nutrigenomics holds promise as a more personalised model for 
health care.  Phytochemicals are integral to this model with SFN arguably a 
promising future candidate for wider application.   
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